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Abstract 
 
 The thesis investigated the influence of centre selection on the generalisability across 
locations of trial-based economic evaluations. A novel methodology to assess and enhance the 
generalisability of trial findings was demonstrated using the comparison between wound-edge 
protection devices (WEPDs) and standard care to reduce surgical site infection (SSI) after 
open abdominal surgery as a case study.  
 A systematic review and a preliminary economic model suggested that WEPDs may 
be effective and cost-effective in reducing SSI compared to standard care, although the 
methodological quality of available studies was poor. ROSSINI was a high quality multi-
centre randomised controlled trial (RCT) which demonstrated that WEPDs are unlikely to be 
effective or cost-effective, so their routine use cannot be recommended. 
 The impact of centre selection on trial results was then investigated using ROSSINI as 
a case study. Mixed methods research demonstrated that most RCTs do not enrol centres so as 
to ensure a representative sample at jurisdiction level. The Generalisability index (Gix) was 
introduced as the basis of a novel methodology to assess generalisability, which was 
demonstrated using simulation methods and ROSSINI data. The results suggested that the 
characteristics of the sample of participating centres can significantly affect RCT clinical and 
cost-effectiveness estimates. 
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 This research focuses on the generalisability across locations of the results of 
economic evaluations conducted alongside randomised controlled trials (RCTs). An 
intervention to reduce surgical site infection (SSI) rate after open abdominal surgery is used 
as a case study: after generating cost-effectiveness evidence by applying a range of standard 
methods, the thesis investigates the importance of centre selection for trial results and 
demonstrates a novel approach to evaluating generalisability. 
This Chapter describes the methodological background of the research and presents 
the structure of the thesis. The first section outlines the principles of RCTs, followed by a 
brief introduction to economic evaluation methods and the current issues concerning the 
generalisability of RCTs and trial-based economic evaluation results. The Chapter ends by 
stating the objectives of the research and by presenting an outline of the thesis’ Chapters. 
 
1.1. Randomised controlled trials 
Clinical trials can be defined broadly as experiments which test a medical intervention 
on human subjects (1). RCTs are a category of clinical trials with two important features: an 
explicit control group, which enables a direct comparison between the intervention(s) being 
tested and a comparator; and a random treatment allocation process,  which ensures that 
participants differ only by chance and the intervention they are about to receive. RCTs are 
conducted in order to answer one or more meaningful research questions concerning the 
benefits and harms of a given intervention relative to the chosen comparator. 
The study outcomes operationalise a RCT’s research questions. The primary outcome 
is the most important outcome in a trial and was defined by the International Conference for 
Harmonisation - Statistical Principles for Clinical Trials (ICH E9, p.5) as “the variable 
capable of providing the most clinically relevant and convincing evidence directly related to 
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the primary objective of the trial” (2). The choice of the primary outcome should be informed 
by the available clinical evidence and key stakeholders such as patients, investigators and 
clinicians. Additional outcomes may include other clinically important variables, safety 
markers, health-related quality of life (HRQoL) and cost-effectiveness; the last two are 
important to policy makers to inform market authorization and reimbursement decisions (3). 
In order to improve comparability, it is recommended that all trials conducted in a particular 
therapeutic area adopt a core set of outcomes (4).  
The principal research question of a given RCT can be formulated, by means of the 
primary outcome, as a testable hypothesis which is usually labelled the ‘null hypothesis’ (H0). 
For example, in a trial of an antihypertensive drug X compared to placebo, a suitable primary 
outcome may be the difference from baseline in systolic blood pressure after 90 days of 
treatment. The null hypothesis may, thus, be that ‘Drug X is not more effective than placebo 
in controlling systolic blood pressure’. In order to test the null hypothesis, primary data are 
collected from an appropriate sample of participants, the relevant sample statistic is calculated 
(e.g. mean difference in systolic blood pressure across treatment groups) and a decision rule 
based on the sample statistic is used to decide whether sample data support the null 
hypothesis or not i.e. H0 can be rejected or not. Upon making such a decision, two types of 
errors can be made: type I error refers to the case when H0 is rejected when it is in fact true; 
the notation for the probability of committing a type I error is α. Conversely, type II error 
refers to the case when H0 cannot be rejected, but it is in fact false; the notation for the 
probability of committing a type II error is β. The power of a statistical hypothesis test 
measures its capacity to reject the null hypothesis when it is indeed false i.e. the capacity to 
make a correct decision (1 – β) (5). 
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The primary outcome is also important because it informs the calculation of the trial 
sample size i.e. the number of patients who need to be recruited in order to maximise 
statistical power. The following generic types of data inputs are necessary to calculate the 
sample size: the minimally important difference in the primary outcome between the trial’s 
arms that investigators expect to observe; the level of statistical significance α (usually 0.05); 
the required power (usually 0.80); and, for continuous outcomes, the standard deviation of the 
measurements (6).   
Bias can be understood as any systematic error in results and is a major concern in any 
experiment (2). RCTs are regarded as the gold standard in clinical research because of their 
potential to minimise the effect of several important biases. For example, randomisation can 
minimise selection bias by ensuring that patients are allocated to the intervention or control 
arm purely by chance and not subject to patient or clinician preferences. This can be achieved 
by using a treatment allocation sequence generation method which is unpredictable and 
cannot be easily tampered with. An acceptable example is a computer-generated sequence 
communicated to researchers via a secure Internet or phone connection, while poor methods 
include the use of sealed envelopes and allocation according to the day of the week. More 
sophisticated randomisation procedures include balancing the trial arms across known risk 
factors (stratification) and randomising sequentially within blocks of patients of random size 
(blocking) to maintain the desired intervention to control allocation ratio. Blinding refers to 
keeping the study personnel and participants unaware of treatment assignment and, if 
implemented appropriately, minimises performance bias i.e. uneven medical attention across 
trial arms. Blinded outcome assessment i.e. the professionals who are conducting the 
assessments are unaware of the treatment allocation, reduces the risk of detection bias, 
thereby ensuring the study outcomes are evaluated objectively. A comprehensive discussion 
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of sources of bias and available options to minimise and assess them is given in the Cochrane 
Handbook of Systematic Reviews of Interventions (7). 
A number of trial designs are available, their appropriateness depending primarily on 
the therapeutic area, the trial intervention and the trial objectives. The most straightforward 
configuration is the parallel design, where patients are randomised to either the intervention or 
control arm and are subject only to the corresponding regimen. By contrast, in cross-over 
designs patients are randomised to either of the arms and after a specified time interval they 
switch to the other arm (8, 9). The main advantages of cross-over designs are that each patient 
acts as their own control and smaller sample sizes are required to observe a significant effect. 
However, these designs are only applicable to chronic, reversible conditions and there are 
issues associated with carry-over effects i.e. the effect of a treatment may be such that by the 
time patients switch to an alternative regimen they are not is the state they would have been 
had they not received the initial treatment. One way to deal with carry-over effects is the 
introduction of a wash-out period, after which all measurements are assumed to be unaffected 
by the previous treatment. 
In factorial designs two or more treatments are evaluated simultaneously; such designs 
are particularly useful if the objective is to understand interactions or to describe dose-
response characteristics (10). Parallel, cross-over and factorial designs are conventional trial 
configurations where the unit of randomisation is the individual (arguably in cross-over trials 
the unit of randomisation is the sequence of interventions that the individual undergoes). 
However, the unit of randomisation can be more complex, such as a health care institution or 
a geographical area, where participants within that unit undergo only the allocated treatment. 
This is the case of cluster randomised trials, which are particularly useful in evaluating 
interventions where randomisation at individual level is problematic (the case of 
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contamination effects, such as in the evaluation of health care professionals training 
programmes) or impossible (the case of environmental factors such as air quality) (11). More 
recently, adaptive designs allow updating trial characteristics based on accumulating 
information without jeopardising the integrity of the analysis (12, 13). 
The trial protocol describes the objectives, design, methodology, statistical 
considerations and organisation of a trial (14). The protocol fulfils several roles: it documents 
how data should be collected, managed and analysed; it presents the trial to funding, 
regulatory and ethics bodies when applying for grants and approvals; it demonstrates the 
trial's compliance with official regulations, norms and guidelines; and it acts as a reference 
document throughout trial conduct. The SPIRIT Initiative (Standard Protocol Items for 
Randomized Trials) have recently published a list of standard items to be included in RCT 
protocols (15). In addition to data collection and analysis methods, the trial protocol must 
include procedures for issues such as confounding and handling missing data. In the case of 
missing data, it is important to investigate the reasons for which the data are missing in order 
to estimate the degree of bias likely to be incurred and to inform the methods for dealing with 
it (16). 
 Missing data are a sensitive topic in RCTs (17, 18). Despite the best efforts to ensure 
complete data collection, small amounts of missing data are inevitable. This is even more the 
case with patient self-completed case-report forms and patient-reported outcomes (PRO) 
assessments, which may be returned incomplete or not returned at all (19). The International 
Conference for Harmonisation - Statistical Principles for Clinical Trials (2) does not specify 
precise guidelines with respect to the volume of missing data, but only require the analyses to 
be “sensible”. Of paramount importance is, however, the mechanism responsible for data 
missingness and researchers are strongly encouraged to investigate this mechanism prior to 
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making definitive decisions. The main types of missingness mechanisms were conceptualised 
by Little and Rubin (20): 
a) ‘missing completely at random’ (MCAR): the probability of an observation to be missing is 
independent of both observable and unobservable variables; 
b) ‘missing at random’ (MAR): the probability of an observation to be missing is dependent 
on observable variables and independent of unobservable variables. MAR is the weakest 
assumption based on which valid inferences can be produced using only the observed data 
and without having any other information regarding the missingness mechanism; and 
c) ‘missing not at random’ (MNAR): the probability of an observation to be missing depends 
on both observable and unobservable variables. Valid inferences can only be obtained by 
considering a joint model of the observed data and the missingness mechanism.  
 The nature of the missingness mechanism can never be known with certainty, 
although a distinction can be made between MCAR and MAR in the sense that close 
inspection of the data can rule out MCAR. It is always the case that a number of assumptions 
have to be made before proceeding to handling missing data. Two types of approaches to 
missing data can be distinguished: traditional (ad hoc) methods and likelihood methods. Ad 
hoc methods (listwise deletion, casewise deletion, mean marginal imputation, last value 
carried forward) make strong assumptions about the data and have been strongly critiqued 
(17, 21).  
 An attractive modern method is multiple imputation (MI) (22). The underlying 
principle is the following: instead of imputing a single value for a missing observation, MI 
imputes m>1 values, generating m alternative complete datasets which can be analysed using 
standard statistical techniques. MI operates under the MAR assumption and the imputed 
values for each observation are conditional on the joint distribution of the missing variables 
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and other observed variables for that observation. A multivariate normal distribution is 
assumed, which raises questions about the method’s suitability for non-normally distributed 
data. However, Graham and Schafer (23) showed that MI performs well even for extremely 
non-normal variables. The estimates of the m analyses are ultimately combined using a set of 
rules formulated by Rubin (22). Although Rubin demonstrated that more than five 
imputations bring negligible gains in efficiency, more recent accounts recommend a larger 
number of imputations (24, 25). 
 Multiple imputation using chained equations (MICE) is a method for generating 
imputed values based on imputation model constructed for each variable with missing data 
(26). The underlying principle is that, following an initial filling of all missing values using 
random sampling with replacement from the observed values, each variable in turn is 
regressed against all the others and the missing values are replaced with values drawn 
randomly from its posterior predictive distribution. The process is repeated for a number of k 
cycles (usually 10-20) and m datasets are produced, similar to MI. The estimates are then 
combined using Rubin’s rules. The important strength of MICE over MI is that it can easily 
handle variables with different distributions. Moreover, each variable can have its own 
imputation model, as opposed to MI which did not distinguish between independent and 
dependent variables. Nevertheless, it does not yet have firm theoretical grounds and is 
sensitive to model (mis)specification.     
Adequate RCT reporting is of utmost importance for assessing the value of the 
findings and for planning future research. The CONSORT (CONsolidated Standards of 
Reporting Trials) Statement aims to provide a framework for the appropriate reporting of 
RCT methods and results (27). CONSORT extensions are also available for various types of 
designs (28, 29) and outcomes (30). 
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1.2. Economic evaluation 
 Drummond et al. (31)  defined economic evaluation as “the comparative analysis of 
alternative courses of action in terms of both their costs and consequences” (p. 9). Given the 
resource scarcity in the health care sector, economic evaluations can inform choices between 
existing alternatives by making explicit the criteria underlying the decision. There are two 
principal economic paradigms from which the evaluation can be conducted: welfarist and 
extra-welfarist (32). The differences between these two perspectives are substantive in what 
concerns the relevant outcomes, the sources of outcome valuation, the weighting of the 
outcomes and the extent to which interpersonal comparisons are possible. Welfarism assumes 
that individuals make rational choices by selecting the options which maximise their welfare; 
individuals are the best judges of their welfare; utility derives from outcomes or behaviours 
rather than from processes; and utility information is the only argument used to assess the 
merit of a given state. Central to the welfarist paradigm is the concept of ‘utility’, which has 
received a range of interpretations across history (33), but can be understood as an 
individual’s preference ordering over bundles of goods or states of the world (32). By 
contrast, extra-welfarism allows the use of other relevant outcomes than utility, does not 
consider individuals as the only source of valuation, explicitly allows outcome weighting 
based on non-preference principles and explicitly allows interpersonal outcome comparisons 
(34, 35). Although extra-welfarism allows the incorporation of relevant outcomes other than 
utility, such as equity, its practical applications have been criticised for focusing solely on 
health (36). 
Several techniques of economic evaluation can be distinguished based on their 
approach to the valuation of consequences of health care interventions. The main types of 
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economic evaluation are cost-benefit analysis (CBA), cost-effectiveness analysis (CEA) and 
cost-utility analysis (CUA) (31). CBA (37) is rooted in the welfare economic theory and 
evaluates the net social benefit of an intervention by comparing the costs and benefits of a 
given alternative, both valued in monetary units. An intervention is judged to be worth 
implementing if the net social benefit is positive i.e. net benefits outweigh net costs. 
Economists noted the methodological and ethical difficulties associated with assigning 
monetary values to health outcomes, a key step in CBA (38).  
Both CEA and CUA assess a given alternative’s value by comparing it to an external 
standard and assume that the decision makers’ objective is to maximise health outcomes, but 
they do not measure benefits using the same unit: CEA uses natural units (e.g. cases averted, 
deaths), while CUA employs HRQoL measures. The two methods are similar in both 
application and interpretation, to the point where no formal distinction is made between them: 
for instance, in the US literature the term ‘cost-effectiveness analysis’ comprises both CEA 
and CUA, and increasingly so in the UK as well (39). Although CEA/CUA avoid a direct 
monetary valuation of health outcomes, in contrast to CBA, an external criterion of value is 
necessary to inform decision-making. An example of such a criterion is an accepted 
willingness-to-pay (WTP) threshold value (40). 
It can be argued that CBA has a broader scope than CUA/CEA. First, by assigning 
monetary values to outcomes, CBA is suitable to compare programmes across different 
sectors of the economy, while CEA and CUA are restricted to comparing interventions which 
produce similar outcomes. Second, CUA/CEA often focus solely on health benefits and thus 
mainly address questions of production efficiency, while CBA can easily inform allocative 
efficiency decisions because it assigns relative values to both health and non-health outcomes. 
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Third, CEA and CUA are less equipped to capture health externalities because they usually 
focus on health outcomes, while CBA can quantify a wider range of effects. 
 Nevertheless, CUA is particularly useful because it allows comparability between 
largely different programmes and provides a means to integrate patients’ preferences in the 
decision process (31). The costing exercise involves accounting for the monetary value of the 
resources associated with the programme’s implementation. The choice of the considered 
costs is a delicate issue and a balance must be struck among several factors e.g. the 
perspective of the evaluation, the costs’ relevance and the resources available for the 
evaluation itself.  
 Benefits in CUA are expressed in quality-adjusted life years (QALYs), a measure 
which combines morbidity and mortality such that it reflects an intervention’s implications on 
both quality and quantity of life (41, 42). QALYs are generated by weighting the life 
expectancy with health utility weights informed by patients’ preferences. Utility weights are 
anchored on death and perfect health and are measured on an interval scale – usually 0 to 1, 
where 0 corresponds to death and 1 to perfect health, although negative values are possible to 
indicate health states perceived as worse than death. A multitude of instruments are available 
for assessing the preference-based utility weights, both general (e.g. EQ-5D (43), SF-6D (44), 
HUI2 (45)) and disease specific (e.g. EORTC QLQ-C30 for cancer patients (46)).  
 The outputs produced by CUA are the costs and QALYs for each of the alternatives 
under scrutiny. In practice, one of the alternatives is usually the current standard of care, be it 
an intervention or simply no intervention. The metric of interest for decision-making purposes 
in CUA and CEA is the incremental cost-effectiveness ratio (ICER), defined as: 
ICER = =  (1.1), 
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where:  
Ci, Ei – costs (monetary units) and effects (QALYs) of the intervention under study; and 
C0, E0 – costs (monetary units) and effects (QALYs) of the comparator (standard care). 
 The ICER represents the additional spending on a medical intervention compared to 
another in order to gain one extra QALY. There are instances where the value of the ICER 
does not communicate much about the relative implications of the two alternatives – for 
example, the ICER is positive both when the intervention is less costly and less effective, but 
also more costly and more effective than the comparator. The cost-effectiveness plane (47) is 
a graphic tool that clarifies such instances, allowing the straightforward visualisation of the 
incremental costs and effects (Figure 1.1). 
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Figure 1.1 The cost-effectiveness plane 
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The decision rule based on the ICER is that an intervention can be judged to be cost-
effective if the ICER is below a set WTP threshold favoured by the decision maker. The UK 
decision body, the National Institute for Health and Clinical Excellence (NICE), currently 
favours interventions with an ICER between £20,000 and £30,000 per additional QALY (39), 
although the legitimacy of this interval is controversial (48, 49).   
 The ICER is constructed as a ratio of two differences between means (equation 1.1). 
While the differences can be assumed to asymptotically normal (if the sample size is large 
enough via the central limit theorem or if costs and effects are normally distributed), the 
sampling distribution of the ratio itself cannot be known. This raises serious difficulties in 
specifying confidence intervals around the ICER. Two types of methods have been suggested: 
a) parametric approaches, including the confidence box method, Fieller’s theorem and Taylor 
series (50); and b) bootstrapping approaches, which include several variations such as the 
normal approximation, the percentile method, the bias-corrected and accelerated method 
(BCa) and parametric bootstrapping (51). 
 The objective of bootstrapping (52) is to make inferences about a population 
parameter based on a sample drawn from that population. The underpinning principle is that, 
given a sample of size n, repeatedly sampling with replacement from this sample and 
calculating the statistic of interest for each of the resulting samples of size n will construct an 
empirical distribution of the sampling distribution of the statistic of interest. While the process 
of obtaining the random samples and the statistic for each of them is straightforward, various 
methods of constructing the confidence intervals based on the empirical sampling distribution 
have been proposed. The normal approximation employs the traditional formulation of the 
variance and assumes that the sampling distribution of the statistic is normal. The percentile 
method involves ranking the statistics obtained from the replicated samples and selecting the 
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ith percentile values and the bounds of the confidence interval. The bias corrected and 
accelerated method (BCa) is a modification of the percentile method which corrects for the 
estimator bias i.e. unequal proportion of bootstrap replicates above and below the sample 
statistic, and for the skew of the sampling distribution (53). The Fieller’s theorem approach 
and BCa have been shown to outperform other methods (54).  
Due to the statistical difficulties in expressing uncertainty around the ICER using 
parametric methods, after rearranging equation 1.1 the incremental net benefit (INB) was 
proposed as an alternative statistic of interest for cost-effectiveness (55): 
INMB = ∆E * λ - ∆C (1.2) 
INHB = ∆E - ∆C/λ (1.3), 
where: 
INMB – incremental net monetary benefit; 
INHB – incremental net health benefit; 
∆E – incremental effect; 
∆C – incremental cost; 
λ – willingness-to-pay threshold (£/QALY). 
 The net benefit (NB) framework has several advantages compared to incremental cost-
effectiveness ratios. First, its interpretation is unambiguous and does not require information 
about the joint distribution of (ΔC; ΔE) pairs: positive values favour the intervention under 
scrutiny, while negative values do not. Second, net benefits are generally asymptotically 
normal, which allows obtaining unbiased estimates of variance. 
 Cost-effectiveness acceptability curves (56) describe the probability of an intervention 
to be cost-effective at a given willingness-to-pay threshold λ. The rules can be formally 
different depending on the chosen cost-effectiveness estimator: for the ICER, the CEAC is 
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specified by the probability that the ICER<λ, if ΔE>0 and ICER>λ, if ΔE<0. In terms of the 
net benefit framework (55), the CEAC is given by the probability of the NB(λ)>0, where 
NB(λ) is the net benefit estimator. A thorough account of the definition, calculation and 
interpretation of CEACs is given by Lӧthgren and Zethraeus (57) and Fenwick et al. (58).  
 It must be noted that the CEAC only refers to a single intervention at a time. When 
multiple alternatives are compared simultaneously, the cost-effectiveness acceptability 
frontier (CEAF) extends the concept of CEAC by depicting the probability of the optimal 
option at each λ to be cost-effective. This may or may not be the alternative with the highest 
probability of being cost-effective, as indicated by the CEAC. 
 Although CEACs bring a more straightforward interpretation to the uncertainty around 
the cost-effectiveness estimator compared, for example, with confidence intervals around the 
ICER, they have been criticised on a number of grounds. Koerkamp et al. (59) pointed out 
that CEACs are insensitive to changes in the joint distribution of costs and effects differences, 
thereby masking potentially significant differences or exaggerating existing differences. 
Barton et al. (60) made a compelling case for not relying solely on CEACs when 
recommending the cost-effective option from a panel of interventions and advocate the 
mandatory representation of the CEAF as well. Jakubczyk and Kaminski (61) demonstrated 
that the properties of the CEAC are strongly influenced by factors such as the skewness of the 
NB estimator and correlation between ΔC and ΔE, and advise their use only for illustration 
purposes. 
 There are two principal types of economic evaluation: trial-based and model-based 
evaluations. The former entails collecting individual patient data on costs and outcomes 
alongside a RCT which compares two or more alternatives (62-64). This is often done using 
case report forms which record resource utilisation and outcome information (such as 
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HRQoL) for every enrolled patient. The quantities of interest for economic evaluation are the 
differences in mean cost and effect between the trial arms. Cost analysis may be particularly 
challenging because of inherent right skewness of cost data, potential difficulties in 
identifying the unit costs (as opposed to prices of health care provider charges) and censoring 
(missing data due to inappropriate data collection processes, patient drop-out or other reasons) 
(65). 
Model-based economic evaluations predict under uncertainty the costs and outcomes 
associated with each alternative by means of a decision-analytic model, which "uses 
mathematical relationships to define a series of possible consequences that would flow from a 
set of alternative options being evaluated” (66, p.6). The key conceptual elements of a 
decision model are its structure and data inputs. Choosing the appropriate model type and 
associated structure are of utmost importance; to that end, categorisations and decision charts 
have been proposed to guide researchers (67, 68). Probabilities and expected values are the 
fundamental types of data inputs. Probabilities can be thought of as the likelihood of each 
possible consequence to occur; in a clinical setting they reflect the fact that clinically identical 
patients who are subject to the same intervention may respond differently. In relation to CUA, 
expected values concern the costs and outcomes (QALYs) associated with each alternative: 
these are calculated as the sum of costs and outcomes, respectively, of each possible 
consequence, weighted by the probability of each consequence. 
Trial-based economic evaluations are now common, but several important 
shortcomings have been highlighted: evaluating a limited number of relevant interventions, 
providing information on restricted patient sub-groups and for a limited time-horizon (69). As 
such, the optimal approach to generating cost-effectiveness evidence entails multiple cycles of 
decision modelling and primary data analyses. 
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1.3. Generalisability of trials and trial-based economic evaluations 
 The generalisability of trial findings is a legitimate concern, both for clinical and 
economic outcomes. This section provides an overview of generalisability issues for RCTs, 
followed by an in-depth look at the generalisability of trial-based economic evaluations. A 
number of gaps in the current body of knowledge are identified and discussed. The section is 
informed by a pragmatic search of the relevant literature. 
  
1.3.1. Clinical trials and external validity 
RCTs have been considered the gold standard research design because of their 
potential to offer unbiased estimates of interventions' effectiveness. The strength of the RCT 
rests on three fundamental features: comparability of effects (through a placebo or control 
arm); comparability of populations in trial arms (through randomisation); and comparability 
of information (through blinding) (70). The extent to which a trial’s results can be trusted is 
reflected in the study’s quality. Quality itself is a complex, multidimensional concept which 
integrates elements of design, conduct, statistical analysis and reporting (71, 72). A definition 
of trial quality was proposed by Verhagen et al. (72) as a result of their Delphi study (p.1239): 
“Quality is a set of parameters in the design and conduct of a study that reflects the validity 
of the outcome, related to the external and internal validity and the statistical model used”. 
Validity is, thus, recognised as an important and conceptually rich dimension of quality. 
Moreover, validity is a fundamental pre-requisite for ethical and valuable research (73). A 
further distinction between internal and external validity was proposed by Campbell in 1957 
(74); although it originated in psychology, this dichotomisation was adopted in social sciences 
and experimental design in general.  
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1.3.1.1 Internal validity 
 Internal validity refers to whether the results of the study are correct for the original 
study population. A study has internal validity when there are no suspicions that the 
differences in outcomes between the patient groups are due to other factors apart from chance 
and the intervention(s) that were administered. By contrast, external validity refers to whether 
the results of the study are applicable to other circumstances, such as a given patient 
population, a particular health care organisation or a geographical setting. External validity as 
a concept is meaningless without specifying the descriptive parameters of the setting where 
results are to be applied. Furthermore, internal validity is a pre-requisite of external validity, 
as misleading results cannot form a reliable basis for any further generalisation. This reality 
has been acknowledged by Campbell himself (p.310): “If one is in a situation where either 
internal validity or representativeness must be sacrificed, which should it be? The answer is 
clear. Internal validity is the prior and indispensable consideration” (74). 
 Assessing internal validity involves identifying the extent to which a study is 
vulnerable to a range of sources of bias. Bias is understood here as a systematic error in 
results or inferences. A formal definition of bias has been proposed by Murphy (p.345): “any 
process at any stage of inference tending to produce results that differ systematically from the 
true values” (75). Detailed lists of possible biases that can occur in experimental research 
have been proposed, for example by Murphy (75) and Sackett  (76) in the late 1970s.  The 
Cochrane Collaboration currently distinguishes between several major types of bias in relation 
to RCTs (7): selection bias – systematic differences between the patient groups being 
compared; performance bias – differential exposure in health care provision or other treatment 
outside the intervention under scrutiny; attrition bias – systematic variation in withdrawals or 
exclusions; detection bias – systematic differences in outcome assessment; and reporting bias 
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– preferential reporting of study’s findings. It must be acknowledged that a methodological 
flaw falling into one of the categories outlined above may or may not actually introduce bias, 
therefore the term ‘risk of bias’ is more appropriate. The methods and procedures to avoid or 
minimise each of these biases have been extensively addressed in the literature (7, 71).  
 
1.3.1.2 External validity 
The conceptual content of ‘external validity’ in the context of RCTs is extremely rich, 
which explains the heterogeneity of its accounts. For example, Dekkers et al. (77) suggested a 
checklist of 11 individual items, grouped in four domains: eligibility criteria for participants 
and centres; temporal, ethnical, socio-economic and geographical aspects; patient 
characteristics going beyond eligibility criteria, such as age and comorbidities; and the 
applicability of study results. A comprehensive account was proposed by Rothwell (78), who 
indicated 39 relevant issues that should be considered and reported, grouped under six 
categories: the setting of the trial; patient selection; characteristics of randomised patients; 
differences between trial protocol and routine practice; outcome measures and follow-up; and 
adverse effects of treatment. Other checklists or frameworks for assessing external validity are 
also available (79, 80). The distinction between the study population and the population from 
which it has been sampled and is thought to represent (the target population) has often been 
the focus of generalisability research in trials (81). The example checklists cited above, 
however, show that there is more to context than the patient population: for example, the type 
of health care setting and the nature of clinical protocols are also important.  
Enhancing the external validity of trials involves creating an experimental 
environment which is as close as possible to real-life settings i.e. pragmatic trials (82), for 
example by relaxing the inclusion/exclusion criteria, selecting a representative sample of 
Chapter 1. Introduction 
21 
 
clinicians and centres, devising protocols that are in accordance with clinical practice and 
evaluating relevant and meaningful outcomes. It must be acknowledged that it is challenging 
for a given RCT to produce results that are widely generalisable. Nevertheless, honest, 
transparent and detailed reporting of the trial’s conduct would allow the readers to make their 
own opinion as to the findings’ generalisability.        
 
1.3.1.3 Enhancing the external validity of RCTs 
The RCT as a research design is particularly valued in the scientific community for 
high internal validity, in other words for the potential to offer unbiased results.  However, 
trials’ potential for external validity has often been questioned (78, 83-85). Indeed, RCTs 
feature several strong limitations: they usually evaluate specific interventions one at a time, 
thus leaving potentially important questions unanswered; they focus on optimizing the 
conditions for obtaining a positive finding by minimising heterogeneity, for example by 
adhering to strict clinical protocols or over-selecting patients; and are bounded by logistical, 
financial and ethical constraints in choosing the questions they can answer (86). These 
limitations, especially the drive for positive findings, hinder the applicability of trial findings 
to real world practice. A wealth of empirical evidence supports this claim. Studies across a 
wide range of therapeutic areas have suggested that trial participants are often 
unrepresentative of the target population (87-94), which can introduce bias in the measures of 
effect (95). For example, Steg et al. reported that eligible patients with acute myocardial 
infarction enrolled in RCTs had lower baseline risk and lower mortality than non-enrolled 
ones (96).  
The choice of participating centres can also influence the generalisability of trial 
results (78), especially in non-pharmacologic trials, as outcomes may be affected by factors 
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like hospital volume (97) and practitioners' expertise (98). For example, the systematic review 
of Halm et al. (97) found that patients treated in higher volume hospitals have better clinical 
outcomes across a wide range of therapeutic areas. In surgical RCTs, restricting participation 
to centres where surgeons have a proven record of success may lead to results which depart 
greatly from real-life estimates (78). Practice guidelines can also differ from one hospital to 
another. For instance, negative pressure wound therapy (NPWT) is a technology currently 
used in the UK for the open abdomen at the discretion of UK National Health Service (NHS) 
trusts in the absence of a nationwide recommendation towards its implementation  (99). 
Limited evidence suggests that RCTs are predominantly carried out in university and teaching 
centres, while non-teaching centres are somewhat better represented in non-randomised 
studies (100). The influence of centre-specific characteristics on treatment outcomes has been 
equally recognized in observational research (101).  
Two types of strategies are available for enhancing the generalisability of clinical 
trials. One of them is, obviously, conducting RCTs which emulate closely ‘real’ clinical 
practice. This approach is based on a more than 40-year old conceptual distinction between 
explanatory and pragmatic clinical trials (102). Explanatory trials are usually conducted in 
tightly controlled, ‘laboratory’ conditions, with the aim of answering a scientific question. On 
the other hand, pragmatic trials would be run in ‘normal’ conditions in order to answer an 
applicability question, such as a policy decision. In accordance with the latter approach, 
pragmatic or practical clinical trial designs have been proposed (103-105) so as to maximise 
the value of trial findings to decision makers. The distinction between explanatory and 
pragmatic trial designs has been commented in more detail by MacPherson (106) and 
Treweek and Zwarenstein (82). Recommendations include comparing clinically relevant 
alternatives (placebo-controlled trials often have little relevance when alternative 
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interventions are already available), enrolling a diverse study population, recruiting from a 
variety of settings and measuring a broad range of relevant outcomes. The issue of relevant 
outcomes is particularly important in at least two aspects: first, outcomes beyond health must 
also be considered, such as economic and quality of life consequences, as more and more 
decision makers include such considerations in their decisions (3). Second, generalisability is 
also linked to between-study comparability, therefore the need for trials to report a core, 
common outcome set for evidence synthesis purposes is more stringent than ever (4, 107).  
Pragmatic clinical trials may appear to solve most of the problems associated with 
external validity, but Karanicolas et al. (108) pointed out that even pragmatism can be 
evaluated from at least three relevant standpoints: the policymaker, the clinician and the 
patient. The corollary is that there is no ‘one size fits all’ pragmatic approach, which can only 
underline even more RCT’s major limitation of not being able to answer multiple questions at 
once. The PRECIS tool, developed by Thorpe et al. (109), introduced a summary measure of 
the pragmatic-explanatory continuum in order to assist both researchers who design trials and 
those who assess trials. While noting that ‘pragmatism’ has become more and more 
fashionable in research during the past two decades, Kent and Kitsios (110) warned against 
over-reliance on the results of pragmatic trials by pointing out that generalising the findings of 
an over-inclusive experiment may be equally as (or even more) flawed as doing the same with 
a severely restrictive one. 
The second strategy involves stimulating the complete and transparent reporting of 
trial conduct and results in order to allow readers to make their own judgement on the general 
quality and, specifically in this case, the external validity of trial results. The CONSORT 
statement (27) provides a minimum set of recommendations for trialists in that respect. 
Initially developed for parallel group RCTs, further CONSORT extensions have become 
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available, for example for pragmatic trials (29) and PRO data collected alongside RCTs (30). 
Since the introduction of the CONSORT statement in 1994 (111), cumulative evidence has 
suggested that RCT reporting has improved, but remains suboptimal (112-115).  
Generalisability is a stand-alone item in the CONSORT 2010 checklist, where it is 
included as ‘Generalisability (external validity) of trial findings’ and invites discussion on 
how the trial’s results can be interpreted in light of the participants, setting, interventions and 
outcomes. The CONSORT extension for pragmatic trials (29) is more specific in guiding the 
discussion of contextual effects, as it requires to “describe key aspects of the setting which 
determined the trial results. Discuss possible differences in other settings where clinical 
traditions, health service organisation, staffing, or resources may vary from those of the trial” 
(p.6). Similarly, the CONSORT extension to RCTs of non-pharmacologic treatments (116)  
requires discussing generalisability in relation to the care providers and centres involved in 
the trial: “Generalizability (external validity) of the trial findings according to the 
intervention, comparators, patients, and care providers and centers involved in the trial” 
(p.W-63). The CONSORT extension to patient-reported outcomes (30) also refers to 
participating centres in the explanation of the generalisability item (p.820): “In addition to the 
design and conduct issues relevant to the generalizability of the RCT overall, several PRO–
specific limitations (including both patient- and center-level characteristics) may affect 
generalizability of the PRO results”. 
However, it is often difficult to ascertain the generalisability of RCT results since 
reporting external validity in trial publications remains poor (117-119). One potential reason 
for this state of affairs is the focus of most guidelines and textbooks on internal rather than 
external validity (120, 121). For instance, the CONSORT Statement has only one item 
explicitly addressing generalisability out of 25 in total. This focus on internal validity has also 
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been recognised by journal editors and the emerging picture is that more effort needs to go 
into improving external validity (122). In addition, the lack of specific information in trial 
reports has been identified as restricting applicability and interpretation (104, 123). 
Transparency is key not only to make an informed qualitative judgement on the transferability 
of trial findings to other settings, but analytical methods are now available to allow a 
quantitative adjustment of trial results to an appropriately specified target population (124). 
 
1.3.2. Generalisability of trial-based economic evaluations 
Trials consume enormous amounts of resources and have become increasingly 
expensive to run (125, 126). Reasons for this include: longer follow-up periods, increasing 
regulatory requirements and the need for ever larger sample sizes as the therapeutic benefit of 
new technologies are more and more marginal. Furthermore, the ethics of reproducing 
research is at least questionable. Under these auspices, the pressure to maximise the output of 
every research endeavour has increased continually and RCTs often recruit across 
jurisdictions (in this context, ‘jurisdiction’ refers to an administrative space where a medical 
intervention will be implemented e.g. a health care system, a local authority). For example, 
multinational trials recruit internationally in order to achieve the required sample size, to 
demonstrate that the clinical findings can be extrapolated to other populations or, in the case 
of industry-driven studies, to obtain the data required by local regulatory authorities for 
market authorisation purposes (127).  
Ensuring the generalisability of RCT results may be particularly challenging for 
economic outcomes, which inform health policy decisions. This is because the relative 
clinical effect of an intervention has been historically assumed constant across settings, albeit 
not without challenges (78, 128, 129); however, this assumption may not hold for economic 
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outcomes. Therefore economic evaluation results should not routinely be assumed to be 
completely transferable between jurisdictions.  
  In one of the earliest pieces of research on this topic, Drummond et al. (130) compared 
a decision model between four countries while allowing for slight adjustments of the model as 
well as for local input data. Their conclusion was that cost-effectiveness results were 
significantly different between countries; and the main drivers of variability were the cost 
variations and the patterns of care. O’Brien (131)  further strengthened this case by 
identifying six generic ‘threats to transferability’ in economic evaluation studies: demography 
and epidemiology of disease; clinical practice and conventions; incentives and regulations for 
health care providers; relative price levels; consumer preferences; and the opportunity cost of 
resources. These issues are equally applicable to decision modelling and trial-based economic 
evaluations and, furthermore, to “all levels of geographical grouping” (p. S39). As a result, it 
is perfectly possible for the same medical technology to be cost-effective in one setting and 
cost-ineffective in another. Such a reality is likely to be of utmost concern for decision 
makers, who are interested in knowing whether results collected in other jurisdictions can 
inform decisions in their own. The focus group study of Hoffmann et al. (6) pointed out, 
indeed, that the generalisability of economic evaluation findings are of great interest UK 
policy makers. The major emergent issue was that economic evaluations too often ask 
narrowly focused questions which do not allow the portability of their results to other 
contexts.  
 Before going any further, a terminology note should be made. 'Generalisability', 
'transferability', 'portability' have all been used to describe the extent to which economic 
evaluation results are applicable from one geographical setting to another. Boulenger et al. 
(132) suggested that 'transferability' may be a broader concept than 'generalisability' as it 
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encapsulates both the intrinsic value of the results and the methods available to assess their 
applicability in various settings. Barbieri et al. (p.1028) defined generalisability and 
transferability as follows: "Studies may be considered generalisable if they can be applied to 
a range of jurisdictions without any adjustment needed for interpretation. In addition, some 
studies may be transferable if they can be adapted to apply to other settings" (133). This 
interpretation has been endorsed by the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) Good Research Practice Task Force (134). No formal 
distinction will be made between these terms throughout the thesis for simplicity. Two 
principal research directions have been intensively explored in the generalisability literature in 
relation to economic evaluations: the factors which influence transferability; and the methods 
that address the transferability of cost-effectiveness results. 
 
1.3.2.1 Factors influencing transferability 
 The factors linked with transferability of economic evaluations received close scrutiny 
in the literature and this sub-section gives an overview of the nature and content of these 
factors by drawing on several comprehensive papers which investigated them in detail. A 
summary of the most relevant factors, as identified in the literature, in presented in Table 7.1. 
Welte et al. (135) published in 2004 a systematic review of 44 studies which aimed to identify 
potential transferability factors i.e. any parameter which may influence economic evaluation 
results and may differ between countries. They identified 14 factors, grouped under three 
broad categories: methodological characteristics of the economic evaluation; health care 
system characteristics; and patient characteristics. In addition, the authors also made a 
judgement on the effort required to check for each factor the correspondence between the 
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study and the decision country; eight out of 14 factors were rated as requiring ‘medium-very 
high’ such effort. 
 
Table 1.1 Factors which influence the generalisability of economic evaluation results 
 
Study Factors 
  
Welte et al.(135) Methodological characteristics: Perspective; Discount rate; Medical cost 
approach; Productivity cost approach. 
Health care system characteristics: Absolute and relative prices in health care; 
Practice variation; Technology availability. 
Population characteristics: Disease incidence/prevalence; Case-mix; Life 
expectancy; Health-status preference; Acceptance, compliance, incentives to 
patients; Productivity and work-loss time; Disease spread. 
 
Sculpher et 
al.(127) 
Patient factors: demographics; epidemiology; case-mix; baseline risk; 
compliance. 
Clinician factors: skill/experience; practice style; incentives. 
Health care system factors: absolute/relative prices; exchange rates; clinical 
practice; resource utilisation; historical differences. 
Wider socio-economic factors: cultural attitudes; health-state preferences. 
 
Goeree et al.(136) Patient characteristics: demographics, education, socio-economic status; risk 
factors, medical history, genetic factors; lifestyle, environmental factors; 
mortality rates, life expectancy; attitudes toward treatment, culture, religion, 
hygiene, nutrition; compliance and adherence rates, ethical standards; population 
values (utilities); population density, immigration, emigration, travelling 
patterns; income, employment rates, productivity, work loss time, friction time; 
type of insurance coverage, user fees, co-payments, deductibles; incentives for 
patients. 
Disease characteristics: epidemiology; disease severity, case mix; disease 
interaction, co-morbidity, concurrent medications; mortality due to disease. 
Provider characteristics: clinical practice, conventions, guidelines, norms; 
experience, education, training, skills, learning curve position; quality of care 
provided; method of remuneration (supplier-induced demand); patient 
identification; cultural attitudes; incentives for providers, liability. 
Health care system characteristics: absolute or relative prices; available 
resources, programs, services; organization of delivery system, structure, level of 
competition; level of technology advancement, innovation and availability; 
available treatment options; capacity utilization, economies of scale, technical 
efficiency; input mix, specialization of labor, joint production; access to 
programs and services, gatekeepers, historical differences; waiting lists, referral 
patterns; regulatory and organizational infrastructure, licensing of products; 
availability of generics or substitutes; market forms of suppliers, payment of 
suppliers, supplier incentives; incentives for institutions. 
Methodological characteristics: costing methodology, estimation procedures; 
study perspective; study factors; timing of the economic evaluation; clinical 
endpoints/outcome measures; discount rates; exchange rates, purchasing power 
parities; opportunity cost; affordability. 
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In a similar but more targeted exercise published in 2005, Barbieri et al. (137) 
systematically reviewed European-wide cross-country comparisons of economic evaluations 
(both model- and trial-based) of pharmaceuticals in order to identify the factors which account 
for variations of cost-effectiveness results between countries. They included 46 inter-country 
comparisons and concluded that differences were not likely to be systematic in the sense there 
was no stable enough pattern to infer that if a given intervention was found cost-effective in 
country A it would automatically be, say, more cost-effective in country B. The principal 
finding of the study was that resource use (when it was allowed to vary1) and the local 
willingness to pay threshold were the main determinants of variation. 
Sculpher et al. (127) published in 2004 a comprehensive account of the determinants 
of generalisability of economic evaluations in health care. They undertook a series of 
systematic reviews to identify, on one hand, the factors associated with variability in 
economic evaluations and, on the other hand, the methods used to assess variability and 
enhance generalisability. Their review was very broad as it referred to both trial-based and 
model-based economic evaluations and, furthermore, to variability across locations and time. 
For their systematic review on factors influencing generalisability, the authors reviewed 36 
conceptual papers and identified 26 factors affecting the geographical variability of economic 
evaluation results, grouped under four categories: patient factors; clinician factors; health care 
system factors; and wider socio-economic factors. The authors highlighted that, at the time, 
generalisability appeared to be a particularly relevant issue in a multinational context as most 
of the included studies investigated cross-national comparisons, with only two studies (from 
the UK and US, respectively) looking at within-country variations.  
                                                 
1 Specifically in trial-based economic evaluations where the analyst does not decide to pool resource use data 
across countries. The authors’ opinion was that resource use should not be pooled whenever possible.  
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In their discussion of the potential effect of local factors on cost-effectiveness results, 
Sculpher et al. referred explicitly to several issues: first, they acknowledged the difference 
between centres which usually participate in clinical trials and those who do not, further 
implying that differences in outcomes between intervention and controls may not be 
transferable across these types of settings; second, they acknowledged the 'clinician effect', 
whereby the training, experience and habits of health care professionals are an integral part of 
the intervention that is being delivered and, therefore, the resulting costs and patient 
outcomes. As a result, local variations may have obvious implications on cost-effectiveness. 
Third, and in relation to the previous issue, the incentives that health care staff have across 
locations, such as payment and reimbursement schemes, also impact performance. Even more 
importantly, different centres are exposed to different population profiles (reflected by 
demographic characteristics such as age, sex and ethnicity), epidemiological profiles 
(reflected by different disease burdens) and, subsequently, to differences in patient case-mix. 
The latter are also correlated with institutional factors, as well - for example, teaching 
hospitals tend to see the more complicated and thus more resource intensive cases, but also 
offer better care than nonteaching hospitals (138).  
Goeree et al. (139) published in 2007 the results of a systematic review where they 
looked at 102 papers (conceptual, empirical and review articles) and derived no less than 77 
factors affecting transferability, grouped into five categories inspired by the earlier review of 
Welte et al. (135), as characteristics of the: patients; diseases; providers; health care systems; 
and methodologies. It has to be acknowledged that this review had a strong focus on 
international comparisons. The provider-specific factors identified in the review were similar 
to the ones pointed out by Sculpher et al. (127): clinical practice; staff experience and skills; 
the quality of care provided; method of remuneration; cultural attitudes; and provider 
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incentives. Most importantly, the authors' final conclusive point drew attention to the 
importance of directing research efforts towards quantifying the relative impact of these 
factors when transferring economic evaluation data. 
While the demographical, epidemiological and health care system characteristics can 
often be considered fixed in a particular context, the centre-specific variability factors are 
arguably of more interest to researchers and decision makers because they are (at least at an 
intuitive level) the most readily amenable to change. The selection of centres and health care 
professionals for inclusion in trials to ensure generalisability has received relatively little 
attention (78), but the limited available evidence suggests that most evaluative research takes 
place in university hospitals, while ‘common centres’ are slightly better represented in 
observational studies (100). 
Unit costs are also expected to vary across locations and Sculpher et al. (127) pointed 
out that such variations exist not only in between-country comparisons, but also in within-
country ones. In the context of trial-based economic evaluations, the issue thus becomes the 
suitability of using average unit costs across all the centres in the trial: in the absence of unit 
costs missing completely at random (MCAR), the average unit cost will most likely 
misrepresent the centre-specific cost (140, 141). This is a legitimate concern: a systematic 
review of economic evaluations conducted alongside trials funded by the UK Health 
Technology Assessment Programme revealed that only 52 of 95 reviewed studies used unit 
costs that were sourced locally (142). Of course, it may be impractical or even impossible to 
collect unit costs from all centres involved in a study, so a number of alternative solutions 
have been suggested: for example, Goeree et al. (23) reported a framework allowing the 
selection of the number of hospitals (one or more) from which unit costs should be used to 
perform economic evaluation calculations across multicentre economic evaluations; and 
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Grieve et al. (140) used multiple imputation to account for missing centre-specific unit cost 
data. However, in the UK the use of nationally averaged (‘off the shelf’) unit costs is accepted 
for the reference case of an economic evaluation (39). 
Another relevant local factor relates to the quality of care provided. The differences in 
quality of care between providers have been documented thoroughly at multiple levels. For 
example, extensive literature reviews have shown that larger health care providers (both 
hospitals and physicians) seem to be associated with better outcomes (97) and that teaching 
hospitals are generally associated with superior health outcomes when compared with non-
teaching hospitals (138, 143). In the case of the UK, there is evidence of variation in quality 
of care across settings both in primary care (144) and hospital care (145).   
The empirical evidence on the variations of patient preferences across settings is more 
controversial. This has relevance for the results of cost-utility analyses i.e. cost per QALY: 
theoretically, if patients in different settings value the same health states differently, the 
results of an economic evaluation will subsequently vary irrespective of other contextual 
factors. For example, several national tariffs as well as a European tariff are available for the 
EQ-5D instrument (146) and there is evidence that valuations differ substantially between 
countries, mostly due to methodological differences in elicitation and cultural attitudes (147). 
However, the evidence on whether such variations affect the economic evaluation results is 
scarce and inconclusive: several studies have shown that using different tariffs to calculate 
QALYs has little impact on the overall cost-effectiveness findings (148, 149), while others 
have suggested that these differences may be relevant (150).  
In summary, the current knowledge on factors influencing the generalisability of 
economic evaluations depicts a complex picture. First, while a plethora of potentially relevant 
factors have been proposed, accounting for the majority of them may be challenging in 
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practice. Second, not all of these factors can be measured straightforwardly e.g. the impact of 
clinician incentives. Third, the impact of these factors on economic evaluation results is 
difficult to measure. Finally, even if the impact can be measured, empirical results on the 
magnitude and direction of these effects have not always been consistent. Some factors are 
less prone to such difficulties than others, such as the cost of the intervention itself, although 
even in this case the cost assumed in a research environment can be different from the one 
that the manufacturer (e.g. the drug company) may eventually agree with local decision 
makers.    
 
 
1.3.2.2 Methods addressing transferability 
 Two broad categories of methods have been suggested to aid decision makers in 
addressing the transferability of economic evaluation results. The first category refers to 
methods which aim to assess the extent to which the results of economic evaluation studies as 
a whole can be transferred across settings. The second category includes methods that address 
transferability involves adjusting the results of an economic evaluation to obtain local cost-
effectiveness estimates. 
 
Methods which assess the transferability of economic evaluations 
Such methods primarily target decision makers and aim to assist them in evaluating 
the extent to which the results of an economic evaluation conducted elsewhere are applicable 
in their own setting. A recent synthesis of these methods was given by Goeree et al. (139), 
whose systematic review of transferability approaches identified seven strategies: five aimed 
to offer a qualitative verdict on transferability and two proposed indices to quantify it. The 
main characteristics of the identified approaches are presented in Table 7.2.
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Table 1.2 Approaches towards the generalisability of economic evaluation studies 
 
Study Type of 
approach 
Preliminary criteria Generalisability factors 
 to be considered 
Comments 
     
Heyland et 
al.(151) 
Checklist Comprehensive description of competing 
alternatives; 
Sufficient evidence of clinical effectiveness or, as 
second best, clinical efficacy; 
Important costs were identified, measured and 
valuated appropriately; 
Appropriate sensitivity analysis taking into 
account all estimates of uncertainty. 
 
Patient characteristics. 
Perspective of the analysis 
Intervention 
Costing methods 
Outcomes 
Discount rate 
No clear decision rule 
Method piloted on 29 Canadian 
economic evaluations in the field of 
critical care, out of which four got 
past the first stage. Overall 
generalisability verdict interpretable. 
Späth et 
al.(152) 
Checklist The study perspective is clear 
Two or more competing options are compared 
The evaluated therapies are described 
The therapies are applicable in the local setting 
Perspective of the analysis 
Patient characteristics 
Health outcome data 
Resource utilisation 
Unit prices and discount rates 
Decision rule: a study must comply 
with all generalisability criteria in 
order to be considered transferable. 
Method piloted on 26 economic 
evaluations (in the area of breast 
cancer) for transfer to the French 
health care system. Six studies met 
the methodological criteria, but none 
was judged to be transferable mainly 
due to insufficient reporting of 
resource use and unit prices. 
 
Welte et 
al.(135) 
Transferability 
chart 
Relevant technology is relevant to local setting 
Comparator is relevant to local setting 
Study has acceptable quality 
Methodological characteristics: 
(4 factors) 
Health care system 
characteristics (3 factors) 
Population characteristics (7 
factors) 
 
Decision chart guides the reader 
towards a generalisability 
assessment 
Method piloted on three case studies 
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Study Type of 
approach 
Preliminary criteria Generalisability factors 
 to be considered 
Comments 
     
Boulenger et 
al.(132) 
Checklist and 
quantitative 
transferability 
index (0% not 
transferable to 
100% 
completely 
transferable) 
None (see Comments) Intervention and comparator 
Countries 
Perspective 
Study population (2 factors) 
Effectiveness (2 factors) 
Benefit 
Costs (5 factors) 
Sensitivity analyses 
 
Methodological quality of each 
study is assessed as an integral part 
of the evaluation, not a pre-requisite. 
Piloted on 25 economic evaluations, 
average transferability index 68.8%. 
Drummond 
et al.(134) 
Four-step 
application 
algorithm 
Relevant technology is relevant to local setting 
Comparator is relevant to local setting 
Study has acceptable quality 
Methodological characteristics: 
(4 factors) 
Health care system 
characteristics (3 factors) 
Population characteristics (7 
factors) 
 
Based on the Welte et al. criteria, the 
authors discuss practical approaches 
to adapting cost-effectiveness results 
to local settings.  
Chase et 
al.(153) 
HTA 
adaptation 
toolkit 
Relevant policy and research questions 
Translation is possible 
Technology is described 
Scope is specified 
Report is peer-reviewed 
Conflict of interest 
Report is not outdated 
Methods are accurately described 
Perspective; Preferences; 
Relative costs; Indirect costs; 
Discount rate; Technological 
context; Personnel 
characteristics; Epidemiological 
context; Factors that influence 
incidence and prevalence; 
Demographic context; Life 
expectancy; Reproduction; Pre- 
and post-intervention care; 
Integration of technology in 
health-care system; Incentives 
Very comprehensive checklist, 
aimed at HTA reports. Checklist 
generated as part of a wide European 
consensus involving 28 HTA 
agencies. Out of five domains, one 
refers to economic evaluation: 26 
questions in total, out of which 3 
refer to transferability. 
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Study Type of 
approach 
Preliminary criteria Generalisability factors 
 to be considered 
Comments 
     
Antonanzas 
et al.(154) 
Transferability 
index (0 not 
transferable to 
1 completely 
transferable) 
The relevant parameters needed to estimate cost-
effectiveness are given in the study 
The quality of the study is acceptable 
Perspective; Intervention and 
comparator; Clinical practice; 
Life expectancy; Health status 
preferences; Productivity 
measures; Epidemiology; 
Discount rate; Costs and health 
effects. 
Global Transferability Index (IT) 
results from aggregating a general 
transferability index (IT1) and a 
specific transferability index (IT2) 
Method piloted on 27 economic 
evaluations on infectious diseases 
conducted in Spain, obtaining IT in 
the range 0.534 to 0.543, denoting 
low to moderate transferability. 
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Five of the seven strategies developed checklists or guidelines to inform a qualitative 
judgement of the extent to which the results of a given study are transferable (115, 134, 135, 
151, 152). Most strategies comprised two steps: the first step was a methodological 
assessment of the study; if judged appropriate, an in-depth assessment of transferability then 
ensued. The criteria for the preliminary methodological assessment are largely similar across 
the checklists, but vary in focus: for example, Heyland et al. (151) emphasised the validity 
and quality of reporting by requiring a comprehensive description of the alternatives under 
scrutiny, evidence of effectiveness and efficacy, appropriate costing and appropriate 
sensitivity analyses. On the other hand, Welte et al. (135)  included relevance as well by 
requiring the relevant technology and comparator to be comparable to the one that will be 
used in the decision country.  
In terms of the generalisability assessment itself, a wide range of criteria were 
proposed. Heyland et al. (151) proposed a list of ten questions related to clinical and system 
generalisability. Spӓth et al. (152) suggested an assessment against five indicators, namely: 
potential users of the economic evaluation, characteristics of the patient population in the 
‘receiving’ setting, the transferability of outcome data, the transferability of resource use and 
the transferability of unit prices. Welte et al. (135) described 14 specific knock-out criteria 
and suggested a flowchart along which the user is guided either towards a clear transferability 
verdict i.e. ‘study results full/qualitatively transferable’ or towards an assessment of whether 
modelling adjustments are needed and how they can be made, followed by a similar 
transferability verdict. Drummond et al. (134) also produced a decision chart which guides the 
reader through an assessment of transferability, with or without adjustment for ‘specific 
knock-out criteria’ such as unit costs, discount rate, time horizon and perspective. Finally, 
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Chase et al.2 (153) developed a comprehensive toolkit to focus the appraisers’ efforts in 
extracting the relevant information from health technology assessments reports conducted 
elsewhere and making an informed judgement on the transferability to their own setting. The 
actual economic evaluation component of the toolkit contains 26 questions that assess 
relevance and reliability and three questions addressing transferability.  
Two of the seven strategies used the generalisability criteria published in previous 
checklists to calculate numerical indices quantifying the measure of transferability (132, 154). 
Boulenger et al. (132) proposed their own checklist of relevant criteria and used it to construct 
a study-level transferability index: a score was assigned to each item in the checklist (1 for 
‘yes’, 0.5 for ‘partially’ and 0 for ‘no/no information’) and an overall score was obtained by 
summation and then division by the maximum number of points, thereby obtaining the 
transferability index as a percentage. When they piloted it on a sample of 25 economic 
evaluations to assess the transferability of results between the UK and France, the authors 
found a mean transferability index of 66.9% for the entire checklist and 68.8% for the 
transferability sub-checklist. Antonanzas et al. (154) proposed a general index (IT1) and a 
specific index (IT2) applicable to economic evaluation studies. IT1 assesses two critical and 16 
non-critical objective factors in order to produce an index that evaluates the methodological 
quality of the economic evaluation. IT2 assesses four critical and eight non-critical subjective 
factors to evaluate the extent to which a study is transferable to a different setting. For each of 
the factors, a score of 1 is given if the factor is completely addressed, 0.5 if partially 
addressed and 0 if not addressed at all. Ultimately, IT1 and IT2 are combined in a global 
transferability index using a number of alternative formulae such that a maximum value of 1 
                                                 
2 In the Goeree et al. systematic review, this document is cited as ‘Turner et al.’ A more comprehensive 
publication of the same project and with the same authors has become available in the meantime with Chase D as 
the first author, therefore it is referred to and referenced in this Chapter as Chase et al. The content of the toolkit 
is identical in Turner et al. and Chase et al. 
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denotes a completely transferable study and 0 denotes non-transferability or insufficient 
information to make such a judgement. The authors tested their method by evaluating the 
transferability of 27 economic evaluations on infectious diseases conducted in Spain and 
found a mean value of the index in the range 0.534 to 0.543, denoting low to moderate 
transferability. 
In summary, the methods proposed to assess the transferability across settings of 
economic evaluation results share a number of fundamental characteristics: first, they are 
predicated on the necessity of evaluating internal validity as a pre-requisite for external 
validity. All the proposed methods start with a preliminary phase where the methodological 
quality of the study is assessed; if deemed acceptable, a thorough investigation of 
transferability then becomes appropriate. Second, they recognise the difficulty of accounting 
for the plethora of factors that are thought to be relevant for the generalisability of economic 
evaluation results and attempt to integrate them in meaningful tools aimed at facilitating the 
decision-making process. Through the use of flowcharts, algorithms and scores, the reader 
(e.g. decision maker) is guided towards a rational and informed decision. Finally, it is 
acknowledged that transferability is a matter of judgement. Most of the reviewed methods 
offered clear-cut verdicts (e.g. findings are transferable/not transferable) only in the extreme 
cases where either all the information is available and appropriate or essential information is 
missing. In real-life policy making, most situations are likely to be mapped somewhere 
between these two extremes, where the decision becomes much more nuanced. Two of the 
seven proposed methods (132, 154) attempted to quantify transferability using indices, but no 
meaningful cut-off points were suggested.  
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Methods which adjust economic evaluation findings 
This category includes analytical methods, aimed primarily at researchers, which can 
be used either independently or in the final stages of the previous category of methods. A 
distinction can be made between decision-modelling studies and trial-based economic 
evaluations: while adapting the results of a decision model to a local context usually involved 
populating the model with local input data (with or without adapting the model structure to 
reflect the local clinical pathways), the methods that obtain local adjustments based on 
individual patient data (i.e. from trials) are more complex. Manca et al. (155) conducted a 
comprehensive critical review of the proposed methods in the context of multinational RCTs 
and identified three broad categories of approaches. 
The first type of approach uses tests for heterogeneity to establish whether the cost, 
effectiveness and cost-effectiveness results of multinational RCTs can be pooled or should 
undergo a stratified analysis. Cook and colleagues (156) proposed this approach and, citing 
the work of Gail and Simon (157), distinguished between qualitative interactions i.e. the 
treatment effect is positive in some countries and negative in others, and quantitative 
interactions i.e. only the magnitude of the treatment effect, but not its direction, varies across 
countries. The authors used a five-country RCT as a case study, calculated country-specific 
measures of effectiveness (mortality and hospitalization rate) and cost-effectiveness 
(incremental cost-effectiveness ratio and net monetary benefit) based solely on patients 
recruited from those countries, and then applied statistical tests for qualitative (157) and 
quantitative interactions (157, 158). This approach has several limitations: heterogeneity tests 
are often underpowered (159, 160); non-statistically significant differences may mask 
different cost-effectiveness recommendations; and, most importantly, this method cannot 
offer context-specific estimates.     
Chapter 1. Introduction 
41 
 
The second type of approach aims to estimate local (country-specific) cost-
effectiveness results without accounting for the hierarchical structure of the trial data i.e. by 
using centre characteristics and a centre-level dummy as regressors. The method involves 
applying a simple regression model of costs and outcomes against a number of patient-level 
and centre-level variables, as well as a centre dummy variable; the parameter of interest is 
thus the treatment coefficient estimate. Coyle and Drummond (161) applied this approach by 
using simple ordinary least squares regression to explain cost variation using data from two 
UK RCTs investigating interventions for head and neck cancer patients. However, such a 
framework does not incorporate the correlation between costs and outcomes (162) and Willan 
et al. (163) later addressed this limitation by regressing costs and effects simultaneously using 
seemingly unrelated regressions.  
Finally, the third type of approach estimates local (country-specific) cost-effectiveness 
results while accounting for the hierarchical structure of the data. The key concept here is to 
account for the fact that individual patients are sampled within higher-level units (such as 
centres or countries) and thus individual effects are assumed to be drawn randomly from a 
distribution of higher-level effects. The advantages of using such a multilevel structure are 
clear: the correlation between individuals and countries can be modelled explicitly; and the 
analysis uses all the information in the trial as opposed to information only from a country-
specific subset. As a result, adjusted country-specific cost-effectiveness estimates can be 
obtained. The application of multilevel modelling in the cost-effectiveness analysis of 
multinational trials was introduced by Manca et al. (164), who regressed net-benefits and then 
estimated centre-specific values using a fully Bayesian procedure (Markov chain Monte Carlo 
shrinkage estimation). Of note, regression on net benefits had been proposed earlier by Hoch 
et al. (165). Further developments of the method allowed for the correlation between costs 
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and outcomes to be explicitly modelled using bivariate hierarchical modelling (166, 167), 
which is currently the method recommended by ISPOR in conducting cost-effectiveness 
analyses of multinational trials (134).  
 In summary, the third type of approach to generalisability uses regression methods to 
account for individual and centre-specific variables in order to obtain appropriately adjusted 
local cost-effectiveness estimates. The methods have varied in complexity as they 
incorporated the multi-level structure of the data and they allowed modelling the correlation 
between costs and outcomes. While bivariate hierarchical modelling is the current norm, it 
relies on the fundamental assumption of exchangeability (168, 169): given a collection of 
independent and identically distributed random variables, the property of exchangeability 
means that the joint distribution of the variables is symmetric or, equivalently, that the joint 
distribution of any permutation of the variables remains constant. In the context of multicentre 
RCT analyses, this means that prior to examining the data there is no reason to expect 
differences between the outcomes of interest at centre- (or country-) level. For example, in the 
simple case of a two-centre RCT, exchangeability holds if the probability of observing an 
incremental cost below £300 in centre A and below £500 in centre B is identical to the 
probability of observing an incremental cost below £500 in centre A and below £300 in centre 
B.  
 Obviously, systematic variations between centres/countries do exist in practice; if they 
could be completely explained by several factors (such as the health expenditure per capita for 
a given country or the proportion of qualified staff employed in each hospital), the assumption 
of exchangeability would still hold as conditional exchangeability - which is to say that 
exchangeability applies for a given set of values of the identified systemic factors. However, 
Manca et al. acknowledged that, in practice, it is rarely known whether the centres (countries) 
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included in RCTs comply with the assumption of exchangeability. They reiterated the earlier 
appeal of Drummond et al. (134) to ensure that the sample of centres (countries) included in 
the RCT satisfies this assumption and that sufficient country- and centre-specific data are 
collected to allow relevant analyses. 
 Two observations can be made in relation to the categories of methods summarised 
above. First, the majority of studies approached transferability from an international 
perspective by referring to multinational RCTs. There remains the question whether existing 
evidence is sufficient to warrant the use of generalisability techniques in refining centre-
specific economic evaluation results of multi-centre single-country RCTs.   
 Second, a series of general recommendations for further research in the area of 
generalisability have been made (127, 134, 155, 170). Despite repeated calls for addressing 
generalisability at the trial design stage, no practical guidance has been offered to date and 
most of the existing research contributions are to be employed in retrospective analyses using 
trial-wide results. The question still remains as to the role and scope for a prospective 
methodology, applicable at the trial design stage, to support generalisability. This issue will 
be addressed in the following sub-section. 
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1.3.3. Identifying knowledge gaps 
 
 Can economic evaluation estimates vary? 
 Extrapolating the results of a trial-based economic evaluation is of interest to decision 
makers, who want to know whether and the extent to which a particular intervention is cost-
effective in their jurisdiction. The first question that arises is: are there reasons to believe that 
economic evaluation results vary systematically across centres in a given jurisdiction? At 
present it is difficult to answer. There are indications in the literature that within-country 
variations in economic evaluation results are possible. For instance, in their article which 
introduced multilevel modelling in economic evaluations, Manca et al. (164) obtained centre-
specific net monetary benefits and cost-effectiveness acceptability curves for each of the 20 
centres in an English RCT and the results clearly suggested that the intervention under 
scrutiny was cost-effective in some settings and cost-ineffective in others. In another study, 
which focused on using MI methods to obtain centre-specific unit costs as opposed to average 
unit costs for a trial-based economic evaluation set in the NHS, Grieve et al. (140) found that, 
for the particular comparison under scrutiny, the intervention was more cost-effective in 
teaching hospitals than in district general hospitals. More specifically, the intervention was 
15% less likely to be cost-effective at £30,000/QALY in non-teaching hospitals compared to 
teaching hospitals when MI methods were used, and 40% less likely to be cost-effective when 
mean reference costs were used. Sculpher et al. (12) had mentioned in their review several 
studies reporting differences in cost-effectiveness estimates between centres as a result of 
differences in unit costs and practice variation. Only one of these studies was UK-based. 
Nevertheless, they suggested that obtaining centre-specific cost-effectiveness results required 
further exploration to establish their usefulness for local policy makers. Goeree et al. (136)  
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acknowledged that "the little evidence that does exist suggests that hospital cost variation 
may be as large within countries as it is between countries" (p. 565). Consequently, variables 
intrinsic to the patient (e.g. age, comorbidities), the health care inputs (e.g. qualification of 
surgeons, availability of particular medical technologies) and the health care system (e.g. 
financing streams) may explain reasonably well the source of these variations. Even in health 
care systems like the NHS where hospital reimbursement relies on largely fixed tariffs 
(Payment by Results), hospital-specific costs are expected to vary (171, 172). Furthermore, 
observational data from the English NHS suggested that between-hospital variation in cost of 
care for all obstetrics patients can be as high as 19% after controlling for patient 
characteristics (173), while between-hospital variation in length of stay for elective hip 
replacement was in the region of 5% (174). Coding inaccuracies, apportioning shared costs 
and managerial inefficiency were all indicated as potential explanations for the observed 
differences. In the light of this evidence and given that the interdependence between costs and 
outcomes is often difficult to quantify, there are reasons to expect a potentially significant 
systematic variation in cost-effectiveness between centres at the very onset of the RCT. This 
should lead to a proportionate interest from the part of local decision makers of accounting for 
as much of this variation as possible in economic analyses of interventions. 
   
 Do economic evaluation results vary? 
 Nevertheless, how can it be ascertained that economic evaluation results actually vary 
across locations? Within the constraints of an experimental design one can only enrol in 
research a sample of the potentially relevant centres, therefore the issue quickly becomes 
whether results vary across the centres involved in the RCT. This question can only be 
reliably answered in retrospect, once the trial results have been analysed. Gail and Simon 
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(157) described such tests for heterogeneity to test the influence of centre on any parameter of 
interest and their methods were applied by Cook et al. (156), as discussed in the previous sub-
section. However, heterogeneity tests are usually underpowered and have limited informative 
value. Notwithstanding, once heterogeneity has been ascertained and the need for adjustment 
acknowledged, the methods outlined in the previous sub-section can be used to refine the 
cost-effectiveness estimates for each of the participating centres. Refining should be 
understood in this context as adjusting the centre-specific cost-effectiveness estimate based on 
the trial-wide results. It must be made clear once more that the existing methods refer to data 
analysis and are retrospective in nature because they are only applicable when the trial data 
have been collected.  
  
 Are adjusted cost-effectiveness estimates valid? 
 This leads to a further question: are there limitations inherent in the retrospective 
approach of these methods that may lead us to question the validity of the adjusted cost-
effectiveness estimates? Two observations must be made. First, none of the existing methods 
makes any verifiable assumption regarding the sample of centres included in the analysis. In 
other words, pooling data from centres from within the same jurisdiction is assumed to 
reliably lead to a representative cost-effectiveness estimate for the entire jurisdiction. For 
example, if a multi-national RCT recruited patients from four centres in country A, adjusted 
cost-effectiveness estimates for country A will be based on information collected from those 
four centres and on trial-wide information. This is what Manca et al. demonstrated in their 
example of the ATLAS trial (167). However, is it correct to assume that the cost-effectiveness 
estimate for country A is valid without knowing how representative those four centres are for 
country A itself?  
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Intuitively, at least, this assumption should hold if the centres enrolled in the RCT 
were representative for the jurisdiction they represent. This could be achieved in two ways: 
either centres were deliberately chosen based on a number of covariates which recommended 
them as representative at jurisdiction level; or the centres were randomly selected from the 
pool of available centres in the jurisdiction. There is no evidence in the literature to date that 
either condition has been satisfied. Moreover, given the host of factors influencing cost levels, 
it is expected that the definition of 'representative' is both complex and difficult to specify. 
Purposive selection of recruiting centres/sites has been previously suggested without further 
details (101, 127, 170). Drummond et al. (170) suggested possible centre-level covariates and 
introduced the concept of minimum patients recruited from each centre, but no consistent 
method to address this suggestion has yet been developed.  
 The issue of randomly selecting centres has been touched upon in the literature rather 
as a limitation and an area where more research should be conducted (155, 164). Furthermore, 
choosing an insufficient number of centres and corresponding sample sizes can only lead to 
biased mean estimates and large variances. As discussed in sub-section 1.3.2, the issue applies 
to centre-specific unit costs, as well. 
 The second observation is that the existing generalisability methods still leave 
decision makers from jurisdictions that were not involved in the trial with difficulties in 
transferring the economic evaluation results. Building on the limitation outlined above, this 
equally applies to centres that belong to a jurisdiction included in the trial but have not 
contributed with primary data. Manca et al. (175) advised towards great caution when 
considering such extrapolations. If the generalisability refinements have not incorporated 
centre-specific covariates (e.g. patient case-mix), one potential approach would be to find a 
similar recruiting centre in terms of the covariates considered in the model and then simply 
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use the economic evaluation result. However, there is no guarantee that such a centre exists 
and, more importantly and in relation with 'representativeness', there is no straightforward 
indication as to what exactly constitutes 'similarity'.  
 Manca et al. (175) also offered a comprehensive account of the analytical strategies 
available depending on the availability of individual-patient data (IPD) and participation in 
the trial. The proposed framework was designed to address multinational studies, but the 
authors suggested that it may be useful for within-country jurisdictions. In the absence of IPD 
and if the jurisdiction of interest did not participate in the trial, decision-modelling was the 
indicated option. Decision models usually offer cost-effectiveness estimates with confidence 
intervals around them according to the uncertainty and sensitivity analyses incorporated; if the 
uncertainty around the point cost-effectiveness estimate is large (i.e. the confidence interval is 
wide), the result is of little use and its applicability is restricted to jurisdictions which are 
assumed to have identical budgets and identical reimbursement priorities. Of course, 
constructing a decision model for each centre would be impractical. An alternative solution 
would be to make the decision model available to all interested decision makers, who may 
adjust the parameters to their own needs. This would involve specifying a transparent and 
user-friendly decision model and circulating it to decision makers. 
 Another approach involves the use of a preliminary decision model (69). For example, 
Glasziou et al. (176) used a preliminary cost-utility analysis to inform data selection and the 
required sample size. The question at hand is the following: when an estimate of cost-
effectiveness robust to sensitivity analyses is already available, under what circumstances is it 
worth collecting prospectively additional centre-specific data (as required by multilevel 
modelling and bivariate hierarchical modelling, for instance, or for selecting centres based on 
centre-specific covariates)? Decision modelling is not ideal because the issue at hand is not an 
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entirely statistical consideration and should not be treated as such. If the sample of 
participating centres is unrepresentative (e.g. a random sample) of the entire population of 
centres, any estimator based on the sample of centres will be biased from the nationwide 
estimator to an unknown degree and in an unknown direction. First, the preliminary decision 
model may often be based on effectiveness and resource use estimates from outside the 
jurisdiction (e.g. another country) and the impact of the differences would be difficult to 
assess, especially in the presence of structural uncertainty. Second, in relation to the concerns 
expressed in the previous paragraph, even if jurisdiction-specific cost-effectiveness estimates 
exist, there is no guarantee that they reflect national practice if the process of centre selection 
(centres from which primary data were collected and the estimates have been calculated) has 
not been justified. Third, the uncertainty around the decision model's cost-effectiveness output 
may be significant enough to prevent any yes/no recommendation to be formulated. Finally, 
let us assume that a jurisdiction-specific decision model exists and wide sensitivity analyses 
around the base-case estimates have proved virtually every scenario to be cost-effective. It 
would thus be expected that the intervention is cost-effective in any given centre within the 
jurisdiction and a yes/no decision can be made. However, a yes/no decision is simply not 
enough, as this would require local decision makers to have the same reimbursement 
priorities. Taking the example of the UK health reforms at hand, where increased 
decentralisation is about to be implemented and commissioning devolved to local clinical 
commissioning groups, this assumption is unlikely to hold (177). 
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Summary 
 The discussion above attempted to identify the knowledge gaps associated with 
retrospective methods concerned with patient-level data analysis from RCTs. Two main 
themes emerged, both giving reason for concern: there usually is no explicit method of 
selecting centres and their corresponding sample sizes, although this has been suggested in the 
literature at a conceptual level. This limitation may hamper the validity of a series of 
computations, from heterogeneity tests to adjusted cost-effectiveness estimates. Furthermore, 
there is no reliable tool available for decision makers representing centres and/or jurisdictions 
which did not participate in an RCT to relate to the trial-wide results when having to make 
decisions in their own settings. Some of the limitations of modelling methods in addressing 
these concerns have also been discussed. These themes suggest that centre selection has not 
been addressed in the literature and it may matter in deriving centre-specific cost-
effectiveness estimates. However, its impact has not yet been established.  
 
1.4. Thesis objectives and structures 
The objectives of the thesis are as follows: first, to evaluate the implications of the 
current practice of centre selection in RCTs in the UK for the generalisability of trial results; 
second, to identify any discrepancies between the current and optimal practice of centre 
selection; and third, to propose and demonstrate a novel methodology i.e. the Generalisability 
index (Gix), as a tool to explore the influence of centre selection on RCT results and to allow 
the selection of representative centres at the trial design stage. The research will consider a 
given intervention as a case study i.e. wound-edge protection devices (WEPDs) to reduce 
surgical site infection (SSI) after open abdominal surgery, and will follow the standard steps 
in generating evidence on the clinical and economic benefits of medical interventions (69). 
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The novel generalisability methodology will be demonstrated using data collected alongside 
the ROSSINI trial (Reduction of Surgical Site Infection using a Novel Intervention), a UK-
based RCT which evaluated the benefits of WEPD against standard care. 
 The thesis is structured as follows: the first part (Chapter 2 to Chapter 6) presents the 
clinical and economic evidence related to the chosen case study i.e. the benefits of WEPDs 
compared to standard care (no WEPDs) in reducing SSI. Chapter 2 introduces the main 
concepts and issues surrounding SSI together with the strategies available to reduce it, 
including WEPDs. Chapter 3 appraises and summarises the existing evidence on the clinical 
effectiveness of WEPDs by means of a systematic review and meta-analysis. Chapter 4 
produces preliminary evidence on the cost-effectiveness of WEPDs compared to standard care 
using an original decision tree informed by secondary data relevant to the UK setting. Chapter 
5 describes the rationale and principal clinical findings of the ROSSINI (Reduction of 
Surgical Site Infection Using a Novel Intervention) trial and presents the results of the trial-
based economic evaluation of WEPDs compared to standard care. Chapter 6 provides an 
integrative discussion of the clinical and economic evidence on the benefits of WEPDs in 
reducing SSI, based on the findings presented in Chapters 3 to 5.  
 The second part of the thesis (Chapter 7 and Chapter 8) discusses in depth the 
generalisability of trial results from the perspective of centre selection and proposes an 
approach to evaluate generalisability, which will be demonstrated using ROSSINI data. 
Chapter 7 presents the methods and findings of a mixed methods study describing the current 
and optimal practice of centre selection for RCTs in the UK. Chapter 8 describes in detail the 
Generalisability index as a tool to explore the influence of centre selection on RCT results and 
demonstrates its utilisation using the ROSSINI trial as a case study. Ultimately, Chapter 9 
offers an integrative discussion of the previous Chapters’ findings. 
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The aim of this Chapter is to introduce the clinical context which serves as a case 
study for the generalisability investigation i.e. surgical site infection (SSI) and the use of 
wound-edge protection devices (WEPDs). The Chapter starts with an exposition of the 
relevant concepts for SSI – definition, classification, epidemiology and consequences – and 
then discusses the types of strategies available to minimise SSI risk, with a focus on WEPDs. 
 
2.1. Background to surgical site infection  
 Health care-associated infection (HCAI) can be defined as "an infection occurring in a 
patient in a hospital or other health-care facility in whom the infection was not present or 
incubating at the time of admission. This includes infections acquired in the hospital, but 
appearing after discharge, and also occupational infections among staff of the facility" (178, 
p.1). In a recent systematic review on the worldwide burden of HCAI (179), the World Health 
Organization (WHO) estimated that 7.1% of hospitalized patients acquire a HCAI, of which 
approximately 20% are SSIs. Surgical infections are postoperative complications with an 
overall average incidence among surgical patients in the range of 1-5% (180, 181). The 
burden of SSI is particularly high in developing countries: a recent systematic review (182) 
suggested a pooled cumulative incidence of SSI of 5.6 cases per 100 surgical procedures, 
almost twice the average value in the US (183) and Europe (184), thus making it the most 
prevalent type of HCAI in such settings. Examples include SSI rates of 12% in Bolivia (185), 
up to 17% in Egypt (186, 187), 24% in Brazil (188) and 26% in Tanzania (189).  
 Data from the US, UK and continental Europe indicate substantial variation in SSI 
incidence for different surgical sites, with hip replacement among the interventions with the 
lowest risk and large bowel surgery at the opposite end of the spectrum (183, 184, 190, 191). 
For example, the cumulative SSI incidence in English hospitals between 2006 and 2011 
(Table 2.1) was 0.6% and 0.8% for knee and hip prosthesis, respectively, and 10.1% for large 
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bowel surgery. These were the lowest and highest SSI rates, respectively, among all the 17 
monitored surgical interventions (192). These concur with European-wide estimates (193), 
where the highest SSI rates were observed for colon surgery (9.2%) and the lowest for knee 
prosthesis (0.7%). In particular colorectal surgery is typically associated with average SSI 
incidence rates of 4-10%, but rates as high as 27% have been reported (194-198), especially in 
studies with intensive patient follow-up i.e. outside the inpatient setting. 
 
Table 2.1 Cumulative SSI incidence by surgical category in England (2006-2011) 
 
Type of surgery 
Operations 
reported 
SSI - 
inpatient & 
readmission 
SSI rate (%) - 
inpatient & 
readmission 
95% CIs 
     
Abdominal hysterectomy 5,388 80 1.5 1.2-1.8 
Bile duct, liver and pancreatic surgery 1,559 126 8.1 6.8-9.6 
Breast 1,484 17 1.2 0.7-1.8 
Cardiac (non-CABG) 1,286 13 1.0 0.5-1.7 
Cholecystectomy 619 11 1.8 0.9-3.2 
Coronary artery bypass graft (CABG) 26,468 1,172 4.4 4.2-4.7 
Cranial 557 5 0.9 0.3-2.1 
Gastric 1,093 48 4.4 3.3-5.8 
Hip prosthesis 150,149 1,169 0.8 0.7-0.8 
Knee prosthesis 162,728 895 0.6 0.5-0.6 
Limb amputation 2,538 126 5.0 4.2-5.9 
Large bowel 13,534 1,370 10.1 9.6-10.6 
Reduction of long bone fracture 7,580 104 1.4 1.1-1.7 
Repair of neck of femur 39,830 647 1.6 1.5-1.8 
Small bowel 2,902 196 6.8 5.9-7.7 
Spinal 13,166 126 1.0 0.8-1.1 
Vascular 7,798 221 2.8 2.5-3.2 
Source: Health Protection Agency (2011)
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2.1.1. SSI definitions  
 The best known definition of SSI is the one elaborated by Horan et al. in 1992 (199), 
endorsed by the US Centers for Disease Control and Prevention (CDC) (200). This definition 
replaced the term 'surgical wound infection' (SWI) (201), which referred to incision 
infections, with 'surgical site infection' in order to comprise infections both at the organ and 
the incision level. Thus surgical infections are categorised according to their site in superficial 
SSIs, deep SSIs and organ/space SSIs (Table 2.2).  
 Nevertheless, a host of SSI definitions are available in clinical practice and research. 
Bruce et al. (202) conducted a comprehensive systematic review of the definition, 
measurement and monitoring of surgical wound infection and three other surgical adverse 
events. They reviewed 82 studies and identified 41 different definitions of surgical wound 
infection. Of the 41 definitions, five were nationally proposed definitions coming from US 
(199, 201) and UK (203-205) collaborative groups, respectively. Other studies used 
definitions largely based on the presence of purulent discharge with or without bacterial 
culture in combination with other criteria. The CDC definition was used in 29 studies from 12 
countries, while the UK definitions were used in three UK-based studies. The plethora of SSI 
definitions and the apparent predominance of the CDC criteria informed the recommendation 
to consider the implementation of the CDC definition in the UK in the interest of consistency 
and comparability. The recommendation was later translated in practice and the current SSI 
definition employed by the UK Health Protection Agency (HPA) is in line with the CDC 
definition (206). 
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Table 2.2 CDC definition of SSI  
 
 
Superficial Incisional SSI 
Infection occurs within 30 days after the operation and 
infection involves only skin or subcutaneous tissue of the incision and 
 at least one of the following: 
1. Purulent drainage, with or without laboratory confirmation, from the superficial incision. 
2. Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial 
incision. 
3. At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, 
redness, or heat and superficial incision is deliberately opened by surgeon, unless incision is culture-
negative. 
4. Diagnosis of superficial incisional SSI by the surgeon or attending physician. 
Do not report the following conditions as SSI: 
1. Stitch abscess (minimal inflammation and discharge confined to the points of suture penetration). 
2. Infection of an episiotomy or newborn circumcision site. 
3. Infected burn wound. 
4. Incisional SSI that extends into the fascial and muscle layers (see deep incisional SSI). 
Note: Specific criteria are used for identifying infected episiotomy and circumcision sites and burn 
wounds. 
 
Deep Incisional SSI 
Infection occurs within 30 days after the operation if no implant is left in place or within 1 year if 
implant is in place and the infection appears to be related to the operation and 
infection involves deep soft tissues (e.g., fascial and muscle layers) of the incision and 
 at least one of the following: 
1. Purulent drainage from the deep incision but not from the organ/space component of the surgical 
site. 
2. A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has 
at least one of the following signs or symptoms: fever (>38ºC), localized pain, or tenderness, unless 
site is culture-negative. 
3. An abscess or other evidence of infection involving the deep incision is found on direct 
examination, during reoperation, or by histopathologic or radiologic examination. 
4. Diagnosis of a deep incisional SSI by a surgeon or attending physician. 
Notes: 
1. Report infection that involves both superficial and deep incision sites as deep incisional SSI. 
2. Report an organ/space SSI that drains through the incision as a deep incisional SSI. 
 
Organ/Space SSI 
Infection occurs within 30 days after the operation if no implant is left in place or within 1 year if 
implant is in place and the infection appears to be related to the operation and 
infection involves any part of the anatomy (e.g., organs or spaces), other than the incision, which was 
opened or manipulated during an operation and 
 at least one of the following: 
1. Purulent drainage from a drain that is placed through a stab wound‡ into the organ/space. 
2. Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space. 
3. An abscess or other evidence of infection involving the organ/space that is found on direct 
examination, during reoperation, or by histopathologic or radiologic examination. 
4. Diagnosis of an organ/space SSI by a surgeon or attending physician. 
Source: Centers for Disease Control and Prevention (1999)
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A comprehensive systematic review concluded that even small differences between 
SSI definitions can account for large variations in reported SSI rates both across institutions 
and across countries; therefore comparing estimates in the literature should be exercised with 
great caution (207). Furthermore, several important shortcomings have been pointed out in 
relation with the CDC definition: first, it relies on a relatively complex algorithm, which 
makes it difficult to implement and open to interpretation; second, it doesn’t consider SSIs 
which occur beyond 30-days post-operatively and thus cannot account for the long-term 
impact of SSI. The authors of the review advocated the need for a more reliable and easy to 
implement definition of SSI before formally using SSI rates as a proxy for quality of health 
care services with a view to comparing hospitals.  
  A further aspect in SSI assessment pertains to the grading of wound infection, a useful 
instrument in SSI diagnosis. The same systematic review of Bruce et al. (202) identified 13 
grading scales for surgical wound infection. The most prominent ones are the ASEPSIS scale 
(208) and the Southampton Wound Assessment Scale (209). The former was developed with 
the aim of evaluating wound healing after cardiac surgery and involves a point-based system 
relying on both clinical signs (serous discharge, erythema, purulent exudate and separation of 
deep tissue) and objective criteria such as antibiotic treatment and inpatient stay. A total score 
greater than 20 points indicates a SSI. The Southampton Wound Assessment Scale was 
developed for the assessment of hernia wounds and comprises five grades from 0 (normal 
healing) to 5 (deep or severe wound infection). Both grading scales were validated (210), but 
their practical implementation was judged to be cumbersome. A more recent comparison 
between the CDC and ASEPSIS definitions pointed out that ASEPSIS is more sensitive than 
CDC and the agreement between them is moderate at best; however, somewhat paradoxically, 
the two scales performed comparably (and also modestly) in predicting outcomes such as 
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postoperative length of stay and the prescription of antibiotics (207). This finding only 
highlights the need for developing a more robust SSI definition in the future. 
 
2.1.2. SSI microbiology 
 SSI can only develop if the surgical site is contaminated with microorganisms, which 
can originate either from the patient or from the environment in the operating room. When the 
skin is incised, the tissue is exposed to the flora on patient’s skin, mucous membranes and 
hollow viscera, which constitute the causative agents of SSI in most cases (211). The 
pathogens responsible for SSI have been known for years and Staphylococcus aureus has long 
been indicated as the leading cause for SSI (200), but the microorganisms responsible for 
infection may differ across countries. For example, the HPA reported that Enterobacter spp 
were the predominant causes of SSI in 2011 (31% of isolated pathogens), followed by 
Staphylococcus aureus (27%), Enterococcus spp (8%), Pseudomonas spp (8%) and 
Coagulase-negative staphylococci (8%). Methicillin-resistant S. Aureus (MRSA) contributed 
6% of all identified pathogens (192). The situation appears to be markedly different in the US, 
where Staphylococcus aureus is the leading causative pathogen (40%), followed by 
Coagulase-negative staphylococci (10%), Streptococcus spp (3.5%) and Enterococcus spp 
(2.6%), with MRSA accounting for 13.7% of infections and rising across time (212). 
Staphylococcus aureus has also been indicated as the major causative pathogen in countries 
such as Switzerland (213) and Egypt (186). The rise of MRSA as a cause for SSIs is an 
indication of the high proportion of immunocompromised individuals, potentially a 
consequence of the widespread use of antibiotics.   
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2.1.3. Risk factors for SSIs 
 The risk factors for SSI have been traditionally classified in two categories: patient 
characteristics and operative characteristics (200). Patient characteristics refer to factors such 
as age extremes, diabetes, smoking, obesity, malnutrition and the presence of infections at 
other sites; operative characteristics include skin antisepsis, the duration of the operation, 
preoperative shaving and preoperative skin preparation (Table 2.3). A further argument has 
been made for a distinct influence of anaesthetic considerations as a separate class of 
determinants, in addition to patient and operative characteristics (214). This is based on the 
influence that variables such as tissue perfusion, the perioperative body temperature and the 
concentration of inspired oxygen have on the wound healing process (Figure 2.1). 
 
 
 
Table 2.3 Risk factors for SSI 
 
Patient characteristics Peri-operative characteristics 
  
Age Duration of surgical scrub 
Diabetes Skin antisepsis 
Smoking Preoperative shaving 
Malnutrition (hypoalbuminemia) Preoperative skin preparation 
Obesity Duration of operation 
Coexistent infections at a remote body site Antimicrobial prophylaxis 
Colonisation with microorganisms Operating room ventilation 
Altered immune response Inadequate sterilization of instruments 
Length of preoperative hospital stay Foreign material in the surgical site 
 Surgical drains 
 Surgical technique: poor haemostasis, failure to 
obliterate dead space, tissue trauma 
Source: Adapted from CDC (1999) 
 
 
Chapter 2. Background to surgical site infection and wound-edge protection devices 
60 
 
 
 
 
 
 
Figure 2.1 Factors affecting surgical-wound healing 
 
 Source: Buggy (2000) reproduced with permission3 
 
 
                                                 
3 Reprinted from The Lancet, 357(9227), Donal Buggy, Can anaesthetic management influence surgical-wound 
healing?, Copyright (2000), with permission from Elsevier. 
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Recent evidence suggested additional several SSI risk factors that hadn’t been 
accounted for in previous studies. For example, it has been shown that a history of skin 
infection is associated with enhanced susceptibility to SSI (215). Additionally, the surgeon 
himself has been found to be an independent risk factor, after controlling for adherence to 
guidelines and experience (216). 
  
2.1.4. SSI risk categories 
 Three types of variables have been suggested as reliable predictors of SSI: 1) the 
intrinsic degree of microbial contamination of the surgical site; 2) the duration of an 
operation; and 3) markers for patient susceptibility (200). In relation to the degree of 
contamination of the surgical site, the widely accepted classification of surgical wounds 
distinguishes between four categories (classes) of wounds: clean, clean-contaminated, 
contaminated and dirty wounds (Table 2.4). At the end of the surgical procedure, a member of 
the surgical team assesses the type of wound according to the agreed criteria; the risk of SSI is 
increasingly higher from clean to dirty wounds.  
  
 
Chapter 2. Background to surgical site infection and wound-edge protection devices 
62 
 
 
Table 2.4 Classification of surgical wounds 
 
Category Description 
  
Clean/ 
Class I 
An uninfected operative wound in which no inflammation is encountered and the 
respiratory, alimentary, genital, or uninfected urinary tract is not entered. In 
addition, clean wounds are primarily closed and, if necessary, drained with closed 
drainage. Operative incisional wounds that follow non-penetrating (blunt) trauma 
should be included in this category if they meet the criteria. 
  
Clean-
contaminated/ 
Class II 
An operative wound in which the respiratory, alimentary, genital, or urinary tracts 
are entered under controlled conditions and without unusual contamination. 
Specifically, operations involving the biliary tract, appendix, vagina, and 
oropharynx are included in this category, provided no evidence of infection or 
major break in technique is encountered. 
  
Contaminated/ 
Class III 
Open, fresh, accidental wounds. In addition, operations with major breaks in 
sterile technique (e.g. open cardiac massage) or gross spillage from the 
gastrointestinal tract, and incisions in which acute, non-purulent inflammation is 
encountered are included in this category. 
  
Dirty-infected/ 
Class IV 
Old traumatic wounds with retained devitalized tissue and those that involve 
existing clinical infection or perforated viscera. This definition suggests that the 
organisms causing postoperative infection were present in the operative field 
before the operation. 
Source: Centers for Disease Control and Prevention (1999) 
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 However, estimating SSI risk solely based on the type of incision is insufficient 
because other variables may also play a role and there is also the risk of an incorrect 
classification. A more comprehensive estimator is the National Nosocomial Infections 
Surveillance (NNIS) SSI risk index (217), which accounts for three independent risk factors 
and takes values between 0 (no risk factor present) and 3 points (all risk factors present), such 
that 1 point is awarded for each of the following instances: a) American Society of 
Anaesthesiologists (ASA) Physical Status Classification greater than 2, signifying a patient 
with severe systematic disease which may threaten his life (218); b) either contaminated or 
dirty/infected wound classification, as defined above; and c) length of operation greater than 
T hours, where T is approximately the 75th percentile of the duration of the specific 
intervention performed (219). Thus the NNIS risk can be regarded as a more reliable and 
objective risk estimator because it not only incorporates the wound classification system, but 
also the ASA class as a surrogate for patient susceptibility and the intervention-specific 
duration of surgery. Moreover, it allows surveillance authorities in each country to calibrate 
individual patient risk based on local data on length of surgery (220).  
Although widely used, further research is needed towards the reliability of the NNIS 
risk index, as noted in the CDC guidelines (200). Indeed, the evidence around its performance 
is controversial: while there are indications that the NNIS risk index is highly correlated with 
SSI rates for some common operations (221), other results indicated that the NNIS index may 
actually have too low a sensitivity to be used as a prognostic tool (222). 
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2.1.5. Patient-level consequences of SSIs 
 SSIs are associated not only with considerable morbidity (223, 224), but also with 
excess mortality; it has been suggested that over one-third of postoperative deaths are related, 
at least in part, to SSI (225). Evidence suggests an increase of up to ten-fold in mortality rates 
in SSI patients compared to uninfected controls (226) and an increased likelihood of hospital 
readmission (227). Other clinical outcomes of SSIs include scars that are cosmetically 
unacceptable, such as those that are hypertrophic or keloid, persistent pain and itching (228).  
 There have been relatively few studies investigating the effects of SSI on health-
related quality of life. The little available evidence suggests that SSI patients reported reduced 
quality of life in comparison with uninfected controls, both in relation to physical functioning 
and mental health (229, 230). A qualitative interview study on Swedish patients having deep 
SSIs revealed experiences of pain, insecurity and isolation extended over several months or 
even years (231). 
 
2.1.6. Costs associated with SSIs  
 SSIs are associated with additional length of stay in hospital in the range of 6 to 17 
days (181, 191, 232, 233) and even up to 23 days in the case of SSI due to Methicillin-
resistant S. aureus (MRSA) (234). Moreover, SSI patients receive more intensive care after 
discharge compared to uninfected patients (226, 230), translated in higher number of home 
visits from a health care professional, ambulatory visits, emergency room visits and 
medication. These factors are responsible for an additional cost of care due to SSI of up to 
£10,500 (191, 195, 224, 235). Most cost studies in the US cited an additional cost due to SSI 
at approximately $3,000, but there is also evidence of differences in excess of $20,000 (229). 
The largest part of the health care costs associated with SSI are due to prolonged inpatient 
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cost, but costs in an outpatient setting have been shown to amount to as much as 15% of total 
health care costs (195). 
 While the fact that SSIs are associated with supplementary costs is undisputed and the 
differences in magnitude between various estimates are most likely due to study design and 
setting, further aspects need to be considered. First, incurred costs are proportional with the 
depth of the SSI i.e. costs are lower for superficial SSI and higher for organ/space SSI (236, 
237). Second, health care costs are only a fraction of the total costs associated with SSI. While 
only few studies have taken a societal perspective in cost-analysis to date (237, 238), the little 
available evidence suggests that health care costs may amount to as little as 10% of total costs 
when lost productivity is considered (239). 
 Evidence suggests that SSIs due to MRSA may be associated with prolonged hospital 
stay and even larger additional costs (240, 241). For example, Anderson et al. (234) collected 
resource use data from 509 patients along a 90-day time horizon and concluded that SSI-
MRSA were associated with a $61,000 increase in total hospital charges compared to 
uninfected controls, as well as with a $24,000 increase compared to SSI cause by Methicillin-
sensitive Staphylococcus aureus. 
   
2.1.7. Strategies for SSI prevention 
 Evidence suggests that both HCAI and SSI are largely preventable, although it has 
been acknowledged that the currently available technologies do not allow 100% prevention 
(242). The effort aimed at reducing the burden of SSIs during the past decades has 
concentrated on three main directions: 1) mitigating the known SSI risk factors; 2) improving 
SSI prediction; and 3) improving SSI detection. In terms of addressing the known SSI risk 
factors, perioperative care factors have been comprehensively addressed in clinical guidelines 
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issued by the US CDC (200) and the UK's National Institute for Health and Clinical 
Excellence (NICE) (243), respectively. The guidelines address in great detail practical 
considerations pertaining to the preoperative (e.g. hair removal, antibiotic prophylaxis, bowel 
preparation), intraoperative (e.g. hand decontamination, skin preparation) and postoperative 
phases (e.g. changing dressings, wound debridement) of the surgical intervention. Moreover, 
NICE clinical guidelines identified key priorities for further investigation, which include the 
benefit of various types of wound dressings, the benefit of nasal decontamination using 
mupirocin against S. aureus, the potential benefit of various techniques for maintaining 
patient homeostasis and the effect of the closure methods on SSI risk (243).  
Second, the need for better prediction of SSI led to the development of more complex 
prognostic models to advance the understanding on protective and contributing factors (244-
246). Prognostic models allow a more precise decomposition of the influence of various 
factors on the SSI risk as opposed to aggregating them in a single risk measure. For example, 
it has been noted that in some countries the NNIS risk index may discriminate poorly between 
high risk and low risk patients or that it may not be correlated with SSI rates at all, while 
locally constructed prognostic models or indices performed better (185, 188, 247). These 
findings highlight the need for constructing local prognostic models with a view to a better 
prediction of SSI occurrence. The same applies to subpopulations with particular co-
morbidities: for example, Anaya et al. have recently developed a cancer specific SSI risk-
stratification tool where preoperative chemotherapy emerged as an independent risk factor 
(248). 
Third, the importance of SSI surveillance programmes for SSI detection has been 
acknowledged. This concerns both inpatient and, most importantly, post-discharge and 
outpatient surveillance. Although SSIs were traditionally believed to present up to six days 
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postoperatively, more recent evidence indicates a later development, in the region of nine to 
13 days postoperatively on the average (194, 195). Given the continuous pressures that 
hospitals face to decrease length of stay, this implies that many SSIs may manifest in an 
outpatient setting. Indeed, a large proportion of SSIs are detected post-discharge: European-
wide data indicated that 48% of SSIs were detected post-discharge (193), in accordance with 
previous estimates from smaller studies in the UK (195, 249) and US (194). Estimates as high 
as 86% have also been cited (250).  
There is still conflicting evidence on the most appropriate methods for post-discharge 
surveillance (PDS). A systematic review identified direct observation, telephone interviews 
with patients and patient questionnaires as the most common methods employed for data 
collection in PDS, but eventually concluded that information on the validity and reliability of 
the existing methods was insufficient to recommend either of them (251). National 
surveillance systems have been implemented in countries such as England (206), Scotland 
(252), France (253), the Netherlands (254), Germany (255) and Australia (256); most reports 
cited an overall reduction of SSI rates along the years of surveillance, thus suggesting the 
demonstrable beneficial effect of PDS in reducing SSI rates. While such a finding is in line 
with local reports (257-259), the difficulty of disentangling the effect of public reporting from 
other infection control measures has to be acknowledged, especially considering that most 
national surveillance schemes are still based on voluntary hospital reporting. Moreover, the 
decline in SSI rates over time only applies to hospitals with a history of SSI surveillance of 
several years and cannot be generalised to all types of surgical procedures (260). 
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2.2. Background to wound-edge protection devices  
 WEPDs are an intervention aimed at reducing SSI rates in patients undergoing open 
surgery (non-laparoscopic). Also known as 'wound guards', they have been used in abdominal 
surgery for more than 40 years, having been firstly mentioned at the end of the 1960s (261). 
There are several types of devices available on the market, but they all have the same basic 
design: a semi-rigid plastic ring placed into the abdomen via the laparotomy wound to which 
an impervious drape is circumferentially attached (262, 263). This plastic drape comes up and 
out of the wound onto the skin surface, thus protecting the incised wound edges from contact 
with contaminated media. The device is inserted in the abdominal cavity by the surgeon as 
soon as the incision has been made and is removed just before wound closure (Figure 2.2). 
The device also has retraction properties i.e. keeping the wound edges apart, which explains 
why it may also be marketed as a ‘wound retractor’. 
 
Figure 2.2 Wound-edge protection device used during open abdominal surgery 
Source: Pinkney et al. (2013), reproduced with permission4 
                                                 
4 Reprinted from BMJ, 347:f4305, Pinkney TD et al.,  Impact of wound edge protection devices on surgical site 
infection after laparotomy: multicentre randomised controlled trial (ROSSINI Trial), Copyright (2013), with 
permission from BMJ Publishing Group Ltd. 
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  Although WEPDs have been used for decades in the interest of reducing SSI rates, 
their mechanism of action is still unclear. Several explanations have been postulated: firstly, 
WEPDs create a physical barrier between the abdominal wound edges and viscera, visceral 
contents, contaminated instruments and gloves; this reduces the accumulation of endogenous 
and exogenous bacteria on the wound edges. In support of this mechanism, Raahave et al. 
(264) found different bacterial densities on and under such a device when used in laparotomy 
wounds. Their findings were replicated more recently in an observational study focusing on 
gastrointestinal surgery (265). WEPDs may also reduce necrosis from long procedure 
exposure of the incised tissue. Moreover, due to intrinsic retraction properties they reduce the 
need for handheld mechanical retraction and thus the associated tissue damage. However, it 
has been hypothesised that, conversely, contaminated intra-peritoneal fluid may advance 
through capillarity along the impervious wound guard and reach the wound edges thereby 
causing infection. 
 A distinction should be made between WEPDs and 'adhesive drapes': the latter are 
plastic drapes adherent to the skin and they do not come into direct contact with the wound 
margins. A Cochrane systematic review summarised the evidence on adhesive drapes and 
concluded that they do not show any benefit in reducing SSI rate (266). This distinction is 
particularly important because, on occasions, WEPDs have been referred to as 'ring drapes' or 
'impervious drapes', such that confusion between the two types of devices may arise. The 
major difference in design between them is that adhesive drapes lack a plastic ring and remain 
entirely on the surface of the patient's skin without coming in contact with the abdominal 
cavity or with the wound edges (266). 
 Despite their potential for reducing SSIs when used intra-operatively by protecting the 
wound margins from contact with any contaminated materials, they have never come to 
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widespread use and they are not even mentioned in the current UK clinical guidelines (243). 
Although there have been RCTs looking at the effectiveness of WEPDs versus that of various 
comparators (267-271), most of these trials are single-centre and the quality of their reporting 
appears to be questionable. Furthermore, there is no meta-analysis available on this topic. 
These factors may explain the limited uptake of WEPDs in current practice, as they are 
currently used solely at the surgeons' discretion. The next Chapter will formally synthesise the 
available evidence on the clinical effectiveness of WEPDs in reducing SSI. 
 
 
2.3. Conclusion 
 SSI is a serious postoperative complication which affects HRQoL and is associated 
with significant costs. WEPDs have been used informally by surgeons for more than 40 years 
to prevent SSI, but the evidence of their effectiveness is controversial and has never been 
systematically reviewed. The following Chapter addresses this gap by presenting the results 
of a systematic review of the clinical effectiveness of WEPDs vs. standard care in reducing 
SSI. 
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A paper based on the work presented in this Chapter has been published as: 
Gheorghe A, Calvert M, Pinkney TD, Fletcher BR, Bartlett DC, Hawkins WJ, Mak T, 
Youssef H and Wilson S on behalf of the West Midlands Research Collaborative and 
ROSSINI Trial Management Group. (2012) Systematic Review of the Clinical Effectiveness 
of Wound-edge Protection Devices in Reducing Surgical Site Infection in Patients 
Undergoing Open Abdominal Surgery. Annals of Surgery 255(6): 1017-1029. 
 
As noted in Chapter 2, WEPDs have been used for decades based on anecdotal 
evidence regarding their effectiveness, but current UK clinical guidelines on SSI management 
do not mention them (243). The question arises whether there is sufficient evidence available 
to make a definitive decision on the appropriateness of their use as a means to reduce the rate 
of SSI. The aim of this Chapter is to appraise the available evidence on the clinical 
effectiveness of WEPDs compared to standard care in reducing the rate of SSIs in patients 
undergoing open abdominal surgery. 
 
3.1. Methods 
 A systematic review was conducted according to a pre-specified protocol based on 
guidance from the Centre for Reviews and Dissemination (272) and the Cochrane Handbook 
of Systematic Reviews of Interventions (7). The review is reported in line with the PRISMA 
statement (273) (Appendix 1). 
 The elements of the research question addressed by the review are reported below in 
the PICOS format (274): 
Population: human patients of any age undergoing open abdominal surgery, both elective and 
emergency. 
Intervention: use of a WEPD (for the purpose of this review, a device was considered eligible 
if it covered the wound's cut edges with an impervious plastic sheet). 
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Comparator: standard care, as defined in each included study. The use of a protective device 
different to the WEPD was accepted if no other control arm was present in the study. 
Outcome: SSI rate was a pre-specified study outcome. 
Study design: acceptable study designs were RCTs, prospective controlled trials (CTs), 
prospective cohort studies and case-control studies. 
 The areas covered by the study protocol are reported below. 
 
3.1.1. Eligibility criteria  
 Study eligibility was judged against the pre-specified inclusion criteria presented 
above in PICOS format. Neither publishing year nor language restrictions were applied. Any 
potentially relevant paper in a language other than English was translated into English. The 
following pre-specified exclusion criteria were applied: studies looking at a different device 
(e.g. adhesive drapes), unless a WEPD was also used in the study; definitions of SSI based 
solely on bacteriological information; study designs with a high risk of bias including case 
reports and retrospective studies. Reviews were not accepted for lack of primary data. 
 Purely bacteriological definitions of SSI were excluded for two reasons. First, the 
current clinical guidelines (200, 243) specify definitions of SSI based predominantly on 
clinical signs (e.g. discharge, pus, localised swelling, erythema). Bruce et al. (202) identified 
41 separate definitions of wound infections in their systematic review looking at the validity 
and reliability of postoperative wound infection assessment. Only five of these were 'standard' 
definitions (issued by the CDC or by UK expert groups) and all of them were substantially 
based on clinical signs. The second argument builds upon the distinction between 
contamination, which is a bacteriological outcome, and infection, which is a clinical outcome. 
Evidence has indicated the difficulty to differentiate infection from contamination when 
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interpreting the positive results of swab cultures, therefore ascertaining the presence of SSI 
based on bacteriological results is not recommended (205, 275).  
 
3.1.2. Information sources  
 The following sources were searched in November 2010: 
 Online bibliographic databases: OVID MEDLINE, OVID EMBASE, EBSCO 
CINAHL, ISI Web of Science (including Science Citation Index and Conference 
Proceedings) and The Cochrane Library; 
 Proceedings of the annual conferences of the Association of Coloproctology of Great 
Britain and Ireland (ACPGBI) and of Association of Surgeons of Great Britain and Ireland 
(ASGBI); 
 The identified manufacturers of WEPDs (3MTM, Applied MedicalTM and MCDTM) 
were contacted and were asked to provide details of any relevant studies they were aware of; 
 The references of the included articles (see below in section Study selection) were 
hand-searched for further relevant studies and for articles citing them; 
 The authors of the selected articles (see below) were contacted and asked to provide 
details about any other relevant studies. 
 
3.1.3. Search strategy 
 A sensitive search strategy was devised in order to capture all the relevant studies. 
Given the variety of names under which WEPDs have been marketed, their four-decade 
history of utilisation and the broad range of surgical interventions considered such an 
approach i.e. a sensitive, encompassing search strategy, was judged appropriate given the 
review’s objective. The pre-specified search terms were grouped in two thematic areas: the 
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WEPD terms and the SSI terms. Truncation was used where appropriate. The search strategy 
was applied to all the online databases, with slight adjustments inherent to the specific 
vocabulary of each database. All terms were searched as keywords. The search was performed 
independently by two researchers (AG and BF5). The search strategies for all databases are 
presented in Appendix 2.  
  
3.1.4. Study selection  
 The study selection process took place in two consecutive steps. In phase 1 potentially 
relevant articles were selected by scanning their title and abstract in relation to the 
inclusion/exclusion criteria, as described in section Eligibility criteria above. In phase 2 the 
full-text versions of the articles selected in phase 1 were assessed in relation to the eligibility 
criteria. When a decision about eligibility could not be made in phase 1 based on the title and 
abstract, the full-text article was obtained. Only studies that fulfilled all the eligibility criteria 
were included. 
 The selection was performed independently by two reviewers (AG and BF). In case of 
disagreement, a consensual decision was made with the help of a third reviewer (MC6). The 
selection process was tested and piloted on a random sample of 20 papers during phase 1 of 
the selection process. 
  
3.1.5. Data extraction 
 For each study having entered phase 2 of the selection, the following information 
items were extracted: study design; total number of participants and stratified by arm; type of 
surgery performed; intervention (including description of WEPD); description of the control 
                                                 
5 Benjamin R. Fletcher – Research Associate, Primary Care Clinical Sciences, University of Birmingham 
6 Melanie Calvert – Reader in Epidemiology, Primary Care Clinical Sciences, University of Birmingham 
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group; pre-specified and reported outcomes; length of follow-up; effect estimates (i.e. effect 
on SSI rate); funding and other competing interests. 
 One reviewer (AG) extracted data for all selected studies in The Cochrane 
Collaboration’s RevMan software 5.0 (276). The accuracy of the extracted data was verified 
for all the included studies by a second reviewer (BF). 
 
3.1.6. Risk of bias in individual studies 
 The 'Risk of bias' tool presented in the Cochrane Handbook of Systematic Reviews of 
Interventions (7) was used to ascertain the suitability of each study selected after phase 2 for 
inclusion in a meta-analysis. Two reviewers (AG and BF) performed the assessment 
independently. In case of disagreement, a consensual decision was made with the help of a 
third reviewer (MC). It was acknowledged that blinding was impossible for surgeons, so 
patient and assessor blinding, respectively, were considered.  
 
3.1.7. Synthesis of results  
 The outcome of interest was dichotomous - presence or absence of an SSI. Given the 
significant variation in the types of surgery considered and in the definitions of SSI applied, it 
was judged that a distribution of effects would realistically describe the influence of WEPDs 
on the SSI rate. Consequently a random-effects model (277) (Mantel-Haenszel method) meta-
analysis was pre-specified. Nevertheless, random-effects models do not produce reliable 
estimates when few studies are included in the meta-analysis (278); therefore the results of the 
meta-analysis are presented both under fixed-effects and random-effects models, and the 
differences are discussed. The degree of heterogeneity between studies was explored using the 
I2 statistic (279). In accordance with recommended practice (280), sources of heterogeneity 
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were explored and subgroup analyses were conducted. A subgroup analysis was pre-specified 
in the protocol to investigate the influence of the degree of contamination (clean/clean 
contaminated/contaminated/dirty) on the SSI rate. This was based on evidence suggesting that 
higher degree of contamination is a risk factor for SSI (200).  
 RevMan 5.0 software (276) was used to perform the quantitative analyses. The main 
outcome measure is the risk ratio (RR), reported with 95% confidence intervals (CI), of 
developing an SSI in the intervention arm compared to the control arm.   
  
3.1.8. Publication bias  
 A pre-specified publication bias assessment was performed by means of a funnel plot. 
Two formal tests for publication bias, Begg's test (281) and Egger's test (282), were also 
carried out using STATA 10 software (Stata Corp, College Station TX, US), as they are not 
supported in RevMan 5.0. 
 
3.2. Results 
3.2.1. Study selection  
 Following the two phases of the study selection process, 12 studies were included in 
the review (267-271, 283-289). Figure 3.1 summarises the stages of the selection process. The 
paper identified from other sources (i.e. not through searches of bibliographic databases) was 
a study by Harrower et al. (290) cited by some of the older studies (267, 268, 270, 283). It 
was subsequently excluded because it used bacteriological count as an outcome, in 
accordance with the pre-specified exclusion criteria. A further two excluded studies (264, 
291) did not use a clinical definition of SSI. Another study was excluded because the WEPD 
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Figure 3.1. PRISMA flowchart for systematic review of WEPD clinical effectiveness 
1368 citations identified by 
searching online databases 
1 citation identified from other 
sources (manufacturers, authors, 
reference lists of selected papers) 
1369 citations to be scanned 
for title and abstract 
124 duplicates removed 
1245 papers after 
duplicates removed 
114 papers excluded for lack of primary 
data (reviews, editorial notes) 
1131 papers assessed for eligibility 
by scanning their title and abstract 
17 potentially eligible papers 
scanned for full-text version 
5 papers excluded (reason for exclusion): 
 Harrower 1968 (bacteriological count); 
 Raahave 1974 (bacteriological count); 
 Nyström and Bröte 1980 (bacteriological 
count); 
 Pollock 1980 (WEPD soaked in povidone-
iodine); 
 Anthony 2010 (bundle of interventions). 
12 papers included in the review 
1114 papers excluded 
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was soaked in povidone-iodine (292), an antibacterial solution which would confound the 
effect of the WEPD according to its postulated mechanisms of action. Finally, one study was 
excluded because the intervention arm used a bundle of five interventions including a WEPD, 
therefore the study design did not allow an assessment of the individual effect of WEPDs 
(293).  
 Two included articles were not available in English: the German study of Batz et al. 
(285) and the French study of Brunet et al. (287), respectively. The full-text versions of these 
papers were analysed following translation into English. The authors of the most recently 
published studies (271, 288, 289) were contacted and asked whether they were aware of any 
other relevant published or unpublished studies. Only one of the authors (Horiuchi) responded 
and no further studies were identified.   There were no disagreements between the two 
reviewers (AG and BF) with respect to the included studies and the extracted data. 
 
3.2.2. Study characteristics  
 Table 3.1 summarises the characteristics of the 12 included studies and Table 3.2 
presents the outcomes and the effect on SSI incidence reported in each study. Three studies 
were conducted in the UK, two in US and Ireland, respectively, and one each in Sweden, 
Germany, France, Japan and Australia. 
 
Study design 
 Ten of the 12 included studies were RCTs and two were controlled trials (CTs) (267, 
287). Two studies (267, 268) divided patients into three groups (two intervention groups and 
one control group) and the remaining ten studies compared two patient groups.    
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Patients 
 The 12 included studies reported data for a total of 1,933 patients. One paper (289) 
specified enrolment of patients over the age of 18 and another study (270) enrolled 'adults', 
but in the remaining studies patients' age was not reported as an inclusion/exclusion criterion. 
 
 
Intervention and Control 
 In ten studies the WEPD used was identifiable by means of the description provided or 
by indicating the manufacturer or both. In the studies of Batz et al. (285) and Brunet et al. 
(287) no description was offered; in both these papers the WEPD was referred to as a 'ring 
drape'. 
 Only two of the 12 studies were multi-centre: one study (289) recruited from four 
hospitals and another study (270) recruited from two hospitals. Three studies (267, 268, 287) 
examined generic abdominal operations, one study (288) focused on appendicectomy and the 
remaining studies looked at gastrointestinal interventions, mostly colorectal surgery. In terms 
of the control group, two studies (288, 289) compared the WEPD against standard retraction 
and one study (285) compared the ring drape against incise drapes. As detailed in section 2.2, 
incise drapes are very similar to adhesive drapes (but different from 'ring drapes') in the sense 
that they do not come in contact with the abdominal cavity and with the wound edges. In the 
remaining studies the control group was described as the group where the WEPD was not 
used. 
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Table 3.1 Characteristics of the studies included in the systematic review 
 
Study 
Study 
type 
Type of 
surgery 
Number of 
patients 
Inclusion/exclusion criteria Intervention group Control group 
Maxwell 
1969(267) 
CT elective or 
emergency 
major 
abdominal 
surgery 
202: 
82 intervention A 
88 intervention R 
32 control 
Inclusion: based on type of surgery. 
No exclusion criteria reported. 
Intervention A: plastic drape adherent to the skin;  
Intervention R: adherent plastic (as above) PLUS a 
circular plastic ring protector 
 
"Towels were applied 
directly on the skin 
[...] and no plastic of 
any kind was used" 
Alexander-
Williams 
1972(283) 
RCT midline or 
paramedian 
laparotomy 
associated 
with the 
opening of 
some part of 
the bowel or 
biliary tract 
167: 
84 intervention 
83 control 
Inclusion: based on type of surgery.  
No exclusion criteria reported. 
"The impervious wound drapes used were vi-Drape 
(Parke-Davis). These are transparent plastic sheets 
having a central hole of 18, 23, or 28 cm diameter, 
around which is fixed a semi-rigid circular collar. 
This collar can be squeezed flat so that the central 
hole in the drape is introduced into the abdominal 
wound. When released the collar springs back to a 
circle beneath the abdominal wall, holding the 
plastic sheet in close proximity to the wound edge" 
"either no wound 
protection or standard 
permeable cloth 
wound guards" 
Psaila 
1977(268) 
RCT abdominal 
surgery 
144:  
51 intervention A 
46 intervention R 
47 control 
Inclusion: based on type of surgery. 
Exclusion: "Patients receiving 
preoperative antibiotics (with the 
exception of non-absorbable 
sulphonamides used for bowel 
preparation) were not included in the 
trial." 
A: "The adhesive skin drape was Steri-Drape 
(Minnesota Mining and Manufacturing Co.)" PLUS 
standard linen towels; 
R: "Vi-Drape (Parke, Davis & Co.) was the plastic 
ring wound drape tested; this was placed through 
the wound itself, the ring being permitted to expand 
against the inner aspect of the abdominal wall and 
the drape being drawn over the wound surfaces" 
PLUS standard linen towels 
 
"linen towels alone 
were used" 
Gamble 
and 
Hopton 
1984(284) 
RCT elective 
colonic 
surgery on 
one general 
surgical firm 
56: 
27 intervention 29 
control 
Inclusion: based on type of surgery. 
No exclusion criteria reported. 
 
 
 
  
"The plastic ring drape consists of a flexible, semi-
rigid plastic ring to the outer rim of which is welded 
a plastic sheet. The ring is compressed, inserted into 
the abdominal cavity and positioned under the 
abdominal wall inside the peritoneum. The plastic 
drape is smoothed out round the wound and clipped 
to the surrounding drapes, thus covering the edges 
of the incised abdominal wall, providing a barrier 
which should, in theory at least, reduce the risk of 
wound contamination" 
"The ring drape was 
not used" 
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Study 
Study 
type 
Type of 
surgery 
Number of 
patients 
Inclusion/exclusion criteria Intervention group Control group 
Nyström 
1984(270) 
RCT elective 
colorectal 
surgery 
involving 
opening the 
bowel 
140: 
70 intervention 
70 control 
Inclusion: adults; 
Preoperative exclusion: deferred surgery; 
Intraoperative exclusion: change of 
operative plans or an unforeseen 
therapeutic situation. 
 
"The drape is made of a polyvinyl plastic sheet with 
a central hole which is fitted with a plastic frame 
that can be adjusted to match the size of the incision 
(Op-drape, Triplus, Sweden). [...] The wound ring 
drape was adjusted to appropriate size and inserted 
into the abdomen before opening the bowel" 
"without ring drape" 
Batz 
1987(285) 
RCT patients 
undergoing 
tumour 
resection for 
colorectal 
cancer 
50: 
25 intervention A   
25 intervention B 
Inclusion: based on the type of surgery. 
No exclusion criteria reported. 
Ring drape 
 
Incise drape 
Redmond 
1994(286) 
RCT gastrointestina
l surgery 
213: 
102 intervention 
111 control 
 
 
Inclusion: based on the type of surgery. 
No exclusion criteria reported.  
 
"wound edge protector" 
 
"received no 
protection" 
Brunet 
1994(287) 
CT all 
interventions 
of abdominal 
surgery, 
elective and 
emergency 
149: 
73 intervention 
76 control 
Inclusion: based on the type of surgery. 
No exclusion criteria reported.  
"champ à anneau", translated by the authors as 
"ring drape" 
 
"no protection" 
Sookhai 
1999(269) 
RCT trans-
abdominal 
surgery for GI 
disease 
 
352: 
170 intervention 
182 control 
Inclusion: based on the type of surgery. 
No exclusion criteria reported.  
"This protector consists of an impermeable plastic 
drape with four adhesive patches that fits onto the 
abdomen. There is a hole in the middle with a semi-
rigid plastic ring that fits into the abdominal wound 
and protects the wound edge from contact with 
viscera, visceral contents, contaminated 
instruments, and gloves" 
"no wound-edge 
protector" 
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Study 
Study 
type 
Type of 
surgery 
Number of 
patients 
Inclusion/exclusion criteria Intervention group Control group 
Horiuchi 
2007(271) 
RCT non traumatic 
gastrointestina
l surgery; 
laparoscopic 
surgery and 
minor surgery 
excluded 
221: 
111 intervention 
110 control 
No inclusion criteria reported. 
Exclusion:  
- patients who had severe adhesion with 
a history of laparotomy; 
- long-term use of steroids; 
- laparoscopic surgery or minor surgery 
such as appendectomy; 
- probable colon perforation. 
"The Alexis retractor, a polyurethane wound 
retractor manufactured by Applied Medical" 
 
"in the Without 
Alexis retractor 
group, a wound 
margin was left 
untreated" 
Lee 
2009(288) 
RCT open 
appendicecto
my 
109: 
61 intervention 48 
control 
Inclusion: 
- clinical diagnosis of appendicitis; 
- planned open appendectomy; 
- and informed consent. 
Exclusion: 
- history of insulin-dependent diabetes; 
- and inability to follow-up owing to 
geographic location. 
"Patients were than randomized [...] to receive 
intra-operative retraction with either standard 
retractors or the small (2.5-6cm) Alexis wound-
protector system (Applied Medical, CA, USA). The 
Alexis wound retractor is a disposable plastic 
surgical retractor that provides 360 degrees 
retraction and wound protection for open 
procedures." 
Standard retractor - 
see cell to the left 
Reid 
2010(289) 
RCT open elective 
colorectal 
resection 
130: 
64 intervention 66 
control 
Inclusion: patients older than 18 years. 
Exclusion:  
- patients who were cognitively impaired 
or otherwise unable to give informed 
consent; 
- and patients undergoing laparoscopic 
colorectal resection. 
 
"This wound protector [Alexis - Applied Medical, 
CA, USA] is made up of 2 stiff rings with a 
cylinder between the 2 rings. The inner ring is 
placed in the peritoneal cavity, and the outer ring is 
placed outside of the abdomen. The outer ring is 
then rolled over the cylinder of impervious plastic 
until the plastic becomes taut circumferentially 
around the wound." 
"in the control group 
wound retraction was 
achieved by retractors 
routinely used by the 
treating surgeon" 
 
Abbreviations: CT - controlled trial; RCT - randomised controlled trial; SSI - surgical site infection; WEPD - wound-edge protection device.
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Table 3.2 SSI incidence in the included studies 
 
Study Outcomes SSI definition used 
Time of assessment/ Length of 
follow-up 
Effect on surgical site 
infection (SSI) incidence 
Maxwell 
1969(267) 
Surgical site infection; 
Wound contamination; 
Various bacteriological 
outcomes 
"abnormal appearance of classical signs of 
inflammation in some area of the wound by the 
resident staff and a positive culture of wound 
exudate" 
Unclear Incidence of SSI:  
14.6% intervention A;  
18.2% intervention R;  
21.8% control. 
Alexander-
Williams 
1972(283) 
Surgical site infection; 
Wound complications 
"...classifying the wound as showing either no 
infection, mild wound infection (erythema), moderate 
wound infection (exudate), or severe wound infection 
(pus)." 
Initially at 3 and 7 days; then at 
7 and 10 days 
Incidence of SSI: 
11.9% intervention;  
12.0% control. 
Psaila 1977(268) Surgical site infection; 
Various bacteriological 
results 
"...at least one of the following criteria was used to 
identify the presence of infection: 1. Erythema 
around the sutures or along the wound edge with 
accompanying pyrexia. 2. Discharge of exudate or 
pus from the wound. 3. Wound breakdown." 
Unclear Incidence of SSI:  
16% intervention A;  
17% intervention R;  
21% control. 
Gamble and 
Hopton 1984(284) 
Surgical site infection; 
Various bacteriological 
results 
"A wound was recorded as infected if a discharge 
occurred from it." 
Unclear Incidence of SSI:  
32% intervention;  
28% control. 
Nyström 1984(270) Surgical site infection; 
Bacteriological results 
"Wound sepsis was defined as pus emptying 
spontaneously or upon incision." 
Up to 30 days post-operatively Incidence of SSI:  
10% intervention;  
9% control. 
Batz 1987(285) Surgical site infection; 
Bacteriological results 
"A wound healing incident was defined as a 
spontaneous opening of the surgical abdominal 
wound with pus discharge." 
Unclear Incidence of SSI:  
4% ring drape;  
28% incise drape 
Redmond 
1994(286) 
Surgical site infection; 
 
"Wounds were deemed infected when there was overt 
pus or a culture-positive discharge." 
At 5, 10 and 30 days post-
operatively 
Incidence of SSI:  
10.8% intervention;  
24.3% control. 
Brunet 1994(287) Surgical site infection; 
Bacteriological results 
"Parietal infection was defined by the presence of pus 
at the wound level within a month following surgery" 
One month post-operatively Incidence of SSI:  
8.2% intervention;  
23.7% control 
Sookhai 1999(269) Surgical site infection; 
 
"Postoperative wound infection was defined as the 
presence of a purulent discharge, a culture-positive 
discharge, pain/tenderness, localised swelling, 
erythema, or cellulitis which occurred within 30 days 
of surgery." 
Up to 30 days post-operatively Incidence of SSI:  
13.5% intervention;  
29.7% control. 
Chapter 3. Systematic review of the clinical effectiveness of WEPDs 
 
85 
 
Study Outcomes SSI definition used 
Time of assessment/ Length of 
follow-up 
Effect on surgical site 
infection (SSI) incidence 
Horiuchi 
2007(271) 
Surgical site infection; 
Bacteriological results; 
Length of stay in 
hospital 
"SSI frequency and properties were analyzed 
according to the criteria of the United States Centres 
for Disease Control and Prevention (CDC)." (no 
reference provided) 
Unclear Incidence of SSI:  
7.2% intervention;  
14.5% control. 
Lee 2009(288) Surgical site infection; 
 
"This [wound infection] was defined as any 
significant subcutaneous SSI necessitating wound 
opening or treatment with antibiotics. This also 
included any subject who was prescribed a separate 
course of antibiotics after discharge from hospital. 
All such events were coded as SSI." 
Up to 3 weeks Incidence of SSI:  
1.6% intervention;  
14.6% control. 
Reid 2010(289) Surgical site infection; 
Surgeons' satisfaction 
with the WEPD; 
Antibiotic usage; 
Length of stay 
"The principal outcome measure was the incidence of 
superficial or deep SSI occurring within 30 days of 
surgery, as defined by the Centres for Disease 
Control and Prevention." 
At days 3 and 5 post-op and at 
discharge. Minimum follow-up 
30 days post-operatively. 
Incidence of SSI: 
 4.7% intervention;  
22.7% control. 
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Outcomes 
 All the included trials pre-specified SSI as an outcome. However, there was 
considerable variation in how SSIs were defined. Only two papers (271, 289) referred to an 
internationally recognised definition of surgical infections, namely the CDC definition (200); 
in nine studies the authors used definitions of their own formulation (Table 3.2).  
 Most studies reported outcomes that had not been pre-specified in their Methods 
sections. With respect to this, seven studies reported various bacteriological outcomes, two 
studies (271, 289) reported the hospital length of stay associated with SSI and two studies 
(269, 288) estimated SSI-related costs. No studies reported patient quality of life as an 
outcome. 
 
3.2.3. Risk of bias within the included studies 
 This section describes in detail the main sources of bias identified in the selected 
papers, discussed in the order of their publishing year. Table 3.3 summarises the risk of bias 
for the 12 included studies, assessed under the risk of bias tool presented in the Cochrane 
Handbook of Systematic Reviews of Interventions (7). Most of the studies were found to 
exhibit a high risk of bias.  
 Maxwell et al. (267) reported a trial where two interventions were evaluated at the 
study onset: a plastic drape vs. a plastic drape and a plastic ring protector used 
simultaneously. Patients were allocated alternately to these two initial study arms, which 
rendered the sequence generation clearly inadequate and allocation concealment unclear at 
best. The authors reported that a control group was introduced later, approximately half way 
through the trial, which explains the smaller number of patients compared to the two 
intervention groups. No information was given on how the allocation was done after the 
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Table 3.3 Risk of bias in the studies included in the systematic review (Cochrane 'Risk of bias' tool) 
 
Study 
Risk of bias category 
Adequate 
sequence 
generation 
Allocation 
concealment 
Blinding 
Addressed 
incomplete outcome 
data 
Free of 
selective 
reporting 
Free of other 
bias 
Maxwell 1969(267) No Unclear Unclear No Unclear No 
Alexander-Williams 1972(283) Unclear No Unclear No Unclear No 
Psaila 1977(268) Unclear Unclear Unclear Yes Unclear No 
Gamble and Hopton 1984(284) Unclear Unclear Unclear Unclear Unclear Unclear 
Nyström 1984(270) Unclear Unclear Unclear No Unclear Unclear 
Batz 1987(285) Yes Unclear Unclear No Unclear Unclear 
Redmond 1994(286) Unclear Unclear Unclear Yes No No 
Brunet 1994(287) No Unclear Unclear Unclear Unclear Unclear 
Sookhai 1999(269) Unclear Unclear Unclear Yes Unclear No 
Horiuchi 2007(271) Unclear Unclear Unclear Yes Unclear No 
Lee 2009(288) Yes Unclear Yes No Unclear No 
Reid 2010(289) Yes Unclear Yes No Unclear No 
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introduction of the control arm. Moreover, there was no mention regarding the blinding of the 
wound assessors. 16 patients were excluded from data analysis for death within ten days of 
surgery, but no indication is given on their allocation arm or their cause of death. The 
exclusion of this group of patients may potentially be significant because it accounted for 
approximately 6% of the total trial sample of studied cases (n=260). 'Wound contamination' 
and 'wound infection rate' were pre-specified outcomes, but other outcomes were reported as 
well, including various microbiological results and the influence of prophylactic antibiotic 
therapy on infection rate. The study is not free of other sources of bias: the time, frequency or 
length of follow-up are not specified, which makes it impossible to tell whether patients were 
reviewed at the same time intervals post-surgery and increases the concern over the influence 
of the 16 patients' exclusion discussed above. 
 In the trial reported by Alexander-Williams et al. (283) the study personnel apparently 
had unrestricted access to the patient allocation scheme, given that treatment allocation was 
recorded on a form (reproduced in the original paper) together with other patient identification 
data. Patients were randomised to either the intervention or control arm in blocks of ten, but 
no details were given as to how the randomisation sequence was generated. Measures 
intended to ensure the blinding of the outcome assessor (the bacteriologist) were presented, 
but no information was provided as to whether the patients themselves were aware of the 
allocation arm. Three patients were excluded from the analysis for having died within 24 
hours of surgery, but no information was given about the treatment arm these patients 
belonged to or the cause of death. Incidence of wound infection was the only pre-specified 
outcome, but non-infectious wound complications were also reported. 
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 The study is not free of other sources of bias: firstly, the first 96 patients were 
reviewed at days three and seven post-operatively and the remainder of the patients were 
reviewed at seven and ten days post-operatively. This was justified by the fact that no 
infection was ever recorded at day three. The short follow-up in general and this alteration in 
particular may have led to missing SSIs that occurred after the seven days post-surgery. 
Secondly, the presence of SSI could not be assessed with certainty in ten patients (five in each 
group), and a brief description of each case was reported as a 'wound complication'. With 
respect to the ten wound complications mentioned above, the authors claimed that "even if 
some or all of them were included with the wound-infection patients the results would not 
materially be affected" (p.145). While this statement is correct, it raises the question of 
whether the SSI definition was accurate enough. This hypothesis is further supported by the 
authors' initial intention to perform a stratified analysis by severity of SSI, which was 
ultimately abandoned and all wound-infections were pooled together. This may be explained 
by the low incidence of SSI reported in the study and may suggest data-driven analysis. 
Finally, a potential source of bias in this study comes from the fact that the manufacturer of 
the WEPD provided assistance in the design and sequence generation of the trial. 
 In the three-arm study of Psaila et al. (268) patients were reportedly randomised to the 
two intervention arms, but no information was given regarding sequence generation or the 
randomisation in the control group. Neither allocation concealment nor blinding could be 
ascertained based on the available information. No patients were lost to follow-up. Although 
wound infection was the only pre-specified outcome, microbiological results investigating the 
correlation between skin and drape contamination, respectively, and wound infection are 
presented. Another source of bias emerges from the failure to report the length of follow-up: 
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wounds were reviewed daily starting with the third day post-operatively, but it is not clear 
whether patients left the study after the same number of days following surgery or not. 
 In the RCT reported by Gamble and Hopton (284) sequence generation and allocation 
concealment could not be established due to lack of available information. No indication was 
given about the blinding of patients or of the outcome assessors, although the wound review 
process was appropriately described. Outcome data were reported for all patients enrolled in 
the study. Wound infection rate was the only pre-specified outcome; microbiological results 
were also reported.  
 Nyström et al. (270) reported the results of an RCT comparing a wound ring drape 
with standard care, but provided no information concerning sequence generation or allocation 
concealment. Furthermore, the authors specified the possibility of excluding patients after 
randomisation and stated that "the postoperative course of the remaining patients is 
accounted for" (p. 451). The number of patients excluded as such was not reported. This 
suggestion of per-protocol analysis is indeed confirmed: "one hundred forty patients were 
treated according to the protocol" (p.452). No indication of blinded outcome assessments or 
patient blinding was given. Although the exact number of patients in the intervention arm for 
whom this was the case was not specified, based on the authors' discussion this may amount 
to seven; given that the overall results reported seven SSI cases in the intervention arm (n=70) 
compared to six SSI cases in the control group (n=70), it can be argued that exclusion of these 
patients from data analysis due to protocol violation may well influence the trial's result. 
 Batz et al. (285) appropriately reported to have used a computer-generated 
randomisation sequence, but making a judgement on allocation concealment could not be 
made based on the published manuscript. The blinding of wound reviewers could not be 
evaluated. Patients were excluded from the study if they died after surgery but no 
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supplementary information was given on the infection status of these excluded patients, 
therefore incomplete outcome data was not properly addressed. The authors apparently used 
the terms 'wound infection' and 'wound healing incident' interchangeably. No details were 
given on the number and frequency of wound assessments, or on the length of follow-up. 
 The RCT reported by Redmond et al. (286) did not accurately describe either 
sequence generation or allocation concealment measures. Blinded outcome assessment was 
ensured, but no mention was made on patient blinding. Data were reported for all the patients 
enrolled in the study. The number of SSI cases per treatment arm, stratified by degree of 
contamination, was reported but the wound infection rate (the pre-specified study outcome) 
was not calculated. While the definition for the SSI was explicit, when a subgroup analysis by 
degree of contamination was conducted no definitions of the three considered categories were 
given. A particular concern arose with respect to this study: the authorship list, the 
intervention and outcomes considered and the results' format were strikingly similar with the 
study of Sookhai et al. (269), published five years later (discussed below). This study's cohort 
is 139 patients smaller than reported by the latter. Two competing hypotheses were generated: 
either Redmond et al. (286) published interim results of the study reported by Sookhai and 
colleagues; or Sookhai et al. (269) conducted an original, larger study based on the smaller 
cohort study of Redmond et al.. The authors of both studies were contacted in order to elude 
this controversy, but no response was received. The study reported by Redmond et al. (286) 
was ultimately included in the analysis as independent research, but it must be noted that its 
originality can be questioned. 
 In the study reported by Brunet et al. (287) patients were allocated to the study arms 
based on an odd day/even day scheme, which renders sequence generation inadequate. No 
information was provided concerning allocation concealment or blinded outcome assessment. 
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Two patients in the intervention arm were excluded from the study because the WEPD could 
not be used, which suggests per-protocol analysis. The definition used for an SSI was explicit, 
but the statistic employed to examine the difference between groups was not clearly defined 
and thus result reporting was ambiguous. Bacteriological results, the influence of surgeon 
qualification on SSI incidence and inpatient length of stay were also presented, although not 
pre-specified. 
 Sookhai et al. (269) gave no information on sequence generation or allocation 
concealment. Wound reviewers were said to have been 'independent', which makes blinding 
unclear. Data were reported for all the patients enrolled in the study. The length of follow-up 
was indicated, but no mention was made regarding the timing and frequency of wound 
reviews. 
 Horiuchi et al. (271) did not give any information on sequence generation or 
allocation concealment. Outcome assessment was blinded, but no reference was made 
regarding patient blinding. The pre-specified outcome (SSI rate) was reported appropriately. 
A subgroup analysis of SSI rate by surgery site (colorectal and gastric surgery, respectively) 
was presented, but complete results with significance levels were presented only for colorectal 
surgery. Another source of bias stems from the failure to specify the length of follow-up as 
well as the timing and frequency of the wound reviews; as such, it is not clear whether 
patients in the two trial arms were assessed at comparable time points. 
 In the RCT reported by Lee et al.(288) patients were randomised using a computer-
generated allocation sequence and were unaware of their treatment arm. Allocation 
concealment, however, was not made explicit. Four patients were lost to follow-up and they 
were excluded from the analysis without further details. No information was given on these 
patients' allocation arm. Most importantly, the trial was discontinued for early evidence of 
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benefit, although the interim analysis which triggered this decision did not appear to be pre-
specified.   
 Reid et al. (289) reported a RCT where patients were randomised in blocks of 20 by a 
computer-generated sequence. Allocation concealment was unclear because "opaque 
envelopes opened at surgery by a third party" were used, but there is no indication whether 
the envelopes were sealed or how 'third party' should be interpreted. Five randomised patients 
were excluded from the analysis: two of these exclusions were due to patient death, but no 
mention was made on the time of death relative to the surgery or the cause of death. Another 
source of bias resides in the unequal balance between the two patient groups in terms of mean 
body mass index (BMI), a known risk factor for SSI: patients in the control group had a 
significantly higher BMI compared to controls; subsequently, SSI rate was unexpectedly high 
in the control group. 
  
 Based on the analysis presented above, several key points can be made regarding the 
risk of bias in the selected papers. First, most categories in the risk of bias tool were judged as 
'unclear' for lack of relevant information available in the full-text versions of the articles. This 
was mainly due to reporting failures therefore a straightforward quality assessment verdict 
was often impossible to reach. Second, when information was available the categories subject 
to bias most often were 'sequence generation' and 'incomplete outcome data'. Third, eight out 
of 12 studies were susceptible to biases falling in the 'Other sources of bias' category. 
Common shortcomings included not specifying either the length of follow-up or the timing 
and frequencies of the wound assessments and not reporting funding sources and competing 
interests.  
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Publication bias  
 The risk of publication bias was examined using a funnel plot (Figure 3.2). The slight 
asymmetry of the plot is due to the two studies of Batz et al. (285) and Lee et al. (288), which 
clearly favoured WEPDs and had some of the lowest sample sizes among all included studies 
(n=50  and n=109, respectively). Neither Begg's test (p=0.631, continuity corrected) nor 
Egger's test (p=0.242) were statistically significant in suggesting publication bias. 
 
 
 
Figure 3.2 Funnel plot of the studies included in the WEPD systematic review 
   
Chapter 3. Systematic review of the clinical effectiveness of WEPDs 
 
95 
 
3.2.4. Results of individual studies and pooled results  
 All 12 studies had a medium or high risk of bias and none of them was judged to be of 
sufficient quality to be formally included in a meta-analysis. Given the lack of robust 
evidence and the contradictory results of the included studies, an exploratory meta-analysis 
was performed based on primary data from the 12 studies. The objective of this quantitative 
analysis was to provide an indication on the estimate of the effectiveness of WEPDs in 
reducing SSI rates. 
 The individual risk ratios and the 95% confidence intervals for the random-effects 
model meta-analysis are presented in Figure 3.3. The five included studies published prior to 
1990 did not show a statistically significant benefit associated with the use of WEPDs. The 
remaining studies clearly favoured WEPDs, reporting a statistically significant benefit with 
the exception Horiuchi et al. (271) (RR 0.50, 95% CI 0.22 to 1.11). Lee et al. (288) reported 
the most favourable result for the use of WEPDs (RR 0.11, 95% CI 0.01 to 0.88).  
 The pooled risk ratio was 0.60 (95% CI 0.41 to 0.86) under a random-effects model. 
When a fixed-effects model was used, the pooled risk ratio was 0.56 (95% CI 0.45 to 0.70). 
These results suggest that the WEPDs appear to reduce the incidence of SSI when compared 
with standard care.  
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Figure 3.3 Summary data, individual and pooled effect estimates for the studies included in the WEPD meta-analysis 
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3.2.5. Heterogeneity 
 Between-study heterogeneity was also assessed: the value of the I2 statistic was 54% 
(P=0.01), suggesting statistically significant moderate heterogeneity (7). The source of 
heterogeneity was further explored by conducting two subgroup analyses: the first analysis 
grouped the studies in two categories according to their year of publishing i.e. pre-1992 and 
post-1992 studies. This analysis investigates the potential influence of the investigators’ 
awareness of the CDC definition of SSI (published in 1992) on specifying SSI definitions. Of 
course, other factors may also have changed over time. Figure 3.4 presents the forest plots for 
the two subgroups together with an evaluation of between-study heterogeneity. The low 
values of the I2 statistics suggest that both pre-1992 and post-1992 studies are highly 
homogeneous. The pooled RR suggest that pre-1992 studies are consistent in showing no 
benefit associated with WEPDs (RR 1.04, 95% CI 0.73 to 1.49), while post-1992 studies are 
largely consistent in demonstrating strong benefit (RR 0.41, 95% CI 0.31 to 0.55).  
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Figure 3.4 Exploratory subgroup analysis in WEPD systematic review - pooled effect estimates by year of publication
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 The second subgroup analysis grouped the included studies according to the design of 
the WEPD: most studies used the one ring design, while only the three most recent studies 
reportedly used the two-ring design. This analysis thus accounts for the potential influence of 
variations within the intervention under investigation. Figure 3.5 depicts the two forest plots 
and the values of the I2 statistic suggest that both subgroups have some degree of 
heterogeneity, especially the trials using the one-ring design (I2=54%). Although the two-ring 
design appears to have a stronger beneficial effect (RR 0.31, 95% CI 0.14 to 0.68) than the 
single-ring design (RR 0.69, 95% CI 0.47 to 1.02), other unexplored factors may contribute to 
between-study heterogeneity and are discussed below.  
 
3.2.6. Pre-specified subgroup analyses  
 A pre-specified subgroup analysis was conducted to investigate the influence of the 
degree of contamination on SSI incidence. This analysis included only the studies where an 
explicit differentiation of different degrees of contamination was made by the authors: the 12 
included papers described with variable amount of detail the type of surgery performed and 
assigning a degree of contamination based on partial descriptions would have led to unreliable 
results.  
 Four studies reported data on the relationship between SSI incidence and the surgical 
degree of contamination (268, 269, 286, 287). The descriptions of the degrees of 
contamination were neither identical nor completely consistent in these four papers: Psaila et 
al. (268) and Brunet et al. (287) used their own categorisations, while Redmond et al. (286) 
did not indicate any definition at all. Nevertheless, it is clear that all four papers referred to 
increasing levels of wound contamination. 
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 Figure 3.5 Exploratory subgroup analysis in WEPD systematic review - pooled effect estimates by type of WEPD design 
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An exploratory subgroup analysis was conducted in order to investigate the effect of 
WEPDs adjusted for the type of wound (clean/clean contaminated/contaminated/dirty). 
Results of this analysis are summarised in Figure 3.6. It is apparent that the use of WEPDs is 
associated with a statistically significant reduction in the risk of developing an SSI in patients 
undergoing contaminated (RR 0.37, 95% CI 0.23 to 0.61) and dirty surgery (RR 0.55, 95% CI 
0.36 to 0.86). The point estimates also suggest a beneficial effect in clean (RR 0.41, 95% CI 
0.08 to 2.09) and clean contaminated surgery (RR 0.62, 95% CI 0.34 to 1.13), but the CIs are 
wide. 
 
3.3. Discussion 
Summary of findings  
 12 prospective studies reporting primary data from 1,933 patients were included in the 
review. The quality assessment of these studies found them all to be at a significant risk of 
bias and six of them failed to address appropriately more than one risk category. Additionally, 
there was little consistency among studies with respect to the intervention used or the 
definition of an SSI. The type of WEPD used was not always accurately described. It appears 
that the device has displayed two different designs over time: the 'traditional design', 
identified up to the 1999 trial of Sookhai et al.(269), featured a plastic ring inserted in the 
abdomen and a large plastic drape emerging from it which covers the wound margins and 
extends out over the surrounding area; this device was also referred to as a 'ring drape' (268, 
270, 285, 287). An alternative design was described in detail by Lee et al. (288) and appears 
to have been used in the three post-2005 studies (271, 288, 289): it had two plastic rings and 
also had retraction properties, therefore it was marketed under the name 'wound retractor'. 
These two designs have yet to be compared against each other. 
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Figure 3.6 Exploratory subgroup analysis in WEPD systematic review - pooled effect 
estimates by type of surgery 
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 The inclusion/exclusion criteria were often not specified (Table 3.1): only two studies 
(288, 289) clearly described inclusion and exclusion criteria for the recruited patients; three 
other studies (268, 270, 271) specified exclusion criteria only; and the seven remaining 
studies did not give any such information. This makes it impossible to accurately assess the 
risk of SSI in recruited patients in most of the included studies. 
 Definitions of SSI varied greatly and belonged to the authors themselves with two 
exceptions (271, 289). This is in line with the finding of Bruce et al. (202), whose systematic 
review of prospective studies on postoperative wound infection published between 1993 and 
1997 revealed 41 distinct definitions of surgical wound infection. In addition to the diversity 
of SSI definitions, the number of SSI assessments and the follow-up period were either 
unclear or inconsistent (Table 3.2). When indicated, the length of follow-up was generally 
within 30 days post-operatively (269, 270, 286, 289). 
 The comparator was not consistent throughout the included studies: the control group 
received either no protection (269, 270, 284, 286), standard retraction (288, 289) or towels 
applied to the skin (267, 268). Moreover, the studies looked at different types of abdominal 
surgery and information about the degree of contamination, an accepted intra-operative risk 
factor for SSI, was available only in four studies (268, 269, 286, 287).  
 A large number of risk factors for SSI are known. Patient related risk factors include 
age, obesity, smoking status, diabetes, and underlying illnesses (243). Perioperative risk 
factors include appropriate preoperative antibiotic prophylaxis, mechanical bowel preparation 
with oral antimicrobials or not, duration of the procedure, and intraoperative blood transfusion 
(200). As previously described (sub-section 2.1.4), the NNIS SSI risk index is an 
internationally recognised predictor for SSI which incorporates simultaneously three 
important risk factors:  the American  Society of Anaesthesiologists score, the wound class 
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and the duration of surgery (217). Table 3.4 summarises the extent to which such risk factors 
were assessed in the included studies. 
Three methods of accounting for variability in the risk of SSI were considered:  
perioperative measures and inclusion/exclusion criteria; stratified randomisation and trial arm 
comparability; and stratified analysis of SSI incidence. Few studies adequately addressed risk 
factors when reporting the results. The most commonly mentioned topics under perioperative 
measures were skin preparation and antibiotic prophylaxis. No study reported patient 
randomisation stratified by risk. Four studies did not report any measure of comparability 
between trial arms (267, 268, 270, 283) and thus it cannot be ascertained whether 
randomisation was effective, while more recent studies presented results so as to allow 
comparing the trial arms with respect to an increasing number of risk factors. One study 
adjusted the results of SSI incidence for average length of inpatient stay (289), two studies 
adjusted for the site of surgery (271, 283) and four studies adjusted for the degree of wound 
contamination (268, 269, 286, 287). The remaining five studies did not stratify for any risk 
factor in their analyses. While reporting of risk factors appears to have improved with time, 
the lack of information on older studies makes it difficult to assess the validity of the results. 
This limitation was not due exclusively to the lack of available evidence at the time of 
publishing: for instance, Lee et al. (288) reported to have recorded operative time for each 
patient, but did not report whether patients in the two trial arms were comparable with respect 
to this parameter. Body weight was first acknowledged as a risk factor in the included studies 
in 1987 (285), but was neglected in the 1990's studies (269, 286, 287), only to be considered 
again (as body mass index) in the three most recent papers. As with the inclusion/exclusion 
criteria discussed previously, not controlling appropriately for risk factors makes it difficult to 
assess the real effect of WEPDs. 
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Table 3.4 Reporting and controlling for surgical site infection (SSI) risk factors in the WEPD systematic review studies 
 
Study Type of surgery 
Reported information on SSI risk factors 
Risk factors addressed via peri-operative 
measures or inclusion/exclusion criteria 
Risk factors addressed via 
stratified randomisation or 
reporting comparability between 
trial arms 
Risk factors adjusted for in 
the analysis of SSI incidence 
Maxwell 
1969(267) 
elective or 
emergency major 
abdominal surgery 
- the operative site was shaved during the morning 
of surgery; 
- standard skin disinfection; 
None reported None reported 
Alexander-
Williams 
1972(283) 
midline or 
paramedian 
laparotomy 
associated with the 
opening of some 
part of the bowel or 
biliary tract 
- surgery type showed a high risk of wound 
contamination; 
- pre-operative antibiotic regimen was not 
standard; 
None reported Site of surgery 
Psaila 
1977(268) 
abdominal surgery - standard skin disinfection; 
- "a standard two-layer method of wound closure, 
using continuous chromic catgut and monofilament 
nylon,  was employed in the majority of cases"; 
- an adhesive dressing was applied over each 
wound; 
- patients who received any other pre-operative 
antibiotics apart from sulphonamides for bowel 
preparation were excluded. 
None reported Degree of contamination (clean) 
Gamble and 
Hopton 
1984(284) 
elective colonic 
surgery on one 
general surgical 
firm 
- standard bowel preparation (metronidazole, 
ampicillin and neomycin); 
- standard skin disinfection; 
 
Trial arms were reported to be 
comparable with respect to age and sex 
None reported 
Nyström 
1984(270) 
elective colorectal 
surgery involving 
opening the bowel 
- no bowel preparation with antimicrobials; 
- antibiotic prophylactic regimen (either 
doxycycline or tinidazole); 
- all wounds were closed; 
None reported None reported 
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Study Type of surgery 
Reported information on SSI risk factors 
Risk factors addressed via peri-operative 
measures or inclusion/exclusion criteria 
Risk factors addressed via 
stratified randomisation or 
reporting comparability between 
trial arms 
Risk factors adjusted for in 
the analysis of SSI incidence 
Batz 
1987(285) 
patients undergoing 
tumour resection for 
colorectal cancer 
- antibiotic prophylactic regimen (cephalosporin); 
- all wounds were closed primarily; 
 
Trial arms were reported to be 
comparable with respect to: age, body 
weight and tumour stage 
None reported 
Redmond 
1994(286) 
gastrointestinal 
surgery 
- standardised antibiotic prophylaxis; 
- standardised skin preparation; 
 
Trial arms were reported to be 
comparable with respect to: age, sex, 
anaesthesia and operating time 
Degree of wound contamination 
(clean contaminated, 
contaminated, dirty) 
Brunet 
1994(287) 
all interventions of 
abdominal surgery, 
elective and 
emergency 
- standard skin preparation (site shaving and skin 
disinfection); 
- antibiotic prophylactic regimen (cephalosporin) 
was given only to patients undergoing colorectal 
surgery; 
 
Trial arms were reported to be 
comparable with respect to: age, length 
of surgery, elective/emergency surgery 
and degree of wound contamination 
Degree of wound contamination 
(clean, contaminated, dirty) 
Sookhai 
1999(269) 
trans-abdominal 
surgery for GI 
disease 
 
- standardised antibiotic prophylaxis; 
- standardised skin preparation; 
 
Trial arms were reported to be 
comparable with respect to: smoking 
status, pre-operative hospital stay, mean 
operation time, intraoperative 
temperature and number of blood units 
transfused 
Degree of wound contamination 
(clean contaminated, 
contaminated, dirty) 
Horiuchi 
2007(271) 
non traumatic 
gastrointestinal 
surgery; 
laparoscopic 
surgery and minor 
surgery excluded 
- antibiotic prophylactic regimen different for 
upper-gastrointestinal surgery (ampicillin and 
cefazolin or flomoxef) and colorectal surgery 
(cefotiam, flomoxef or cefmetazol); 
- excluded patients with long-term steroid use; 
Trial arms were reported to be 
comparable with respect to: sex, age, 
preoperative albumin level, body mass 
index, operative time, amount of blood 
loss during the operation, the lowest 
body temperature during the operation, 
amount of blood transfusion and the 
highest postoperative blood sugar level 
 
Site of surgery (gastric surgery, 
colorectal surgery) 
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Study Type of surgery 
Reported information on SSI risk factors 
Risk factors addressed via peri-operative 
measures or inclusion/exclusion criteria 
Risk factors addressed via 
stratified randomisation or 
reporting comparability between 
trial arms 
Risk factors adjusted for in 
the analysis of SSI incidence 
Lee 
2009(288) 
open 
appendicectomy 
- standard antibiotic prophylactic regimen 
(piperacilin-tazobactam or moxifloxacin); 
- all wounds were closed primarily; 
- excluded patients with insulin-dependent 
diabetes; 
Trial arms were reported to be 
comparable with respect to: age, sex, 
body mass index, smoking status, 
history of diabetes and severity of 
appendicitis 
 
None reported 
Reid 
2010(289) 
open elective 
colorectal resection 
- standardised antibiotic prophylaxis; 
- standardised skin disinfection; 
- use of oxygen and patient warming devices both 
intra- and post-operatively; 
- standard wound closure and wound dressing; 
 
Trial arms were reported to be 
comparable with respect to: age, sex, 
body mass index, mechanical bowel 
preparation, immunosuppressant use, 
diabetes, preoperative 
chemoradiotherapy, anaemia, 
malnutrition, alcohol abuse, smoking 
history, skin disease, hypertension, ASA 
score, type of intervention and mean 
length of stay. 
 
Total length of inpatient stay 
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Inadequate reporting together with the lack of stratification and adjustment for SSI risk factors 
are major limitations of the included studies. 
 Two studies reported advantages and disadvantages of using the WEPD as perceived 
by the operating surgeons, but these accounts are contradictory. Psaila et al. (268) noted that 
the ring drape may be associated with "difficulty of access and even damage to intra-
abdominal viscera" (p.732). Reid et al. (289) included surgeons' satisfaction as an outcome in 
their study by means of a visual analogue scale (0 - WEPD offers no assistance; 10 - WEPD 
offers best possible assistance): the average score elicited from the eight participating 
surgeons was 7 (range 5-10). While it is clear that the two cited studies were conducted more 
than 30 years apart and refer to different WEPD designs, the result reported by Reid et al. 
(289) should be interpreted with caution due to the small number of respondents (n=8). 
 The quality of the studies was generally poor. Their methodological drawbacks 
primarily concerned inadequate sequence generation, inadequate blinding and questionable 
outcome reporting. In addition, failure to adequately specify SSI definitions, the wound 
assessment frequency and length of follow-up seriously hindered the reliable interpretation of 
individual study results. Moreover, the studies' sample sizes were generally low and the 
majority were single centre. 
 Given these limitations, the quantitative analysis presented in this review can only 
have exploratory value. Under a random-effects model, the pooled risk ratio was 0.60 (95% 
CI 0.41 to 0.86), indicating that WEPDs may reduce the average risk of developing an SSI in 
open abdominal surgery by approximately 40% compared to standard care. The results did not 
differ greatly when a fixed-effects model was used (pooled RR 0.56, 95% CI 0.45 to 0.70). 
The proposed biological mechanism responsible for the device's effect is based on the 
physical separation between wound margins and contamination sources at the surgical site. 
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Horiuchi et al. (294) have found that use of a WEPD protects wound margins from bacterial 
invasion. 
 Although there was moderate heterogeneity between studies (I2=54%, P=0.01), the 
results of the fixed and random effects models were comparable. This suggests that 
heterogeneity did not greatly affect the pooled estimates and that the smaller trials had little 
effect on the pooled estimate. The exploration of heterogeneity sources by means of subgroup 
analysis led to two findings:  first, the SSI definition and WEPD design could be major 
sources of between-study heterogeneity; and second, other unexplored factors are also likely 
to cause systematic variation between the studies' results. These could relate to patient 
characteristics, the type of surgical intervention and perioperative measures. Unfortunately, 
information on these characteristics is both incomplete and highly variable across the included 
studies; therefore a further investigation of these factors is fraught with difficulties. The same 
applies to trial design characteristics, which were often reported incompletely.   
 Most of the included studies were single-centre, with two exceptions (270, 289). In 
these two studies patients were recruited from four hospitals and two hospitals, respectively. 
Furthermore, in the study of Reid et al. (289) it appears that surgeons from only one hospital 
operated in all the four recruiting hospitals. This undermines the multi-centre character of the 
trial since practitioner expertise is an important dimension of centre-specific characteristics 
(98). This seriously limits the external validity of the individual results. Despite fairly 
consistent risk ratios, the variation in patient characteristics, surgical technique and hospital 
may have significantly altered the effect estimates.  
 Publication bias was investigated by means of a funnel plot. Two studies contributed 
to the slight asymmetry of the plot (285, 288). Apart from their small sample sizes, these 
particular papers are at high risk of bias due to the methodological issues previously 
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discussed, thus it is difficult to ascertain that the funnel plot is actually indicating publication 
bias. This is in accordance with the non-significant results of both Begg's test and Egger's test, 
thereby suggesting that overall results are unlikely to have been influenced by publication 
bias.  
 The subgroup analysis by degree of contamination (Figure 3.6) revealed that WEPDs 
may be efficient in reducing SSI rates following surgery of various contamination degrees, 
although in this exploratory analysis statistical significance was reached only for 
contaminated and dirty surgery, respectively. This finding should be interpreted as merely an 
indication based on the existing evidence available to date. Considerable caution is needed 
when observing the results of this exploratory quantitative analysis: the poor quality of the 
studies, their small sample sizes, and the relative closeness of the risk ratio point estimates 
across the contamination groups and the inconsistent definitions of the contamination 
categories give reasons for concern. It is likely that only a larger, good quality RCT 
addressing these methodological drawbacks can provide a reliable answer as to which type of 
surgery by degree of contamination mostly benefits from the use of WEPDs. 
 It is apparent from the forest plot (Figure 3.3) that the clinical effectiveness of WEPDs 
improved with time: the recent trials reported a greater benefit from the intervention 
compared to earlier trials. Table 3.5 presents the SSI rates in the both the intervention and 
control arms of the included studies. While no trend is readily noticeable in the control 
groups, it appears that SSI rates have gradually declined over time in the intervention arms. 
This observation should be interpreted cautiously with respect to the protective effect of the 
device itself because the differences between these two categories of studies are significant. 
First, older studies are more susceptible to methodological limitations compared to more 
recent studies as the guidelines for conducting clinical trials have evolved substantially since 
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the publication year of the oldest included study. The quality assessment (Table 3.3) confirms 
this hypothesis. Second, the two largest trials in the review belong to the 'recent trials' group. 
Third, an issue worth discussing is balancing group characteristics between treatment arms. 
The risk factors of SSI are now widely known, with evidence around them starting to gather 
during the 1980s (200). The majority of the included studies did not use stratified 
randomisation by risk factors; additionally, the older studies did not produce descriptive 
statistics to demonstrate the comparability between trial arms with respect to such risk factors. 
There is, thus, a potential for bias in an unknown direction for these studies, especially given 
their generally small sample sizes.  
 
Table 3.5 WEPD systematic review: surgical site infection (SSI) rates over time in the 
intervention and control groups  
 
Study 
Control Intervention 
SSI 
cases 
Total 
patients 
SSI rate 
(%) 
SSI 
cases 
Total 
patients 
SSI rate 
(%) 
Maxwell 1969(267) 12 82 14.63 16 88 18.18 
Alexander-Williams 1972(283) 10 83 12.05 10 84 11.90 
Psaila 1977(268) 10 47 21.28 9 46 19.57 
Gamble and Hopton 1984(284) 6 70 8.57 7 70 10.00 
Nyström 1984(270) 8 29 27.59 10 27 37.04 
Batz 1987(285) 7 25 28.00 1 25 4.00 
Redmond 1994(286) 27 111 24.32 11 102 10.78 
Brunet 1994(287) 18 76 23.68 6 73 8.22 
Sookhai 1999(269) 54 182 29.67 23 170 13.53 
Horiuchi 2007(271) 16 110 14.55 8 111 7.21 
Lee 2009(288) 7 48 14.58 1 61 1.64 
Reid 2010(289) 15 66 22.73 3 64 4.69 
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Strengths and limitations 
 The strength of this review lies in the comprehensive assessment of the relevant 
evidence regarding the use of WEPDs in open abdominal surgery. To my knowledge, this is 
the first review looking at the reduction in SSI incidence associated with this type of device. 
The review identified several studies that were seldom or never cited in the widely known 
papers belonging to this therapeutic field (284, 285, 287). 
 The findings have several limitations. First, it is possible that the search strategy failed 
to identify some unpublished studies or trials that are published in journals not included in the 
bibliographic databases. Only clinically based SSI definitions were accepted in order to 
increase relevance for the present clinical context. The review is limited to open abdominal 
surgery. Studies have been published on the use of WEPDs of a similar design in laparoscopic 
interventions (295, 296). However, SSI rates are much lower in laparoscopic surgery 
compared to open surgery across a range of interventions (197, 297-300) and it would be 
inappropriate to combine data for open and laparoscopic surgery. Finally, poor reporting of 
inclusion/exclusion criteria and inappropriate accounting for SSI risk factors in the included 
studies may limit the validity of the results. 
Following the completion and submission for publication of this systematic review in 
April 2011, new evidence regarding the clinical effectiveness of WEPDs has emerged in the  
form of a parallel systematic review and two RCTs. Edwards et al. (301) systematically 
reviewed RCTs where WEPDs were evaluated in reducing SSI rate after gastrointestinal and 
biliary tract surgery. Their review included 6 studies (1008 patients in total), all of which had 
been included in the systematic review (269-271, 284, 288, 289). The pooled risk ratio 
estimated under a random-effects model was 0.55 (95% CI 0.31 to 0.98), thus largely 
comparable with the finding of this review. Edwards and colleagues also acknowledged the 
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effect of the WEPD design as a potential source of between-study heterogeneity and 
conducted subgroup analyses based on structural design. The modern dual-ring design was 
associated with a larger reduction in SSI rate compared to the traditional one-ring design (RR 
0.31, 95%CI 0.14 to 0.67 vs. RR 0.83, 95%CI 0.38 to 1.83). 
 The results of two further single-centre RCTs have been published. Theodoridis et al. 
(302) enrolled 231 women undergoing caesarean section at a general hospital in Thessaloniki 
(Greece) and used the Alexis wound retractor in the intervention group and a conventional 
Doyen retractor in the control group. The authors reported 3/116 (3%) SSI cases in the control 
group compared with 0/115 (0%) SSI cases in the intervention group. Due to insufficient 
reporting the methodological quality of the study could not be adequately assessed. Moreover, 
the surveillance period was not specified, although it was mentioned that patients were 
monitored only during hospitalization. Cheng et al. (303) enrolled patients undergoing 
colorectal resection at a university hospital in Kuala Lumpur (Malaysia) and investigated the 
effect of WEPD in preventing SSI. They reported 6/30 (20%) infections in the control group 
compared with 0/34 (0%) infections in the study group. While patients were followed-up for 
30 days post-operatively and blinding appears to have been appropriately ensured, their study 
featured a potential risk of selection bias due to allocation concealment using sealed 
envelopes. Furthermore, their sample size is strikingly small because it relied on a very high 
effectiveness of the WEPD i.e. 1% SSI rate in the intervention group vs. 20% SSI rate in the 
control group, suggesting a RR of 0.05. This assumption was not supported by references and, 
in the light of any known published study, can be regarded as very optimistic: the most 
favourable studies for WEPDs (285, 288) estimated a RR in excess of 0.10.  
 Furthermore, new research is currently under preparation. A protocol for a Cochrane 
systematic review on the effectiveness of WEPDs has been recently published (304). 
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Furthermore, Mihaljevic et al. (305) published a protocol for a RCT (the BaFO trial) 
investigating the effectiveness of WEPDs (the one-ring design) in reducing SSI in adult 
patients undergoing midline and transverse laparotomy on the occasion of general and 
visceral surgery. The study aims to recruit 600 patients from 15 German hospitals and a 50% 
reduction in SSI informed the sample size calculation, which resonates with the result of 
Horiuchi et al.(271). The CDC definition of SSI will be used and patients will be monitored 
for 45 days post-operatively, the longest surveillance period in all trials known to date. BaFO 
initiated recruitment in September 2010 and is expected to finish in summer 2013. 
 
3.4. Conclusion  
 The body of evidence surrounding the use of WEPDs in reducing SSI in patients 
undergoing open abdominal surgery is relatively rich and this review identified 12 relevant 
articles. The results of the exploratory meta-analysis suggested that WEPDs may significantly 
reduce the incidence of SSI post-operatively in patients undergoing open abdominal surgery 
when compared with standard care. However, the quality of the available evidence is 
generally very poor due to methodological flaws and reporting failures. All the included 
studies were single-centre with two exceptions and their sample sizes were generally low. 
This may explain why WEPDs have not yet been widely adopted in current practice. 
 Given the potential clinical benefit of WEPDs in reducing SSI, it is of interest to 
explore their potential economic benefits. Chapter 4 presents the methods and findings of an 
original decision analytic model which estimates the cost-effectiveness of WEPDs compared 
to standard care in the UK context.  
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 The principal conclusion of Chapter 3 was that, based on the existing evidence, 
WEPDs are likely to be effective in reducing SSI rate following open abdominal surgery. 
However, there is currently no available evidence on the cost-effectiveness of WEPDs, 
against any comparator, in any setting and for any patient population. The aim of this Chapter 
was to produce preliminary evidence, based on the best available information, on the cost-
effectiveness of WEPDs compared to standard care when used in adults undergoing open 
abdominal surgery in the UK context. 
 A cost-utility analysis was conducted such that patient outcomes were measured in 
QALYs and the result was expressed in incremental costs (£) per QALY gained. A 
preliminary literature search revealed there is only limited evidence on utility values 
associated with SSI and this evidence has not yet been reviewed systematically. This type of 
evidence is necessary to inform the decision model. The Chapter is, therefore, structured in 
two sections: a systematic review of SSI utility values; and the actual decision model, 
informed by the SSI utility systematic review and the evidence on the clinical effectiveness of 
WEPDs presented in Chapter 3. 
 
4.1. Systematic review of SSI utility values  
The aim of this systematic review was to identify utility values associated with SSI in 
order to inform the outcomes of the SSI health states in the decision model. The review was 
conducted according to a pre-specified protocol based on guidance from the Centre for 
Reviews and Dissemination (272). 
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4.1.1. Methods 
The elements of the question addressed by the systematic review are reported below in 
PICOS format (274): 
Population: human patients undergoing open surgery; 
Intervention: if applicable, any type of intervention aimed at improving surgical wound 
outcomes; 
Comparator: if applicable, any comparator; 
Outcomes: utility information was collected from or used to model a cohort of patients 
experiencing a SSI; 
Study design: any type of study was accepted, including studies reporting primary data, 
reviews and model-based economic evaluations. 
  
Eligibility criteria 
The review included studies of any design where utility values for SSI were invoked 
(e.g. decision models) or elicited (e.g. valuation exercises) or at least one generic or specific 
non-preference based instrument was applied to a cohort of SSI patients (e.g. clinical trials, 
burden of illness studies). All definitions of SSI were accepted as long as they were explicit 
and ‘surgical wound outcomes’ were one of the main outcomes of the study. Only studies 
investigating outcomes of patients after open surgery were accepted. No language restrictions 
applied. 
The following categories of studies were excluded: studies that did not explicitly 
report utility values or HRQoL data for a cohort of SSI patients; studies that did not explicitly 
investigate surgical wound outcomes; studies where HRQoL data were elicited at more than 6 
months after surgery without an explicit mention that patients still had a SSI at the time of 
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elicitation; studies that had as a primary outcome a composite of multiple surgical outcomes, 
even if it included SSI or wound healing; and studies looking at non-surgical wounds (e.g. 
burns, diabetic ulcers, radiation wounds) or infections (e.g. systemic infections). Study 
protocols and conference abstracts were also excluded. 
 
Information sources 
The following databases were searched from the starting date until October 2011: 
OVID MEDLINE and MEDLINE-In-Process, OVID EMBASE, ISI Web of Knowledge 
(Science Citation Index) and NHS Economic Evaluation Database (NHS EED). The 
information sources were selected as such with the intention to include economic evaluations 
(both model- and trial-based) of interventions aimed at reducing SSI and standalone HRQoL 
studies on relevant cohorts of surgical patients. 
 
Search strategy 
 The devised search strategy included two categories of search terms: terms associated 
with wound infection, largely inspired by the systematic review of clinical effectiveness of 
WEPDs presented in the previous Chapter; and a range of terms relevant for HRQoL studies, 
thus capturing both widely used generic preference-based multi-attribute utility instruments, 
such as EQ-5D (43), HUI2 (306) and HUI3 (307), QWB (308) and SF-6D (44), as well as 
non-preference-based generic health status measures, such as SF-12 (309) and SF-36 (310, 
311) health surveys. The latter are of interest because their scores can be mapped through 
statistical algorithms to preference-based measures and thus generate utility values (312). The 
detailed search strategies are presented in Appendix 3. The search was performed in October 
2011. 
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Study selection 
The study selection process comprised three phases: in phase 1 the titles and abstracts 
of returned papers were scanned against the inclusion/exclusion criteria. Articles 
demonstrating any of the exclusion criteria were eliminated. Where a decision could not be 
made based on the title and abstract, the article was entered into phase 2. In phase 2 the full-
text versions of the papers resulting from phase 1 were obtained and scanned against the 
inclusion/exclusion criteria. Only studies fulfilling all the inclusion criteria were accepted. In 
phase 3 backward and forward reference searches were conducted for the studies kept in the 
review at the end of phase 2 in order to identify other potentially relevant articles.  
 
Data extraction 
The following data items were extracted from the papers included after phase 3:  
study type; setting; type of surgery; sample size (of the cohort/subgroup where SSI values 
were elicited from); HRQoL instrument(s) used (e.g. EQ-5D); time of elicitation (e.g. 4 weeks 
after surgery); and utility values/HRQoL scores. 
 
Data analysis  
The characteristics of the included studies and the utility values/HRQoL data relevant 
to SSI patients were tabulated and summarised in a narrative review. The main objective of 
the review was to inform the decision model, so a formal quality assessment of the included 
papers was not performed. One researcher (I) performed the searches, screening, study 
inclusion and data extraction. 
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4.1.2. Results of the systematic review of SSI utility values  
 4,427 papers were identified through the database search: 957 papers were retrieved 
from MEDLINE and MEDLINE in Process, 1,239 from EMBASE, 1,580 from ISI Web of 
Knowledge and 651 papers were retrieved from NHS EED. After removing 807 duplicates, 
3,620 papers were scanned for title/abstract and 3,572 were excluded (phase 1). In phase 2, 48 
full-text papers were read and further 37 studies were excluded for not complying with the 
inclusion/exclusion criteria. The list of excluded full-text articles and accompanying 
justifications are presented in Appendix 4. Eleven studies entered phase 3 and no relevant 
further studies were identified through the reference list search. The study of Elliott et al. 
(313) was excluded as it duplicated the previous publication of the same research team (314), 
leaving a total of ten studies included in the systematic review. The study selection process is 
presented in Figure 4.1. 
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Figure 4.1 Summary of the study selection process in the SSI utility systematic review 
 
 
 
4427 citations identified by 
searching online databases 
807 duplicates removed 
3620 papers scanned for title and 
abstract after duplicates removed 
48 potentially eligible papers scanned 
for full-text version 
37 papers excluded for not complying with the 
inclusion/exclusion criteria (the full list and reasons 
for exclusion in Appendix 4) 
1 paper excluded for duplication 
10 papers included in the review 
3572 papers excluded 
Chapter 4. Preliminary evidence on the cost-effectiveness of WEPDs: a decision-analytic 
model 
 
122 
 
The characteristics of the ten papers included in the review are summarised in Table 
4.1. Seven studies were conducted in the US (230, 315-320), while the remaining three were 
specific to the UK (314), Canada (321) and Denmark (322). Three studies considered 
orthopaedic surgery (314, 316, 318) and one study each considered cosmetic surgery (321), 
cardiac surgery (323), vascular surgery (320), caesarean delivery (319) and abdominal surgery 
(315). Furthermore, two studies considered a mix of surgical patients (230, 322). Eight 
articles were decision modelling studies (314-316, 318-321, 323) that cited utility values 
informing cost-utility analyses and two papers elicited SSI patients' own valuation of their 
health states using standardised questionnaires (230, 322). The utility data from the included 
studies are summarised in Table 4.2. 
 All eight modelling studies used decision trees to produce cost-effectiveness estimates 
for interventions aimed to reduce the risk of postoperative infection. The utility decrements 
associated with SSI varied from 0 i.e. no disutility (318), to 0.4 (315). However, the study 
with a null SSI utility decrement did not rely on published data for this decision, but rather 
assumed that SSI utility was equal to the utility of hospital confinement (318). A number of 
studies across several types of surgery cited utility decrements in the range 0.1 to 0.2 (314, 
316, 321, 323). 
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Table 4.1 Characteristics of the studies included in the SSI utility systematic review 
 
Study ID Study type Type of surgery Country Population characteristics Intervention Control 
Brasel 
1997(315) 
Decision 
model 
Appendicectomy US 
Hypothetical cohort of men and 
women with contaminated wounds 
Primary wound closure; 
delayed primary wound closure Secondary wound closure 
Cranny 
2008(314) 
Decision 
model 
General surgery UK 
Unclear, but data inputs compatible 
with a hypothetical cohort of 65-
year old UK men 
Glycopeptide prophylaxis: 
cephalosporin; vancomycin; 
cephalosporin and vancomycin 
Unclear 
Lee 
2010(323) 
Decision 
model 
Cardiac surgery US 
Hypothetical cohort of 1,000 
patients with median age 65 
Surveillance strategy i.e. 
preoperative MRSA screening 
and decolonization 
No MRSA surveillance strategy 
Perencevich 
2003(230) 
Primary 
Study 
General surgery US 
267 patients: SSI group - mean age 
55.7, 48.3% male; control group - 
mean age 57.5, 52.8% male 
SF-12 Individual domain scores MCS, 
PCS 
Slobogean 
2010(318) 
Decision 
model 
Surgical treatment 
of closed fractures 
US 
Hypothetical cohort of 52-year old 
men 
Single-dose antibiotic 
prophylaxis 
Multiple-dose antibiotic 
prophylaxis 
Thoma 
2003(321) 
Decision 
model 
Breast 
reconstruction 
Canada 
Unclear, but utility input data are 
compatible with a hypothetical 
cohort of 45-year old women 
Free transverse rectus 
abdominis myocutaneous 
(TRAM) for breast 
reconstruction 
Unipedicled TRAM for breast 
reconstruction 
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Study ID Study type Type of surgery Country Population characteristics Intervention Control 
Bailey 
2011(316) 
Decision 
model 
Orthopaedic surgery US 
Hypothetical cohort of 1,000 
patients of age 63 
Preoperative home-based 
chlorhexidine bathing cloth kits No bathing cloth kits 
Lee 2009(320) 
Decision 
model 
Vascular surgery US 
 
Hypothetical cohort of patients with 
median age 73 
Surveillance strategy i.e. 
preoperative MRSA screening 
and decolonization 
No MRSA surveillance strategy 
Lee 2011(319) 
Decision 
model 
Caesarean delivery US 
Hypothetical cohort of 27-year old 
women 
Preoperative S. aureus 
screening and decolonization No S. aureus surveillance 
Poulsen 
1997(322) 
Primary 
study 
General, 
gynaecologic and 
orthopaedic surgery 
Denmark 
1301 patients: 47% over age 50, 
52% male 
GHQ and IADL 
Infected minus uninfected 
differences 
Hospital cohort: 
-0.47 on GHQ scale 
0.23 on IADL scale 
Patient cohort: 
0.45 on GHQ scale 
-0.04 on IADL scale 
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Table 4.2 SSI utility data in the studies included in the SSI utility systematic review 
 
Study ID Study type 
HRQOL instrument 
/source 
Time of elicitation HRQoL mean values for SSI 
Brasel 
1997(315) 
Decision 
model 
Clinical opinion 
n/a 
0.6 utility 
(0.4 utility decrement) 
Cranny 
2008(314) 
Decision 
model 
Clinical opinion: cited from Tengs and Wallace (2000), 
in its turn cited from Tsevat (1989) n/a 
0.9 utility 
(0.1 utility decrement) 
Lee 
2010(323) 
Decision 
model 
Cited from Selai and Rosser (1995) 
Unclear 
0.642 utility  
(0.198 utility decrement) 
Perencevich 
2003(230) 
Primary 
Study 
SF-12 8 weeks after 
surgery 
Individual domain scores MCS, PCS 
Slobogean 
2010(318) 
Decision 
model 
Time trade-off, cited from Kuntz et al (2000), in its turn 
cited from Torrance (1987) n/a 
0.34 utility TTO 
(0 utility decrement) 
Thoma 
2003(321) 
Decision 
model 
Clinical opinion: a sample of 33 plastic surgeons 
n/a 
0.73 with drainage  
(0.14 utility decrement) 
Bailey 
2011(316) 
Decision 
model 
Clinical opinion: cited from Tengs and Wallace (2000), 
in its turn cited from Tsevat (1989) n/a 
0.9 utility 
(0.1 utility decrement) 
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Study ID Study type 
HRQOL instrument 
/source 
Time of elicitation HRQoL mean values for SSI 
Lee 2009(320) 
Decision 
model 
Cited from Sackett and Torrance (1978) 
Unclear 
0.642 utility (utility decrement 
unclear) 
Lee 2011(319) 
Decision 
model 
Clinical opinion: cited from Brasel et al (1997)  
n/a 
0.6 utility 
(0.32 utility decrement) 
Poulsen 
1997(322) 
Primary 
study 
GHQ and IADL 5.5 and 10 months 
after surgery 
Infected minus uninfected differences 
Hospital cohort: 
-0.47 on GHQ scale 
0.23 on IADL scale 
Patient cohort: 
0.45 on GHQ scale 
-0.04 on IADL scale 
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 The references for utility values invoked in the modelling studies were rarely primary 
studies themselves and cited other studies in their turn, sometimes of ambiguous relevance. 
For example, in the orthopaedic infection prophylaxis study of Brasel et al. a 0.1 SSI disutility 
was assumed, informed by the paper of Tengs and Wallace (324), which had reported a 0.9 
utility for an infection of an artificial joint. The 0.9 value in the Tengs and Wallace review 
was in its turn informed by the 1989 decision modelling study of Tsevat et al. (325), who had 
assumed, based on their own judgement, 0.9 QALYs for a patient hospitalized for a year due 
to an infected artificial joint. In another example, Lee et al. used a utility value of 0.84 for an 
otherwise healthy patient following cardiac surgery and a utility of 0.642 for an infected 
surgical wound; the latter estimate was based on the 1995 study of Selai and Rosser (326). 
The study of Selai and Rosser was a pilot micro study on a sample of 40 patients in a UK 
general hospital whose aim was to compare the EQ-5D utility values of a sample of inpatients 
with those of the general population. It is not clear how many of the patients in this micro 
study actually experienced a SSI. The authors (Selai and Rosser) were contacted by email in 
an attempt to obtain a report of the original study: they responded and initially agreed to assist 
upon retrieving the document from their own archive, but eventually failed to provide the 
data.  
There were also instances of unclear reporting: for example, Lee et al. used a 0.642 
utility for SSI informed by the 1978 paper of Torrance and Sackett (327), but the utility 
decrement itself is unclear because the utility associated with uncomplicated surgery was not 
reported. Moreover, their paper appears to contain a referencing error: the paper of Torrance 
and Sackett did present utility values for hospital and home confinement due to dialysis and 
some contagious diseases, but not specifically for SSI and the numerical value of 0.642 did 
not even appear anywhere in their paper. However, a 0.642 utility associated with SSI appears 
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in the Selai and Rosser study (326), discussed above, which was also referenced in a study of 
the same team (320) as a source for line infection utility. 
 Two included studies explicitly derived utility values based on expert opinion or 
clinical judgement (315, 321). Furthermore, the primary sources for three further studies (314, 
316, 319) also relied on expert opinion to derive utility values. The methods of eliciting 
expert opinion also varied from the authors’ own judgement (315) to conducting a survey 
among practicing surgeons (321). Thoma et al. acknowledged that utility values elicited from 
patients themselves are generally preferable, but argued that expert generated values are 
recommended when evaluating novel surgical interventions, as was their case (321). 
Only one decision modelling study used a systematic review of the literature to inform 
its utility input data. Cranny et al. conducted systematic reviews of the effectiveness and cost-
effectiveness of glycopeptide antibiotics and identified one economic evaluation study which 
reported HRQoL information for SSI using the SF-36 questionnaire (229). However, the 
authors of that study did not respond to their request for access to individual patient data, 
which would have allowed the derivation of utility scores. Eventually, Cranny et al. used a 
utility decrement of 0.1 for SSI based on Tengs and Wallace's (324) estimate of 0.9 utility for 
an infection of an artificial joint, which was described above. 
Two primary studies employed standardised HRQoL instruments. Perencevich et al. 
(230) employed the SF-12 questionnaire and compared the health status of 50 patients with 
SSI at 8 weeks after surgery to that of 123 matched uninfected controls. Case-patients 
reported significantly lower scores than controls on the mental health component score of SF-
12 (MCS-12); the difference between the groups was small, but not statistically significant on 
the physical health component (PCS-12). The authors were contacted by email and asked 
whether the individual patient scores for the SF-12 instrument were still available and could 
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be shared. This would have allowed mapping the SF-12 scores onto the EQ-5D instrument 
and thus generate utility values (328). The authors promptly replied and reported that the 
original patient dataset had been deleted since the termination of their study and there was no 
backup copy. Given this situation, the mapping exercise could not be performed and utility 
values could not be calculated. 
Poulsen et al. (322) enrolled 1301 Danish patients and compared the HRQoL between 
patients with and without a surgical wound infection (SWI). The authors looked at two 
cohorts: in the hospital cohort, the SWI was diagnosed while inpatient by a surgeon; this 
group included 58 cases and 648 controls. In the patient cohort, only SWIs diagnosed after 
discharge were included, either by the antibiotics prescription or a reopening of the wound 
because of purulent discharge. Patient outcomes were assessed using the 12-question edition 
of the General Health Questionnaire (GHQ) and the Instrumental Activity of Daily Living 
(IADL) questionnaire, which were mailed to patients twice (median 5.5 months and 10 
months postoperatively). The differences between groups (infected vs. uninfected) were 
small, not statistically significant and inconsistent across cohorts (Table 4.2). A recent 
systematic review identified no mapping studies of GHQ or IADL to preference-based 
measures (312), therefore utilities cannot be calculated from these data. 
 
4.1.3. Discussion 
This systematic review identified ten studies which investigated interventions meant to 
reduce SSI following a range of surgical procedures, including general surgery (230), 
orthopaedic surgery (316) and caesarean delivery (319). The primary sources of utility values 
in the eight modelling studies were often informed by authors’ own judgement or expert 
opinion. There also appear to be very few primary studies eliciting patient preferences on SSI 
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health states. Circular referencing across the identified publications was common, thus 
indicating that the available literature on SSI utility values is scarce.  
Given that the use of WEPDs lends itself mostly to open abdominal surgery, the 
appendicectomy study of Brasel et al. (315) appears to be the most relevant in this instance, 
especially given the 30-day time horizon which is in line with the SSI definition applicable in 
the UK. However, the utility value cited in this study was based solely on authors' own 
judgements and so its validity can be easily questioned. In this situation, I looked at the 
overall utility decrement associated with SSI in all the studies identified by the review in 
order to use (with due caution) all the available information on the impact of SSI on surgical 
patients' HRQoL.    
 In the eight modelling studies the utility decrement associated with a SSI was in the 
range of 0 i.e. no difference from uninfected surgical patients, to 0.4. Unfortunately, the utility 
scores could not be calculated from the two studies that elicited SSI patients' scores using 
validated questionnaires due to the lack of the individual patient data or absence of mapping 
algorithms. Two studies (314, 321) used a utility decrement of 0.1 for SSI and it was decided 
to use this estimate in the base-case analysis of the economic model for WEPDs. The impact 
of this value on the cost-effectiveness of WEPDs was explored in sensitivity analyses (see 
below sub-section 4.2.3). 
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4.2. SSI decision model 
The aim of the decision model was to use the best available evidence to produce 
preliminary evidence on the cost-effectiveness of WEPDs compared to standard care in 
reducing SSI in order to inform decision makers on the wider benefits of using WEPDs in 
current surgical practice and on the need to gather additional evidence on the topic. The 
methods and results are reported below in line with the recommendations of the CHEERS 
Statement (329) (Appendix 5).  
 
4.2.1. Methods 
 A model-based cost-utility analysis was conducted using TreeAge Pro 2011 software 
(330). The patient population considered in the base-case is represented by adult patients aged 
60 undergoing open large bowel surgery in the UK. Large bowel surgery was chosen because 
it is one of the surgical procedures with the highest SSI incidence rates in the UK (192).  
 
Setting and perspective 
The model setting is the English NHS, where there is considerable interest in the 
surveillance of hospital-acquired infections in general and of SSI in particular (206, 331). The 
majority of the surveillance efforts refer to NHS hospitals, although the pathway of care of 
SSI patients also continues in primary care after discharge (195). There is less evidence about 
patterns of care in the primary setting than for inpatient care.  
 The model perspective was that of the NHS. Only resource utilisation relevant to the 
NHS was considered for costing purposes. 
 The base-case considered the use of a WEPD in adults undergoing open large bowel 
surgery compared with standard care (i.e. not using the WEPD). The comparator was chosen 
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as such since the current clinical guidelines do not recommend any other intervention for the 
purpose of wound-edge protection, thus there is no obvious competitor for WEPD apart from 
the bundle of prophylactic measures used in surgery. 
 
Time horizon 
The model time horizon was 30 days post-operatively. Most SSI surveillance 
programmes as well as the SSI definitions used by the HPA (206) and the CDC (200) cite a 
30-day interval post-surgery during which wound infections are being monitored and classed 
as an SSI, respectively. The minimum time horizon would, thus, be one month post-
operatively. Moreover, the majority of SSIs do heal and patients recover full functionality. In 
the absence of published data on the average healing time of a SSI, a group of health care 
professionals were informally approached on this matter (two surgical registrars on rotation at 
University Hospitals Birmingham, one general practitioner (GP) with academic tenure in 
Primary Care Clinical Sciences – University of Birmingham, two district nurses affiliated 
with Sandwell Primary Care Trust and one practice nurse at University Hospitals 
Birmingham). In addition, the GP and the nurses were consulted about the likely resource 
utilisation and patient pathways in primary care. Their views were that SSIs can heal from as 
soon as several days to as long as several months, depending on the gravity of the infection 
and on patient co-morbidities. Given the under-reporting of SSIs, the paucity of data 
regarding SSI progression in time and the fact that most of the evidence concerning resource 
utilisation comes from studies with a 30-day period, the time horizon for the model was 
selected as 30 days after surgery. The implications of the time horizon on the cost-
effectiveness findings are discussed later in the Chapter under Strengths and limitations. No 
discount rate for costs and outcomes was applicable due to the short time horizon. 
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Outcomes 
Outcomes were measured in QALYs. Prior to the inclusion in the decision model, all 
utility values were adjusted accordingly for the one month time horizon. The utility associated 
with uninfected open abdominal surgery was informed by the study of Janson et al. (332), 
who elicited EQ-5D values from patients undergoing colon resection, one of the most 
common intervention in the 'large bowel surgery' category. A 0.1 utility decrement was 
assumed for SSI patients based on the systematic review presented in the previous section 
(section 4.1). The value of the utility decrement was varied in sensitivity analyses. 
 
Clinical effectiveness 
The clinical effectiveness estimates for the WEPD were informed by the findings of 
the systematic review of WEPD clinical effectiveness studies, which was presented in detail 
in Chapter 3. The base-case value for the relative risk of SSI associated with using the WEPD 
compared to standard care was 0.60 (95%CI 0.41 to 0.86). 
 
Resource use and costs 
All costs in the model are given in UK £ (2010 value). The price of the WEPD was 
sourced from the manufacturer 3MTM (Steri-Drape©). Four WEPD sizes are available with 
differing prices and the medium sized WEPD was considered in the base-case. The Hospital 
and Community Health Services combined pay and price inflation index (HCHS) (333) was 
used to inflate all relevant costs obtained from the literature.  
For inpatient care, the length of stay for uninfected patients and the additional length 
of stay for patients with superficial and with deep/organ-space SSI were informed by the 
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study of Coello et al. (191). No conclusive evidence has yet suggested that MRSA-SSI affects 
the length of stay for patients undergoing large bowel surgery in the UK setting, although 
there is evidence from US hospitals that MRSA-SSI is associated with increased length of 
stay (234, 334). Since discharge practices are not transferable between countries, for the 
purpose of this model patients with MRSA and non-MRSA SSI were assumed to spend the 
same number of inpatient days and the impact of this assumption is discussed below under 
Strengths and limitations. The difference between the two types of infection was reflected 
through additional costs due to MRSA (i.e. barrier nursing), assumed to start being incurred 
half-way through the inpatient stay. The unit costs for an inpatient day, with or without SSI, 
were also informed by the study of Coello et al. and updated to the 2010 value (191). The unit 
costs for MRSA care, applicable to patients experiencing MRSA-SSI, were taken from the 
modelling study of Elliott et al. (313) and were added to the usual inpatient day cost. Patients 
who die in hospital as a result of a SSI have been assigned the cost for three organ support 
critical care (335).  
Unit costs for care received in a primary setting (GP visit, district nurse and practice 
nurse time) were informed by Curtis (336). Costs for medication and painkillers prescribed by 
the GP (i.e. Co-fluampicil 250/250 and Co-codamol 8/500 4 times daily for 7 days, informed 
by discussion with one GP) were informed by Prescription Cost Analysis England 2010 (337). 
 
 
 
Chapter 4. Preliminary evidence on the cost-effectiveness of WEPDs: a decision-analytic 
model 
 
135 
 
Model structure and assumptions 
The chosen model structure was a decision tree. This decision is supported by decision 
modelling methodological guidelines (338, 339) which recommend the use of decision trees 
to model interventions with relatively short duration outcomes beyond which the patient is 
expected to fully recover. 
 The model structure can be summarised as follows (Figure 4.2): following surgery, a 
patient may or may not develop a SSI. The SSI can be diagnosed during the initial inpatient 
phase or after discharge. If the SSI is diagnosed while in hospital, three main alternatives were 
explored: 1) the patient remains in hospital until the infection is healed; 2) the patient is 
discharged with a SSI and continues treatment in primary care; or 3) the patient dies in 
hospital as a result of the SSI or other complications. If discharged with a SSI (option 2), the 
infection may continue to heal or not in a primary care setting. If the infection does not heal, it 
has been assumed that patients will visit the GP, who may either refer them back to hospital 
or prescribe antibiotics and send the patient home. If the SSI develops after discharge, it was 
assumed that patients would visit the GP, who may refer them to hospital or not, as above. 
The model distinguished between MRSA and non-MRSA SSIs because evidence 
suggests that MRSA-SSIs are associated with higher costs and higher mortality compared to 
non-MRSA SSIs (234). The model also differentiated between superficial and deep/organ-
space SSIs because the inpatient length of stay has been shown to vary between the two 
categories (191). Superficial, deep and organ-space SSI can be distinguished according to 
severity and site (199). 
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 Figure 4.2 The structure of the decision model (WEPD arm) 
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It was assumed that patients with a SSI diagnosed whilst inpatients visit their GP once 
and receive seven visits from the district nurse after discharge. There is one exception: 
patients who are diagnosed with a SSI whilst an inpatient and remain in hospital until the SSI 
is cured will receive two district nurse visits upon discharge. In addition, if they have a 
recurrent SSI and the GP does not refer them to hospital, two practice nurse visits were 
considered. Patients for whom the SSI becomes apparent only after discharge visit their GP 
once and do not receive district nurse visits. Patients developing a MRSA-SSI after discharge 
visit their GP twice, undergo two practice nurse visits and they are referred back to hospital. 
These assumptions were informed by discussions with health care professionals, as described 
above. 
 A proportion of SSI inpatients were assumed to be discharged with a SSI and 
continue antibiotic therapy at home and in primary care, while the rest would remain as 
inpatients. A significant proportion of SSIs are diagnosed after discharge (250, 251, 340) and 
the clinical reality suggests that only a fraction of GPs will refer patients with a SSI back to 
hospital - in most cases wound care will continue in a primary setting under antibiotic 
treatment. Moreover, if the GP prescribes antibiotics for a non-MRSA-SSI, it was assumed 
that it would heal in primary care. On the other hand, it was assumed that MRSA-SSIs would 
not heal in primary care and would require hospital readmission. 
It was also assumed that the use of a WEPD affects mortality and the probability of 
developing a SSI, but does not influence the probability of acquiring a particular type of SSI 
(i.e. MRSA/non-MRSA, superficial/deep/organ-space) or any other process variable (e.g. 
probability of detecting an SSI while inpatient, GP referral rate) compared to patients in the 
control group. For three probabilities (the probability of being discharged with a SSI, the 
probability of GP referral to hospital and the probability of having a recurrent SSI) there was 
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no literature information available and the point estimates were informed by consultations 
with health care professionals, as described above.  
 
Analytical methods 
A probabilistic analysis was conducted in the base-case to reflect the uncertainty of the 
model input parameters, namely probability values, costs and utility values. Each model 
parameter was assigned a distribution reflecting the amount and pattern of its expected 
variation. Cost-utility results were calculated by simultaneously selecting random values from 
these distributions over 10,000 replications in a Monte Carlo simulation. The results of the 
simulations were depicted graphically using cost-effectiveness scatter plots and cost-
effectiveness acceptability curves (CEACs) (58). The latter reflect the probability of either 
alternative being cost-effective at varying WTP thresholds, currently considered by NICE in 
the range of £20,000 to £30,000 per QALY gained (39). 
 
Deterministic sensitivity analyses 
A range of deterministic sensitivity analyses were carried out by varying the base-case 
values for the following parameters: the probability of discharging patients with a SSI; the 
probability of being referred to the hospital by the GP when developing a SSI; the utility 
decrement for SSI patients compared to uninfected patients; the length of stay for uninfected 
patients; the clinical effectiveness of WEPDs, reflected in the model by the relative risk of 
SSI in the WEPD arm; and the cost of the WEPD. These parameters were subject to 
sensitivity analyses because their base-case values were associated with the greatest 
uncertainty as there were no literature sources available to inform their estimates. For the first 
two probabilities, the intervals were chosen arbitrarily in order to investigate their influence 
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on the ICER. In the sensitivity analysis of the utility decrement, the lower and upper bound 
have been set at 0 (no difference) and 0.4, respectively, according to the extreme values 
identified in the systematic review of SSI utility values (section 4.1). The lower bound of the 
length of stay analysis was informed by an average estimate for lower digestive tract surgery 
cited in Hospital Episode Statistics for England 2010 (341) and the upper bound was 
arbitrarily set at 20 days. The length of stay for uninfected patients influences that of SSI 
patients because the additional inpatient days due to SSI have been added to this core value. 
The relative risk of SSI in the intervention arm was varied across the entire possible range (0 
to 1) to identify the threshold value at which the cost-effectiveness recommendation changes. 
The cost of the WEPD was varied from 0 to £100 – a conservative range given that the 
highest price for a WEPD, as communicated by the manufacturer 3MTM, was £25. 
 
Scenario analyses 
In addition to the base-case, two alternative scenarios were analysed using 
probabilistic sensitivity analysis (PSA). The first scenario looked at the cost-effectiveness of 
WEPDs in small bowel surgery, as patients undergoing this type of intervention have a lower 
SSI risk compared to large bowel surgery. The average length of stay and extra length of stay 
due to SSI were modified accordingly (191). The second scenario referred to large bowel 
surgery, as in the base-case analysis, but assumed receiving more care in the primary setting; 
the relevant resource utilisation parameters (i.e. district nurse visits and medication) were 
informed by the study of Tanner et al. (195). 
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Structural uncertainty 
Structural uncertainty in decision models refers to a wide range of sources of 
uncertainty, which cannot be classed as parameter or methodological uncertainty. These 
sources can be grouped under four main categories: inclusion/exclusion of relevant 
comparators; inclusion/exclusion of relevant events; statistical models to estimate specific 
parameters; and clinical uncertainty (342). In this particular case, there was some degree of 
uncertainty regarding the care pathway, given that SSI management is highly individualised 
and reported incompletely in the literature.  
The base-case model attempted to reflect accurately the clinical reality underpinning 
SSI care, but it also relied on a large number of assumptions and had a complex structure. 
Consequently, an alternative decision model (model 2) was developed to explore the impact 
on the cost-effectiveness estimates of modelling a different patient pathway (Figure 4.3). The 
alternative model differed from the main decision model in two important aspects: it had a 
much simpler structure, thus making fewer assumptions about the pathway of care; and it 
used a bulk cost for SSI care as reported by Tanner et al. (195) as opposed to summing the 
individual cost elements. The total cost for SSI care included additional resource use due to 
SSI: inpatient days; district nurse, practice nurse and outpatient visits; medication and 
consumables (wound dressings, wound swabs); and readmission costs.  The patient pathway 
can be summarised as follows: after undergoing open abdominal surgery, patients may or may 
not develop a SSI. In either case, they may survive or not. After discharge, all patients were 
assumed to receive two district nurse visits. The cost of death was assimilated with that of 
critical care for three organs, as in the main model. The cost of inpatient care was calculated 
by multiplying the average inpatient length of stay for large bowel surgery with the average 
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unit cost of an inpatient day; in SSI patients, the cost attributable to SSI care was added to the 
total cost of inpatient care. All relevant probabilities, unit costs and utility values were the 
same as in the main model. The alternative model did not differentiate between severities of 
SSI (superficial vs. deep/organ) or causative agents (non-MRSA vs. MRSA). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 4.3 Structure of the alternative decision model (model 2) 
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4.2.2. Results  
Study parameters 
 Probability values (point estimates and 95%CI where applicable) for the base-case 
analysis and for the alternative scenarios are presented in Table 4.3 together with the 
corresponding data sources. Resource use, health utility and unit cost data are presented in 
Table 4.4 together with the corresponding data sources. For the probabilistic analysis, 
transition probabilities and utility values have been assigned beta distributions, while costs 
have been assigned gamma distributions (343). No uncertainty was modelled around unit 
costs and resource utilisation parameters. Where no information was available on the 
variability around the point estimate, the standard error was assumed 0.1 of the mean for 
probabilities and utilities and 0.2 of the mean for costs in acknowledgement of usual right 
skewness of cost data (65). 
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Table 4.3 Probability values used in the decision model  
 
Description 
Point estimate 
(95% CI) 
Source 
Base-case   
Probability of developing a SSI after large 
bowel surgery, inpatient and readmission 
0.095 
(0.090 to 0.101) 
Health Protection Agency, 2011 
(192) 
Relative risk of developing an SSI in the 
WEPD arm 
0.600 
(0.410 to 0.860) 
Systematic review (Chapter 3) 
Probability of having a SSI caused by MRSA 0.100* 
Derived from Health Protection 
Agency, 2011 (192) 
Probability of developing a superficial SSI 
after large bowel surgery 
0.571* 
Health Protection Agency, 2011 
(192)  
Probability of death after large bowel 
surgery, uninfected 
0.061 
(0.054 to 0.067) 
Derived from Coello et al, 2005 
(191) 
Probability of death with superficial SSI 
after large bowel surgery 
0.040 
(0.020 to 0.059) 
Derived from Coello et al, 2005 
(191) 
Probability of death with deep/organ-space 
SSI after large bowel surgery 
0.105 
(0.069 to 0.141) 
Derived from Coello et al, 2005 
(191) 
Probability of detecting a SSI at readmission 
0.093 
(0.075 to 0.110) 
Derived from Health Protection 
Agency, 2011 (192) 
Probability of being discharged with a SSI 0.700* 
Assumed, informed by 
consultation with clinicians 
Probability of being referred to the hospital 
by the GP if SSI develops post-discharge 
0.200* 
Assumed, informed by 
consultation with GPs 
Probability of recurrent SSI post-discharge 0.100* 
Assumed, informed by 
consultation with clinicians 
Scenario 1: small bowel surgery   
Probability of developing a SSI after small 
bowel surgery, inpatient and readmission 
0.082 
(0.071 to 0.095) 
Derived from Health Protection 
Agency, 2011 (192) 
Probability of developing a superficial SSI 
after small bowel surgery 
0.518* 
Derived from Health Protection 
Agency, 2011 (192) 
Probability of death after small bowel 
surgery, uninfected 
0.059 
(0.052 to 0.065) 
Derived from Coello et al, 2005 
(191) 
Probability of death with superficial SSI 
after small bowel surgery 
0.069 
(0.055 to 0.083) 
Derived from Coello et al, 2005 
(191) 
Probability of death with deep/organ-space 
SSI after small bowel surgery 
0.185 
(0.149 to 0.221) 
Derived from Coello et al, 2005 
(191) 
 
*: Where the 95% CI could not be calculated based on the information in the data source, the 
standard error was assumed to be 10% of the point estimate for the purpose of the 
probabilistic sensitivity analysis. 
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Table 4.4 Resource use, unit costs and utility data in the decision model 
 
Description Value Source 
Resource use - inpatient care   
Average length of stay after large bowel 
surgery, uninfected patients 
11.3 Coello et al, 2005 (191) 
Additional length of stay after large bowel 
surgery, patients with superficial SSI  
7.8 Coello et al, 2005 (191) 
Additional length of stay after large bowel 
surgery , patients with deep/organ-space SSI  
12.6 Coello et al, 2005 (191) 
Average length of stay after small bowel 
surgery, uninfected patients 
11.5 Coello et al, 2005 (191) 
Additional length of stay after small bowel 
surgery, patients with superficial SSI  
12.9 Coello et al, 2005 (191) 
Additional length of stay after small bowel 
surgery , patients with deep/organ-space SSI  
13.4 Coello et al, 2005 (191) 
Unit costs Value (£)  
Cost of antibiotic and painkillers 
prescription from GP 
19 NHS The Information Centre, 2011 (337) 
Cost of critical care per spell, 3 organ 
support 
1 400 
NHS Reference Costs 2009-2010, 2011 
(335) 
Cost of inpatient day, uninfected 462 Derived from Coello et al, 2005 (191) 
Cost of inpatient day, SSI 507 Derived from Coello et al, 2005 (191) 
Cost of MRSA care per day 407 Derived from Elliott et al, 2010 (344) 
Cost of GP visit 36 Curtis 2010 (336) 
Cost of district nurse home visit 27 Curtis 2010 (336) 
Cost of practice nurse procedure 10 Curtis 2010 (336) 
Cost of WEPD, medium size 16.5 Manufacturer 
Cost of medication – scenario 2: intensive 
primary care  
41 Tanner et al, 2009 (195) 
Utility values (EQ-5D)   
Baseline utility 0.800 Kind et al, 1999 (345) 
Utility for uninfected patients 0.752 Janson et al, 2007 (332) 
Utility for SSI patients 0.653 
Derived from Janson et al, 2007 (332) 
and literature review (section 4.1) 
 
Note: Resource use for primary care has been discussed above. Given the lack of published 
data, the number of GP visits, practice nurse visits and district nurse visits has been assumed 
and is described in the text of Chapter 4 (sub-section 4.2.1). Primary care resource use for 
scenario 2 was informed by Tanner et al, 2009. 
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Base-case analysis 
 In the base-case analysis (Table 4.5) the WEPD strategy was associated with an 
average cost of £5,196 and a benefit of 0.0606 QALYs, while standard care costs on an 
average £5,240 and yielded a benefit of 0.0605 QALYs. The WEPD appears to be less 
expensive and slightly more effective than standard care, which is thus dominated. Figure 4.4 
presents the output of the Monte Carlo simulations on the cost-effectiveness plane; only 1,000 
of the 10,000 incremental cost-incremental QALY pairs are presented. The WTP threshold 
was set at £20,000 per QALY gained. The distribution of the incremental cost-incremental 
QALY pairs covers all the four quadrants, but the majority of the pairs fall below and to the 
right of the WTP threshold, suggesting that the WEPD appears to be cost-effective compared 
to standard care. In the corresponding CEAC the WTP threshold has been varied in the range 
£0 to £100,000 per QALY gained (Figure 4.5). The WEPD has 86.6% probability of 
generating a positive net monetary benefit at a threshold of £20,000/QALY and 87.6% at 
£30,000/QALY. 
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Table 4.5 Results of the decision model cost-utility analysis 
 
 
Scenario Alternatives 
Mean cost 
(£) 
Mean effectiveness 
(QALYs) 
ICER (£/QALY) 
Base-case 
WEPD 5,196 0.06061 Standard care is  
dominated standard care 5,240 0.06051 
Scenario 1: Small bowel surgery 
WEPD 5,286 0.06062 Standard care is  
dominated standard care 5,330 0.06048 
Scenario 2: Intensive primary care 
WEPD 5,221 0.06060 Standard care is  
dominated standard care 5,272 0.06051 
Alternative decision model (model 2) 
WEPD 5,672 0.06051 Standard care is  
dominated standard care 6,056 0.06036 
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 Figure 4.4 Decision model: probabilistic sensitivity analysis for the base-case – incremental cost-effectiveness scatter plot 
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Figure 4.5 Decision model: cost-effectiveness acceptability curves for the base-case and alternative scenarios  
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Deterministic sensitivity analyses 
 Six deterministic sensitivity analyses were performed and their results are summarised 
in Table 4.6. The WEPD dominated standard care across the range of inspected discharge 
policies, but it must be noted that the incremental cost decreased as the probability of 
discharging patients with a SSI increased, from £62 when 50% of SSI patients are discharged 
with a SSI to £16 when all patients with a SSI are discharged before full recovery. The second 
analysis looked at the influence of GP behaviour and varied the probability of patients being 
referred to the hospital by the GP when the SSI develops after discharge. The WEPD 
dominated standard care across the range of inspected referral policies; the incremental cost 
increased from £34 when 10% of SSI patients are referred back to hospital to £122 when all 
SSI patients are referred back to hospital. In the third sensitivity analysis the utility decrement 
associated with having a SSI was varied from 0 (i.e. having a SSI does not affect quality of 
life) to 0.40 (0.10 in base-case). The WEPD dominated standard care for any value of the 
utility decrement larger than 0.02. There was very little variation in the incremental 
effectiveness, from 0.059 QALYs when the utility decrement is null to 0.056 QALYs when 
the utility decrement is 0.4. When inpatient length of stay for uninfected patients was varied 
from 6.1 to 20 days (11.3 days in base-case), standard care was also dominated across the 
range of investigated values: the incremental cost varied from £40 (6.1 days inpatient stay) to 
£50 (20 days inpatient stay). 
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Table 4.6 Results of the deterministic sensitivity analyses in the decision model 
 
Parameter varied 
Base-case 
value 
Range tested 
Effect on cost-effectiveness 
(WEPD vs. standard care) 
Probability of discharging 
patients with SSI 
 
0.7 0.5 to 1.0 Standard care is dominated across the range 
Incremental costs decrease across the range from £62 (0.50) to £16 (1.0) 
Probability of GP referring SSI 
patients to hospital 
 
0.2 0.1 to 1.0 Standard care is dominated across the range 
Incremental costs increase across the range from £34 (0.10) to £122 (1.0) 
Utility decrement associated with 
SSI 
 
0.1 0 to 0.4 Standard care is dominated for utility decrements larger than 0.02 
Uninfected inpatient length of 
stay 
 
 
11.3 6.1 to 20.0 Standard care is dominated across the range 
Incremental costs increase from £40 (6.1) to £50 (20) 
Relative risk of SSI in the WEPD 
arm 
 
 
 
0.6 0 to 1.0 Standard care is dominated for relative risk lower than 0.89 
Standard care is cost-effective for relative risk between 0.89 and 0.90 
Standard care optimal but cost-ineffective for relative risk higher than 0.90 
Price of WEPD (£) 16.5 0 to 100 Standard care is dominated for prices of WEPD lower than £61 
WEPD is cost-effective at £20,000/QALY for prices between £61 and £66 
WEPD is optimal but cost-ineffective for prices higher than £66 
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Varying the relative risk of SSI in the intervention arm (thus modifying the clinical 
effectiveness of WEPD) across the entire range of possible values revealed that the WEPD 
strategy dominates standard care for all RR values lower than 0.89. Standard care becomes 
the optimal option when the RR is higher than 0.89. Ultimately, varying the price of the 
WEPD in the range 0 to £100 indicated that WEPD dominates standard care for prices lower 
than £61. Thus standard care becomes the optimal option for WEPD prices beyond £61. A 
willingness-to-pay threshold of £20,000 per QALY gained was considered in all 
interpretations of the sensitivity analyses results. 
  
 Scenario analyses 
 The first alternative scenario used UK-specific data for small bowel surgery 
(probability of SSI, postoperative mortality and inpatient length of stay) as opposed to large 
bowel surgery in the base-case. WEPD is associated with an average cost of £5,286 and an 
average benefit of 0.0606 QALYs, while standard care yielded an average cost of £5,330 and 
an average benefit of 0.0605 QALYs (Table 4.5). The CEAC indicated that the WEPD has 
89.1% probability of generating a positive net monetary benefit at a threshold of 
£20,000/QALY and 90.1% at £30,000/QALY (Figure 4.5). 
 The second scenario investigated the effect of more intensive care received for the SSI 
in a primary setting, after discharge. The WEPD was associated with an average cost of 
£5,221 and an average benefit of 0.0606 QALYs, while standard care yielded an average cost 
of £5,272 and an average benefit of 0.0605 QALYs (Table 4.5). The WEPD has 89.0% 
probability of generating a positive net monetary benefit at a threshold of £20,000/QALY and 
89.8% at £30,000/QALY (Figure 4.5). 
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 Structural uncertainty 
 The alternative decision model (model 2) indicated that the WEPD strategy was 
associated with an average cost of £5,672 and a gain of 0.0605 QALYs, while standard care 
was associated with an average cost of £6,056 and a 0.0604 QALY gain (Table 4.5). WEPD 
thus dominates standard care as it is cost saving and more effective. CEACs suggest that 
WEPD is highly likely to be cost-effective across the range of reasonable WTP thresholds 
(Figure 4.5).  
 
 
4.2.3. Discussion 
Summary of findings 
 The results of the decision model suggested that, based on the best available data, the 
WEPD strategy appears to be cost-effective compared to standard care (i.e. not using the 
WEPD) when used in adult patients undergoing large bowel surgery. This finding was 
generally robust to a range of sensitivity analyses and scenario analyses as well as to an 
alternative model structure. WEPD was the dominant strategy across all the considered 
scenarios; in the base-case analysis the WEPD strategy was on average £43 less costly and 
brought an average additional benefit of 0.0001 QALYs compared to standard care. No other 
economic evaluations looking at the cost-effectiveness of WEPDs have been identified, so 
these results cannot be compared to any other study. 
 Varying the parameters reflecting the behaviour of health care providers i.e. 
probability of discharge with SSI, inpatient length of stay and GP referral attitude, did not 
affect the cost-effectiveness recommendation: the WEPD strategy dominated standard care 
across the range of plausible values. In the proposed decision model these parameters only 
bear an influence on costs: the more time spent as an inpatient (either by delaying the 
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discharge or by encouraging hospital readmissions from GPs), the larger the incremental cost 
associated with the WEPD option. In other words, the longer a patient stays in hospital the 
more likely it is that preventing a SSI will be cost-saving. These findings are in line with 
intuition and previous research, which showed that inpatient care has the largest contribution 
to health care costs attributable to SSI (section 2.1). Indeed, the scenario analysis which 
considered intensive primary care resource utilisation returned similar results to the base-case 
in that WEPDs were highly likely to dominate standard care. The same finding was obtained 
in the scenario assuming that patients undergo small bowel surgery.  
 
Impact of uncertainty 
 The structure of the base-case model attempted to incorporate the intricacies of SSI 
management, which rely on the interaction between secondary and primary health care 
services. Modelling SSI care is further complicated by a number of particularities which 
include the lack of reliable and rich data on SSI management as well as the difficulties of 
accounting for the various types of SSI and their implications on cost and patient outcomes. 
The model attempts to account simultaneously for SSI causative pathogens, SSI severity and 
the behaviour of health care professionals towards managing SSI patients. This is in line with 
the decision model for antibiotic prophylaxis after orthopaedic surgery in the UK, developed 
by Cranny et al. (314): the authors incorporated both the distinction between non-MRSA and 
MRSA SSI and that between superficial and deep/joint SSI, but did not include any primary 
care costs in their analysis. Three other decision models offered a US perspective: Slobogean 
et al. (318) investigated the cost-effectiveness of antibiotic prophylaxis for fractures and 
accounted only for the severity of SSI (superficial vs. deep). Neither the model of Thoma et 
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al. (321) nor that of Lee et al. (315) differentiated between any type of SSI at all, using 
aggregate costs for SSI care.   
 The sensitivity analyses did not suggest that these assumptions affect the cost-
effectiveness recommendation. An alternative, simpler decision model was constructed with 
the aim to ascertain whether the base-case model was unnecessarily complex and to 
investigate the extent to which complexity (or, equally, simplicity) in measuring and valuing 
resource utilisation affects the overall findings. Although the recommended method of 
accounting for structural uncertainty is constructing a general model and parameterising 
uncertainty directly in the model, a review found that most UK Health Technology 
Assessment (HTA) models accounted for structural uncertainty by providing parallel 
estimates for the alternative models (342). In this case, the conclusion of the alternative model 
was similar to that of the base-case analysis in suggesting that the WEPD option was highly 
likely to be cost-effective by dominating standard care and by offering an additional 0.0001 
QALY gain. The difference between the two models was in terms of the incremental cost 
associated with WEPDs: the alternative model returned an average incremental cost of -£384 
compared to -£43 in the base-case and higher than the cost differences indicated in any 
sensitivity analysis. This suggests that the WEPD strategy could be even more cost saving 
than originally thought, hence more cost-effective. However, if we reverse the perspective this 
finding may also suggest that accounting for subtle particularities of SSI care may actually 
prove any intervention to be less cost-effective than it may appear based on analyses informed 
by bulk costs. This suggests that incorporating SSI severity and causative pathogens in the 
model’s cost inputs does make a difference and highlights the need for equally detailed 
HRQoL (specifically health utility) data.  
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 Health utility evidence 
 The systematic review of the HRQoL data on SSI revealed there is very little reliable 
information available to describe in terms of utility the experience of SSI patients. The 
relevant model-based economic evaluations identified in the review relied for their SSI utility 
values either on clinicians’ own judgements or on generic valuations which appear to have 
been informed by anyone but SSI patients. Only two studies used validated instruments, 
namely the SF-12 generic health survey, the GHQ and the IADL questionnaires. Mapping 
from non-preference based health measures to generic preference-based measures is possible 
(312), but the individual patient data was not available for the SF-12 study in order to 
generate utility scores, despite contacting the authors. Furthermore, no evidence was 
identified of a relevant mapping exercise for SSI utilities. No study used the EQ-5D 
instrument, which is currently recommended by NICE for the purpose of evaluating patient-
level outcomes for economic evaluations in the UK (39). Nevertheless, one of the studies that 
were screened but excluded from the systematic review used EQ-5D to evaluate the HRQoL 
in surgical patients with MRSA complications, but reported data for a bundle of soft 
skin/tissue infections and not specifically for SSI (346). Nevertheless, the authors reported a 
utility decrement of 0.22, which was included in the sensitivity analyses accompanying the 
proposed model. In the light of all these considerations, the validity of the utility values 
identified in the systematic review and subsequently used in the decision model can be 
questioned. Nevertheless, the sensitivity analysis revealed that under the base-case 
assumptions using WEPDs is likely to be cost-effective for a utility decrement as little as 
0.02. Considering that it has been suggested in the literature that the minimum clinically 
significant utility difference is 0.03 (347) and that SSI diagnosis is predominantly based on 
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clinical signs, it is unlikely that this piece of information biased the overall cost-effectiveness 
recommendation in this case. However, this threshold relies on the substantial clinical benefit 
demonstrated by WEPDs: should this change, the need for more accurate utility data may 
become more stringent. An exploratory deterministic two-way sensitivity analysis explored 
the joint impact of variation in the relative risk of SSI in the WEPD arm and the utility 
decrement (Figure 4.6). For values of the RR below 0.89 and beyond 0.92 the optimal 
strategy is clear, namely the WEPD option or standard care, respectively. However, if the RR 
lies between 0.89 and 0.92, the exact utility decrement can be decisive in establishing the 
cost-effective alternative. 
Several important questions regarding SSIs remain unexplored in the HRQoL 
literature. Do patients offer different valuations for SSI across various types of surgical 
interventions e.g. is the utility for SSI after orthopaedic surgery different to that of SSI after 
cardiac surgery, ceteris paribus? Do SSI utilities reflect the severity of infection e.g. is the 
utility for deep SSI lower than that of superficial SSI? And how do SSI utilities vary over 
time, especially for slow-healing infections? Reliable answers to these questions are pre-
requisites for future economic evaluations of technologies and interventions aimed to reduce 
SSI. 
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Figure 4.6 Decision model: two-way sensitivity analysis - joint impact of cost-
effectiveness of the WEPD effectiveness and SSI utility decrement 
 
Note: The figure indicates which option is cost-effective for the corresponding combinations 
of the two parameters, either WEPD (blue) or standard care (red). 
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Strengths and limitations 
 The decision model features several strengths: first, it accounts for evidence-based 
factors that influence the risk and burden of SSI (i.e. type of SSI, pathogenic agents, care 
received in secondary and primary settings). At the risk of challenging the parsimony 
principle (338, 339), the model incorporates all these considerations because they are 
supported by evidence in the literature and they have straightforward implications on the costs 
and outcomes associated with SSI management. Second, the model is informed by two 
systematic reviews, one on the clinical effectiveness of the intervention under evaluation 
(Chapter 3) and the other on the HRQoL associated with SSI (section 4.1). Third, the model is 
based on literature sources and official statistics that are as relevant as possible to the current 
clinical context of the UK. Fourth, a range of additional analyses have been conducted to test 
the robustness of the main findings. 
 It could be argued that a longer time horizon would have been more relevant, but the 
absence of reliable data would have led to making further assumptions; for instance, constant 
health utility across time had to be assumed for SSI patients. A short time horizon does not 
favour the WEPD because it can be expected that slow-healing SSIs are also the most costly 
and burdensome. No apparent consensus on the appropriate time horizon is available in the 
literature: for example, the decision model of Lee et al. (320), which looked at wound 
infection after caesarean delivery, also used a one month horizon, while other models took a 
lifetime perspective (314). The same line of reasoning applies for the assumption that MRSA 
and non-MRSA SSI cases spend the same number of inpatient days: the international 
literature suggests that MRSA-SSI patients are likely to have longer spells and to incur higher 
costs, thus favouring the cost-effectiveness of WEPDs. Although determined by limited 
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available data, these two assumptions are undoubtedly conservative because they favour 
standard care and therefore have little potential to introduce bias in the model’s conclusions. 
 The main limitation of the model is that several probability values have only been 
assumed and informed by discussions with relevant medical staff, given the lack of relevant 
published sources discussing the type of care delivered in a primary setting for SSI. Expert 
opinion (surgeons, GPs, district nurses and practice nurses) informed the number of GP, 
practice nurse and district nurse visits as well as the antibiotic regimen in primary care. 
However, the sensitivity analyses explored this limitation and found that the influence of 
these variables was little. Furthermore, the SSI surveillance programmes referred to in the 
model have only studied hospital-related care, while all the medical professionals approached 
in the development stage of this model conveyed the message that an important part of care is 
received after discharge, where little reliable data are currently available. Due to the lack of 
reliable data, the model also ignored the cost of consumables such as wound dressings and 
wound swabs. However, incorporating these costs would increase the cost of SSI care and 
thus favour the cost-effectiveness of WEPDs, making the current base-case estimate slightly 
conservative. Indeed, such resource items were incorporated in the total SSI care costs which 
informed the alternative decision model and suggested even larger cost savings than in the 
base-case analysis. 
 As pointed out before in section 4.1, few studies explicitly and reliably investigated 
SSI-related health utility and the utility decrement used in the base-case relied on the most 
reliable estimate. This casts some doubt over any utility decrement that can inform the model 
at this point. Moreover, the model assumed that the utility decrement does not differ with 
respect to the severity of the SSI (superficial vs. deep/organ), the causative agent (non-MRSA 
vs. MRSA) and the type of surgery (large bowel vs. small bowel) as there is yet no evidence 
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in the literature to support this. The utility score for non-infected patients was informed by the 
study of Janson et al. (332): although the study sample comprised Swedish patients, the 
authors reportedly used the UK value set (348) to convert the EQ-5D scores into utilities. 
 A further limitation relates to the clinical effectiveness of the WEPD itself. The meta-
analysis (Chapter 3) that informed the decision model identified 12 studies conducted over a 
span of more than 40 years, but they all had poor quality and the largest sample size was 360 
patients. The threshold analysis suggested that WEPDs would still be cost-effective for RR 
lower than 0.89; in other words, as little as 11% relative decrease in SSI rate would be enough 
under the model’s assumptions for the WEPD strategy to be cost-effective. 
 Finally, the findings of the model were found to change very little as a result of the 
uncertainty around most parameters. It has been outlined in the literature that robustness per 
se should not be regarded as a desirable property of decision models, as a model whose 
conclusions do not change when varying the input data may reflect a modelling error (339). A 
modelling error is unlikely to explain robustness in this case: the pivotal inputs to the cost-
effectiveness of WEPDs, as demonstrated in the threshold analyses, are the low price of 
WEPDs relative to the cost of SSI care and the seemingly large clinical benefit associated 
with the use of WEPDs (reflected in the relative risk of SSI in the WEPD arm). While the 
price cannot be expected to change dramatically, the clinical effectiveness estimate is based 
on poor quality RCTs and more reliable evidence is still expected. When these estimates 
become available and are used to inform the model, a re-assessment of the cost-effectiveness 
drivers may offer further insights.     
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 Relation to other studies 
 No other economic evaluations of WEPDs have been identified, so the decision 
model’s findings cannot be directly compared to other results. The most recent study which 
offers data on SSI care in a primary setting in the UK was published by Tanner and colleagues 
in 2009 (195). Their study collected data on 29 SSI patients following colorectal surgery and 
found that primary care costs amount to about 15% of total SSI costs (on average £1,563 out 
of £10,523 per SSI patient), thus suggesting that the largest part of the SSI cost burden comes 
from inpatient care. Furthermore, district nurse visits only accounted for approximately 80% 
of primary care costs. These results support the model's finding that primary care costs are 
unlikely to influence the cost-effectiveness recommendation for WEPDs. However, the study 
published by Tanner et al. (195) reported total and average resource use and costs, 
respectively, without any mention of the variability around these quantities. For example, the 
authors reported a total of 623 inpatients days and 553 district nurse visits as part of SSI care, 
but gave no measure of variation around these estimates, so the reader is left without knowing 
how nurse visits were distributed in the study sample. Such variability is an important aspect, 
as illustrated by the older study of Davey et al. (349): out of seven patients with a SSI in 
primary care, one patient alone received 57 district nurse visits, another patient received two 
visits and the rest no visit at all. The absence of any measure of reported variability is the 
main justification why the results of Tanner and colleagues did not inform the base-case 
analysis; still, they informed one of the scenario analyses and the alternative decision model 
and their findings have been discussed above.  
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Further research 
 The findings of the decision model presented in this Chapter need to be interpreted 
within the larger perspective of health care decision making processes. It has been recognised 
that economic appraisal in health care needs to take an incremental and iterative approach 
where newly gathered evidence is interpreted and integrated with previous information to 
generate valid findings and new research questions (69, 350). The framework proposed by 
Sculpher et al. (69) suggested five stages in conducting economic evaluations of health 
technologies, namely: identifying decision problems; synthesis and modelling given available 
evidence; setting research priorities; primary research; and synthesis and modelling (Figure 
4.7).     
 When applying the decision framework above onto the issue of using WEPDs to 
reduce SSI, it can be noted that the systematic review of clinical effectiveness of WEPDs 
(Chapter 2) and the decision model presented in this Chapter are part of stages 2 and 3, where 
existing evidence is synthesised and interpreted to form early judgements on the potential 
effectiveness and cost-effectiveness of WEPDs. All the available evidence suggests that 
WEPDs are likely to be both effective and cost-effective. Still, it must be acknowledged that 
existing data are of questionable quality (especially regarding clinical effectiveness), largely 
absent (especially HRQoL information) and based on a number of assumptions (e.g. pathways 
of care in a primary setting). These lay the premises for advancing the evidence generating 
process to stage 4, i.e. primary research, in order to offer reliable answers to the withstanding 
questions.  
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Figure 4.7 The five stages of conducting economic evaluation of health care technologies 
Source: Sculpher et al. (2006), reproduced with permission 
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 In the light of the above considerations, a definitive RCT with a reasonably large 
sample size and embedded health-related quality of life data collection is required to offer 
reliable estimates of the clinical effectiveness of the WEPD and the patient burden of SSI. 
Beyond offering reliable estimates of effectiveness and cost-effectiveness, such a RCT could 
provide better information about the care received by SSI patients in a primary care setting 
and the pragmatic discharge policies of SSI patients (to be presented in Chapter 5). 
 The role of early modelling is not limited to warranting further research, as outlined in 
the iterative approach above, but also to focus future data collection on relevant processes. 
Therefore the importance of early model-based economic evaluations to inform the design of 
RCTs has long been recognised (351). In the case of evaluating the potential benefit of 
WEPDs in reducing SSI, the decision modelling exercise identified inpatient length of stay 
and the SSI utility decrement as potentially important cost-effectiveness drivers, which 
suggests that the RCT must ensure close patient follow-up within the relevant time horizon in 
order to capture the patient events occurring at the secondary care - primary care interface 
(especially readmissions) and the relevant HRQoL information. 
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4.3. Conclusion 
 Based on the best available evidence, including the estimated clinical effectiveness 
presented in Chapter 3, WEPDs are likely to be cost-effective when compared to standard 
care in reducing SSI rate after open abdominal surgery. This result was robust to the 
sensitivity and scenario analyses as well as to an alternative model structure. The clinical 
effectiveness of WEPDs emerged as the main driver of cost-effectiveness estimates. In line 
with the iterative approach to the economic evaluation of medical technologies, these findings 
warrant the conduct of a large, high quality RCT with an embedded economic evaluation that 
can offer reliable effectiveness and cost-effectiveness estimates on the benefit of WEPDs 
compared to standard care. The methods and findings of such a trial are presented in the 
following Chapter. 
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ROSSINI trial results have been published as: 
 
Pinkney TD, Calvert M, Bartlett DC, Gheorghe A, Redman V, Dowswell G et al. (2013). 
"Impact of wound edge protection devices on surgical site infection after laparotomy: 
multicentre randomised controlled trial (ROSSINI Trial)." BMJ 347:f4305. 
 
The previous Chapters demonstrated that, based on the best available evidence, 
WEPDs are likely to be both effective (Chapter 3) and cost-effective (Chapter 4) in reducing 
SSI rates in adults undergoing open abdominal surgery, when compared to standard care. As 
discussed at the end of Chapter 4, substantial uncertainty surrounded these findings due to the 
unsatisfactory methodological quality of existing studies.  Further research was therefore 
warranted to provide high quality evidence of WEPD benefit. This Chapter presents the 
methods and results of the cost-effectiveness analysis in the ROSSINI trial, which compared 
the use of wound-edge protection devices (WEPDs) with standard care in adults undergoing 
laparotomy. The first section of the Chapter outlines briefly the methods and main results of 
the ROSSINI trial. The second section presents the methods and results of the within-trial 
economic evaluation of WEPDs informed by primary data collected alongside ROSSINI.  
 
5.1. The ROSSINI trial 
5.1.1. ROSSINI methods 
The ROSSINI (Reduction of Surgical Site Infection using a Novel Intervention) trial 
aimed to assess the benefits to the patients and to the NHS of using WEPDs to reduce SSI in 
adult patients undergoing laparotomy. The main characteristics of the trial are briefly 
presented here, as ROSSINI methods have been described in detail elsewhere (352). 
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Objectives 
 The trial's primary objective was to determine the WEPD's effectiveness in reducing 
SSI rates 30 days after surgery. Secondary objectives were: to determine the effectiveness of 
the WEPD by degree of surgical wound contamination (clean, clean-contaminated, 
contaminated, dirty); to assess the impact of the use of WEPD on patient health-related 
quality of life; to assess the impact of the use of WEPD on length of stay in hospital; and to 
investigate the cost-effectiveness of the WEPD compared to standard care. 
 
Trial design 
 ROSSINI was a multicentre, randomised, controlled, parallel group trial where adult 
patients undergoing laparotomy were randomised in a 1:1 ratio to either the control arm i.e. 
standard intra-operative care, or the intervention arm i.e. standard intra-operative care plus 
use of a WEPD during the intra-abdominal part of the operation. Patients undergoing 
laparotomy for any indication were included in order to maximise the generalisability of the 
findings. Patients less than 18 years of age, laparoscopic cases and patients who had had a 
laparotomy within the past three months were excluded (352). 
 Patients were randomised while in the anaesthetic room, immediately prior to surgery, 
using a secure online portal hosted by the Centre for Clinical Trials at the University of 
Birmingham. Stratification with embedded minimisation was employed according the 
following strata: urgency of surgery, likelihood of opening a viscus and likelihood of creating 
a stoma. The participating patients and all health care staff involved in post-operative care 
and wound assessments were blinded to the treatment allocation. ROSSINI recruited from 
general surgical units within NHS hospitals across England. 
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Outcomes 
 The primary outcome was occurrence of SSI within 30 days post-operatively, 
assessed according to the CDC criteria (Chapter 2) (200). The main hypothesis was that use 
of WEPD would reduce SSI rate by 50%, informed by the study of Horiuchi et al. (271). 
Assuming a conservative 12% SSI rate in the control arm and a 5% dropout rate, the target 
sample size was 750 patients.  
 Wound assessors undertook online training by completing an e-learning module and 
quiz to minimise the potential for inter-assessor variability in wound assessments. Secondary 
outcomes were: the degree of wound contamination; presence of major comorbidity; HRQoL; 
length of stay in hospital; health care utilisation and cost-effectiveness of WEPDs compared 
to standard care; and adverse events. HRQoL was measured using the validated EuroQol EQ-
5D instrument (43) at three time points: at baseline (before surgery), at 5-7 days post-
operatively and at 30-33 days post-operatively. 
 
Analysis 
 All the analyses were based on the intention-to-treat (ITT) principle. The primary 
outcome was analysed using generalised linear models with logit link, binomial error and 
with surgeon as random effects (353). Continuous data were analysed with the use of mixed 
models, which include surgeons as random effects. The rates of adverse events were 
compared between groups by means of Fisher’s exact test.  
 A prospective within trial cost-effectiveness analysis was undertaken from the 
perspective of the NHS. The chosen time horizon for the analysis was 30 days post-
operatively. The incremental cost per additional QALY of the WEPD strategy compared to 
standard care was assessed to inform clinicians and policy makers of the cost-effectiveness of 
WEPDs. The detailed methods and results of the cost-effectiveness analysis are presented in 
the following section. 
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5.1.2. ROSSINI results 
 ROSSINI results are reported in detail elsewhere (354). Briefly, between February 
2010 and January 2012 a total of 760 patients from 21 surgical centres across the UK were 
enrolled in the study and randomised to the WEPD (n=382) or control (n=378). 376 patients 
in the WEPD group and 373 patients in the control group received a laparotomy and were 
included in the study (Figure 5.1). The characteristics of ROSSINI patients are presented in 
Table 5.1.  
ROSSINI results are presented in Table 5.2. In total, 184 patients experienced an SSI 
within 30 days of surgery, 91/369 (24.7%) of patients in the WEPD group and 93/366 
(25.4%) in the control group (odds ratio (OR) 0.97 95% CI 0.69 to 1.36; p=0.85). The results 
were consistent across the assessments made at different time points within the study and by 
different observers, with both the formal clinician wound assessments and the patient self-
reported data showing no difference (Figure 5.2).   
A WEPD was used in four patients randomised to the control arm and was not used in 
29 patients randomised to receive the device. A sensitivity analysis was undertaken to explore 
the effect of treatment cross-over on the estimate of WEPD effectiveness. In this ‘best-case 
scenario’ analysis (in which a maximal benefit from use of WEPD is assumed), all patients 
allocated to the control group but that received a device were assumed to have had an SSI 
within 30 days, conversely those patients randomised to WEPD who did not receive a device 
were assumed to have had no event. In this extreme case analysis the effect of WEPD was 
still statistically non-significant (OR 0.77; 95% CI 0.54 to 1.09, p=0.14). 
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 Figure 5.1 CONSORT flow diagram for the ROSSINI trial 
 
Source: Pinkney et al. (2013), reproduced with permission7 
 
 
 
                                                 
7 Reprinted from BMJ, 347:f4305, Pinkney TD et al.,  Impact of wound edge protection devices on surgical site 
infection after laparotomy: multicentre randomised controlled trial (ROSSINI Trial), Copyright (2013), with 
permission from BMJ Publishing Group Ltd. 
Chapter 5. Cost-effectiveness analysis of WEPDs vs. standard care: the ROSSINI trial 
 
172 
 
Table 5.1 Patient characteristics in ROSSINI trial 
 
Characteristic WEPD (n=376) Control (N=373) 
Age (years)   
Median 66.37 64.23 
Interquartile Range 54.79 to 74.69 55.51 to 72.83 
Male gender (%) 200 (53.19%) 193 (51.74%) 
Body Mass Index    
Median 26.50 26.00 
Interquartile Range 23.10 to 30.00 23.05 to 29.07 
Serum Albumin level   
Median 41.00 40.00 
Interquartile Range 34.00 to 44.00 35.00 to 44.00 
Diabetes (%) 62 (16.49%) 51 (13.67%) 
Current smoker (%) 64(17.02%) 57 (15.28%) 
On steroids or immunosuppressed (%) 35 (9.31%) 31 (8.31%) 
Clinically jaundiced (%) 21 (5.59%) 20 (5.36%) 
Documented MRSA colonisation (at any site) previously (%) 9 (2.39%) 10 (2.68%) 
Operation urgency (%)   
Elective 181 (48.14%) 183 (49.06%) 
Expedited 117(31.12%) 117(31.37%) 
Urgent 75 (19.95%) 71 (19.03%) 
Immediate 3 (0.80%) 2 (0.54%) 
ASA Grade   
1 36 (9.57%) 49 (13.14%) 
2 203 (53.99%) 186 (49.87%) 
3 113 (30.05%) 95 (25.47%) 
4 4 (1.06%) 7 (1.88%) 
5 0 (0.00%) 1 (0.27%) 
Unknown 20 (5.32%) 35 (9.38%) 
Operation site (%)   
Large bowel 247 (65.69%) 237 (63.54%) 
Small bowel 34 (9.04%) 48 (12.87%) 
Hepatobiliary 77 (20.48%) 72 (19.30%) 
Gastric 15 (4.02%) 8 (2.14%) 
Cholecystectomy 1 (0.27%) 2 (0.54%) 
Vascular 1 (0.27%) 0 (0.0%) 
Abdominal hysterectomy 0 (0.0%) 2 (0.54%) 
Unknown 1 (0.27%) 4 (1.07%) 
Stoma created (%) 109(28.99%) 106 (28.42%) 
Cancer resection (%) 223(59.31%) 219 (58.71%) 
Skin Prep used (%)   
Chlorhexidine 136 (36.17%) 135 (36.19%) 
Aqueous Betadine 215 (57.18%) 197 (52.82%) 
Alcoholic Betadine 16 (4.26%) 29 (7.77%) 
Towels/mops used on wound edges (%) 42 (11.17%) 78 (20.91%) 
Type of surgery performed (%)   
Clean 24 (6.38%) 31 (8.31%) 
Clean-contaminated 275 (73.14%) 268 (71.85%) 
Contaminated 48 (12.77%) 48 (12.86%) 
Dirty 29 (7.71%) 25 (6.70%) 
Duration of surgery (hours)    
Median 3.0 2.73 
Interquartile Range 2.0 to 4.0 2.0 to 4.0 
NNIS index    
Median 1 1 
Interquartile Range 0 to 1 0 to 1 
Prophylactic antibiotic given (%)   
On Induction 321 (85.37%) 322 (86.33%) 
During procedure 25 (6.65%) 18 (4.83%) 
Catheters left in place (%) 6 (1.60%) 6 (1.61%) 
Grade of operating surgeon (%)   
Consultant 302 (80.32%) 280 (75.07%) 
Trainee 69 (18.35%) 82 (21.98%) 
Grade of surgeon closing fascia (%)   
Consultant 186 (49.47%) 197 (52.82%) 
Trainee 182 (48.40%) 157 (42.09%) 
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Table 5.2 Primary and secondary outcomes in ROSSINI trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: 
IQR=interquartile range  
*Odds ratio 
†n=318 
‡n=313 
§Difference in means 
¶Hazard ratio 
 
Outcome WEPD Control Estimate (95% CI) P value 
 
Primary outcome 
Surgical site infection (SSI) within 30 days 91/369 (24.7) 93/366 (25.4) 0.97* (0.69 to 1.36) 0.85 
     
Secondary outcomes 
Mean (SD) EQ-5D 0.69 (0.29)† 0.69 (0.30)‡ 0.001§ (−0.04 to 0.05) 0.95 
Median (IQR) length of hospital stay (days) 9 (6 to 15) 9 (6 to 14) 1.03¶ (0.88 to 1.19) 0.82 
Degree of wound contamination: 
Clean 8/24 (33.3) 7/29 (24.1) 1.76* (0.40 to 7.70) 0.43 
Clean-contaminated 61/269 (22.7) 63/263 (24.0) 0.94* (0.62 to 1.42) 0.76 
Contaminated 10/48 (20.8) 15/48 (31.3) 0.601* (0.23 to 1.63) 0.31 
Dirty 12/28 (42.9) 7/25 (28.0) 1.85* (0.50 to 6.87) 0.33 
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 Figure 5.2 SSI rates by treatment group at various time points in the ROSSINI 
trial 
 
Source: Pinkney et al. (2013), reproduced with permission8 
 
 
 
 
 
  
 
                                                 
8 Reprinted from BMJ, 347:f4305, Pinkney TD et al.,  Impact of wound edge protection devices on surgical site 
infection after laparotomy: multicentre randomised controlled trial (ROSSINI Trial), Copyright (2013), with 
permission from BMJ Publishing Group Ltd. 
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5.2. Economic evaluation of WEPDs vs. standard care alongside ROSSINI 
The aim of the within-ROSSINI economic evaluation was to provide evidence on the 
incremental cost-effectiveness of WEPDs compared to standard care in reducing SSI when 
used in adults undergoing open abdominal surgery. The methods for conducting economic 
evaluations using clinical trials data have been described previously (62-64) and the 
principles have been outlined in Chapter 1 (section 1.2). The present economic evaluation is 
reported according to the CHEERS Statement 2013 (329) (Appendix 6). 
 
5.2.1. Methods  
Characteristics of ROSSINI patients were given in Table 5.1. ROSSINI was 
conducted in NHS hospitals. The trial-based economic evaluation took a health care provider 
perspective and thus considered only cost centres relevant for the NHS and Personal Social 
Services. The intervention under scrutiny was the use of a WEPD during surgery. The 
comparator was no WEPD use. In order to enhance the generalisability of the trial, the 
surgical teams were given the liberty to use retraction and SSI prophylactic procedures of 
their choice. The time horizon was 30 days post-operatively, in accordance with SSI 
monitoring in the English NHS(206). Given the short time horizon, no discounting was 
applied to costs and outcomes. 
Health outcomes, preference-based outcomes and resource use data were collected 
from the participating sites using custom designed paper-based case report forms (CRFs), 
which were completed by patients or trial staff, as appropriate, at each site then managed 
centrally at the Centre for Clinical Trials at the University of Birmingham. Information on 
clinical outcome data was reported above (sub-section 5.1.2). 
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Health-related quality of life 
HRQoL was assessed using the EuroQol EQ-5D 3L questionnaire (the English 
version and validated for use in the UK, Appendix 7), a standardised generic preference 
based  instrument that describes a patient’s health status using a single index value (43). EQ-
5D has five dimensions (mobility, self-care, usual activity, pain/discomfort and 
anxiety/depression) and each dimension has three mutually exclusive levels the patient has to 
choose from (no problem, some problem or extreme problem). There are 243 different health 
states described by the EQ-5D, each health state being associated with a HRQoL weight 
derived from the preferences of a representative sample of the UK population using the time 
trade-off technique. The EQ-5D score is bounded to 0 (death) and 1 (perfect health), but 
negative scores are possible for states perceived to be worse than death (348).  
There has been relatively little research in the HRQoL assessment of SSI. Very little 
is also known about the comparative validity of different quality of life instruments. The 
systematic literature review of SSI utility values (Chapter 4) identified a small number of 
studies, the majority of which used historical and unspecific (e.g. hip infection) utility values. 
EQ-5D was chosen as the HRQoL instrument in this study for the purpose of its relevance for 
the UK policy makers, particularly NICE (39).  
The EQ-5D was administered to patients in ROSSINI at three time points: at baseline 
(prior to surgery), at 5 to 7 days post-operatively and at 30 to 33 days post-operatively. The 
first assessment was conducted in clinic, after the patient provided informed consent and 
before randomisation. The second assessment (5 to 7 days) was performed on the hospital 
ward if still inpatient or at discharge, as applicable. The third assessment (30 to 33 days) was 
performed on the hospital ward if still inpatient or, more often, in the outpatient clinic on the 
occasion of the scheduled follow-up visit. 
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Resource use 
Data on resource utilisation of health care resources in both secondary and primary 
care settings was collected using the custom designed CRFs (Appendix 8). CRF6 recorded 
resource use items related to inpatient care, filled in by research nurses or dedicated trial staff 
at each site, using hospitals’ databases and patient notes as appropriate. CRF4 recorded 
resource utilisation in primary care setting i.e. access to GP, practice nurse, district nurse and 
outpatient clinic, together with any medication received. This information was recorded by 
patients in clinic on the occasion of the scheduled follow-up visit at 30 to 33 days post-
operatively. 
For subjects who were diagnosed with an ongoing SSI or were still inpatients at this 
follow-up visit, an individualised follow-up procedure was set-up. This involved telephoning 
the respective patients and asking for their consent to contribute data to the follow-up 
procedure. Upon gaining consent, the trial office posted the primary care resource use CRF 
(CRF4a) and an EQ-5D questionnaire at the patient’s home address. Patients were asked to 
complete the forms and post them back to the trial office using the freepost envelope 
provided in the pack. Due to the 30-day time horizon, information collected during the 
extended follow-up was used only in the cost analysis of SSI care and not in the present 
economic evaluation. 
A wound-dressing diary was devised as a separate document shortly after recruitment 
started and ethical approval for its introduction in ROSSINI was issued on 7th September 
2011, when more than 550 patients had been recruited. The aim of the wound dressing diary 
was to capture the effect of the WEPD on the total cost of dressings utilised in wound care, 
both in a secondary and primary setting. Due to regulatory delays, the wound-dressing diary 
was ultimately implemented as a pilot in four sites and the information collected as such was 
not included in the present economic evaluation. 
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Unit costs 
Unit costs were valued in £ (2011 value). Inpatient care items were sourced from the 
NHS Reference Costs 2010-2011. Primary care items were sourced from the Personal Social 
Services Resource Unit (PSSRU) Unit Costs and Social Care 2010-2011 (333). Medication 
unit costs were taken from the British National Formulary 2011 (355). 
All unit costs were average national costs (Table 5.3). Consistent with the NHS 
perspective, only resource use items affecting the NHS budget were considered. Total 
resource costs were obtained by summation of the individual resource costs for each category 
of resource item accessed by trial patients. Individual resource costs were obtained by 
multiplying the resource use by the corresponding unit costs. 
 
Data analysis 
The base-case analysis included all the patients with complete primary outcome data 
(information on SSI status). Any missing cost and HRQoL data as well as patient-level 
characteristics were imputed using the multiple imputations using chained equations method 
(MICE) (see paragraph Missing data below). The analysis included descriptive statistics for 
the resource use items, resource costs (both at aggregate and individual level) and HRQoL 
scores.  
QALYs were calculated by multiplying the utility weight associated with each 
individual health state and the time spent in that health state. QALYs were calculated based 
on the baseline and 30-day EQ-5D assessments and were adjusted for baseline utility (356). 
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Table 5.3 ROSSINI trial: unit costs at 2011 value 
 
Resource Unit cost (£) Source 
   
WEPD (intervention) 15.1 Manufacturer 
   
HOSPITAL CARE   
Day on general ward 311.0 NHS Reference Costs 2010/2011 (357) 
Day in ITU 1,515.0 NHS Reference Costs 2007/2008* (358) 
Day in HDU 856.0 NHS Reference Costs 2007/2008* (358) 
   
PRIMARY CARE   
GP visit 36.3 Curtis 2011 (333) 
Practice nurse visit 13.2 Curtis 2011 (333) 
District nurse visit 73.0 Curtis 2011 (333) 
Outpatient clinic visit 101.0 NHS Reference Costs 2010/2011 (357) 
Medication (antibiotics, painkillers) as appropriate British National Formulary 2011 (355) 
 
* The unit costs for a day in Intensive Therapy Unit (ITU) and a day in High Dependency 
Unit (HDU) were not available in NHS Reference Costs 2010/2011. The last available 
document where they were given explicitly was the 2007/2008 edition. For the purpose of 
this analysis, the 2007/2008 unit costs were updated to their 2011 value using the appropriate 
Hospital and community health services (HCHS) pay and price inflation (Curtis 2011). 
 
 
The average differences in costs and outcomes, as well as the 95% confidence intervals 
around the point estimates and the ICER, were calculated using bias-corrected and 
accelerated (BCa) non-parametric bootstrap methods with 1,000 replications (54). The 
differences in costs and effects were plotted on the cost-effectiveness plane, a visual decision-
aiding tool representing the incremental costs and effects of the intervention under evaluation 
relative to the next best option (47). One alternative is said to dominate another if both the 
average costs and average effects associated with it are relatively lower than another’s. If the 
evaluation does not show a case of dominance, the ICER is calculated as the ratio between 
the difference in mean costs and the difference in mean QALYs between the intervention and 
the comparator (Chapter 1, equation 1.1). Cost-effectiveness acceptability curves (CEACs) 
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were plotted, indicating the probability of the two alternatives to be cost-effective at varying 
thresholds of the decision makers’ willingness to pay for an additional unit of outcome (58).  
Sensitivity analyses were performed to check the robustness of cost-effectiveness 
findings, as follows: 
1. A complete case analysis based on trial subjects with complete primary outcome, 
cost and HRQoL data.  
2. Adjusted analyses for both base-case and complete case scenarios, where 
differences between the trial’s arms were investigated using generalized linear models. Total 
costs and EQ-5D scores were modelled using the intervention (treatment arm) and other 
relevant baseline characteristics as covariates (identified with clinical input): treatment arm, 
baseline utility (only for adjusting incremental QALYs), plan to create a stoma, plan to create 
a viscus (defined as any internal organ), elective/emergency surgery, age, BMI, diabetes, 
current smoking status and SSI. The total cost and QALY values were regressed against the 
variables above using generalised linear models with an identity link (353). A gamma 
distribution was assumed for costs and a normal distribution was assumed for QALYs. All 
the analyses were performed using SAS 9.2® software (304) and R 2.15.3 software (359).  
 
Missing data 
Missing data on costs and health utilities were imputed using independent chained 
equations (MICE) methods (26). The imputations were performed using the mice package 
available in R statistical software (359). Resource costs and EQ-5D data were imputed using 
an algorithm which predicted the missing values based on a wide range of variables: patient 
and operative characteristics (age, BMI, smoking status, diabetes, plan to open viscus, plan to 
create a stoma, elective/emergency surgery, ASA grade, duration of surgery); hospital care 
cost items (cost of days on ward, cost of ITU days, cost of HDU days); primary care cost 
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items (cost of GP visits, cost of GP-prescribed medication, cost of district nurse visits, cost of 
practice nurse visits and cost of outpatient clinic visits); and EQ-5D scores at baseline, at 5-7 
days post-operatively and at 30-33 days post-operatively. 
In addition, the MICE imputation model included age and SSI status, for which 
complete data were available. The predictive mean matching method was used to impute 
patient-level characteristics: following each cycle of the imputation model, the observed 
value which was the closest to the predicted value was chosen in order to ensure that only 
plausible values are imputed. Costs were bounded to be positive and EQ-5D scores were 
bounded between -0.594 and 1, in accordance with  the UK scoring algorithm (348). 
Aggregate hospital costs, primary care costs and total costs were imputed based on the sum of 
individual cost items resulted from the imputation model to ensure their convergence. Twenty 
datasets (each obtained after 20 iterations/cycles of the imputation algorithm) were generated 
from the imputation process, and then entered the bootstrapping process. 
 
 
5.2.2. Results 
Resource use 
The average utilisation of health care resources is presented in Table 5.4. There is no 
apparent difference between the two treatment groups for secondary care or primary care 
services, as confirmed by the corresponding p-values. The only notable exception is the 
number of practice nurse visits: patients in the standard care arm reported twice as many 
practice nurse contacts than WEPD patients. However, this may well be an artefact of the 
data collection process, as the information on primary care utilisation was reported by 
patients themselves, who may not have accurately discriminated between practice nurse and 
district nurse visits when reporting.  
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Table 5.4 ROSSINI trial: summary of resource use by treatment group, detailed 
 
Resource use item WEPD (n=369) 
Standard care 
(n=366) 
p-value 
    
HOSPITAL CARE    
Inpatient days  
N 
Mean (SD) 
SE 
Median 
 
359 
12.55 (15.46) 
0.82 
9 
 
358 
11.56 (11.68) 
0.62 
9 
 
0.3350 
 
Days in ITU 
N 
Mean (SD) 
SE 
Median 
 
369 
0.93 (3.12) 
0.16 
0 
 
366 
1.06 (5.46) 
0.28 
0 
 
0.6913 
 
Days in HDU 
N 
Mean (SD) 
SE 
Median 
 
369 
0.60 (1.67) 
0.09 
0 
 
366 
0.55 (1.51) 
0.08 
0 
 
0.6396 
 
    
PRIMARY CARE    
GP visits 
N 
Mean (SD) 
SE 
Median 
 
364 
0.43 (0.81) 
0.04 
0 
 
358 
0.51 (1.03) 
0.05 
0 
 
0.2474 
 
District nurse visits 
N 
Mean (SD) 
SE 
Median 
 
360 
3.43 (7.24) 
0.38 
0 
 
355 
3.52 (6.94) 
0.37 
0 
 
0.8644 
 
Practice nurse visits 
N 
Mean (SD) 
SE 
Median 
 
366 
0.16 (0.70) 
0.04 
0 
 
361 
0.32 (1.21) 
0.06 
0 
 
0.0355 
 
Outpatient clinic visits 
N 
Mean (SD) 
SE 
Median 
 
364 
0.42 (1.09) 
0.06 
0 
 
363 
0.31 (0.71) 
0.04 
0 
 
0.1205 
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This potential source of bias is further explored in Table 5.5, where the difference 
between the two arms is explored in terms of 'primary care contact points', a variable 
encompassing all types of care received in a primary care setting, and 'nurse visits', a variable 
which aggregates district nurse and practice nurse visits. Moreover, a large proportion of 
patients reported no GP visits or nurse visits within the 30 day time horizon. A secondary 
analysis explored the difference between treatment arms for patients who reported at least 
one primary care visit, in order to investigate whether differential proportions of zero values 
in the two groups mask any underlying difference (Table 5.5). The decision to conduct this 
secondary analysis was prompted by the large number of zero values for the number of 
practice and district nurse visits. Neither of the analyses revealed any difference between 
patients in the two arms in terms of the volume of care received. 
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Table 5.5 ROSSINI trial: summary of resource use by treatment group, overview 
 
Resource use item WEPD (n=369) 
Standard care 
(n=366) 
p-value 
    
HOSPITAL CARE    
 
Inpatient days  
N 
Mean (SD) 
SE 
Median 
359 
12.55 (15.46) 
0.82 
9 
358 
11.56 (11.68) 
0.62 
9 
 
0.3350 
 
 
    
PRIMARY CARE    
 
Primary care points of contact (includes GP visits, all nurse visits and outpatient clinic visits) 
N 
Mean (SD) 
SE 
Median 
350 
4.38 (7.59) 
0.41 
1 
347 
4.47 (7.02) 
0.38 
2 
0.8795 
 
 
Nurse visits (includes district nurse visits and practice nurse visits) 
N 
Mean (SD) 
SE 
Median 
357 
3.54 (7.16) 
0.38 
0 
352 
3.74 (6.81) 
0.36 
0 
 
0.6939 
 
 
 
A large number of patients did not report any primary care visits (median is 0). The table section 
below only looks at patients who reported at least one primary care visit (GP, practice nurse, district 
nurse or outpatient clinic) and at least one nurse visit, respectively.  
 
Primary care points of contact (includes GP visits, all nurse visits and outpatient clinic visits) 
N 
Mean (SD) 
SE 
Median 
242 
6.88 (8.57) 
0.57 
3 
247 
6.80 (7.70) 
0.51 
3 
0.9163 
 
 
Nurse visits (includes district nurse visits and practice nurse visits) 
N 
Mean (SD) 
SE 
Median 
188 
7.18 (8.83) 
0.66 
4 
189 
7.54 (8.04) 
0.61 
4 
0.6937 
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Missing data 
Despite very low levels of missing data for the primary outcome, the amount of 
missing data for resource utilisation and patient-reported outcomes was somewhat higher 
(Table 5.6). EQ-5D scores at 30 days post-operatively were not available for 14% of patients, 
while hospital and primary care data were unavailable cumulatively for less than 10% of 
patients (6.66%). Overall, 20.4% of patients had incomplete observations in terms of resource 
use or HRQoL data. However, there was no imbalance between the two arms with respect to 
the levels of missing data, which suggests that having complete observations was not 
influenced by receiving the intervention or not.  
Data missingness was further explored by looking at differences in missing 
observations in subgroups defined by relevant patient, intraoperative and clinical 
characteristics. Table 5.7 compares the levels of missing EQ-5D data at 30-33 days by several 
patient-level variables and the results suggest there is no difference with respect to 
completeness of HRQoL information based on these characteristics. A similar analysis was 
carried out for resource use data (Table 5.8). It appears that there are differences in levels of 
missing cost data with respect to two patient-level variables: age and BMI. More specifically, 
there is more missing cost data in patients below 65 years compared to those above 65 years 
(9.9% vs. 5.7%, p=0.03). Patients with a higher BMI had more missing cost data than patients 
with BMI lower than 26.75 (12.5 vs. 6.4%, p<0.01).  
It appears that SSI status i.e. having been diagnosed with a SSI or not, does not 
influence the level of missingness either for HRQoL or for resource use data. Thus there is no 
evidence to suggest that missing data was influenced by the primary outcome, while there is 
some evidence that several patient level-variables (age and BMI) may be associated with 
missingness. The assumption of data missing at random (MAR) appears thus to be plausible.  
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Table 5.6 ROSSINI trial: summary of missing data, by treatment group 
 
Missing data item 
Missing observations  
(% of trial arm) 
 
WEPD (n=369) 
Standard care 
(n=366) 
Trial arm 
differences 
 (p-value) 
    
HOSPITAL CARE    
Inpatient days 10 (2.7%) 8 (2.2%) 0.64 
    
PRIMARY CARE    
GP visits 5 (1.4%) 8 (2.2%) 0.39 
Practice nurse visits 3 (0.8%) 5 (1.4%) 0.47 
District nurse visits 9 (2.4%) 11 (3%) 0.63 
Outpatient clinic visits 5 (1.4%) 3 (0.8%) 0.48 
    
PATIENT-REPORTED OUTCOMES    
EQ-5D data, any time point  51 (13.8%) 53 (14.5%) 0.79 
 
 
 
 
Table 5.7 ROSSINI trial: summary of missing EQ-5D data at 30-33 days by patient-level 
variables 
 
Variable 
Total  
observations 
Missing 
observations (%) 
p-value 
Age 
Age <= 65 years 383 61 (15.9%) 
0.64 
Age > 65 years 352 43 (12.2%) 
     
Diabetic 
Yes 
No 
111 
624 
17 (15.3%) 
87 (13.9%) 
0.70 
     
Smoker 
Ever smoker 
Never smoker 
370 
365 
49 (13.2%) 
55 (15.1%) 
0.48 
     
BMI 
BMI <= 26.75 
BMI > 26.75 
559 
176 
82 (14.7%) 
22 (12.5%) 
0.47 
     
Duration of surgery 
 <= 170 minutes 
> 170 minutes 
375 
360 
56 (14.9%) 
48 (13.3%) 
0.53 
     
ASA grade 
ASA grade <= 2 
ASA grade > 2 
482 
253 
63 (13.1%) 
41 (16.2%) 
0.25 
     
SSI status 
SSI 
No SSI 
551 
184 
73 (13.2%) 
31 (16.8%) 
0.23 
 
Note: Threshold values for variables Age, BMI and Duration of surgery are median values 
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Table 5.8 ROSSINI trial: summary of missing resource use data by patient-level 
variables 
 
Variable 
Total  
observations 
Missing 
observations (%) 
p-value 
Age 
Age <= 65 years 383 38 (9.9%) 
0.03 
Age > 65 years 352 20 (5.7%) 
     
Diabetic 
Yes 
No 
111 
624 
10 (9.0%) 
48 (7.7%) 
0.63 
     
Smoker 
Ever smoker 
Never smoker 
370 
365 
28 (7.6%) 
30 (8.2%) 
0.74 
     
BMI 
BMI <= 26.75 
BMI > 26.75 
559 
176 
36 (6.4%) 
22 (12.5%) 
<0.01 
     
Duration of surgery 
 <= 170 minutes 
> 170 minutes 
375 
360 
33 (8.8%) 
25 (6.9%) 
0.35 
     
ASA grade 
ASA grade <= 2 
ASA grade > 2 
482 
253 
40 (8.3%) 
18 (7.1%) 
0.57 
     
SSI status 
SSI 
No SSI 
551 
184 
40 (7.3%) 
18 (9.8%) 
0.27 
 
Note: Threshold values for variables Age, BMI and Duration of surgery are median values 
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Results of the base-case analysis 
The base-case analysis used information from all patients with complete primary 
outcome data (n=735). Figure 5.3 depicts the results of the imputation process across 
iterations for variables total cost (c_final), baseline EQ-5D score (score0) and EQ-5D score at 
30-33days (score EQ3); the imputation sets appear to converge for all the variables from the 
very beginning and no trend in the imputed values is apparent along the iterations, which 
suggests that the results of the imputation can be used with confidence (360).  
 
Health-related quality of life 
There were no significant differences between patients in the two groups with respect 
to EQ-5D scores at either time point. At 30 days postoperatively, intervention and control 
patients reported utility scores of 0.683 and 0.684, respectively (Table 5.9). 
 
Costs 
The use of the WEPD was associated with slightly higher inpatient costs than standard 
care (Table 5.9). Moreover, the difference in primary care costs was minimal. It appears that 
inpatient care accounts for the largest part of costs within the 30 day time horizon.  
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Table 5.9 ROSSINI trial economic evaluation base-case analysis: summary of costs and 
HRQoL data by treatment group  
 
 Mean (SE) 
Variable WEPD (n=369) Standard care (n=366) 
Cost of hospital care 5,089.32 (246.80) 4,812.39 (234.14) 
Cost of primary care 315.89 (28.65) 317.88 (28.85) 
EQ-5D score at baseline 0.751 (0.016) 0.752 (0.016) 
EQ-5D score at 30 days 0.683 (0.016) 0.684 (0.016) 
 
Note: SE values were calculated assuming a Gamma distribution for costs and a normal distribution 
for EQ-5D scores 
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Figure 5.3 ROSSINI trial: multiple imputation diagnostics for three variables (total cost, 
baseline EQ-5D and final EQ-5D) 
 
Note: Depicted variables (vertical axis) are total cost £ (c_final), baseline EQ-5D score (score0) and 
final EQ-5D score (scoreEQ3). For each variable the results of the multiple imputation exercise (20 
sets) across 20 iterations (x axis) are depicted for the mean and standard deviation. 
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Cost-effectiveness 
Patients in the WEPD arm accessed health care worth £5,420 on average, compared to 
£5,130 for patients in the standard care arm (Table 5.10). The use of the WEPD was 
associated with 0.02131 QALYs, compared to 0.02133 QALYs in the control group. Overall, 
the WEPD strategy was on average £290 more costly (95%CI -372 to 948) and 0.00002 
QALYs (95%CI -0.0018 to 0.0017) less beneficial than standard care, thus suggesting that 
WEPD was dominated by standard care (Table 5.10). The distribution of the cost-
effectiveness pairs on the cost-effectiveness plane are presented in Figure 5.4. Just as the 
confidence intervals and the cost-effectiveness plane suggest, there is a great amount of 
uncertainty around the point estimates of both incremental costs and incremental QALYs. 
The cost-effectiveness acceptability curves (CEACs) indicate that the WEPD is 
approximately 20% likely to be cost-effective for a willingness-to-pay threshold within the 
£20,000-30,000/QALY range. Its probability of cost-effectiveness slowly increases with the 
WTP threshold but still remains below 40% at a threshold in excess of £1 million per QALY 
(Figure 5.5). 
The results of the adjustment models for costs and QALYs are presented in Table 5.11 
and Table 5.12, respectively; the coefficient estimates and their variances were combined 
using Rubin's rules (22). Adjusted estimates for total costs and QALYs are presented in Table 
5.13.  
Using the WEPD was associated on average £310 more costly (95% CI -273 to 1012) 
and more effective (0.00018 QALYs, 95% CI -0.0015 to 0.0019) compared with not using the 
device (Table 5.13). The associated CEAC suggests that the WEPD is approximately 16% 
likely to be cost-effective at a willingness-to-pay threshold between £20,000 and £30,000 
(Figure 5.5). 
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Table 5.10 ROSSINI trial economic evaluation base-case analysis: mean difference in costs and outcomes by treatment group 
(unadjusted) 
 
 
Variable 
Mean (SE) 
Mean difference 
(WEPD – standard care) 
95% BCa CI ICER 
WEPD (n=369) Standard care (n=366) 
Total cost (£) 5,420.31 (246.16) 5,130.27 (233.74) 290.04 -371.70 to 948.49 
WEPD is 
dominated 
QALY 0.02131 (0.00141) 0.02133 (0.00139) -0.00002 -0.0018 to 0.0017 
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Figure 5.4 ROSSINI trial economic evaluation base-case analysis: cost-effectiveness 
plane 
Note: Willingness-to-pay threshold set at £20,000/QALY 
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Figure 5.5 ROSSINI trial economic evaluation base-case analysis: cost-effectiveness acceptability curves 
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Table 5.11 ROSSINI trial economic evaluation base-case analysis: results of the 
adjustment model for total costs 
 
Variable Coefficient estimate SE p-value 
Intercept 4,341.32 585.56 <0.001 
Intervention arm 310.86 307.44 0.312 
Plan to open viscus -58.79 432.37 0.892 
Plan to create stoma 481.86 415.58 0.246 
Emergency surgery -768.19 358.30 0.033 
.Age (55-65) 1,403.09 442.56 0.001 
.Age (65-75) 955.08 418.61 0.002 
.Age(75-85) 886.01 484.04 0.007 
.Age(85+) -30.64 849.26 0.971 
.BMI(23.2-26.7) 29.42 546.66 0.957 
.BMI(26.7-30) -332.19 526.31 0.529 
.BMI(30+) -22.65 599.42 0.969 
Current smoker 665.98 461.45 0.149 
Diabetic 451.90 472.99 0.339 
SSI 952.35 395.91 0.016 
 
 
Table 5.12 ROSSINI trial economic evaluation base-case analysis: results of the 
adjustment model for QALYs 
 
Variable Coefficient estimate SE p-value 
Intercept 0.02458 0.00230 <0.001 
Intervention arm 0.00018 0.00093 0.844 
Baseline EQ-5D score -0.03312 0.00184 <0.001 
Plan to open viscus -0.00031 0.00151 0.837 
Plan to create stoma -0.00012 0.00128 0.936 
Emergency surgery 0.00050 0.00100 0.619 
.Age (55-65) 0.00032 0.00134 0.809 
.Age (65-75) -0.00034 0.00138 0.804 
.Age(75-85) -0.00098 0.00166 0.553 
.Age(85+) -0.00630 0.00315 0.462 
.BMI(23.2-26.7) 0.00018 0.00170 0.914 
.BMI(26.7-30) 0.00082 0.00165 0.620 
.BMI(30+) -0.00330 0.00197 0.100 
Diabetic -0.00146 0.00136 0.286 
Current smoker -0.00027 0.00140 0.843 
SSI -0.00456 0.00114 <0.001 
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Table 5.13 ROSSINI trial economic evaluation base-case analysis: mean difference in 
costs and outcomes by treatment group (adjusted) 
 
 
Variable 
Mean difference 
(WEPD – standard care) 
95% BCa CI ICER 
Incremental cost (£) 310.86 -272.88 to 1011.67 
1,712k/QALY 
Incremental QALY  0.00018 -0.0015 to 0.0019 
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Results of the complete case analysis 
A complete case analysis was also performed, using information from patients who 
had complete data on resource use, HRQoL (all time-points) and primary outcome (n=532). 
The average cost in the intervention arm was £5,049 while the average cost in the control arm 
was £4,812 (Table 5.14). The use of the WEPD was associated with an average HRQoL effect 
of 0.02038 QALYs, compared to 0.02070 QALYs in the control arm.  
The bootstrapping exercise revealed that using the WEPD is on average £237 more 
costly (95% CI -407 to 892) and more effective (0.00032 QALYs, 95% CI -0.00235 to 
0.00162) compared with not using the device (Table 5.14), yielding an ICER of 
approximately £740,000 per additional QALY. The distribution of the incremental cost-
incremental effectiveness pairs on the cost-effectiveness plane still suggests a great amount of 
uncertainty around the point estimates (Figure 5.6). The associated CEAC suggests that the 
WEPD is approximately 23% likely to be cost-effective at a willingness-to-pay threshold 
between £20,000 and £30,000 (Figure 5.7). 
The results of the complete case adjustment models for costs and QALYs are 
presented in Table 5.15 and Table 5.16, respectively. In the adjusted analysis using the WEPD 
was associated on average £369 more costly (95% CI -214 to 976) and less effective               
(-0.00016 QALYs, 95% CI -0.00218 to 0.00193) compared with not using the device (Table 
5.17). The associated CEAC suggests that the WEPD is approximately 13% likely to be cost-
effective at a willingness-to-pay threshold between £20,000 and £30,000 (Figure 5.7). The 
combined findings of the base-case and alternative analyses are presented in Table 5.18 and 
Figure 5.8. 
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Table 5.14 ROSSINI trial economic evaluation complete case analysis: mean difference in costs and outcomes by treatment group 
(unadjusted) 
 
Variable 
Mean (SE) 
Mean difference 
(WEPD – standard care) 
95% BCa CI ICER 
WEPD (n=369) Standard care (n=366) 
Total cost (£) 5,049.5 (232.9) 4,812.4 (229.4) 237.1 -406.90 to 891.87 
£ 740k/QALY 
QALY 0.02038 (0.00159) 0.02070 (0.00162) 0.00032 -0.00235 to 0.00162 
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Figure 5.6 ROSSINI trial economic evaluation complete case analysis: cost-effectiveness 
plane 
 
Note: Willingness-to-pay threshold set at £20,000/QALY 
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 Figure 5.7 ROSSINI trial economic evaluation complete case analysis: cost-effectiveness acceptability curves 
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Table 5.15 ROSSINI trial economic evaluation complete case analysis: results of the 
adjustment model for total costs 
 
Variable Coefficient estimate SE p-value 
Intercept 4,608.71 566.96 <0.001 
Intervention arm 369.03 315.67 0.243 
Plan to open viscus 3.51 452.47 0.994 
Plan to create stoma 687.38 456.05 0.132 
Emergency surgery -789.97 322.84 0.015 
.Age (55-65) 319.85 443.28 0.471 
.Age (65-75) 550.01 432.50 0.204 
.Age(75-85) 166.34 486.44 0.732 
.Age(85+) -655.91 801.68 0.414 
SSI 591.51 400.64 0.140 
 
Table 5.16 ROSSINI trial economic evaluation complete case analysis: results of the 
adjustment model for QALYs 
 
Variable Coefficient estimate SE p-value 
Intercept 0.02151 0.00220 <0.001 
Intervention arm -0.00016 0.00102 0.877 
Baseline EQ-5D score -0.03168 0.00193 <0.001 
Plan to open viscus 0.00035 0.00147 0.811 
Plan to create stoma 0.00058 0.00140 0.677 
Emergency surgery 0.00012 0.00107 0.909 
.Age (55-65) 0.00082 0.00147 0.575 
.Age (65-75) 0.00048 0.00139 0.731 
.Age(75-85) 0.00121 0.00164 0.461 
.Age(85+) -0.00422 0.00322 0.189 
SSI -0.00452 0.00122 <0.001 
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Table 5.17 ROSSINI trial economic evaluation complete case analysis: mean difference 
in costs and outcomes by treatment group (adjusted) 
 
Variable Mean difference 95% BCa CI ICER 
Incremental cost (£) 369.03 -214.23 to 976.28 
WEPD is 
dominated 
Incremental QALY  -0.00016 -0.00218 to 0.00193 
 
 
 
 
Table 5.18 ROSSINI trial economic evaluation: summary of incremental costs and 
QALYs across the analysed scenarios 
 
Scenario Variable 
Mean difference 
(WEPD – standard 
care) 
95% BCa CI ICER 
Base-case 
unadjusted 
Total cost (£) 290.04 -371.70 to 948.49 
WEPD is 
dominated 
QALY  -0.00002 -0.0018 to 0.0017 
Base-case 
adjusted 
Total cost (£) 310.86 -272.88 to 1011.67 
£1,712k/QALY 
QALY  0.00018 -0.0015 to 0.0019 
Complete case 
unadjusted 
Total cost (£) 237.1 -406.90 to 891.87 
740k/QALY 
QALY  0.00032 -0.00235 to 0.00162 
Complete case 
adjusted 
Total cost (£) 369.03 -214.23 to 976.28 
WEPD is 
dominated 
QALY  -0.00016 -0.00218 to 0.00193 
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Figure 5.8 ROSSINI trial economic evaluation: comparison of cost-effectiveness acceptability curves 
 Legend: MI - Base-case analysis; CC - complete case analysis
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The cost and HRQoL burden of SSI  
The comparison of resource utilisation between SSI and uninfected patients revealed 
that hospital care was comparable across the two groups in terms of number of inpatient days 
(Table 5.19). However, SSI patients consumed more resource in primary care, after discharge, 
as they had significantly more GP visits (average 0.73 vs. 0.38, p=0.0003) and district nurse 
visits (average 6.54 vs. 2.45, p<0.0001) than uninfected controls. When primary care points of 
contact and nurse visits, respectively, were aggregated the differences remained statistically 
significance (Table 5.20). 
On average, having a SSI was associated with an additional cost of £1,069 (95% CI 
£237 to £1,901) and a decreased utility of 0.12 (95% CI 0.07 to 0.17) at 30 days post-
operatively (Table 5.21). SSI patients received more expensive care both in an inpatient 
(£739, 95% CI -76 to 1,555) and outpatient setting (£330, 95% CI £242 to £417).  
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Table 5.19 ROSSINI trial: summary of resource use by SSI status, detailed 
 
Resource use item SSI (n=184) No SSI (n=551) p-value 
    
HOSPITAL CARE    
    
Inpatient days  
N 
Mean (SD) 
SE 
Median 
 
181 
13.02 (14.86) 
1.10 
9 
 
536 
11.73 (13.29) 
0.57 
9 
 
0.3015 
 
    
Days in ITU 
N 
Mean (SD) 
SE 
Median 
 
184 
1.21 (4.41) 
0.32 
0 
 
551 
0.93 (4.46) 
0.19 
0 
 
0.4473 
 
    
Days in HDU 
N 
Mean (SD) 
SE 
Median 
 
184 
0.59 (1.69) 
0.12 
0 
 
551 
0.57 (1.56) 
0.07 
0 
 
0.8837 
 
    
PRIMARY CARE    
    
GP visits 
N 
Mean (SD) 
SE 
Median 
 
178 
0.73 (0.09) 
0.09 
0 
 
544 
0.38 (0.03) 
0.03 
0 
 
0.0003 
 
    
District nurse visits 
N 
Mean (SD) 
SE 
Median 
 
179 
6.54 (8.64) 
0.65 
2 
 
536 
2.45 (6.16) 
0.27 
0 
 
<0.0001 
 
    
Practice nurse visits 
N 
Mean (SD) 
SE 
Median 
 
178 
0.33 (1.17) 
0.09 
0 
 
549 
0.21 (0.92) 
0.04 
0 
 
0.2410 
 
    
Outpatient clinic visits 
N 
Mean (SD) 
SE 
Median 
 
179 
0.52 (1.38) 
0.10 
0 
 
548 
0.31 (0.71) 
0.03 
0 
 
0.0575 
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Table 5.20 ROSSINI trial: summary of resource use by SSI status, overview 
 
Resource use item SSI (n=184) No SSI (n=551) p-value 
HOSPITAL CARE    
Inpatient days  
N 
Mean (SD) 
SE 
Median 
181 
13.02 (14.86) 
1.10 
9 
536 
11.73 (13.29) 
0.57 
9 
0.3015 
 
PRIMARY CARE    
Primary care points of contact (includes GP visits, all nurse visits and outpatient clinic visits) 
N 
Mean (SD) 
SE 
Median 
170 
8.03 (8.67) 
0.66 
6 
527 
3.26 (6.40) 
0.28 
1 
<0.0001 
 
Nurse visits (includes district nurse visits and practice nurse visits) 
N 
Mean (SD) 
SE 
Median 
175 
6.67 (8.29) 
0.63 
3 
534 
2.65 (6.19) 
0.27 
0 
 
<0.0001 
 
 
GP visits 
  
 
N 
Mean (SD) 
SE 
Median 
178 
0.73 (1.20) 
0.09 
0 
544 
0.38 (0.79) 
0.03 
0 
0.0003 
 
 
 
Table 5.21 ROSSINI trial: summary of costs and HRQoL data by SSI status 
 
Variable 
Mean (SE) Difference 
(SSI - no SSI) 
95% CI* 
SSI (n=369) No SSI (n=366) 
Total cost 6,077.49 (381.86) 5,008.19 (182.09) 1,069.29 237.71 to 1900.87 
Cost of inpatient care 5,506.01 (371.06) 4,766.21 (185.71) 739.79 -75.77 to 1555.35 
Cost of outpatient care 564.01 (38.56) 234.35 (22.36) 329.65 241.97 to 417.34 
EQ-5D score at baseline 0.718 (0.023) 0.762 (0.013) -0.044 -0.096 to 0.008 
EQ-5D score at 7 days 0.464 (0.028) 0.514 (0.015) -0.049 -0.011 to 0.110 
EQ-5D score at 30 days 0.594 (0.023) 0.714 (0.013) 0.119 0.067 to 0.172 
 
Note: 95%CI computed assuming a Gamma distribution for costs and a normal distribution for EQ-5D 
scores 
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5.2.3. Discussion 
Summary of findings 
The results of the economic evaluation give a strong indication that using the WEPD 
in adults undergoing open abdominal surgery is unlikely to be cost-effective when compared 
to standard care i.e. no WEPD. In the base-case analysis the intervention was found to be 
more costly and less effective than standard care: the WEPD was associated with an 
incremental cost of £290 and a 0.00002 QALY loss, thus being dominated by standard care. 
Since the willingness to pay threshold for most medical technologies lies between £20,000-
30,000 per QALY gained, the most likely recommendation is not to adopt the WEPD. Within 
this WTP interval, the WEPD was less than 30% likely to be cost-effective compared to 
standard care in all analyses (Figure 5.8). The recommendation was robust to a range of 
sensitivity analyses (Table 5.18). 
There remains uncertainty around the point estimates of costs and HRQoL outcomes, 
reflected in the width of the confidence intervals. The estimation of uncertainty used non-
parametric bootstrapping with n=1,000 replications and confidence intervals were calculated 
using the bias corrected and accelerated method, in line with methodological 
recommendations (54). It also is very unlikely that ROSSINI was underpowered: the pre-
specified sample size in the statistical analysis plan (n=750), based on the best available 
evidence to date, assumed a 50% reduction in SSI and a 12% SSI rate in the study population. 
The trial recruited well and included n=735 patients in the final analysis, while the overall SSI 
rate was much higher than predicted, at 25.4%, therefore overall ROSSINI was rather 
overpowered for its original study question. This suggests there may be a large amount of 
variability in the cost and HRQoL gains associated with the use of the WEPD. In support of 
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this hypothesis, the primary outcome also exhibited considerable uncertainty (OR 0.97, 95% 
CI 0.69 to 1.36).  
Almost all differences between trial arms in terms of costs and EQ-5D scores were not 
statistically significant (Tables 5.4 and 5.9). The only exception is the cost of practice nurse 
visits, which appears to have been somewhat higher in the control arm than in the intervention 
arm as control patients received about twice as many practice nurse visits than WEPD patients 
(Table 5.4). However, this difference may well be an artefact because resource utilisation in 
primary care was informed by patient-completed forms and there may have been some 
confusion regarding the exact nature of the health care professional who led the visit, for 
example not differentiating between practice nurse and district nurse visits at the time of 
filling in the CRF. Indeed, when the total number of primary care contact points was 
summarised there was no difference between the two groups (Table 5.5). Furthermore, the 
cost of practice nurse visits only had a small contribution to the total cost and it is unlikely 
that it could have biased the overall results. 
 
Sensitivity analyses 
735 patients were included in the primary analysis of the trial based on availability of 
primary outcome data. Of these, n=532 patients had complete resource use, HRQoL and 
primary outcome data, leading to approximately 25% missing data for the purpose of the 
economic evaluation (Table 5.6). The largest proportion of the missing information referred to 
EQ-5D scores at baseline and at 30-33 days postoperatively (n=104 observations). No pattern 
of missingness was apparent upon inspection of the missing values. Patients below 65 years 
old and with a BMI larger than 26.75 had larger amounts of missing data than their 
counterparts, respectively, but this only applied to resource utilisation data and not to EQ-5D 
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scores. No other observed variables were associated with missingness. As such, the MCAR 
mechanism can be ruled out, while MAR may hold and thus informed the imputation 
exercise. 
  Results of the base-case were compared with the complete case analysis, which used 
information only from the 532 patients with complete data (Table 5.21). In the complete case 
analysis, incremental costs were lower than in the base-case (£237 vs. £290) and the QALY 
gain was positive (0.00032 vs.-0.00002). While the results are different between the two 
scenarios, they both lead to the same recommendation of not adopting the WEPD. The 
difference between the two results could be explained by the large amount of heterogeneity 
that appears to be inherent to the dataset. The 95% BCa confidence intervals for incremental 
costs and QALYs are comparable across the scenarios, thus suggesting that most of the 
variation in point estimates is due to natural variability, especially considering that the QALY 
gain is negligible. 
The results of the adjusted analyses were similar to the unadjusted results: in the base-
case analysis, the incremental cost increased from £290 to £311, while the QALY gain 
increased from -0.00002 to 0.00018. Although the WEPD is no longer dominated in the base-
case adjusted analysis, it remains cost-ineffective when considering the NICE WTP threshold. 
In the complete case scenario, following adjustment the incremental cost increased from £237 
to £369 and the incremental effectiveness decreased from 0.00032 to -0.00016 QALYs (Table 
5.21). While the adjusted analyses did not change the final recommendation, the increase in 
incremental costs results deserves comment. The most plausible explanation is that the 
variables used for adjustment, which were recognised SSI risk factors, reflected a slight 
imbalance in the two trial arms as a result of the randomisation procedure (Table 5.1): patients 
in the WEPD arm were slightly older and a slightly higher proportion had diabetes. These 
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may have impacted on the severity of the SSIs they acquired, which needed more intensive 
care. However the WEPD’s probability of cost-effectiveness, as reflected by CEACs, was 
largely unaffected by the adjustment: Figure 5.8 depicts the CEACs for adjusted and 
unadjusted base-case and complete case analyses, respectively, and the variations are 
minimal. There is great uncertainty around the point estimates in all three scenarios but the 
WEPD appears to be cost-ineffective under all the considered scenarios.  
 
Cost-effectiveness drivers 
It appears that inpatient costs are the main drivers for the total cost (Table 5.9). In both 
trial arms inpatient costs accounted for approximately 94% of total costs incurred. Patients in 
the intervention arm consumed more resources in hospital care, which may be primarily 
explained by the fact that patients in the WEPD arm spent, on an average, an extra day in 
hospital compared to patients in the control arm, but this difference was not statistically 
significant (Table 5.5). There are no reasons to believe, however, that blinding was violated: 
the SSI rates at 5-7 days postoperatively were comparable between the two arms (Figure 5.1) 
and no significant difference between the two arms was highlighted in the time to first 
hospital discharge analysis (hazard ratio 1.03, 95%CI 0.88 to 1.10) (Table 5.2).  
Primary care costs accounted for less than 10% in the total costs of postoperative 
management. This is in line with the findings of the analytic decision model (Chapter 4), 
which indicated that primary care costs would not be a major driver in the economic 
evaluation. The costs were comparable between the two groups and the difference was 
negligible. It appears that the largest part of primary care costs were due to district nurse 
visits, but again the differences between the two arms were negligible. The issue of practice 
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nurse visits was discussed above and the possibility of an artificial difference cannot be ruled 
out. 
 
Strengths and limitations 
 The economic analysis considered a range of scenarios to account for missing data and 
the effect of confounding variables on cost-effectiveness estimates. Multiple imputation using 
chained equations was used in the base-case analysis to account for missing data, in line with 
current recommendations (17, 26). Non-parametric bootstrapping and the bias corrected and 
accelerated method were employed to quantify the uncertainty around costs and outcomes in 
order to avoid any distributional assumptions (54).  
 Several limitations of the economic evaluation deserve consideration: the proportion 
of missing data, the time horizon, the complexity of SSI management and data collection. Just 
over 20% of patients had at least one cost of HRQoL missing data item, which may lead one 
to question the appropriateness of a complete case analysis. Nevertheless, the results of the 
base-case and complete case analyses are largely comparable and there are no reasons to 
believe that the proportion of missing data brings into question the results of the cost-
effectiveness analysis.  
 A 30-day time horizon after surgery was chosen for the economic evaluation due to 
ROSSINI's design, where the primary outcome was the occurrence of SSI within 30 days 
post-operatively, in line with the international guidelines on SSI diagnosis (200, 206). A 30-
day time horizon was also adopted in other decision models which evaluated interventions 
reducing SSI (314). In clinical practice two things must be considered: first, not all SSIs 
develop immediately after surgery. This was reflected in ROSSINI, which found that the 
majority of SSIs were diagnosed in the interval 7-30 days post-operatively (Figure 5.1). 
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Second, the time required for a SSI to heal is highly variable, ranging from several days to 
several months, depending on factors like the severity of the infection, the nature of the 
underlying pathogens and co-morbidities (see Chapter 4, section 4.2). 11% of patients still 
had an ongoing SSI at 30 days post-operatively. A further limitation refers to the complexity 
of SSI management, especially in primary care. NICE clinical guidelines on SSI care provide 
evidence that the weekly cost of wound dressings can be up to £100, depending on the type of 
wound and the type of dressing (243). Although an ethics amendment was put through to 
extend follow-up and to introduce a wound dressing diary for health care professionals and 
patients to complete to gather primary data on the type and frequency of dressings used, the 
procedures could not be implemented in due time because of regulatory delays; these aspects 
were eventually excluded from the analysis. Nevertheless, the WEPD did not show any sign 
of clinical benefit and there are little reasons to believe that it could reduce the burden of 
severe, long-term SSIs. The wound dressing diary was only piloted in four centres and the 
economic impact of their use remains unknown. However, if working under the assumption 
that district nurses are the health care professional most likely to apply the wound dressings in 
a primary care setting, the trial arms were more than comparable regarding the number of 
district nurse visits, which reduces the potential effect of not costing wound dressings (Tables 
5.4 and 5.5).  
  
Chapter 5. Cost-effectiveness analysis of WEPDs vs. standard care: the ROSSINI trial 
 
213 
 
5.3. Conclusion 
 Based on the findings of the ROSSINI trial, WEPDs are unlikely to be cost-effective 
in reducing SSI when compared to standard care. Total costs were higher in the intervention 
arm, mostly due to higher inpatient costs, but the differences were not statistically significant. 
Furthermore, HRQoL gains associated with the WEPD were negligible. There was a great 
deal of uncertainty around the point estimates of both incremental costs and incremental 
QALYs. WEPDs are approximately 20% likely to be cost-effective considering the NICE 
WTP threshold range. The results were robust to the adjustment for confounding factors and 
to a complete case analysis. The following Chapter discusses these findings in the context of 
previous evidence on WEPD effectiveness.  
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The aim of this Chapter is to integrate the evidence of clinical and cost-effectiveness 
of wound-edge protection devices (WEPDs) compared to standard care, which has been 
presented previously in Chapter 3 to Chapter 5. The findings of the systematic review, 
decision model and ROSSINI analyses will be presented and contrasted. Ultimately, 
consolidated findings will be formulated.  
 
6.1. Integrating the evidence on the clinical effectiveness of WEPDs 
 Two sources of evidence are available for the clinical effectiveness of WEPDs 
compared to standard care in reducing SSI after open abdominal surgery: the systematic 
review and exploratory meta-analysis presented in Chapter 3; and the ROSSINI trial, 
presented in Chapter 5. The exploratory meta-analysis included data from 12 trials (n=1,850 
participants) and suggested that WEPDs are likely to be effective when compared to standard 
care (RR 0.60, 95%CI 0.41 to 0.86). On the other hand, the ROSSINI trial randomised 760 
patients between two arms (WEPD vs. standard care), of which 735 were included in the final 
analysis. 91 patients in the intervention arm (n=369) and 93 patients in the control arm 
(n=366) developed a SSI after laparotomy, thus suggesting no benefit associated with the use 
of WEPDs (RR 0.97, 95%CI 0.76 to 1.25).  
 These two results are, thus, markedly different: while the systematic review suggested 
that WEPDs are largely effective, the ROSSINI trial demonstrated no benefit at all. The 
following paragraphs discuss the potential reasons and implications of this discrepancy. 
 First, the systematic review (Chapter 3) concluded that the methodological quality of 
the identified studies was generally poor: the sample sizes were generally small; there were 
concerns about the methods used for randomization and blinding; it was often unclear whether 
the reported outcomes had been pre-specified or not; and ten of the 12 included trials were 
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single-centre. In addition, most studies reported insufficient information to allow appropriate 
judgements on the Cochrane ‘Risk of bias’ categories. Nevertheless, the included trials 
spanned a large time interval (over 40 years) along which the methodological standards of 
conducting evaluative research have improved considerably: indeed, the more recent trials 
had better quality than older ones. In the light of these arguments, the results of the meta-
analysis were purely exploratory and this has been clearly specified at the outset. 
 The question then becomes how much can the results of such meta-analyses which 
included poor quality studies be trusted. A published commentary (361) to the systematic 
review outlined this very point and reinforced the need of more methodologically sound 
evidence to support the indicative results of the systematic review. No matter how 
methodologically sound its methods, a meta-analysis informed by poor quality data cannot 
offer a valid result. 
 Second, ROSSINI addressed most of the methodological limitations of earlier trials: it 
incorporated electronic randomisation with a minimisation procedure and stratification by 
three risk factors (elective/emergency surgery, intention to create a stoma, intention to open a 
viscus), group concealment, blinding of wound assessors and patients, and a robust follow-up 
protocol including training in wound assessment. In addition, the patient groups in ROSSINI 
were well matched with no significant over-representation of any patient or operative 
characteristic in either arm (Table 5.1). Moreover, ROSSINI found a baseline infection rate of 
25.4%, significantly higher than the conservative 12% predicted baseline rate, which offered 
increased power to detect potential benefit. SSI was assessed according to internationally 
accepted CDC guidelines at three time points: 5-7 days post-operatively (clinician assessed), 
7-30 days post-operatively (patient assessed) and 30-33 days post-operatively (clinician 
assessed). There was no significant difference between the intervention and control arms at 
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either time point (Figure 5.1). Furthermore, no difference was discernible in time to discharge 
analysis, health-related quality of life and cost-effectiveness, which suggests that ROSSINI 
findings are robust. 
 Third, ROSSINI aimed to provide as generalisable results as possible by accurately 
reflecting standard clinical practice. As such, it recruited from a large number of centres in 
England (21 general hospitals). The inclusion criteria were deliberately broad and referred to 
any type of open surgery requiring laparotomy. In addition, the study protocol was not 
prescriptive in relation to the prophylaxis measures to be taken: these were left at the 
discretion of each surgical team to reflect current local practice, but were also recorded and no 
difference was apparent between the two arms. This differs from the studies included in the 
systematic review, which usually focused on a particular type of surgery (such as 
appendicectomy or colon surgery) and had strict protocols for perioperative care.  
 Finally, two WEPD designs are available: the single-ring one, which features a plastic 
drape expanding from the ring; and the double-ring one, with a plastic semi-rigid drape 
linking the two rings in the shape of a cylinder. Historically speaking, the single-ring design 
precedes and has been around for much longer than the double-ring one: as a result, it was 
used in nine of the 12 trials included in the systematic review. The ROSSINI trial tested the 
single-ring design, whose effectiveness had last been suggested by the RCT of Sookhai et 
al.(269). All three major manufacturers of WEPD devices of all designs were invited to take 
part in ROSSINI: 3MTM (SteriDrape©); Applied MedicalTM (Alexis©); and Medical Concepts 
DevelopmentTM (Vi-Drape©). Only 3MTM responded to the invitation. On the other hand, the 
meta-analysis pooled data from studies irrespective of the design type they used. Sensitivity 
analyses suggested that there may be a difference in effectiveness favouring the double-ring 
design i.e. the exploratory subgroup analysis in the meta-analysis (section 3.2) and the 
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published analysis of Edwards et al. (301). Still, this indication is inevitably affected by the 
poor quality of the trials informing it. Without a head-to-head comparison of the two devices 
and accurate knowledge of how pathogens infect the surgical wound, it is still difficult to 
ascertain what ROSSINI actually demonstrated: that the WEPD mechanism of action is 
invalid; or that the single-ring design is not effective. 
 In light of these arguments, ROSSINI results appear to be more robust and 
generalisable than those of the exploratory meta-analysis. If the quality of ROSSINI and that 
of previous studies had been comparable, the next step in the evidence generating process 
would have been to update the results of the meta-analysis by incorporating ROSSINI results. 
This is not the case: ROSSINI is the only good quality RCT investigating this research 
question and a de novo systematic review would most likely only include ROSSINI and 
discard the previous trials. For exploratory purposes, however, an investigation was 
undertaken into how bringing together the evidence from all available trials, including the two 
more recent trials published after the systematic  review (both with methodological quality 
issues, as discussed at the end of Chapter 3) and ROSSINI, would impact the estimate of 
clinical effectiveness of WEPDs. As Figure 6.1 suggests, adding the recently available 
information did not change the point estimate of WEPD effectiveness compared to the 
original result (RR 0.60, 95% CI 0.43 to 0.85).  
ROSSINI appears to be the best available evidence on the clinical effectiveness of 
WEPDs compared to standard care. As such, the use of WEPDs cannot be routinely 
recommended to reduce SSI after open abdominal surgery.  
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Figure 6.1 Exploratory meta-analysis with all the available evidence on the clinical effectiveness of WEPDs 
Study or Subgroup
1.5.1 Original meta-analysis
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Psaila 1977
Nystrom 1984
Gamble Hopton 1984
Batz 1987
Brunet 1994
Redmond 1994
Sookhai 1999
Horiuchi 2007
Lee 2009
Reid 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.20; Chi² = 24.08, df = 11 (P = 0.01); I² = 54%
Test for overall effect: Z = 2.78 (P = 0.005)
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Theodoridis 2011
Cheng 2012
ROSSINI 2012
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 1.73; Chi² = 5.13, df = 2 (P = 0.08); I² = 61%
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.22; Chi² = 36.33, df = 14 (P = 0.0009); I² = 61%
Test for overall effect: Z = 2.89 (P = 0.004)
Test for subgroup differences: Chi² = 0.37, df = 1 (P = 0.55), I² = 0%
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6.2. Integrating the evidence on the cost-effectiveness of WEPDs 
 There are two available sources of evidence for the cost-effectiveness of WEPDs 
compared to standard care: the preliminary decision model, discussed in Chapter 4; and the 
economic evaluation alongside the ROSSINI trial, discussed in Chapter 5. The comparative 
results of the two evaluations are jointly presented in Table 6.1: while the decision model 
suggested that use of the WEPD dominates standard care across the entire range of explored 
scenarios, the trial-based cost-effectiveness analysis showed that the WEPD was either 
dominated or cost-ineffective, depending on the scenario considered. The unadjusted base-
case analysis of ROSSINI data suggested that the WEPD option is on average £290 more 
expensive than standard care and generates 0.00002 less QALYs. When incorporating 
uncertainty in the results and assuming a decision maker's WTP threshold of £20,000/QALY, 
the decision model base-case analysis indicated that the WEPD is 86.6% likely to be cost-
effective as opposed to 20% in the ROSSINI base-case analysis. 
 These are, again, contrasting results: the decision model depicts the WEPD as highly 
cost-effective, while the in-trial analysis indicates the opposite. This can also be observed in 
Figure 6.2, which depicts the cost-effectiveness acceptability curves from both the decision 
model scenarios and ROSSINI analyses. The decision model rests on the assumption that the 
WEPD is clinically effective, as suggested by the systematic review and meta-analysis in 
Chapter 3. However, as discussed in the previous section of this Chapter, there are reasons to 
believe that ROSSINI findings, however different, are more robust than those of the meta-
analysis. In that respect, a direct comparison of the decision-model and ROSSINI results is 
difficult because the two are informed by utterly different clinical realities.
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 Table 6.1 Comparison of decision model and ROSSINI economic evaluation results 
 
Source Type of analysis Alternative Total cost (£) 
Incremental 
Cost (£) 
Total 
QALY 
Incremental 
QALY 
Decision 
        
ROSSINI trial Base-case 
unadjusted 
WEPD 
Standard care 
5,420  
5,130  
290 
- 
0.05975 
0.05985 
-0.00010 
- 
WEPD is dominated 
        
 Complete case 
unadjusted 
WEPD 
Standard care 
5,049 
4,812 
237 
- 
0.06073 
0.06169 
-0.00096 
- 
WEPD is dominated 
        
Decision model Base-case WEPD 
Standard care 
5,196 
5,240 
-44 
- 
0.06061 
0.06051 
0.00010 
- 
Standard care is dominated 
        
 Scenario 1 WEPD 
Standard care 
5,286 
5,330 
-44 
- 
0.06062 
0.06048 
0.00014 
- 
Standard care is dominated 
        
 Scenario 2 WEPD 
Standard care 
5,221 
5,272 
-51 
- 
0.06060 
0.06051 
0.00009 
- 
Standard care is dominated 
        
 Alternative 
model 
WEPD 
Standard care 
5,672 
6,056 
-384 
- 
0.06051 
0.06036 
0.00015 
- 
Standard care is dominated 
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Figure 6.2 Comparison of cost-effectiveness acceptability curves: original decision model and ROSSINI results 
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In absolute terms, the decision model appears to have predicted reasonably well the 
magnitude of average costs in both arms, ranging in the interval £5,000 to £5,500 in both 
base-case analyses. However, the decision model mis-estimated the incremental costs as it 
predicted that the WEPD alternative would be cost-saving. In terms of predicting 
effectiveness, the decision model estimates of total QALYs are compatible with those resulted 
from ROSSINI; the discrepancy between positive incremental QALYs in the decision model 
and negative incremental QALYs in ROSSINI is most likely a result of the assumption that 
the WEPD was effective.  
 Two key assumption made in the decision model with respect to estimating QALYs 
appear to have been appropriate. First, the decision model assumed a utility decrement of 
approximately 0.05 as a result of uninfected surgery at 30-days postoperatively, calculated as 
the difference between baseline utility (0.800, informed by UK population norms for age 
group 55-64) and the EQ-5D score reported by Janson et al. (332) after open colon resection 
(0.752). On the other hand, the difference between baseline (0.762) and 30-day EQ-5D score 
(0.714) for uninfected patients was also 0.05, thus closely compatible with the model 
estimate. Second, the 0.1 utility decrement assumed in the model also appears to be 
defensible, as the comparison of utility scores between SSI and non-SSI patients in ROSSINI 
suggested a difference at 30 days postoperatively of 0.119 (95%CI 0.067 to 0.172). 
 In order to investigate the effect of the clinical effectiveness estimate on the results of 
the decision model, the original effectiveness parameter (RR 0.60, 95%CI 0.41 to 0.86) was 
replaced with ROSSINI's estimate of effectiveness (RR 0.97, 95%CI 0.76 to 1.25). The results 
are shown in Table 6.2: under the new assumption of no clinical benefit of the WEPD, the 
base-case and two scenarios of the decision model yield positive incremental costs and 
marginally positive QALY gains, thus suggesting that the WEPD option is more costly and 
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more effective than standard care. However, the resulting ICERs are in excess of 
£1million/QALY, therefore the WEPD is clearly cost-ineffective at a WTP threshold of 
£20,000/QALY.  
 Figure 6.3 depicts the cost-effectiveness acceptability curves from the updated 
decision model scenarios and ROSSINI results. An alternative decision model was developed 
in Chapter 4 to explore structural uncertainty, and deliberately had a simpler structure than the 
base-case model. It appears that the alternative model offers the closest estimate of the 
WEPD’s probability of cost-effectiveness to trial-based results. By contrast, the base-case 
decision model appears to yield results which are the least compatible with ROSSINI. This 
may prove to be an argument towards using a simpler model structure; however, it has to be 
fully acknowledged that the simpler model is much more dependent on the accuracy of data 
inputs. As shown in Figure 6.3, the alternative decision model clearly favoured the WEPD 
based on the evidence emerging from the systematic review. Moreover, the alternative 
decision model also overestimated the magnitude of total costs in both arms the most among 
all investigated scenarios (Table 6.2).  
In light of all these findings, it appears that the base-case decision model produced a 
conservative estimate of the WEPD’s cost-effectiveness. Of all the considered scenarios, it 
appears that the ‘alternative’, less sophisticated model, had a higher predictive value of cost-
effectiveness than the other scenarios, although the latter better predicted absolute costs and 
effects, which may also be of interest to decision makers. 
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Table 6.2 Results of the decision model’s reassessment using the ROSSINI clinical effectiveness estimate 
 
Source Type of analysis Alternative Total cost (£) 
Incremental 
Cost (£) 
Total QALY 
Incremental 
QALY 
Decision 
        
ROSSINI trial Base-case WEPD 
Standard care 
5,420  
5,130  
290 
- 
0.05975 
0.05985 
-0.00010 
- 
WEPD is dominated 
 Complete-case WEPD 
Standard care 
5,049 
4,812 
237 
- 
0.06073 
0.06169 
-0.00096 
- 
WEPD is dominated 
        
Decision model 
 
Base-case WEPD 
Standard care 
5,274 
5,261 
13 
- 
0.06053 
0.06052 
0.00001 
- 
WEPD not cost-effective at 
£20k/QALY 
(updated with 
ROSSINI clinical 
Scenario 1 WEPD 
Standard care 
5,344 
5,333 
11 
- 
0.06050 
0.06049 
0.00001 
- 
WEPD not cost-effective at 
£20k/QALY 
effectiveness 
estimate) 
Scenario 2 WEPD 
Standard care 
5,293 
5,282 
11 
- 
0.06051 
0.06050 
0.00001 
- 
WEPD not cost-effective at 
£20k/QALY 
 Alternative model WEPD 
Standard care 
6,040 
6,054 
-14 
- 
0.06038 
0.06037 
0.00001 
- 
Standard care is dominated 
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Figure 6.3 Comparison of cost-effectiveness acceptability curves: updated decision model and ROSSINI results 
Chapter 6. Reassessing the evidence on the clinical and cost-effectiveness of WEPDs 
 
227 
 
A limitation of both the decision model and ROSSINI was that the use of wound 
dressings was not accounted for. There was insufficient evidence in the literature to inform an 
appropriate model input and the ethical approval for a close monitoring of wound dressings in 
ROSSINI came in too late to be fully implemented. There are indications that wound 
dressings are an important component of wound care (243); this has also been reflected in the 
differential number of nurse visits between SSI and non-SSI patients (Table 5.19). Future 
studies investigating interventions aimed at reducing the burden of SSI should incorporate this 
element in the study design in order to obtain more accurate representations of the care 
received in a primary setting.  
 
6.3. Conclusion 
The evidence on the clinical effectiveness of WEPDs appears to be contradictory. 
However, the methodological quality of the ROSSINI trial is superior to that of previous 
smaller trials and thus ROSSINI results are more robust. For this reason, it is very likely that 
WEPDs are not associated with any significant benefit compared to standard care in reducing 
SSI in patients undergoing open abdominal surgery. Consequently, both the updated decision 
model and trial-based analyses suggested that WEPDs are also unlikely to be cost-effective. 
In light of this evidence, WEPDs cannot be currently recommended for routine use in the 
NHS.  
 Generalisability has been of the principal aims of ROSSINI design. The following 
Chapters will explore the potential impact of centre selection on trial results and will use 
ROSSINI as a case study to demonstrate a novel approach to quantify this impact. 
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The work presented in this Chapter has been published as: 
Gheorghe A, Roberts TE, Ives JC, Fletcher BR, Calvert M (2013) Centre Selection for 
Clinical Trials and the Generalisability of Results: A Mixed Methods Study. PLoS ONE 8(2): 
e56560. doi:10.1371/journal.pone.00565 
 
Section 1.3 of the Introduction argued for the necessity of understanding the current 
practice of centre selection for RCTs in order to ascertain whether there is a potential for bias 
in the clinical and economic results of contemporary trials. The remainder of the thesis 
presents an empirical exploration of the practice of centre selection (Chapter 7), followed by 
the development of a novel methodology (Chapter 8) which will be demonstrated using the 
ROSSINI trial (Chapter 5) as a case study. This Chapter presents the methods and results of 
an investigation into the current and ideal practice of centre selection for clinical trials in the 
UK. 
 
7.1. Introduction 
 As pointed out in Chapter 1 (sub-section 1.3.1), the external validity (generalisability) 
of RCTs may be questioned (78, 83, 84). For example, evidence suggests that trial 
participants are often unrepresentative of the target population (87-92), which can introduce 
bias in the measures of effect  (95). The choice of participating centres also has a role (78), 
especially in non-pharmacologic trials, as outcomes may be affected by factors like hospital 
volume (97) and practitioners' expertise (98). Ensuring the generalisability of RCT results 
may be particularly challenging for economic outcomes informing health policy changes. 
Whilst the relative clinical effect of an intervention has been historically assumed constant 
across settings, albeit not without challenges (78, 128, 129), this assumption may not hold for 
economic outcomes (130, 131). Modelling methods are one way to retrospectively address 
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this limitation, but they rely on inferences made on a sample of centres whose 
representativeness to their jurisdiction is unknown (134, 155, 164, 167, 362).  
 Given that the sample of participating centres may impact on the generalisability of 
trial results, especially with respect to decision making based on cost-effectiveness evidence, 
the question arises as to whether the current practice of clinical trials design and conduct 
allows for such a bias to occur. This piece of research had two objectives: first, to establish 
which factors currently drive centre selection in trials; and second, to reveal what is perceived 
as good practice in terms of enrolling centres.  
 A mixed methods approach was employed: a systematic review of protocols of RCTs 
funded by the National Institute for Health Research - Health Technology Assessment 
(NIHR-HTA) programme was conducted; two focus groups with clinical trial professionals; 
and an online survey distributed to clinical trials professionals in the 48 UK Clinical Research 
Collaborative Clinical Trials Units (UKCRC CTUs) and 10 NIHR Research Design Services 
(RDS). Two steps were envisaged: first, to assemble a comprehensive list of considerations 
that trialists consider when including centres in RCTs (by means of the systematic review and 
focus groups); and second, to have these considerations inform a national survey of UK 
trialists on the topic of centre selection. As such, the survey design and content were informed 
by the systematic review and the two focus groups. 
 The approach targeted RCTs conducted with a clear view to influence policy and thus 
included studies with a built-in economic evaluation funded by the UK NIHR-HTA stream. It 
was judged that the systematic review alone would be insufficient to achieve the research 
objectives and it was decided that it should be complemented with focus groups and a survey 
of trialists for the following reasons: 1) there is a large amount of heterogeneity in the 
structure of HTA trial protocols and reporting criteria for selecting sites/clinicians is not a pre-
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requisite, so any such reporting is at the discretion of researchers; 2) there is evidence in the 
literature on poor adherence to trial protocols (363, 364); and 3) there is no guarantee that the 
trialists involved in writing the (sections relevant for centre selection of the) protocol are the 
ones who actually perform the selection in practice, so new considerations could be brought in 
the process. Considering all the above, the aim was to obtain a first-hand account of centre 
selection from trialists and compare it with the findings of the systematic review. Current and 
optimal practice were contrasted in order to explore trialists' views on the extent to which 
generalisability in centre selection should be explicitly considered in trial design. The 
following three sections present the results and methods of the systematic review, focus 
groups and online survey. 
 
7.2. Systematic review of trial protocols 
7.2.1. Methods  
 The objective of the systematic review was to investigate the process of centre 
selection in RCTs with a parallel economic evaluation in the UK. More specifically, the 
review aimed to answer two research questions:  
1) How did RCT investigators report the rationale for selecting and including centres in the 
RCT? and 
2) How did RCT investigators report the intention to use methods of addressing the 
generalisability by location of the trial-wide economic evaluation results? 
 The review included multi-centre RCTs with a parallel economic evaluation. Any type 
of economic evaluation was accepted as long as both costs and outcome data were collected 
alongside the RCT; it was not necessary for costs and outcomes to be formally combined in a 
cost-effectiveness or cost-benefit metric. Multinational RCTs were accepted if at least one 
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participating centre in the RCT was in the UK. Only RCTs started after 1st January 2005 were 
included. 
 Studies with the following characteristics were excluded: RCTs without an explicit 
economic evaluation component described in the protocol; RCTs initiated before 1st January 
2005; analytic decision modelling studies based on one or more RCTs; other types of studies 
apart from RCTs: cohort studies, case-control studies, follow-up studies, diagnostic accuracy 
studies; studies where UK centres did not participate; studies that involved animal subjects; 
studies for which the protocol was not available; and pilot RCTs or feasibility studies. No 
ethical approval was necessary for the systematic review. 
 
Data sources 
 Trials were searched in the National Institute for Health Research - Health Technology 
Assessment (NIHR-HTA) Primary Research (trial) repository, available at the address 
http://www.hta.ac.uk/projectdata/PjtSearchResult.asp. This source lists details of publicly-
funded studies commissioned by the NIHR. The search was performed in July 2011. 
 
Study selection 
 The study selection process comprised three phases: in Phase 1, all the projects listed 
in the NIHR HTA Primary Research repository were scanned against the inclusion/exclusion 
criteria based on the information in the project abstract and, if necessary, the study protocol. 
In Phase 2, the protocols of all included RCTs and all accompanying publications, as listed on 
the NIHR website, were downloaded and scanned against the inclusion/exclusion criteria. In 
Phase 3, the RCTs included at the end of Phase 2 underwent data extraction. 
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 The three-phase approach was applied to all the projects listed in the NIHR HTA 
Primary Research repository. For validation a second researcher (BF9) performed Phase 1 and 
Phase 2 on 20% of the projects which were randomly selected using the online random 
numbers generator www.random.org.   
 
Data extraction 
 For all the included studies (Phase 3) the full study protocol and any accompanying 
publications were scanned for relevant information.The following information items were 
extracted: study authors; project start year; acronym of RCT; study design 
(parallel/cluster/cross-over/other); type of intervention (pharmacologic/non-pharmacologic); 
intervention; control; rationale for centre selection (free text); rationale for centre selection 
(yes/no); discussion on generalisability across locations of economic evaluation results (free 
text); discussion on generalisability across locations of economic evaluation results 
(yes/no/unclear). 
 The following definitions were used to ascertain whether a given trial protocol 
accounted for centre selection and generalisability of economic evaluation results, 
respectively: 
Rationale for centre selection 
'Yes': the protocol explicitly mentioned one or more reasons or considerations that justify or 
describe the choice of particular centres for the RCT to the detriment of others. The mere 
enumeration of recruiting centres did not fall into this category.  
'No': the protocol did not identify any obvious consideration to justify or describe the choice 
of particular centres for the RCT to the detriment of others. 
                                                 
9 Benjamin R. Fletcher, Research Associate, Primary Care Clinical Sciences, University of Birmingham 
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Discussion on generalisability of economic evaluation results 
'Yes': the protocol explicitly mentioned that generalisability across locations would be 
addressed in subsequent analyses of the economic evaluation results and specified the 
methods that would be employed. 
'Unclear': the protocol explicitly mentioned that generalisability across locations would be 
addressed in subsequent analyses of the economic evaluation results, but did not identify the 
methods that would be employed. 
'No': the protocol did not mention explicitly that generalisability across locations would be 
addressed in subsequent analyses of the economic evaluation results. 
  
The protocols were downloaded in pdf format from the NIHR website. The 
information on centre selection was identified using the 'Find' command embedded in Adobe 
Reader© with the following search terms entered separately: 'centre', 'site', 'clinic', 'hospital' 
and 'practice'. The information on generalisability across locations of economic evaluation 
results was identified using the 'Find' command embedded in Adobe Reader© with the 
following search terms entered separately: 'economic' and 'cost'. I performed data extraction 
for all the included studies. Another researcher (BF) checked data extraction for the included 
studies in the random sample of 20% considered for Phase 1 and 2. 
  
Data analysis 
 Following the extraction of free text information relevant for the two review questions, 
the free text was analysed using the meta-summary method (365), such that the information 
was abstracted, reformulated and categorized into meaningful units i.e. themes, categories and 
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sub-categories. A frequency effect size was calculated for each emerging category as the ratio 
between the number of studies containing that particular finding and the total number of 
included studies. 
 The  qualitative data analysis was performed using NVivo 8 software (366): this 
involved developing the codes and manually coding the extracted free text information in all 
the included studies. A second researcher (BF) reviewed the code structure and the manual 
coding for all the included studies. Any disagreements were resolved by discussion. 
 Centre selection reporting can be confounded by the trial characteristics. In some types 
of trials, such as those testing non-pharmacologic interventions, one can expect variation in 
effectiveness across locations because the expertise and practice of local health care 
professionals influence the patient-level outcomes. Moreover, cluster RCTs may be more 
likely to justify the choice of participating centres (clusters) compared to parallel RCTs. In 
acknowledgement of these considerations, an exploratory analysis compared centre selection 
reporting across non-pharmacologic/pharmacologic RCTs and cluster/non-cluster RCTs to 
identify such disparities.  
  
7.2.2. Results 
 365 projects in the UK NIHR HTA Primary Research portfolio were reviewed, of 
which 129 RCTs met the inclusion criteria; these had a target sample size total of more than 
317,000 participants (Figure 7.1). The main reasons for study exclusion were initiation before 
January 2005 (n=233; 64%) and non-randomised design (n=46; 13%). The majority of 
included RCTs had a parallel design (n=112; 87%) and investigated non-pharmacologic 
interventions (n=96; 74%). The vast majority of the included studies compared the 
intervention against standard care or (an)other intervention(s) and only nine studies were 
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placebo controlled. Mental health was the best represented therapeutic area (n=25; 19%), 
while the proportions of studies in areas such as oncology, respiratory disorders, neurology 
and cardiology were comparable and ranged between 5 and 7% of total. Table 7.1 presents a 
descriptive summary of the included studies. Appendix 9 contains a full list of the included 
studies.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 7.1 Systematic review of trial protocols: Study inclusion flowchart 
 
 
 
 
129 RCTs included in meta-summary 
233 studies excluded: 
 135 started before January 2005 
 46 not RCTs 
 19 pilot/feasibility RCTs 
 19 did not have an available 
protocol 
 5 single-centre RCTs 
 9 RCTs without an economic 
evaluation 
 
362 studies screened  
after duplicates removed 
365 studies identified in the 
NIHR-HTA portfolio 
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Table 7.1 Systematic review of trial protocols: characteristics of included RCTs 
 
Characteristic 
Number of studies 
(%, n=129) 
International recruitment  
Yes 9 (7%) 
No 120 (93%) 
  
Design  
Parallel 112 (87%) 
Cluster 14 (11%) 
Factorial 3 (2%) 
  
Intervention  
Pharmacologic intervention  33 (26%) 
Non-pharmacologic intervention  96 (74%) 
  
Comparator  
Placebo 9 (7%) 
Standard care or other intervention(s) 120 (93%) 
  
Therapeutic area  
Mental health 25 (19%) 
Oncology 9 (7%) 
Musculoskeletal disorders 9 (7%) 
Respiratory disorders 8 (6%) 
Obstetrics and gynaecology 8 (6%) 
Behavioural medicine 8 (6%) 
Neurology 7 (5%) 
Infectious diseases 6 (5%) 
Digestive tract disorders 6 (5%) 
Cardiology 6 (5%) 
  
Note: Other therapeutic areas with less than 5% of studies were (number of studies): obesity 
(5), diabetes (5), urology (5), haematology (5), circulatory disorders (5), dermatology (3), 
dentistry (3), emergency medicine (2), ageing (2) and five other miscellaneous areas. 
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Considerations for centre selection  
 Of 129 included trials, 78 (60%) reported one or more considerations related to centre 
selection. The meta-summary identified 53 unique centre selection considerations (Appendix 
10) that were grouped into three themes comprising 13 categories (Table 7.2). 
 
Theme 1: ‘Diversity and Representativeness’ 
 'Diversity and representativeness' refers to trialists' explicit concern for enrolling 
representative or diverse centres in the RCT. Although diversity and representativeness have 
different meanings, in this context both concepts strongly relate to ensuring that the trial is 
conducted in such conditions (for example in terms of population, health care setting, clinical 
practice) so that its results can be generalised at national level. As such they both denote an 
interest for generalisability and for this reason they were analysed together under one theme. 
In 31 studies (24%) the rationale for centre selection explicitly referred to the need for a 
diverse or representative sample. The considerations that trialists invoked with respect to 
ensuring diversity/representativeness pertained to three categories: population characteristics, 
health service delivery and centre setting. 
 'Population characteristics' refers to an interest for recruiting from centres which serve 
diverse populations. 14 study protocols (11%) included such considerations in their 
description of centre recruitment. Diversity was categorised according to terms which 
described three sub-categories, namely socio-economic status (n=10; 8%), ethnicity (n=9; 
7%) and cultural background (n=1; 1%).  
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Table 7.2 Systematic review of trial protocols: centre selection considerations, results of 
the meta-summary 
 
Themes Frequency 
(effect size) 
PROVIDED CONSIDERATIONS FOR  CENTRE SELECTION 78 (60%) 
  
Diversity and representativeness in terms of... 31 (24%) 
Population characteristics 14 (11%) 
Health service delivery 15 (12%) 
Centre setting 15 (12%) 
Centre characteristics 57 (44%) 
Centre setting 4 (3%) 
Health service delivery 16 (12%) 
Trial intervention 31 (24%) 
Research 19 (15%) 
Centre size (catchment area/patient throughput) 22 (17%) 
Trial participation 37 (29%) 
Recruitment 17 (13%) 
Trial constraints (time, budget) 5 (4%) 
Ensuring trial processes and requirements 24 (19%) 
Support for running the trial  7 (5%) 
Willingness 9 (7%) 
DISCUSSED THE GENERALISABILITY OF ECONOMIC 
EVALUATION RESULTS 
18 (14%) 
Methods of addressing the generalisability of economic evaluation results  
Sensitivity analyses 13 (10%) 
Multilevel modelling 2 (2%) 
Collecting costs from representative centres 2 (2%) 
Regression modelling 2 (2%) 
  
Model interpretation: Of 31 RCTs (24% of total) which mentioned at least one consideration for centre 
selection pertaining to diversity and representativeness, 14 RCTs (11% of total) were concerned with 
diversity in terms of population characteristics, 15 RCTs (12% of total) mentioned diversity in terms 
of health service delivery and 15 RCTs (12% of total) referred to diversity in terms of centre setting. 
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Examples of relevant excerpts are given below: 
"The four centres [...] serve a population that includes people from a variety of different 
ethnic communities." [ID3] 
 
"We will use Census and deprivation data to select a higher number of practices located in 
low socio-economic areas to ensure full representation of smokers from areas of high 
deprivation" [ID14] 
 
"To further increase generalisability recruitment will be from urban and rural settings, 
including a large urban setting with a culturally more diverse population (Bristol) and across 
localities with the full range of deprivation indices expected in the UK" [ID74] 
 
 ‘Health service delivery’ denotes an interest towards ensuring recruitment from 
centres with a wide range of health care provision characteristics. 15 study protocols (12%) 
explicitly documented this intention, most often in relation to the types of organisations or 
practitioners (n=9; 7%), but also regarding patient case-mix (n=2; 2%), intervention 
throughput (n=1; 1%) and the range of services offered (n=4; 3%). The category is illustrated 
by several relevant excerpts below:   
"In the UK, study centres will be UK Dermatology Clinical Trials Network (UK DCTN) 
dermatologists in a mixture of district general and teaching hospitals." [ID59] 
 
"We will recruit obese adults from GP practices, exercise on prescription schemes, 
commercial weight loss programmes, gyms and the community. The multiple sources of 
recruitment should increase the generalisability of the study results." [ID98] 
 
"Coverage by the screening programme in [...] is similar to that for England as a whole." 
[ID118] 
 
 15 protocols (12%) included considerations pertaining to 'centre setting', thereby 
referring to recruitment from locations with a wide range non-health care delivery 
characteristics, such as urban-rural mix (n=8; 6%), geographical region (n=3; 2%), size (n=1; 
1%) and type of community (n=1; 1%). Examples include: 
"Recruitment will take place in eight secondary care referral centres in the UK serving a 
variety of ethnic and social groups and including both urban and peri-urban dwellings." 
[ID117] 
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"We aim to involve all regions of the UK." [ID102] 
 
"To aid generalisability participants will be from a range of community settings in the four 
study sites including [...]" [ID83] 
 
Theme 2: ‘Centre characteristics’ 
 The 'centre characteristics' theme refers to clarity when the trial aim is to enrol centres 
with particular features (such as location, size and research activity) that reflect a centre’s 
day-to-day setting and activity. The content of some of the categories and sub-categories 
under this theme overlaps with that of the units in the previous theme 'Diversity and 
Representativeness'. The difference between the two resides in why the individual 
considerations were specified: in 'Diversity and Representativeness', certain characteristics 
were invoked to enhance generalisability; on the other hand, considerations counted as 'Centre 
characteristics' were not explicitly invoked with the aim of ensuring generalisability. Most 
often they relate to elements of study design and to the nature of the clinical question the trial 
addresses. In some cases no explanation is apparent as to why trialists preferred certain 
characteristics over others, such as hospitals of a given dimension.  
 57 studies (44%) provided such a rationale for centre selection. Five categories 
emerged, namely: ‘centre setting’, ‘health service delivery (research ready)’, ‘trial 
intervention’, ‘research’ and ‘centre size’.  
 Protocols which specified a particular 'centre setting' (n=4; 3%) referred to aspects 
such as geographical location (n=2; 2%) and deprivation status (n=1; 1%). One RCT recruited 
in a particular centre because it was the only available facility in the region: 
"The University Hospitals of [...] NHS Trust is the only facility within the county of [...] 
providing inpatient emergency medical care to the inhabitants of [...]" [ID131] 
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 The 'Health service delivery (research-ready)' category groups considerations which 
relate to centres' health care provision characteristics (n=16; 12%). In addition, some of these 
characteristics put the centre in a good position to undertake research activities (these are to 
be distinguished from particular requirements for trial participation, which are discussed 
separately in a dedicated theme). Most protocols specified they would recruit from NHS 
centres (n=7; 5%) and are interested in organisations/practitioners with a clear interest in the 
clinical question under investigation (n=6; 5%). 
"All centres will be NHS Trusts" [ID128] 
 
"Each participating centre (and investigator) has been identified on the basis of: [...]; having 
at least one lead clinician with a specific interest in, and responsibility for, supervising and 
managing children who present with acute exacerbations of asthma" [ID15] 
 
"Each participating centre (and investigator) has been identified on the basis of: lead 
clinicians in radiology, respiratory medicine, pathology and surgery with a specific interest in 
the management of early lung cancer" [ID37] 
 
 Other protocols mentioned more specific considerations, such as being a centre of 
excellence (n=1; 1%) and the centre having received satisfactory peer review (n=1; 1%). 
"The [...] hub in made up of [...] hospital, a Centre of Excellence in the Treatment of 
Musculoskeletal disease and a Rheumatology centre for the region." [ID24] 
 
"The criteria of participation for a centre are as follows: [...] 2. Centre received a 
satisfactory peer review within last 2 years" [ID43] 
 
 The 'Trial intervention' category (n=31; 24%) relates to centre-specific considerations 
which are relevant for the intervention being investigated in the RCT. This was the best 
represented category both in this theme and the entire analysis: approximately a quarter of the 
included studies and approximately 40% of the ones that reported any explicit centre selection 
consideration invoked such intervention-related characteristics. Most protocols referred to the 
generic suitability of implementing the intervention in the enrolled centres (n=16; 12%) and 
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the amount of experience centres/practitioners have in delivering the intervention (n=13; 
10%). Experience was referred to equivocally: while most protocols asked for a given level of 
previous experience, several of them specifically looked for centres where the intervention 
had never been delivered before (n=6; 5%). 
"The entry criteria for a site to participate in the [...] trial are that participating surgeons 
must have inserted at least 3 fistula plugs." [ID104] 
 
"All centres will have carried out a minimum of over 250 BYPASS procedures before entering 
patients into the trial." [ID128] 
 
"The following criteria must be met for a site to participate in [...] - a site must: [...]; not be 
providing early, goal-directed, protocolised resuscitation as part of standard resuscitation 
practice" [ID73] 
 
 Several protocols went further and required a given level of demonstrated performance 
in service delivery (n=5; 4%): 
"The choice of centres has been informed by a national audit of ureteric stone management 
undertaken by the British Association of Urological Surgeons (BAUS) Section of Endourology 
in 2007 (co-led by our group)" [ID65] 
 
"They must be able to provide CT scans of sufficient quality to the study centre in Newcastle." 
[ID70] 
 
 'Research' comprises considerations which speak about a given centre's specific 
research capabilities, as judged by the trialists. 19 protocols (15%) included such criteria, 
which most often referred to the centre being part of a research network/group (n=10; 8%) 
and the centre having previous research experience (n=10; 8%).  
"In the UK, study centres will be UK Dermatology Clinical Trials Network (UK DCTN) 
dermatologists" [ID59] 
 
"all but one [centres] have close association with the Mental Health Research Network if the 
National Institute for Mental Health (England)" [ID3] 
 
"All three centres have a strong record of research in primary care and experience of, and 
commitment to, mental health trials." [ID20] 
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"The Southern hub consists of eight NHS trusts that have previously participated in RA hand 
research." [ID24] 
 
 Finally, the 'Centre size' category (n=22; 17%) refers to trials which explicitly targeted 
centres of a given size. Most protocols defined size based on patient throughput (n=11; 9%), 
while others invoked catchment area (n=7; 5%) or the actual size of the centre (n=5; 4%). 
"Participating stroke units provide organised stroke care to a population of over 1.5 million 
and admit over 3,000 stroke patients per year." [ID119] 
 
"All centres will be NHS Trusts, with surgical units carrying out at least 50 bariatric surgery 
operations per year." [ID128] 
 
"The Midlands hub consists of three large acute trusts in the region" [ID24]  
 
Theme 3: ‘Trial Participation’ 
 The 'Trial participation ' theme groups criteria that are meant to ensure a centre's 
successful integration in the RCT processes. They reflect trialists' desire to recruit from 
centres which are likely to successfully deliver the research within the specified time frame 
and budgetary constraints. This translates to clarity in the protocol, on the one hand, about the 
recruitment targets, trial processes and particular requirements that centres are expected to 
meet upon participation; and, on the other hand, about the centres' own commitment to 
participate in the RCT, reflected in their willingness and the support they would receive from 
other stakeholders. Furthermore, the centre selection process is influenced by the trial's own 
constraints, independent of centre characteristics, such as budget, calendar and regulatory 
requirements. The theme thus includes five sub-categories, as follows: recruitment; particular 
trial constraints; ensuring trial processes and requirements; support; and willingness. In total 
37 studies (29%) reported such considerations.  
 17 trial protocols (13%) explicitly targeted centres that can recruit patients in a timely 
manner (n=10; 8%) and that have access to the relevant study population (n=8; 6%). The level 
Chapter 7. Centre selection in RCTs in the UK: current and optimal practice 
 
245 
 
of detail to which recruitment was specified varied: some protocols were fairly generic (e.g. 
protocol ID9), while others were much more prescriptive (e.g. protocols ID59 and ID80). 
Moreover, there were instances when trialists inspected the centres' previous recruitment rates 
or patient throughput data to inform their inclusion decision (e.g. protocols ID124 and ID31). 
"Hubs will be selected upon the basis of: [...] identifying that they will be able to recruit the 
required number of patients;" [ID9] 
 
"Each centre will need to recruit approximately 7 participants over a 3 year recruitment 
period to meet the recruitment target." [ID59]  
 
"Criteria for selection of trial sites & clinicians: [...] the site has the potential to recruit at 
least 10 patients within the 12-18 month recruitment period;" [ID80] 
 
"Referral rates for all the clinical sites for people with OCD range from between 60-100 
patients per year. To ensure recruitment we have checked waiting lists in both primary and 
secondary care in our clinical sites and waiting lists range from 4 to 18 months." [ID124] 
 
"Hospitals have been selected on the basis of recruitment rates in previous trials." [ID31] 
 
 The 'Trial constraints' category refers to protocols (n=5; 4%) which explicitly selected 
centres based on constraints that the RCT as a whole faced, such as time frame (n=1; 1%), the 
cost of including a centre (n=2; 2%) and proximity to study site (n=2; 2%). 
"We will focus our efforts on recruiting from these practices in the first instance to reduce the 
number of practices required and to reduce costs." [ID95] 
 
" In order to recruit a sufficient number of centres within the time frame of the project, it will 
be implemented in three different regions, one in Wales, one in England and one in Scotland, 
with a combined population of 5-6 million" [ID19] 
 
"We will approach around 100 AOTs and CMHTs in total that are based within reasonable 
distance of the study sites so that regular travelling to the teams in realistic." [ID60] 
 
 Most protocols mentioned considerations related to the centre 'Ensuring trial processes 
and requirements' (n=24; 19%). The majority of these fell into two sub-categories, namely: 
ensuring compliance with trial procedures and regulatory requirements (n=17; 13%) and 
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having the required time, staff and facilities to undertake the trial (n=16; 12%). Several 
examples are presented below. 
"Centre/clinician inclusion criteria: [...] 3.Local principal investigator who acknowledges 
and agrees to conform to the administrative and ethical requirements and responsibilities, in 
compliance with Good Clinical Practice and regulatory requirements." [ID35] 
 
"Centre/clinician inclusion criteria: [...] 4. the centre has an adequate number of experienced 
staff to conduct the trial properly and safely according to GCP i.e. to be able to be trained to 
follow the treatment protocol required and record all of the assessments at the appropriate 
times as described in Sections 7 and 8" [ID55] 
 
"Each participating centre (and investigator) has been identified on the basis of: [...] 
ensuring that enough time, staff and facilities are available for the study; " [ID37] 
 
 A smaller number of protocols included more specific considerations, such as ensuring 
communication with the trial office (n=6; 5%), arranging patient follow-up (n=1; 1%) and 
identifying local champions to advance trial delivery (n=1; 1%). 
"Each participating centre (and Investigator) has been identified on the basis of: [...] 
providing information to all supporting staff members involved with the trial or with other 
elements of patient management;" [ID89] 
 
"Each site must identify emergency medicine, critical care medicine and acute medicine 
"champions"."[ID73] 
 
 The 'Support' category includes protocol statements which referred to prospective 
centres being supported by relevant stakeholders to participate in the trial (n=7; 5%). Most 
accounts envisaged support from the centre's management body (n=4; 3%), but local 
commissioners (n=1) and the relevant research network (n=1) were also mentioned.  
"Each service will have: [...] 3. written agreement to participate from the service manager." 
[ID19] 
 
"Each participating centre (and investigator) has been identified on the basis of: [...] support 
from the Trust's CEO;" [ID37] 
 
"We will prioritise invitations to centres that have support from their local commissioners" 
[ID38] 
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 Finally, 'Willingness' refers to trialists explicitly mentioning a centre's willingness as a 
relevant consideration towards its participation. Several formulations are apparent, such as 
willingness to randomise, willingness to perform the intervention and willingness to 
participate. 
"The only exclusion criteria are lack of willingness to participate and [...]" [ID60] 
 
"Trial sites will be selected on the basis of the following criteria: willingness to participate in 
the study; [...]" [ID95]   
 
 Two exploratory analyses were performed to compare centre selection reporting 
across non-pharmacologic/pharmacologic and cluster/non-cluster RCTs (Appendix 10). 
Pharmacologic RCTs did better in reporting centre selection considerations compared to non-
pharmacologic RCTs (67%, n=22/33 vs. 58%, n=56/96). Non-drug trials performed much 
better in including diversity and representativeness considerations (27%, n=26/96 vs. 15%, 
n=5/33), especially those pertaining to population characteristics and health service delivery. 
Nevertheless, a larger proportion of drug trials identified specific centre characteristics (55%, 
n=18/33 vs. 41%, n=39/96) and trial participation considerations (42%, n=14/33 vs. 24%, 
n=23/96). 
 There was only a small proportion of cluster RCTs in the sample (14 trials vs. 115 
non-cluster trials), but almost all of them (93%, n=13/14) included centre selection 
considerations in the protocol, as opposed to non-cluster designs (57%, n=65/115). Cluster 
RCTs were more prescriptive about centre selection than non-cluster RCTs across all the three 
themes, particularly 'Diversity and representativeness' (43%, n=6/15 vs. 22%, n=25/115) and 
'Trial participation' (57%, n=8/15 vs. 25%, n=29/115). One of the largest discrepancies related 
to ensuring diversity/representativeness in terms of health service delivery, where very few 
non-cluster trials included considerations (8%, n=9/115 vs. 43%, n=6/15). 
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Methods of addressing the generalisability of economic evaluation results 
18 RCT protocols (14%) mentioned explicitly the intention to address the 
generalisability of economic evaluation results (Table 7.2). The majority of these (n=13 
studies) mentioned they would perform “sensitivity analyses” to explore the extent to which 
their findings are applicable to other settings. Two studies each referred to multilevel 
modelling methods, collecting costs from representative centres and regression modelling, the 
latter without giving any further details. 
 
7.2.3. Discussion 
Summary of findings 
 365 studies were screened and 129 met the inclusion criteria. The meta-summary 
identified 53 centre selection considerations and 4 strategies to explore the generalisability of 
economic evaluation results. The centre selection considerations were grouped in three 
themes i.e. diversity and representativeness, centre characteristics and trial participation, and 
13 categories.  
 Of 129 trial protocols reviewed, 78 (60%) provided at least one explicit centre 
selection consideration. Approximately a quarter of them (n=31; 24%) referred to diversity 
and representativeness, while more studies invoked particular centre characteristics (n=57; 
44%) and trial participation considerations (n=37; 29%). In terms of ensuring generalisability, 
the emphasis was comparable across population characteristics (11%), health service delivery 
(12%) and centre setting (12%). 18 protocols (14%) mentioned the intention to explore the 
generalisability of economic evaluation results. 
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Interpretation of findings 
 The considerations for centre selection appear to be currently under-reported in RCT 
protocols, thus making it difficult to ascertain the characteristics of the sample of participating 
centres at the design stage. Most explicit considerations concern particular centre 
characteristics, often in relation to the trial intervention and the centre size, and specific trial 
requirements, particularly recruitment and meeting regulatory requirements. These findings 
indicate that the trialists’ main concern is to include centres which can support the attainment 
of the trial’s successful completion. It appears that some centres may be perceived by trialists 
as being more aligned than others with the values and practical requirements of conducting 
clinical research, either in terms of capability or intent. An assessment of centre-level research 
capability was beyond the scope of this research, but such an investigation would help answer 
whether trialists’ perceptions are objective i.e. some centres are indeed more ‘research-ready’ 
than others, or not. In terms of intent, of particular interest is the willingness sub-theme, 
which was nuanced as ‘willingness to randomize’, ‘willingness to participate in a particular 
trial’ or ‘willingness to perform the intervention’. There is considerable overlap between these 
formulations; furthermore, it is possible that willingness may also include broader 
considerations which were not explicitly named here, such as ‘willingness to take part in a 
particular trial’ or ‘willingness to take part in research’. The scope of the meta-summary is 
limited in this respect, but willingness will be discussed again in the following sections.   
    The choice of trial protocols as data sources for the review was informed by existing 
evidence on selective or biased reporting in trial publications (367, 368). For example, 
previous reviews assessing the compatibility between protocols and reports found that the 
latter either omit or distort information pertaining to outcomes (369), statistical methods (370) 
and eligibility criteria (371). In that respect, protocols can be judged to better reflect trialists’ 
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intentions. Still, it has to be acknowledged that there is no guarantee that protocol 
specifications will be fully enacted. Although the CONSORT statement requires all protocol 
deviations to be reported (27), a systematic review found that reporting of protocol violations 
is poor, especially with respect to enrolment and randomisation (372). I did not look for such 
protocol deviations in this study. 
Meta-summary has been used in health care research, both in specific clinical areas 
(373) and to address methodological questions. For example, Limkakeng et al. explored the 
attitudes towards medical research in emergency settings (374) and Fletcher et al. explored 
the barriers to clinician recruitment in RCTs (375). To my knowledge, however, this is the 
first time when meta-summary was used to analyse information in clinical trial protocols. It 
has been noted that the distinction between meta-summary and meta-synthesis is a fine one 
because synthesis is inherent to any summarizing effort (365); the ‘interpretive’ component of 
this particular analysis was intentionally kept to a minimum because the aim of this research 
was to identify the features of centre selection rather than to generate a working theory of 
centre selection, therefore the findings should be viewed in this light.  
 The effect size of individual considerations must be interpreted with caution as it may 
not reflect the true importance of a given consideration, as perceived by trialists, or the extent 
to which it actually informs the centre selection process in practice. Instead, it can indicate the 
extent to which each consideration is perceived as important enough to be mentioned 
explicitly in the trial protocols. 
 It emerged from the analysis that RCT protocols in the NIHR portfolio have a 
heterogeneous structure: there was no common format that they followed; not all of them had 
a table of contents; and information on centre selection considerations was not confined to a 
particular section. For example, several protocols had a dedicated section entitled 
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‘Inclusion/exclusion criteria for clinicians [or sites]’, where such considerations were 
presented in detail (for example ID35, ID 55, ID 95, ID 112 and ID122). However, these 
instances were few in this sample of trial protocols. It is likely that had there been a standard 
protocol format that all RCTs had to comply with, the findings would have been different. 
This heterogeneity could be the result of the lack of unified guidance on protocol design. A 
recent systematic review of guidelines for RCT protocols found substantial variations in the 
recommendations and enforced the need for an evidence-based, systematically developed 
document (376). The release of the SPIRIT  2013 statement (15) and the availability of 
protocol writing tools (377) may contribute to closing this gap.     
The uptake of analytical methods to explore the generalisability across locations of 
economic evaluation results appears to be low. Since the extensive systematic review of 
Sculpher et al. was published in 2004 (127), more sophisticated methods accounting for 
hierarchical structure of the data have been proposed (164, 167). ISPOR currently endorses 
bivariate hierarchical modelling as the preferred approach to address such concerns at the 
analysis stage (134). Although these methods have been demonstrated and are especially 
useful in the context of multinational RCTs, this is unlikely to be the reason why they haven’t 
been adopted more in the UK setting since their proponents have constantly argued that the 
methods are equally applicable to within-country settings, as well.   
 
Strengths and limitations 
 The NIHR repository was chosen as the data source because it allowed access to the 
original, full-text study protocols, thereby allowing a close investigation of trialists’ explicit 
intentions towards centre selection. This resource has been used before for trial methodology 
research: for example, Jones et al. examined the documentation of 48 NIHR-funded trials to 
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identify whether their design was informed by systematic reviews (378). Several advantages 
are associated with this data source. First, it offers access to information about the version 
history and protocol development. Second, it includes publicly funded RCTs with a distinct 
view to influence policy and practice, therefore utterly relevant for the generalisability issue; 
it is reasonable to assume that funders are interested in the trials obtaining representative 
results that are directly relevant to the NHS context. Conversely, this also acts as a limitation 
because the sample may not be representative of the clinical trial practice in the UK. 
However, it can be argued that RCTs funded through alternative streams (e.g. industry or 
charity-led studies) may have less of an explicit concern in ensuring generalisability. 
Therefore these findings may actually overestimate the current interest towards 
generalisability in centre selection. 
 The review only included trials with an explicit economic evaluation component. 
Before considering this as a limitation, two further points must also be considered. First, the 
UK decision making body (NICE) requires evidence of cost-effectiveness before advising on 
the nationwide adoption of a medical technology. The economic evaluation component is 
therefore mandatory for such policy changes, which makes it extremely relevant in the 
context of generalisability and we attempted to incorporate it accordingly. Furthermore, and 
lending strength to the previous consideration, only 9 trials out of the 365 trials considered 
were excluded from the systematic review because they did not have an explicit economic 
evaluation component (Figure 7.1). This suggests that their exclusion is unlikely to have 
biased the sample and confirms that most UK trials do indeed evaluate economic outcomes. 
The 1st January 2005 inclusion threshold was chosen as such because the seminal HTA 
publication concerning the factors affecting the generalisability of economic evaluations was 
published in 2004 (127).   
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It was not always possible to make a clear distinction between the emerging sub-
themes therefore there is some overlap between and within several codes. For example, the 
recruitment requirements and the time frame of trial have been coded individually, although 
in practice they are clearly interdependent. Furthermore, as discussed above, ‘willingness’ is a 
broad sub-theme which may include willingness to do research, willingness to participate in a 
particular RCT at a given time, willingness to randomise against a particular intervention and 
so on. These considerations may often be intertwined and a textual analysis can only draw 
artificial distinctions between such concepts. The present analysis was guided by the explicit 
information provided in the protocols. In that respect, the results reveal only what the trialists 
thought appropriate to include in the protocol. 
It can be argued that the potential bias associated with centre selection is more 
relevant to some trials (e.g. primary care and surgery trials) than to others (e.g. drug trials), 
therefore the meta-summary may have overestimated the extent of centre selection 
misreporting by pooling together various types of RCTs. However, the sample was dominated 
by non-pharmacologic trials and an exploratory subgroup analysis (Appendix 10) revealed 
that pharmacologic trials actually did better than non-pharmacologic trials in reporting centre 
selection considerations (67% vs. 58%), but, as expected, were less concerned with 
generalisability (15% vs. 27%). The study sample included a high proportion of non-
pharmacologic trials, which may limit the applicability of the findings. 
An exploratory sub-group analysis was performed to investigate the differential 
reporting of centre selection considerations in cluster RCTs and non-cluster RCTs, 
respectively (Appendix 10). The effect sizes suggest that cluster RCTs perform better than 
non-cluster RCTs in reporting centre selection considerations (93% vs. 57%), especially in 
relation to representativeness (43% vs. 22%) and trial participation (57% vs. 25%). Such a 
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finding is in line with the interest towards accounting for setting-dependent effects in cluster 
trials, but the small number of such RCTs in the sample i.e. 14 out of 129, preclude any strong 
inferences to be made.  
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7.3. Focus groups  
The objective of the focus groups was to complement the centre selection 
considerations which had emerged from the systematic review of trial protocols so as to 
ensure that no relevant considerations are missed. Due to the potential discrepancies between 
study protocols and study conduct and the lack of structure in the NIHR-HTA protocols, it 
was considered that eliciting trialists’ views on the centre selection process could identify and 
fill any gaps in the findings of the systematic review, thereby leading to a consolidated list of 
considerations to inform a national survey (section 7.4 below).   
Focus group methodology was useful here because it allowed the capture of data that 
resulted from discussion and negotiation (379), and thus helped distinguish between factors 
that affected participants as a group and those that were specific to individuals. The focus 
groups did not aim to reach consensus on the practice of centre selection, but to identify as 
many relevant issues and considerations as possible in order to inform the design and content 
of the online survey.  
 
7.3.1. Methods 
The Science, Technology, Engineering and Mathematics Ethical Review Committee at 
the University of Birmingham favourably reviewed this phase of the study (Ref. no. ERN_11-
0792).  
Email invitations to participate in focus groups were circulated in August 2011 to all 
staff affiliated with the Birmingham Centre for Clinical Trials, comprising three distinct trials 
units: Cancer Research UK Trials Unit, Birmingham Clinical Trials Unit and Primary Care 
Clinical Research Trials Unit (Appendix 11). Participants who expressed an interest to 
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participate were distributed a link to an online poll where they could mark their availability 
for all working days in September 2011.  
Participants were asked for written informed consent (Appendix 12) prior to their 
participation in the study, which was provided on forms approved by the Ethical Review 
Committee. Participants were not reimbursed for their participation, but lunch was provided. 
Two focus groups were conducted (n=6 and n=4 participants, respectively – please see 
details about group composition below) exploring trialists' thoughts and experiences of centre 
selection with the aim to identify potential reasons for centre selection not already identified 
in the systematic review. The first focus group was attended by a clinical investigator, four 
trial managers and one health economist; and the second focus group was attended by a trial 
manager, two trial methodologists and a biostatistician. There were at least two trialists from 
each of the three trials units which comprise the Birmingham Centre for Clinical Trials. Each 
focus group was moderated by one experienced qualitative researcher (JI10 and NG11, 
respectively) and co-moderated by myself. I took detailed notes throughout and both sessions 
were audio recorded for later transcription.  
Discussions were structured using a topic guide (Appendix 11) that ensured key issues 
were explored (380). While mainly informed by the systematic review of trial protocols, the 
topic guide also inquired about several aspects outside the scope of the review, such as the 
relative importance of these considerations, the time frame of making such decisions and the 
relevant professionals involved in the decision-making process. The topic guide was 
developed and agreed upon by myself, JI and both my supervisors. Participants were also able 
to direct the content of the discussion, allowing unanticipated themes to arise. At the 
                                                 
10 Jonathan C. Ives, Senior Lecturer in Biomedical Ethics, Primary Care Clinical Sciences, University of 
Birmingham 
11 Nicola K. Gale, Lecturer in Medical Sociology, Health Management Services Centre, University of 
Birmingham 
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beginning of each focus group, the participants were presented by the moderator with a 
scenario describing a generic parallel RCT with a concurrent economic evaluation (RCT-EE). 
The topic guide then inquired about the considerations the participants would find relevant 
when selecting centres to participate in such a study, and who is more likely to be the major 
driver behind this decision.  
 Discussions were transcribed verbatim and analysed using simple conventional 
content analysis (381), in which the data were coded and arranged into meaningful 
organizational units, from which themes were derived that described the participants' views. 
The analysis was performed by myself and reviewed entirely by another (JI).  
 
7.3.2. Results 
There were no disagreements between the two researchers (myself and JI) on the 
coding of focus group data. Four overarching themes and nine sub-themes emerged during the 
analysis. The four themes were: considerations that influence the decision of including a 
centre in a RCT-EE; professionals involved in the centre selection process; characteristics of 
the centre selection process; and the role of health economics in RCT-EEs. The following 
paragraphs present the content of these themes in more details, supported by selected 
quotations. Participants’ identities have been coded to preserve anonymity and the provenance 
of each quotation is marked as either FG1 (focus group 1) or FG2 (focus group 2). 
 
Considerations that influence the decision of including a centre in a RCT-EE 
The participants touched upon a large number of issues influencing the decision to 
include a centre in a RCT-EE. The umbrella term 'considerations' was used here to encompass 
both centre-level characteristics and external influences, as explained below. Three sub-
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themes were identified: minimum requirements, preference-based considerations and non-
preference based considerations. The sub-themes are defined below. 
 
Minimum requirements 
There was general consensus across the focus groups about minimum requirements 
that a centre must fulfil in order to qualify for inclusion in the RCT-EE.  
"Participant 1 (FG1): There are minimum requirements for every trial [general agreement], 
you have to say 'Yes' to these questions...and we always ask these questions at the beginning 
because we don't want to spend three months with a site to find out that they haven't got a 
radiotherapy person [general agreement] or the person is on maternity leave and might be 
back for a year and a half or whatever." 
 
Three such fundamental issues became apparent: the existence of available resources, 
an interest towards the trial and having access to the relevant patient population. 
"Participant 2 (FG1): We take anyone who's got the space, the staff and is enthusiastic" 
 
"Participant 1 (FG1): Who's willing, who can do it and have they got the patient group..." 
 
In terms of available resources, a range of requirements was mentioned. Having 
relevant specialist staff was the most often mentioned topic, but more pragmatic issues such 
as having an Internet connection or available physical space were also discussed.  
"Participant 1 (FG2): And if you need a specialist member of staff, like somebody to be able 
to deliver that treatment, then if you don't have anybody at a particular centre with that 
specialist training, then that centre will already be eliminated out of your..." 
 
"Participant 3 (FG1): Sometimes it's physical space...space for storage of drugs or 
equipment, space for parking." 
 
Having the necessary licenses for delivering the intervention (e.g. environmental 
license for radiotherapy) was also noted. 
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"Participant 1 (FG1): So the first selection was: 'Have you got this environmental license?'. If 
you have, then we'll go and ask 'Are you interested?'. If you don't have an environmental 
license and you're not going apply for an environmental license or you haven't got a 
radiotherapy therapeutic team, then you said 'No' to the first questions and there's no point 
going further." 
 
The second major category of minimum requirements was related to serving a patient 
population relevant to the study question. Socio-demographic indicators such as deprivation 
and ethnicity were cited to lead the centre selection process towards particular areas, where 
applicable. 
"Participant 1 (FG2): I definitely want to know that the patients that are coming through from 
those centres were what we were expecting and that there wasn't some bizarre ... why they 
were at a certain end of the scale, say better or more poorly than you'd expect." 
 
"Participant 2 (FG2): [...] if you're working in a particular ethnic group or you want to 
specifically target people in areas of high deprivation, for example, then you're obviously not 
going to go somewhere fancy and posh to do that you're going to go to the place where those 
patients generally are or get referred to or are treated." 
 
Displaying an interest towards the study question was widely seen as a key factor. 
"Participant 4 (FG1): I think it has got a lot to do with who's actively interested in taking 
part, it's the main thing. They're not going to finish unless they're interested, no matter how 
good their research staff is. If there's no one there who's interested, they're not going to put 
patients in. So there's got to be their interest there." 
 
"Participant 2 (FG1): [...] so I think that comes back to their original buy in and enthusiasm. 
So, for me that's quite a big part of...if you can work out which GPs or hospital doctors or 
whatever are the ones that are enthusiastic and actually buy into your study, then that would 
be a good way of selecting people that would recruit successfully, I think, and ethically, 
hopefully."  
 
Preference-based considerations 
A different set of considerations are those for which participants expressed 
unambiguous preferences towards or against and which may clearly influence their decision 
to do research in one centre or another. As a result, preference-based considerations refer 
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either to centre characteristics that are sought by researchers or to characteristics that make a 
centre undesirable for inclusion in a RCT-EE. 
 
a. Desirable centre characteristics 
A topic that was recurrent throughout the focus groups was the ability to recruit 
patients in the study. Investigators clearly wanted to conduct research in centres that can 
deliver in terms of recruitment targets and recruitment time. Although this particular analysis 
did not have a quantitative remit, 'being a good recruiter' was by far the most often mentioned 
topic across both focus groups. 
"Participant 3 (FG2): We usually start by sending brief questionnaires to all our existing 
collaborators, saying 'We're thinking about this, are you interested? Do you have people, you 
know, who does speech language therapy or whatever it is we're studying? And how many 
people will you be able to recruit?'" 
 
"Participant 2 (FG1): Your main focus is to get patients into your study and that's you 
main...your study either succeeds or fails on whether you get your patients or not." 
 
Another topic that was touched upon was the local clinicians' understanding of clinical 
trials, and it was suggested that this helps the communication between trial centre and local 
centres. 
"Participant 1 (FG2): I think it can have an impact on recruitment because if you've got a 
clinician who understands the whole clinical trial background and the whole reasoning for 
randomisation etc. they can sell that to a patient" 
 
Building on the previous point, having a good communication relationship with centre 
staff was referred to as desirable. 
"Participant 2 (FG2): Isn't it also more about communication with the people who are at the 
potential centres...because you're never going to recruit anybody unless you've got a working 
relationship that you can use and they can build on as well.” 
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"Participant 4 (FG2): Well the people on the ground... picking the poke, aren't they? Because 
you don't know that until you start the study...the actual people who are going to be doing 
work." 
 
A convenient location of the involved centres was deemed preferable, especially in 
cases where site visits have to be carried out within short time intervals (e.g. for collecting 
biological samples). 
"Participant 5 (FG1): I think location is one. We have a small one...in [study name] we don't 
need that many practices and...because it's blood samples coming back to University and, you 
know, we don't need huge numbers of practices so we're only going for the really local ones 
so that we can be going out managing them on a fairly regular basis." 
 
It also emerged that the engagement of the staff involved in research is highly 
desirable. This refers, on the one hand, to the trial's question being meaningful to them and, 
on the other hand, to being able to 'sell the trial to patients'. 
"Participant 3 (FG2): I think it's that and I think also it's about the PIs at the sites have to buy 
into your trial. However how you try and minimise it, it's always extra work for them [general 
agreement] so it's got to be meaningful to them and you've got to make it as attractive to them 
as possible, make it as simple but also it's got to be a question they recognise needs 
answering and they want answering." 
 
The computer systems compatibility between the trial centre and local practices 
appears to play a role as well in centre selection. 
"Participant 2 (FG1): Plus I think, for us, sometimes we've selected on kind of what computer 
system they've got, for example [...]" 
 
A final point relates to generalisability: the group discussions revealed the aspiration 
that included centres retained generalisability in terms of the target population. 
"Participant 1 (FG2): [...] by selecting certain centres you need to make sure that you're not, 
that you're still retaining that generalisability to that population" 
 
"Participant 4 (FG2): [...] none of us would argue against generalisability because it's 
obviously something desirable" 
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b. Undesirable centre characteristics 
A number of characteristics would keep investigators from approaching a particular 
centre or from actually enrolling them in the study. The majority of these considerations 
mirror the desirable characteristics detailed in the previous section. One of these undesirable 
features was the lack of interest for the clinical question of the study. 
"Moderator: This is again blue sky, naive thinking, but are there any practical situations that 
couldn't be overcome by increased resources? 
Participant 3 (FG1): Yes. People not being engaged [agreement]. If someone's not interested, 
it doesn't matter what amount of money there is. You got to be engaged at a really high level 
early on..." 
 
Having a difficult communication relationship with local staff was also mentioned. 
"Participant 4 (FG2): So I just think: 'I don't want to do any more research in [centre name] 
if I can avoid it because I'd rather do the research than have these stupid discussions'" 
 
The clinicians not agreeing with the intervention has been highlighted as a potential 
barrier in undergoing research in a particular centre. 
"Participant 1 (FG1): [...] the two things that will not start a trial if it's got 
unlimited...endless money is: patients not want to go to and basically if the doctors don't 
agree with the intervention." 
 
Processing paperwork slowly was cited as an undesirable feature: investigators 
strongly stressed that they would explicitly avoid locations with a known history of taking a 
long time to obtain research and development (R&D) approvals or to send completed trial 
documents. 
"Participant 2 (FG1): But when it takes, you know, six to nine months to get approvals for a 
straightforward study and you know you're not going to choose to go to one where it's going 
to take you 18 months to do the same thing...so it definitely factors into your choice."  
 
"Participant 3 (FG1): I don't want to count the time waiting in the R&D department to turn 
around a piece of paper or find out... I want the real research time to be counted, the time 
taken from the admin process to get happening, the whole things." 
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For all the considerations detailed above, both desirable and undesirable, participants 
were generally not in disagreement about their influence on the centre selection decision. This 
was not the case for previous experience in conducting research, where participants’ views 
differed with respect to its desirability. 
"Participant 3 (FG2): The other thing that is really ideal is knowing you've got a site with a 
particular PI who has a track record in clinical trials, who really understands what it is that 
we're doing and why it is important." 
 
"Participant 2 (FG1): [...] in my experience some of the best recruiters we've had were 
practices that have never taken part in research before. They might be really small, single-
handed practices of...just interested in the study, have never done before, and they've actually 
been far easier and far more successful than some of the big, established, well-known 
practices. So I think, for me, I'm very less...ok, I'm motivated by sort of what population 
they've got, what area they're in and how easy it is to get going there, but I don't necessarily 
look at whether they've done research ever before." 
 
 
Non-preference based considerations 
The third sub-theme within factors that influence the decision of including a particular 
centre in the study has been labelled 'non-preference based considerations': this describes a 
collection of categories that are not necessarily amenable to personal preferences i.e. they are 
not intrinsically desirable or undesirable by trialists; they are neutral considerations that are 
factored in the process of enrolling centres. 
A rich category includes a range of centre characteristics. One of them is merely the 
type of centre that the study requires (e.g. GP practices or hospitals). 
"Participant 2 (FG2): [...] because those two types of centres [GP surgeries and hospitals] 
are so different, the criteria that you'd have to work to in order to select or to establish 
centres are really different." 
 
The degree to which local staff feels incentivised to participate, the position of the 
centre on the rural-urban continuum and local staff fluctuations (e.g. due to maternity leaves 
or changing jobs) have all been mentioned as being important. 
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"Participant 3 (FG2): Or that can be difficult if people move jobs or people go on maternity 
leave or they get ill or all sorts of things" 
 
Another important category included requirements of the funding and regulatory 
bodies and their impact on the trial conduct. 
"Participant 1 (FG2): [...] we'll have to have the PI send an email to say that he will support 
this study if it was endorsed by CRUK" 
 
"Participant 2 (FG2): [...] but high up level the Department of Health and the NIHR 
[National Institute for Health Research] and all these...all they do is look at the spreadsheets 
and they look at the figures and they say 'Oh! You're not recruiting, you're not meeting your 
target. Do something about it!'" 
 
The local research environment i.e. the number and nature of other studies conducted 
concurrently at a centre were named to influence participation. 'Competition' and 'trial fatigue' 
have been used to describe this phenomenon. 
"Participant 2 (FG2): [...] then maybe a less prestigious centre somewhere else would be 
better for your overall recruitment because they wouldn't have this competition and this 
pressure on them to see all these patients and to process them through a load of different 
studies" 
 
"Participant 2 (FG2): I think the trial fatigue thing is important. Because if you are, I don't 
know, for a lot of our studies we tend to use the same centres because we do know the people 
there and we've worked with them before, but if they are the kind of specialist centres in some 
cases that attract a lot of the patients with a given condition, but they attract a lot of the 
research studies as well." 
 
A large number of considerations relate to the trial itself. Issues like cost and time 
constraints, the rarity of the disease and logistics were touched upon.  
"Participant 3 (FG2): So depending on what you need in terms of how many patients and how 
long a time period you got to collect them and how rare a condition it is will feed into what 
we're looking for in sites" 
 
"Moderator: I was going to ask if that was primarily visiting cost considerations or out of 
convenience or practical considerations, as well? 
Participant 2 (FG1): It's all of that, all of that...all of the above, really. I guess you have 
limited amount of time to spend on a study.  If you spend a whole day driving somewhere and 
driving back, you know..." 
Chapter 7. Centre selection in RCTs in the UK: current and optimal practice 
 
265 
 
A fertile sub-category here consists of study design considerations: participants 
repeatedly mentioned that factors such as intervention design, total sample size, total number 
of required centres and the pool of eligible centres (e.g. for a highly specialised therapy) are 
all factored in the decision. 
"Participant 3 (FG2): [...] And so if you only have one therapist, once you've recruited 
someone in that arm of the trial, they probably can't manage another person on that arm of 
the trial...there are two other arms, but they can't go for another randomisation until that 
person's finished their treatment, so it can make a huge difference if you've got two speech 
and language therapists...just kind of how the local setups are...so depending on how intense 
the treatments are going to be...they can really affect... 
Participant 1 (FG2): Select a centre for you in itself, almost... [general agreement]" 
 
Patient convenience is also thought to be important when selecting a centre and related 
to issues such as travel distance and incurred costs (e.g. on-site parking). 
"Participant 1 (FG2): I think also there's a cost to the patient...The one I know, it was 
mentioned in one of our TMG [Trial Management Group] meetings about recruitment of a 
certain centre where the car parking was astronomical and because patients had to come five 
consecutive days, the car parking was adding up. There wasn't generally...literally down to 
how much car parking was having an impact on whether the patient chose to go into the trial 
or not, you just wouldn't believe. And there's obviously ways around that, you can do...you 
can sort things out, but unless you're aware of them...." 
 
"Participant 3 (FG1): If it's healthy patients then the things that seem to matter to them are 
about: geography - if it's coming to your own GP surgery, that's fine. If they have got to go to 
a community hospital three miles away, well ok. But ask them to go to a hospital 10-15 miles 
away and they think...they just say 'No'." 
 
Professionals involved in the centre selection process 
The participants were asked to identify the types of decision makers involved in 
identifying and selecting centres for a trial. The lead clinical investigator, the trial coordinator 
and research networks all appear to have a prominent role in the selection process. 
"Participant 1 (FG1): It's not here because basically what will happen with R&D 
departments is...if the local doctor is interested he will make things happen [smiles, general 
agreement]." 
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"Participant 3 (FG2): [...] research networks...ours is usually [research network name] for 
dementia and neurodegenerative diseases, they're also actively looking for sites for us" 
 
"Participant 2 (FG1): [...] and then, as a trial manager, you say 'Well, we did a trial on this 
last year and centres X,Y and Z were very good, as well. " 
 
Participants also mentioned the participation of health economists, statisticians, Trial 
Management Group (TMG) members as a group and members of the Data Monitoring 
Committee (DMC) as being involved in the decision. 
"Participant 1 (FG2): So it's that key sort of group, isn't it, who make those decisions 
[agreement], who are responsible for writing the protocol, responsible for getting the trial 
design right, responsible for putting the grant application in that cohort" 
 
"Participant 3 (FG2): We tend to have these TMGs and the TMG will often, being brought 
together from a previous study, so you bring with it the people who are experienced from a 
previous study. I think through that TMG you can identify who are going to be good centres to 
open up first and then which other centres in the second phase of signing are opened." 
 
"Participant 1 (FG2): I mean we've just had a DMC for a study yesterday and a centre that 
hadn't been...it's quite special, it's treatment so there's only two centres so far in the country 
that are involved...But the actual chair of the DMC made a proposition for a particular centre 
and a particular person to be involved and one of the major action points that came out of the 
DMC was to target this centre that nobody had never thought of before." 
 
Characteristics of the centre selection process 
Although not specifically asked about the mechanics of centre selection, participants 
provided throughout their discussions a wide range of insights regarding how the process of 
identifying and enrolling centres unfolds. Four sub-themes emerged: (i) identifying centres; 
(ii) information resources; (iii) the nature of the selection process; and (iv) time 
considerations. 
 
Identifying centres 
Two main types of approaches to identifying eligible centres are apparent: a top-down 
approach, where investigators purposely scan the clinical and research communities; and a 
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bottom-up approach, where the trial centre is being approached by interested centres 
themselves. The principal activities related to the top-down approach involve assessing and 
eliciting interest for the trial.  
"Participant 1 (FG2): And if in the mean time you've been in a conference and you've 
managed to do a bit of publicity and somebody approaches you, then that centre will then be 
discussed." 
 
"Participant 3 (FG2): We usually start by sending brief questionnaires to all our existing 
collaborators, saying "We're thinking about this, are you interested?" 
 
Obtaining information about particular centres and offering incentives in some cases 
were also mentioned. 
"Participant 3 (FG2): And that now is not... because of the UK CRN everybody has to be...for 
our trials we have to be uploading them onto their website monthly about all our recruitment 
and all the rest of it. It's not just known from your own experience who is and who isn't good 
recruiters, but presumably your portfolios can potentially look at that...across all the trials 
there [agreement] supporting across the country. I think that sort of information is becoming 
a lot more transparent and readily available [general agreement]." 
 
"'Participant 2 (FG2): We're doing this study, you're going to get x amount of service support 
costs if you help us' because you're not getting anything out in practice unless you pay them 
for it." 
 
As far as the bottom-up approach is concerned, participants have mentioned a number 
of times that there are cases when centres want to be part of the trial and contact the trial 
centre. 
"Participant 1 (FG2): [...] we've had these situations before where somebody's approached us 
to set them up" 
 
"Participant 3 (FG2): We've also had R&D's approach us, research and development units 
from the hospital trusts, who are looking on the UK CRN portfolio websites..." 
 
A particular situation was described as 'natural selection' and refers to centres being 
eligible in relation with the study requirements. 
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"Participant 1 (FG1): You want to start off with 30 or 40 centres but you very soon know that 
actually I'm constrained on the first five because I get an email back within seven days, rather 
than seven months or seven weeks. So you actually have...you may select 30 or 40 centres but 
then, by natural selection, the centres that have a decent system will be open first..." 
 
A remark that was made in relation with bottom up selection refers to centres 
themselves playing the decisive role in trial participation. 
"Participant 3 (FG1): It's not so much about us choosing them, it's them choosing us 
[agreement]. Whether they say 'Yes' to us..." 
 
"Participant 4 (FG2): What we're saying is that we make choices about which sites we'd like, 
but they make choices whether they wish to participate in reality [agreement]." 
 
Information resources 
A variety of resources are used by investigators to identify and gather information 
about potential centres. Databases of practices and clinicians, past and existing collaborators, 
history of trial participation, informal networks and personal contacts were all mentioned as 
means to inform the selection process. 
"Participant 3 (FG1): In the trials unit we keep databases of all the practices we have ever 
done any research with and how difficult were the trials that they've done." 
 
"Participant 3 (FG2): We first, and again this is mostly hospital based, I don't know if it's 
relative to this scenario. We start out with people we already work with." 
 
"Participant 1 (FG2): [...] the trial coordinator may have a mail shot from a previous trial, 
that kind of mailing list." 
 
"Participant 4 (FG2): And then there are lots of things that are about history...you bring in 
your history, your knowledge and informal networks that tell you that things have changed 
somewhere or got worse somewhere or got better somewhere" 
 
Nature of the selection process 
Participants in both focus groups agreed that centre selection is best characterised by 
the challenge to merge ideal and pragmatic considerations. Moreover, it emerged that a purely 
rational selection is implausible. 
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"Participant 4 (FG2):  I don't think that any of us could claim that we use purely scientific 
criteria or we picked sites randomly because we know that wouldn't necessarily work. But at 
the same time none of us would say it's an art, none of us would say that we just make it up as 
we go along, it's so creative [some laughter]. It's somewhere between the two, isn't it, a craft 
really that ascribing that you have certain desirable characteristics [agreement] and you 
maximise them..." 
 
Time 
In terms of the timing of selecting centres for a trial, two ideas were expressed: first, 
the sooner the selection is planned, the better. 
"Participant 1 (FG2): I just can't emphasise enough that the earlier you start considering 
these things [general agreement]. You just can't think about these things too early [laughter]. 
Because if you don't get your centres right, you are not going to have a successful trial, so it 
has to be considered upfront." 
 
And second: enrolling centres is an ongoing process throughout the trial, as 
unexpected changes may appear such as some centres recruiting slowly or even dropping out 
from the trial altogether. 
"Participant 3 (FG2): [...] and then adjust it as you go through [agreement]...the weird and 
wonderful things that you never thought possible in your trial [laughter] with remarkable 
regularity." 
 
The role of health economics in RCT-EEs 
The fourth theme that emerged from the discussions was the position of health 
economics within such a RCT. Two sub-themes were identified in the analysis: the role of 
health economics in the trial; and generalisability of economic evaluation results. 
 
The role of health economics 
It was agreed that health economics is a secondary consideration in running the trial in 
general and in selecting centres in particular. There are little reasons to believe that health 
economics issues may influence the choice of a particular centre. 
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"Moderator: [...] but in terms of determining if you might select a new centre in order to... 
Participant 3 (FG2): Not solely based on health economics, no... [agreement]" 
 
"Participant 2 (FG2): It's not to say health economics is the poor relation or anything 
[laughter] but they are generally secondary considerations, I think it is fair to say 
[agreement]." 
 
Generalisability 
Building on the previous point, there is a concern about having generalisable 
economic evaluation results from the RCT (particularly in relation with costs), but as 
previously mentioned this is less likely to play an active role in centre selection compared 
with the preference and non-preference based considerations detailed above. 
"Participant 4 (FG1): That's the same at PCT level, you know...because if you know a 
particular region is particularly awkward when you're trying to get approvals from them then 
I tend to avoid going back there. [agreement] 
Participant 3 (FG1): Not worth going. 
Participant 4 (FG1): No, it's not, it's not worth it. So... 
Participant 6 (FG1): That's a worry, because that's affecting the generalisability of the 
results." 
 
"Participant 2 (FG1): And all the members of the trial team - the statisticians, the health 
economists - basically...we just have to make the best of what we get [laughter, agreement] 
and then prompt in our discussion how the generalisability was...or lack of generalisability, 
we may have to deal with it." 
 
7.3.3. Discussion 
Summary of findings 
The focus groups identified a wide range of themes and sub-themes pertaining to 
centre selection in RCTs. An important distinction that trialists made is that between key 
considerations, which have been denoted ‘minimum requirements’, and other considerations 
which factor in the centre selection decision. Results suggest that trialists tend to seek certain 
centre-level characteristics and avoid others. These preferences appear to be largely driven by 
pragmatic imperatives, such as the proximity to trial office, administrative ease and the 
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expectation of successfully recruiting patients. The importance of ensuring generalisability by 
means of centre selection was acknowledged, mostly in relation to the trial population, but 
there was general agreement that it is a secondary consideration in the centre selection 
decision.  
 
Interpretation of findings 
A large number of the centre selection considerations which emerged from the focus 
groups were identified in the systematic review of trial protocols. These include: the level of 
motivation of centre staff, meeting recruitment targets, research experience, the regulators’, 
funding bodies’ and sponsors’ requirements. This enforces the findings of the systematic 
review of trial protocols and supports the relevance of these considerations for current 
practice. Furthermore, it appears that, overall, the sample of trial protocols in the review 
contained most of the relevant considerations, thus suggesting that protocol texts serve their 
purpose as a reflection of how trialists will actually proceed. However, this must still be 
interpreted cautiously and on a case by case basis in light of the great amount of heterogeneity 
in trial protocol structure and content (sub-section 7.2.3). 
There were several novel considerations that the focus groups revealed. These include 
patient convenience and the state of the local research environment. More importantly, they 
allowed insights in the process of centre selection, specifically on the professionals involved 
and the time frames.  
No other centre-level variables were mentioned in relation to generalisability apart 
from ensuring a representative patient population. However, other centre-level variables are 
also known to influence the generalisability of trial findings, as well, such as the experience 
and training of health care professionals, local economic environment and the managerial 
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performance of the centre’s leadership (section 1.3). It may be the case that research findings 
on these latter topics have not penetrated enough in the trialists’ community so as to become a 
prominent concern. 
Although not originally designed towards this end, a major contribution of the focus 
groups was to reveal a classification of centre selection considerations, which wouldn’t have 
been possible on the basis of the systematic review alone. Thus, there is a set of minimum 
considerations (resources, willingness and access to the relevant population) which must be 
met before any reasoning takes place. Further, there are desirable and undesirable centre-level 
characteristics. Preference appears to be established in relation to the expectation of meeting 
pragmatic requirements such as processing documents, ensuring communication and meeting 
recruitment targets. Furthermore, there are considerations towards which no explicit 
preference was revealed, but which must be accounted for in the centre selection decision. 
Besides the research environment, this latter category includes study design elements, patient 
convenience and further centre characteristics such as the type of centre, thus suggesting that 
the approach to selecting centres has a strong trial-specific component.  
The focus groups also revealed what appears to be a tension between pragmatism and 
ideal practice. This applies both to study design in general and to health economics 
considerations in particular. On the one hand, trialists’ accounts often emphasised the 
pressures and requirements that centre selection and the trial in general must meet. On the 
other hand, there were indications that generalisability is obviously seen as desirable, albeit 
not often acted upon. The focus groups were not designed to explore this topic further, but 
this finding contributed to the design of the survey (section 7.4) and is explored further below. 
The focus groups did not aim to inform a standalone theory of centre selection and 
trial conduct, but merely to complement the list of centre selection considerations which 
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emerged from the systematic review of trial protocols. Nevertheless, elements of the process 
of conducting RCTs surfaced throughout the discussions. For example, trialists highlighted 
the types of pressures they are faced with when planning and conducting the studies. The 
most prominent of these related to meeting the recruitment targets, time and budget 
constraints, the requirements of the funding bodies and sponsors. This suggests that one 
potential reason why generalisability is currently a secondary consideration is that regulatory 
bodies do not explicitly require it. With respect to the time frame of centre selection, it was 
agreed that early planning is essential in targeting the appropriate locations, but also that 
centre inclusion is a continuous activity throughout the RCT. This reality is especially 
relevant in relation to two issues: first, participants agreed that unpredictable developments 
are very likely throughout the lifetime of a RCT. Second, there has equally been agreement 
around the fact that centre selection cannot be an entirely rational or entirely subjective effort. 
In light of these observations, it becomes apparent that any developments in centre selection 
practices must incorporate trialists’ need for flexibility and permanent adjustment to changing 
conditions throughout the lifetime of the study.      
Although the focus groups did not aim to generate consensus on the current or ideal 
practice, there was spontaneous agreement between the participants in relation to a large 
number of centre selection considerations. This lends strength to these findings and suggests 
that they are largely applicable to the wider clinical trials community. The only consideration 
where explicitly opposing views were expressed referred to approaching centres with or 
without research experience. 
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Strengths and limitations 
Due to time constraints, only trialists from trials units based at the University of 
Birmingham were invited to participate. It is, therefore, inevitable that participants’ 
contributions are influenced by the institutional culture to which they belong. The values and 
practices in other UK clinical trials units may be different. Nevertheless, the breadth of the 
participants’ professional roles, the diverse therapeutic focus of the trials unit that they 
represented as well as the excellence status of Birmingham Centre for Clinical Trials (382), 
are arguments towards the relevance of the results.   
The number of focus group participants was limited due to practical considerations. 
Despite invitations to participate having been sent to more than 50 staff at the Birmingham 
Centre for Clinical Trials, common availability was identified only for ten of them, 
respectively. Given that the findings of the focus groups would inform the development of the 
online survey and that the survey was due to be sent out early January 2012, the aim was to 
conduct the focus groups not later than September 2011 in order to allow sufficient time for 
data analysis and survey development. It is possible that self-selection occurred and the 
sample of focus group participants predominantly included professionals with an interest in 
trials methodology and centre selection in particular. Trial managers were overrepresented in 
the sample, with four out of ten participants. Still, there was general agreement that trial 
managers appear to have an important and continuous role in the centre selection process.  
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7.4. Survey  
The principal aim of the survey was to elicit UK trialists’ views on the considerations 
which inform centre selection for RCTs. In particular, it was of interest to explore the role of 
generalisability concerns for centre selection. The secondary aim was to identify trialists’ 
perspectives on optimal practice.    
 
7.4.1. Methods 
The considerations emerging from the systematic review and the focus groups 
informed an online survey circulated to trialists at the UK Clinical Research Collaborative 
(UKCRC) registered Clinical Trials Units (CTUs) and NIHR Research Design Services 
(RDS). The survey had two sections: the first section asked the respondents about the current 
practice of centre selection for RCTs in terms of influential considerations and key 
professionals involved in the process; and the second section used the same questions to elicit 
respondents’ views about what should constitute optimal practice (Appendix 14). The 
structure of the survey was informed by the main themes of the focus group analysis, as 
follows: respondents were asked to assume that the minimum centre requirements for 
participation in the trial were met i.e. access to the study population and required time, staff 
and facilities for running the RCT; the first two questions asked about preferable and neutral 
considerations relevant for centre selection, respectively; and the third question asked about 
the professionals involved in the centre selection decision. These three questions were used 
both in the current and optimal practice sections of the survey. In addition, the ‘current 
practice’ section also inquired about the participants’ views on the current role of health 
economics considerations in centre selection.  
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For each question concerning centre selection considerations, the participants had to 
choose a minimum of three and a maximum of five items they considered to be most 
important for centre selection from a comprehensive list. No explicit ranking was required. 
All questions had a free text field where participants could input additional information. Prior 
to distribution the survey was piloted with the focus group participants, who commented on 
its structure and content. 
A secure web-link to the survey was distributed by email to the direct email addresses 
(not via automated distribution list) of directors and deputy directors of all 48 UKCRC CTUs 
and ten NIHR RDS, who were invited to complete the questionnaire and forward it to relevant 
staff within their units i.e. through a snowballing approach (Appendix 15). The CTUs and 
their directors/deputy directors were identified by accessing the UKCRC CTU website 
(www.ukcrc-ctu.org.uk). When the (deputy) directors did not have a CTU domain specific 
email address, their academic email address was used. Relevant staff’ explicitly referred to: 
clinical investigators, trial coordinators/trial managers, statisticians, health economists and 
any other academic position (e.g. research associate, research fellow). One reminder email 
was circulated two weeks after the initial distribution. The online survey was distributed on 
24th January 2012 and data collection ended on 27th February 2012. 
Only the complete responses were included in the analysis, which was performed 
using STATA 10 software (Stata Corp, College Station TX, US). In addition to descriptive 
statistics for the response items, a response consistency analysis was conducted to identify 
which response items were selected for optimal practice but not for ideal practice and vice 
versa. This made it possible to identify which considerations which were subject to 
differences between current and optimal practice in terms of perceived importance. 
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The Science, Technology, Engineering and Mathematics Ethical Review Committee at 
the University of Birmingham have favourably reviewed this study (Ref. no. ERN_11-1347). 
Respondents were asked for informed consent on the first page of the survey and before 
contributing any information. The survey was anonymous: the only personal information 
items referred to the participants’ professional role and their experience (years) in the design 
and/or conduct of RCTs. 
 
7.4.2. Results 
77 responses were received, of which 70 were complete and entered the analysis. One 
further response was received in April 2012, after the database had been locked, and it was 
discarded. Trial managers were the best represented professionals (n=21; 30%).  Most 
respondents (n=49; 70%) had been involved in the design and/or conduct of RCTs for more 
than five years (Table 8.3).  
 
Table 7.3 Survey: profile of survey participants 
 
Characteristic 
Respondents 
(%, n=70) 
  
Professional role  
Clinical investigator 
Statistician 
Trial coordinator 
Health economist 
Clinical trials methodologist 
Epidemiologist 
Other academic position  
Other professionals 
9 (13%) 
13 (19%) 
21 (30%) 
5 (7%) 
7 (10%) 
1 (1%) 
7 (10%) 
7 (10%) 
  
Experience in design/conduct of RCTs  
Less than 2 years 
Between 2 and 5 years 
Between 5 and 10 years 
More than 10 years 
3 (4%) 
18 (26%) 
19 (27%) 
30 (43%) 
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Overview of results 
In current practice, the most desirable centre characteristics were: the ability to recruit 
patients, centre staff displaying interest in the RCT and good communications with the trial 
office (Table 7.4). Most respondents reported that including a centre in a RCT is influenced 
by the centre staff’s motivation to participate in the RCT (n=52; 74%) and the local research 
environment i.e. trial fatigue and competing trials (n=48; 69%). Ensuring generalisability in 
terms of population characteristics and clinical practice were mentioned by 33% (n=23) and 
29% (n=20) of respondents, respectively, while 7% (n=5) of them referred to the 
generalisability of economic evaluation results. The trial coordinator and the chief 
investigator appear to be the key drivers in the process of centre selection. 26% of 
respondents reported that health economics considerations have a limited influence in centre 
selection, while 74% reported no such influence. 
In optimal practice, the majority of survey participants indicated the ability to recruit 
(n=52; 74%) as desirable, followed by ensuring generalisability in terms of clinical practice 
(n=42; 60%), population characteristics (n=40; 57%) and economic evaluation results (n=32; 
46%), respectively. Most respondents indicated that trial-design characteristics e.g. sample 
size and number of centres required, and centre staff motivation for the RCT should influence 
centre selection. Trial management group members as a team should ideally drive centre 
enrolment. 
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Table 7.4 Survey: current and optimal centre selection for RCTs (n=70)
Survey questions 
Current  
practice 
Optimal  
practice 
 N % N % 
1. Desirable centre characteristics     
Ability to recruit patients 61 87% 52 74% 
Understanding RCTs 10 14% 16 23% 
Good communication with trial office 37 53% 26 37% 
Convenient geographical location 17 24% 3 4% 
Having support from local commissioners 16 23% 10 14% 
Part of a relevant research network 11 16% 9 13% 
Ability to obtain necessary approvals timely 33 47% 25 36% 
Showing interest in the RCT 44 63% 28 40% 
Computer systems are compatible with the trial centre 4 6% 1 1% 
Retains/contributes to generalisability 
(population characteristics) 
23 33% 40 57% 
Retains/contributes to generalisability (clinical practice) 20 29% 42 60% 
Retains/contributes to generalisability 
(economic evaluation) 
5 7% 32 46% 
Centre staff have experience with conducting RCTs 28 40% 23 33% 
     
2. Considerations influencing the process of centre selection   
Centre staff are motivated to participate 52 74% 41 59% 
Centre staff know the Chief Investigator 29 41% 4 6% 
Geographical setting (rural vs. urban) 8 11% 18 26% 
Requirements of funding/regulatory bodies 13 19% 14 20% 
State of local research environment 48 69% 24 34% 
Recruiting time frame of the RCT 27 39% 31 44% 
Budget of the RCT 21 30% 14 20% 
Efficiency of local R&D department 26 37% 17 24% 
Disease rarity 9 13% 17 24% 
Trial-design characteristics 40 57% 52 74% 
Patient convenience 6 9% 22 31% 
     
3. Professionals driving the process of centre selection     
Chief Investigator 38 54% 19 27% 
Trial coordinator/Trial manager 45 64% 33 47% 
Research networks 16 23% 24 34% 
Trial statistician 0 0% 1 1% 
Trial health economist 1 1% 6 9% 
Trial Management Group members as a team 25 36% 41 59% 
Data Monitoring Committee members 0 0% 2 3% 
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Table 7.5 Survey: number of chosen items by question 
 
Survey questions 
Number of 
available items* 
Number of items 
allowed 
Current practice Optimal practice 
Average number of 
items (SD) 
Average number of 
items (SD) 
Desirable centre characteristics 14 Min 3, max 5  4.44 (0.73) 4.42 (0.80) 
Considerations influencing the centre selection process 12 Min 3, max 5  4.07 (0.82) 3.72 (0.87) 
Professionals driving the centre selection decision 7 Min 1, max 2  1.84 (0.37) 1.87 (0.34) 
 
 Excluding the ‘Other’ free text option, which was available for all questions 
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Table 7.5 presents the number of items chosen for each question. The respondents 
appear to have selected comparable number of items for each question across current and 
optimal practice. There were slightly more items included in current (mean 4.07, SD 0.82) 
compared to optimal practice (mean 3.72, SD 0.87) for considerations which influence the 
centre selection process. 
 
Detailed results 
The following paragraphs present detailed results for each survey question (Table 7.4). 
In addition, the results of a response consistency analysis are presented, which describe the 
extent to which current and optimal practice choices agree at respondent level (Table 7.6).   
a) Desirable centre characteristics 
Most respondents reported the ability to recruit patients (87%) and displaying interest 
in the RCT (63%) as characteristics they want to see in centres. compatibility of computer 
systems with the trial office (6%) and contributing to the generalisability of economic 
evaluation results (7%) were least reported. Approximately a third of respondents reported an 
explicit interest in the centre contributing to generalisability in terms of population 
characteristics (33%) and clinical practice (29%). Suggested characteristics outside the 
provided list included a track record in recruitment, expertise in the given disease area and 
staff engagement (Appendix 16). 
In ideal practice, the ability to recruit patients was still a leading consideration for 
most respondents (74%), followed by the generalisability in terms of clinical practice (60%), 
population characteristics (57%) and economic evaluation results (46%). Few respondents 
indicated computer systems compatibility (1%) and convenient geographical location (4%).
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Table 7.6 Survey: response consistency 
 
Legend: 
‘Current, NOT ideal’ – item was selected in ‘Current practice’, but not in ‘Ideal practice’ 
‘Ideal, NOT current’ – item was selected in ‘Ideal practice’, but not in ‘Current practice’ 
‘Consistent’ – item responses are the same in ‘Current practice’ and ‘Ideal practice’ 
Survey questions Response consistency (%) 
 
Ideal,  
NOT current 
Consistent Current, 
NOT ideal 
1. Desirable centre characteristics    
Ability to recruit patients 4% 79% 17% 
Understanding RCTs 14% 80% 6% 
Good communication with trial office 13% 59% 29% 
Convenient geographical location 3% 74% 23% 
Having support from local commissioners 4% 83% 13% 
Part of a relevant research network 9% 80% 11% 
Ability to obtain necessary approvals timely 10% 69% 21% 
Showing interest in the RCT 9% 60% 31% 
Computer systems are compatible with the trial centre 1% 93% 6% 
Retains/contributes to generalisability (population 
characteristics) 
29% 67% 4% 
Retains/contributes to generalisability (clinical practice) 34% 63% 3% 
Retains/contributes to generalisability (econ. evaluation) 41% 56% 3% 
Centre staff have experience with conducting RCTs 11% 70% 19% 
    
2. Considerations influencing the process of centre 
selection 
   
Centre staff are motivated to participate 9% 67% 24% 
Centre staff know the Chief Investigator 0% 64% 36% 
Geographical setting (rural vs. urban) 20% 74% 6% 
Requirements of funding/regulatory bodies 14% 73% 13% 
State of local research environment 7% 51% 41% 
Recruiting time frame of the RCT 23% 60% 17% 
Budget of the RCT 13% 61% 26% 
Efficiency of local R&D department 16% 80% 4% 
Disease rarity 24% 69% 7% 
Trial-design characteristics 27% 69% 4% 
Patient convenience 6% 90% 4% 
    
3. Professionals driving the process of centre selection    
Chief Investigator 4% 64% 31% 
Trial coordinator/Trial manager 3% 77% 20% 
Research networks 21% 69% 10% 
Trial statistician 1% 99% 0% 
Trial health economist 7% 93% 0% 
Trial Management Group members as a team 3% 97% 0% 
Data Monitoring Committee members 4% 93% 3% 
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Additional ideal characteristics included the ability to collect resource use data and good 
working relationships between research staff and local service providers (Appendix 16). 
41%, 34% and 29% of respondents who did not indicate generalisability in terms of 
economic evaluation results, clinical practice and patient population, respectively, as preferred 
characteristics in current practice did so in optimal practice (Table 7.6). Conversely, 31% of 
participants indicated ‘showing interest in the RCT’ as relevant in current practice, but not so 
in ideal practice; 23% did the same for ‘convenient geographical location’. The largest degree 
of consistent responses was for the compatibility of computer systems with the trial office. 
 
b) Considerations influencing the centre selection process 
The majority of trialists indicated staff’s motivation to participate in the RCT (74%) 
and the state of local research environment (69%) were influential considerations for centre 
selection in current practice. Few respondents suggested that patient convenience (9%) and 
the disease rarity (13%) as relevant. Free text responses also referred to the centre relationship 
with the study CI, the support that the centre receives and whether centre staff perceive the 
research question as being important to them (Appendix 16). 
In ideal practice, trial design characteristics (74%) and staff motivation (59%) were 
most often seen as important considerations, while the centre’s staffs knowing the Chief 
Investigator was rarely included in the respondents’ choices (6%). The importance of a 
meaningful clinical question was mentioned again in the free text comments (Appendix 14). 
Accounting for trial design characteristics and disease rarity were the considerations that most 
trialists did not include in current practice, but did so when referring to ideal practice (27% 
and 24%, respectively). On the other hand, 41% of respondents indicated that the state of the 
local research environment is currently important, but didn’t include it in ideal practice; 36% 
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of respondents similarly indicated the centre’s staff knowing the Chief Investigator (Table 
8.6). 
 
c) Professionals driving the centre selection process 
Most respondents indicated that the trial manager (64%) and the Chief Investigator 
(54%) currently drive centre selection. It was suggested in the free text comments (Appendix 
14) that sponsors (especially commercial sponsors) and the trial statistician may also be 
involved in the process (the latter in relation to cluster RCTs). In ideal practice, the Trial 
Management Group as a team was seen as the key personnel that should be responsible for 
centre selection (59%). Several free text responses emphasised the role of local investigators 
(Appendix 16). 
Response consistency analysis suggested an increased role for research networks in 
ideal practice as opposed to current practice (21%); furthermore, 31% of respondents who 
indicated the Chief Investigator as a major driver in current practice did not maintain their 
choice in ideal practice (Table 7.6). 
 
d) Health economics considerations and centre selection 
18 respondents reported that health economics considerations influence centre 
selection decision to a limited extent (26%), while 52 reported no such influence (74%). Free 
text comments indicated that health economics concerns are usually minor and rarely given 
separate consideration (Appendix 16). 
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e) Other comments 
The final page of the survey invited the respondents to share any comments or 
feedback about the survey in a free text field (Appendix 16). Several comments reported that 
the questions appeared difficult to understand and/or difficult to answer, mainly because they 
could be approached from a multitude of angles e.g. methodological or pragmatic. A further 
comment suggested that not defining what the questions meant by ‘ideal practice’ made 
answering difficult.   
   
7.4.3. Discussion  
Summary of findings 
The survey results suggest that considerations such as meeting recruitment targets and 
having good working relationships with front line investigators appear to drive centre 
selection for RCTs in current practice. The importance of ensuring generalisability in terms of 
the population and, more broadly, centre characteristics is acknowledged by trialists and 
ideally should be more explicitly incorporated in practice than it currently is. The Chief 
Investigator and Trial Manager are key professionals in the decision-making process, but 
ideally the process should involve more the TMG as a team. Health economics considerations 
appear to play a minor role in centre selection and they are incorporated as ‘socio-economic 
characteristics’ of the centres. 
 
Interpretation of findings 
The survey was divided in two identical and distinct sections i.e. current practice and 
ideal practice, in order to investigate further the tension which became apparent during the 
focus groups. The survey results are consistent with the focus groups findings in highlighting 
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this discrepancy between what trialists currently do and what they think they should do in 
ideal practice. In addition, the results specify better where this tension lies. As such, there are 
aspects of centre selection which trialists perceive should be different in ideal practice: 
generalisability considerations and patient convenience should be incorporated more; the role 
of the TMG and the trial team in the decision should be more prominent; trial fatigue and 
previous knowledge of centre staff should play a lesser role (Figure 7.2). Conversely, there 
also seem to be considerations which currently receive the attention they deserve; these 
include the ability to recruit successfully, identifying highly motivated centres and ensuring 
good communication.  
 
Figure 7.2 Survey: discrepancies between the current and optimal practice of centre 
selection for RCTs.  
 
Note: Only survey items with a difference larger than 20% of responses between current and 
optimal practice are displayed. 
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The survey findings on the importance of generalisability are compatible with those of 
the meta-summary presented in section 7.2: approximately 30% of survey respondents 
reported that generalisability considerations are currently taken into account; similarly, 24% 
of RCT protocols included at least one consideration aimed at ensuring a diverse or 
representative sample of participating centres. Although the two metrics i.e. the survey 
response frequency and the met-summary effect size, were not designed to be directly 
comparable and the aim of this research was not quantitative per se, it is reassuring that they 
appear to illustrate the same reality: the majority of RCTs do not explicitly account for 
generalisability in centre selection. It must be noted, of course, that given the UK focus of this 
research, it is very likely that a large proportion of the survey respondents may also have been 
responsible for designing and writing the protocols included in the systematic review. This 
argument is particularly notable when considering the high proportion of experienced trialists 
(more than 5 years) in the survey sample (Table 7.3). However, it does not limit the validity 
of the findings in the absence of any indication that either the included protocols or the 
sample of trialists were unrepresentative.    
 
Strengths and limitations 
The survey asked the respondents to choose between a minimum and a maximum 
number of considerations. The entire list of considerations was not left open for choice 
because all the options were relevant for trial design, at least for methodological purposes, 
and it is likely that very few options would have been left out. A full ranking exercise was 
also ruled out due to the cognitive burden, as two questions had more than 12 considerations 
each. In the absence of clear guidance on such a matter in the survey literature, the choice was 
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to allow approximately a third of the available considerations (8, 12 and 14, respectively), 
thus obtaining three to five options open for choice, without explicit ranking.  
The sample size is a limitation and ideally more respondents would have answered the 
survey. However, this could not be controlled because of the heterogeneous websites of the 
CTUs and RDS, such that individual contacted details were not always available. This context 
led to relying on unit directors and deputy directors to distribute the survey link to the 
indicated professionals. This snowballing approach was the main reason why a survey 
response rate could not be calculated. This limitation can be partly justified by the lack of 
prior knowledge about the process of centre selection for RCTs, so I was interested in the 
views of a wide range of trialists. With a more specific question the survey sample could have 
focused on fewer professional roles, as did, for example, McPherson et al., who recently 
published the results of a survey where they inquired statisticians in UK CTUs on their 
approach to randomization (383). The limited sample size was the main reason why subgroup 
analyses by age and professional role were not performed.  
 In psychology, priming refers to previous experience of a stimulus influencing later 
responses that stimulus (384). Although a priming effect is possible when comparing current 
and ideal practice in this survey, the results are not consistent with such an effect: on the one 
hand, the centre’s ability to recruit patients and staff’s motivation to participate in the RCT 
were the most prominent both in current and optimal practice, which testifies their importance 
for trialists. On the other hand, the largest relative increase in importance from current to 
optimal practice was for the three generalisability items. The invitation email (Appendix 15) 
and the survey (Appendix 14) did not mention generalisability as a research interest. 
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7.5. Discussion of the mixed methods study 
A mixed methods approach was used to explore centre selection considerations in 
current and ideal practice of conducting RCTs in the UK. Mixed methods have been used 
before in the context of trial methodology, more often with a focus on informing the design or 
evaluation of particular studies (385-388). For instance, Brady et al. used a combination of 
medical records review, semi-structured interviews with staff and a validated questionnaire 
alongside a feasibility study to inform the design of a definitive trial of a complex oral health 
care intervention (386). However, mixed methods have also been used to address broad 
methodological questions. Kaur et al. recently developed an online survey on barriers and 
facilitators to RCT recruitment using an approach similar to the one described in this Chapter: 
first they conducted a literature review and identified a list of relevant factors which led to the 
initial version of the survey; and afterwards the survey underwent a succession of piloting 
stages until the final version was agreed upon (389). Hamm et al. used an online survey of 
trialists whose results informed the topic guide of semi-structured interviews to identify the 
barriers in conducting unbiased trials in paediatric care in Canada (390). 
The findings of the three methods used in this study are generally in agreement. As 
such, there was significant overlap between the centre selection considerations identified in 
the systematic review of protocols and focus group discussions with trialists. The survey 
results confirmed the reported tension between current and ideal practice that became 
apparent during the focus groups. Furthermore, the meta-summary effect size and survey 
response frequency for the generalisability items in current practice were compatible in 
suggesting that the large majority of RCTs do not currently recruit centres with 
generalisability in mind.   
Chapter 7. Centre selection in RCTs in the UK: current and optimal practice 
 
290 
 
 Pragmatic considerations such as recruitment and communication seem to drive the 
centre selection process in current practice. In ideal practice, however, trialists acknowledged 
concerns such as generalisability of results and patient convenience. There appears, thus, to be 
a tension between what trialists report as currently being done and what they think ought to be 
done. Ensuring generalisability is one of the objects of this tension in the sense that its 
importance is acknowledged, but other considerations currently take precedence. 
Two sets of explanations are possible. First, it may be that generalisability is not 
currently a prime consideration because it rightfully isn’t an overarching concern. As one of 
the free text commentaries suggested (Appendix 16), there may be no substantial difference 
between recruiting and non-recruiting centres, which would make the issue of 
representativeness in centre selection rather trivial. However, there is little literature available 
to substantiate this claim and the little available evidence suggests that most evaluative 
research takes place in university centres (100). The two focus groups made apparent trialists’ 
concerns that some centres are more suited to recruiting than others and that it is important to 
approach the ‘right’ ones. This suggests that centres are indeed different; therefore the 
selection process can make a difference both to the RCT’s completion and its findings. 
Furthermore, approximately 75% of the RCTs included in the systematic review did not 
explicitly account for generalisability when including centres and only two studies used a 
random process. More often than not, the RCT protocols included in the review included 
statements such as “We recruited from a representative sample of centres [...]” without any 
other details on how the investigators assessed representativeness and what were the 
characteristics of their reference sample (for example ID16, ID24, ID76 and ID87). In the 
light of these issues, it can be concluded that there is still insufficient evidence to claim that 
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generalisability should not be a prime concern on the basis of no significant differences 
between recruiting and non-recruiting centres.  
Second, the RCT funders’ interest in generalisability may yet not be compelling 
enough for trialists to modify the practice in this direction. As pointed out in sub-section 
7.2.3, the structure of the RCT protocols included in the systematic review was highly 
heterogeneous and there were no set headings on either centre characteristics or centre 
selection processes, leaving the reporting of such considerations at investigators’ discretion. 
The funders’ lack of explicit interest towards these issues could be explained by the absence 
of evidence on why generalisability across locations for within-country studies is important. 
The importance of centres’ willingness to participate is a particularly interesting 
finding of this research. While it emerged as a relevant consideration in the meta-summary, 
focus group discussions went further and suggested that willingness to participate is essential 
for centre selection. The survey results confirmed the importance of local staff showing 
interest in the trial and of their motivation in current and ideal practice. When corroborated, 
these findings have two implications: first, trialists perceive motivation to participate as key 
for successful trial completion; second, and most importantly, centres have different levels of 
engagement, which under specific conditions makes some more desirable than others.  
Variation in willingness to participate can have multiple causes: for example, not 
being ready to randomise against or perform a particular intervention suggests that some 
clinicians are not in equipoise, a key ethical requirement of RCTs (73). If anything, this can 
be interpreted as a healthy concern; if the large majority clinicians and patients agreed on the 
relative merits of one intervention against the other prior to obtaining evidence, there would 
be no RCTs at all because nobody would agree to (be) randomise(d) at 50:50 probability 
against an inferior intervention (391). Furthermore, the pragmatic barriers to research 
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participation as perceived by clinicians have been documented and include: time constraints, 
lack of training, concerns about the research impact on the doctor-patient relationship and 
answering an interesting clinical question (392). Nevertheless, generic solutions for health 
care organisations to address such shortcomings have been suggested (393) (e.g. selecting 
research questions that are of interest to clinicians, setting a transparent reimbursement 
schedule for research tasks and provide technological support to practices) and innovative 
business models to guide the design and conduct of RCT processes have been proposed (394). 
Another source of controversy may be that some centres are highly sought after in the 
research community and have limited capacity to take on new projects; this explanation is 
supported by trialists’ perception that the characteristics of the research environment should 
be less relevant for centre selection in ideal practice than it currently is (Figure 7.2). It 
remains unclear whether current research activities surpass research capacity or research is 
simply concentrated around selected centres while others are idle. If the latter is the case, it 
may constitute the foundation of a self-enforcing limitation, as the centre selection process is 
influenced, to some extent, by previous research experience. If such centres are currently left 
out of research, they are likely to be left out in the future, too. Finally, an extreme explanation 
of variation in research uptake would be the sheer refusal to take part in research in the 
absence of any capacity constraints. In that respect, the obligation to participate in research 
has been firmly established in the bioethical literature (395, 396) and, thus, such an attitude 
cannot be justified. Future research on the validity and relative extent of these considerations 
may guide research commissioners’ efforts to mitigate them.  
The finding that pragmatism takes precedence before generalisability may at first seem 
obvious, but this rather enforces its importance because this is, to my knowledge, the first 
time that the tension between pragmatism and generalisability is explored based on evidence 
Chapter 7. Centre selection in RCTs in the UK: current and optimal practice 
 
293 
 
from RCT protocols and trialists. The focus of this research was on generalisability and how 
its role is perceived among the other relevant trial considerations. However, this is not to say 
that generalisability and pragmatism are in direct competition. First, the results do not suggest 
that pragmatism should be downplayed, but rather report that trialists’ perceptions appear to 
indicate that there is clearly room for addressing generalisability more conscientiously. 
Second, several potential reasons why generalisability is currently regarded as less important 
than pragmatism were discussed; none of them implies that trialists face an informed choice 
between the two, mostly because there is currently little guidance towards incorporating 
generalisability.  
There is evidence in the literature on the positive impact of guidelines on the quality 
improvement of clinical trial design and reporting (115). However, few guidelines explicitly 
refer to representativeness and centre selection. On the design side, the SPIRIT 2013 
statement contains a 33-item checklist which acts as a guideline for the minimal content of a 
RCT protocol (15). The characteristics of participating centres are required under the ‘Study 
setting’ and ‘Eligibility criteria’ items, but there is no explicit requirement to address 
generalisability in selection or in data analysis (397). On the reporting side, only one 
CONSORT extension requires explicit reporting of the extent to which participating centres 
and practitioners are representative to wider settings (116). Thus, it appears that 
generalisability currently receives insufficient attention in trial design and analysis, which 
may explain why trialists currently regard it as a secondary consideration. It must be 
acknowledged that a stronger focus on generalisability in widely recognised guidelines is no 
guarantee of improved practice: Zarin et al.’s analysis of the ClinicalTrials.gov records 
revealed that much less controversial methodological decisions, such as the selection of a 
single primary outcome, are sub-optimally implemented (398). However, explicitly 
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incorporating generalisability in trial guidelines could contribute, in time, to the conduct of 
increasingly valid and relevant trials. 
This mixed methods study focused on UK publicly-funded RCTs. The generalisability 
of the findings to privately-funded trials and to other countries, respectively, is unknown and 
can be viewed as a limitation. Nevertheless, it is likely that the interventions evaluated in 
industry-led RCTs are often drug therapies as opposed to complex interventions and, as such, 
patient-level characteristics are more important than centre-level ones. In terms of the 
international scope of the results, there is little evidence of centre selection practices in other 
settings to enable informed comparisons. Only the replication of various components of this 
research in other research settings can add an international perspective to these findings. 
 
7.6. Conclusion 
The rationale for centre selection appears to be underreported in RCT protocols in the 
UK. Enrolling a representative sample of recruiting centres, which can ensure or contribute 
towards the generalisability of trial findings, is currently a secondary consideration in centre 
selection. Pragmatic considerations such as meeting recruitment targets and ensuring good 
communication take precedence. Trialists acknowledge the importance of generalisability and 
would ideally incorporate it more in the centre selection process.  
Generalisability across settings is currently insufficiently present in major guidelines 
on conducting and reporting research, which may explain the current state of affairs. More 
importantly, there is a need for evidence as to whether the sample of centres participating in a 
RCT can influence its clinical and economic results. In the next Chapter a method that can 
address, to some extent, this need is proposed. 
  
 
 
CHAPTER 8. ENHANCING THE 
GENERALISABILITY OF TRIAL-BASED 
ECONOMIC EVALUATIONS USING A 
GENERALISABILITY INDEX (GIX) 
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 The conclusion of the previous Chapter was that the inclusion of centres in RCTs with 
a view to ensuring generalisability is currently acknowledged as being important but is rarely 
implemented. The impact of this suboptimal practice on the generalisability to the jurisdiction 
level of the results of trial-based economic evaluations is unknown. In this Chapter a real-
world example illustrating this impact is presented and a novel methodology is proposed that 
can assess and potentially enhance the generalisability of trial results. The cornerstone of this 
methodology is the Generalisability index (Gix), which is a measure of representativeness and 
can be computed at centre- and trial-level. The application of the Gix will be demonstrated 
using a case study drawing on the ROSSINI trial, which was presented at length in Chapter 5. 
 
8.1. A real-world example 
 The ROSSINI trial, which was presented at length in Chapter 5, will be used to 
illustrate the potential impact of the sample of recruiting centres on trial results. ROSSINI 
recruited patients from 21 UK hospitals and randomised 760 patients. The embedded 
economic evaluation took an NHS perspective and evaluated the cost-utility of the device 
compared to standard care over a 30-day post-surgery time horizon. 
  
 Method 
 The working hypothesis was that different samples of participating centres yield 
different overall cost-effectiveness estimates. In order to test the hypothesis, the 21 recruiting 
centres in ROSSINI were treated as the complete population of centres and standard cost-
effectiveness methods were applied on incremental sub-samples of 1, 2, 3 ... 21 centres. 
Centres were considered in the chronological order in which they started contributing 
patients; data from all patients in a particular centre were analysed. For example, the third 
sub-sample included all patients recruited from the first three recruiting centres; the seventh 
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sub-sample included all patients recruited from the first seven recruiting centres and so on. 
The 21st sub-sample included all patients and is equivalent to the trial-wide analysis. 
  
 Results 
 The error bars in Figure 8.1 depict the point estimate of the incremental net monetary 
benefit (55) for each incremental sub-sample of participating centres together with the 95% 
BCa confidence intervals. The incremental net monetary benefit (INMB) was calculated using 
a willingness to pay threshold of £20,000, in accordance with NICE guidance (39). Based on 
information from patients recruited in the first 13 centres (~ 90% sample size), it is apparent 
that the point estimate of the INMB is positive, suggesting that the intervention may be cost-
effective, only to eventually become slightly negative, suggesting that the intervention is not 
cost-effective when complete trial data were analysed. The width of the confidence interval 
gradually decreases with sample size, as expected. 
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 Figure 8.1 Illustration of the changing incremental net monetary benefit estimate in ROSSINI as recruitment progressed 
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Discussion 
This example suggests not only that cost-effectiveness estimates differ among centres 
within the same country, but, more importantly, that the sample of participating centres can 
influence the cost-effectiveness decision. Had a couple of other major recruiters been 
included, trial-wide results could have been quite different. While there is constantly 
considerable uncertainty around the INMB, reflected in the width of the confidence intervals, 
the changing point estimates and upper/lower confidence bounds impact the shape of cost-
effectiveness acceptability curves (CEACs) and potentially the cost-effectiveness 
acceptability frontier (CEAF). For interventions which are borderline cost-(in) effective, the 
sample of centres may change the decision makers’ belief in the cost-effectiveness likelihood 
of an intervention. It must be acknowledged that in the particular case of ROSSINI recruiting 
from a different sample of centres is unlikely to have had a major impact on the final results 
because of the lack of clinical effectiveness and great uncertainty in clinical and economic 
results. However, it appears that the sample of participating centres introduces variation in 
trial results and the magnitude of this variation deserves further exploration. 
  
8.2. Suggested way forward and proposed plan 
 The previous section argued that the sample of participating centres may influence the 
trial-based cost-effectiveness findings. This section introduces the research plan that aims to 
address the current lack of knowledge in relation to the impact of recruiting centres and 
generalisability. 
 The first point to be made stems from the fact that decision makers often have to make 
nationwide decisions informed by research findings from a sample of centres. Thus two 
conceptual decision spaces can be described: the policy space, defined as all centres in the 
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jurisdiction that have the potential to use the intervention being evaluated; and the research 
space, defined as all the centres participating in the given RCT. The overarching problem is 
the difficulty to quantify the overlap between these two types of decision spaces. 
 Figure 8.2 depicts two hypothetical scenarios where the research space is described by 
the cost-effectiveness point estimate from the RCT and the associated 95% confidence ellipse 
derived from a bootstrapping exercise. It must be acknowledged that current methods of 
expressing uncertainty around the cost-effectiveness estimator, such as the cost-effectiveness 
plane, CEACs and CEAFs, compare types of policy scenarios and not real-world distributions 
of policy scenarios. The same applies for decision models informed by RCT findings, which 
are nowadays instrumental to more and more health technology assessments. Base-case and 
sensitivity analyses influence the point estimate of the cost-effectiveness metric and the 
uncertainty around it, but these quantities can only refer to one policy scenario at a time. In 
reality, policy makers are interested in evaluations of real-world distributions of scenarios 
(e.g. distributions of centres and patient populations) which reflect the policy contexts they 
face. The available methods cannot address the relationship between the two decision spaces 
and the only reasonable assumption is that the policy space is likely to contain the trial-based 
point estimate. However, a decision informed by the research space may or may not apply to 
the policy space (Figures 8.2a and 8.2b). The distinction between the two types of decision 
spaces is important because it can guide researchers towards providing decision makers with 
the estimate they really want, i.e. ‘the cost-effectiveness of an intervention when implemented 
across a specifiable (real) population of scenarios (centres)’ as opposed to ‘the cost-
effectiveness of an intervention when implemented in a perfectly homogeneous population of 
scenarios (centres)’. 
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Figure 8.2 The research space and the policy space
Δ Cost 
Δ Effect 
WTP threshold 
Research space 
Policy space ? 
Panel A: Hypothetical scenario where the centres participating in 
the RCT are representative of centres within the jurisdiction which 
have the potential to use the intervention of interest. The extent 
and direction of the overlap in relation to the acceptable WTP 
threshold suggest that decisions based on the cost-effectiveness 
estimate from the research space can be extrapolated to the policy 
space. In other words, it is likely that the intervention will still be 
cost-effective when implemented in other centres in the 
jurisdiction that were not part of the RCT.  
Δ Cost 
Δ Effect 
WTP threshold 
Research space 
Policy space ? 
Panel B: Hypothetical scenario where the centres participating in 
the RCT are not representative of centres within the jurisdiction 
which have the potential to use the intervention. The extent and 
direction of the overlap in relation to the acceptable WTP threshold 
may lead to different policy decisions. In other words, the results of 
the research space cannot be so obviously applied to the policy 
space because in a significant number of non-participating centres 
the intervention may not be cost-effective.  
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Building on this conceptual distinction and on the limitations of current 
generalisability methods (sub-section 1.3.3), a legitimate research aim appears to be 
investigating how the sample of centres included in a given RCT influence the trial-wide cost-
effectiveness results. First, there is a need for reliable evidence on how centres are currently 
included in RCTs. This has been addressed and discussed at large in Chapter 7: the results of 
the mixed-methods study suggested that the majority of UK publicly-funded RCTs do not 
explicitly aim to recruit from a representative sample of centres (399). Furthermore, it 
emerged from focus groups (section 7.3) and a survey of UK trialists (section 7.4) that 
ensuring generalisability should be considered when approaching trial centres, but pragmatic 
considerations, such as the proximity to trial office and a history of successful recruitment, 
currently take precedence. 
 Second, there is a need to operationalise ‘generalisability’; one way to achieve this is 
to propose a centre-level generalisability index which measures the extent to which a given 
centre is representative to a larger population of centres. Such an index would allow trialists 
to evaluate and ensure representativeness at trial design stage.  
 This research may be beneficial from a multitude of angles. First, empirical evidence 
will test the assumption that centres are representative for the jurisdictions they represent and 
thus potentially warrant the validity of current adjustment methods. Second, a methodology 
based on the generalisability index can be envisaged to assist retrospective modelling 
techniques in assessing the external validity of the trial as it was designed and in pursuing 
more and more precise cost-effectiveness estimates, to a reasonable level. Third, an advance 
in clinical trials recruitment would be made possible by providing a method to identify at the 
trial design stage the centres which are of more interest than others in terms of extrapolating 
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economic evaluation results. Such a method may also inspire the centre selection process in 
multi-centre studies that do not necessarily have an economic evaluation component.  
 
8.3. Methods 
The working hypothesis is that current methods of centre selection for RCTs result in 
unrepresentative samples of centres, which may lead to biased estimates of both effectiveness 
and cost-effectiveness. This Chapter proposes a novel quantitative measure of 
representativeness called the generalisability index (Gix). The Gix measures the extent to 
which a given centre and a given trial are representative of the jurisdiction to which they 
belong. The aim is to establish whether a measure of generalisability, such as the Gix, is 
associated with the extent to which a trial’s results are generalisable to the jurisdiction where 
it recruited from.  
The research has two objectives: first, to define a conceptual framework for the Gix 
and to consider how it can be applied at the centre, RCT and jurisdiction level. The proposed 
conceptual framework is illustrated using a real-world multi-centre RCT, namely the 
ROSSINI trial, which was presented at length in Chapter 5. The second objective is to 
investigate, by way of a simulation study, how biases in the treatment effect and cost-
effectiveness estimates vary depending on RCT-level measures of representativeness. 
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This section will first provide an overview of the methodological approach and then 
will discuss the steps in detail. The proposed Gix is a measure of representativeness which 
can be defined at two levels: 
- at the centre-level, the centre-Gix (Gixc) measures the extent to which a given centre is 
representative of its jurisdiction (e.g. NHS England and Wales) according to several 
relevant characteristics. 
- at the RCT-level, the trial-Gix (Gixt) measures the extent to which the sample of 
centres and corresponding patients enrolled in a given RCT are representative of the 
jurisdiction-wide distribution of centres and patient throughput. 
 
The RCT-level and centre-level Gix indices are compared to the jurisdiction-wide 
distribution of the Gixc, summarised by the Gixj. The purpose of introducing these metrics is 
to assess the extent to which trial recruitment, both at centre and patient level, is 
representative of the jurisdiction it recruits from. There is a conceptual distinction between the 
three types of metrics: the centre- and trial-Gix are measures of representativeness at centre 
and study level, while Gixj is a metric that the study-level representativeness is judged 
against. It must be noted that the Gix is currently designed to be meaningful in the context of 
a specific research question or therapeutic area. 
The conceptual outline of applying these concepts to evaluate the generalisability of 
trial results is the following: 
i. First, the ‘jurisdiction’ is defined by identifying the relevant centres i.e. all centres 
where the intervention under investigation can be applied and is expected to be implemented 
if found to be clinically and cost-effective. 
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ii. Second, the dimensions of generalisability are decided upon and inform the 
calculation of the Gixc for all centres in the jurisdiction. A jurisdiction-wide distribution of 
Gixc values is generated, which is summarised (Gixj) using a metric such as the median, 
geometric mean or weighted (patient throughput) mean.  
iii. Third, considering a RCT identified by participating centres and their respective 
patient recruitment, the Gixt is calculated as the weighted (patient recruitment) mean of the 
Gixc values of participating centres. The assumption is that trial recruitment is equivalent to 
patient throughput as a measure of patient volume for reasons that will become obvious in 
sub-section 8.3.5 below. 
iv. Finally, the Gixt is compared to the jurisdiction-wide distribution of Gixc, more 
specifically to its summary measure Gixj, by calculating the standardised mean difference. 
 
The following sub-sections present the steps above in detail with the exception of the 
first step i.e. defining the jurisdiction, which is assumed to be straightforward.  
  
8.3.1. The dimensions of the Gix 
As the Gix is a measure of representativeness, appropriate measures or indicators of 
representativeness must be determined. Two large systematic reviews identified a large 
number of factors which may influence the generalisability of economic evaluation results 
(127, 136). In addition to these reviews, a pragmatic literature search was conducted to 
identify further centre-level characteristics which were investigated in relation to between-
centre variation in health care costs and outcomes. Given the ROSSINI trial was to be used as 
a case study a pragmatic decision was made to focus on those factors which may affect 
hospital care. 
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The following characteristics were included in the Gix, based on their potential to 
influence the effectiveness and cost-effectiveness results of the assumed RCT: centre 
size/capacity; teaching function; economic environment; cost performance; and degree of 
specialisation (Table 9.1). These are termed the dimensions of the Gix (Box 9.1) and the 
evidence around them is discussed in more detail below: 
 Centre size/capacity. Provider capacity has often been investigated in relation to 
health care costs and outcomes. There is evidence from a large number of studies that larger 
providers, both physicians and hospitals, are associated with better health outcomes (97). In 
terms of cost, studies from China (400) and US (401-404) as well as several multi-national 
investigations (405, 406) suggested that hospital size may be (usually positively) associated 
with health care cost. However, the issue remains controversial and is unlikely to extend to all 
clinical specialties as studies in Italy (407), France (408) and US (409, 410) have not found 
any significant effect of hospital capacity. 
 Teaching status. Teaching hospitals appear to deliver superior health outcomes than 
non-teaching hospitals (138, 143). There is also evidence of an association between teaching 
status and health care costs (400, 411-414). Similarly to capacity, controversy remains as 
there are also studies which did not identify such a relationship (173, 415).  
 Specialisation. Both comprehensive systematic reviews (127, 136) identified the 
provider’s experience, skills, training and learning curve characteristics as potential factors 
that affect generalisability. Daidone and D’Amico found that specialisation is negatively 
associated with inefficiency in Italian hospitals and proposed a hospital-level specialisation 
index bounded at 0 and 1 which quantifies the proportion of patient episodes of a particularly 
type seen in a given hospital (416). In their recently published study of 153 English hospitals, 
Gutacker et al. found that specialisation was positively associated with superior HRQoL 
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outcomes following hip replacement, but not so for knee replacement, groin hernia repairs or 
varicose veins surgery (417). 
 Market environment. It has been argued that hospital reimbursement arrangements 
incorporate additional payments for providers facing higher costs for reasons outside their 
control (418). For this purpose, the Department of Health uses the Market Forces Factor 
(MFF), a metric which accounts for three main categories of capital costs: labour (non-
medical staff and medical staff), land and buildings (419). The MFF is set to average at 1.0 so 
that organisations with an index higher than 1.0 face input costs higher than the average, 
while organisations with an index lower than 1.0 face input costs lower than the average 
provider. Kristensen et al. incorporated the MFF in their analysis of cost variation in diabetes 
care across English hospitals and found a significant positive association between the index 
and inpatient costs, which explained the largest amount of cost variation (420). Laudicella et 
al. found similar results when looking at costs across English obstetrics departments (173). 
 Cost performance. The MFF, which is ultimately a measure of provider exposure to 
environmental factors, is used to calculate a metric of provider performance, namely the 
Reference Cost Index (RCI). RCI is a measure of relative efficiency across NHS organisations 
and shows the relative cost of a given NHS trust’s casemix compared to the cost of delivering 
that casemix at national average cost (421). Providers with costs equal to the national average 
score 100; higher cost providers score above 100 and lower cost providers score below 100.  
 Other factors that were considered for inclusion in the Gix were: staff mix; staff 
specialisation; and urban/rural setting. They were not pursued due to lack of readily available 
and interpretable data. Such a development may be the object of future research. 
Nevertheless, the current choice of dimensions appears to be reasonable in terms of relevance 
to the English NHS context. 
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Table 8.1 Dimensions of the centre-Gix 
 
 
Dimension Operationalised as Data source 
Size/capacity Number of beds NHS The Information Centre – Hospital Estates 
and Facilities Statistics 2011/2012 (422) 
Teaching 
function 
Teaching status NHS The Information Centre – Hospital Estates 
and Facilities Statistics 2011/2012 (422) 
Economic 
environment 
Market Forces Factor (MFF) Department of Health - Reference Cost Index 
2011/2012 (423) 
Cost efficiency Reference Cost Index (RCI) Department of Health - Reference Cost Index 
2011/2012 (423) 
Specialisation % of relevant finished 
consultant episodes (FCEs) 
from total FCEs in one 
calendar year 
Health & Social Care Information Centre - 
Hospital Episode Statistics 2011/2012 (424) 
 
 
 
 
Box 8.1 The dimensions included in the centre-level Gix 
 
1. Centre size/capacity – a measure of volume, thereby reflecting potential 
economies of scale; 
2. Teaching status – a measure of technical expertise;  
3. Specialisation – a measure of concentration, also reflecting potential economies 
of scale and learning curve effects;  
4. Market environment – a measure of the organisation’s external environment; 
5. Cost performance – a measure of the organisation’s efficiency.  
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8.3.2. The centre-level Gix 
 As outlined above, the aim of the centre-Gix is to quantify the extent to which a given 
centre is representative of its jurisdiction. More specifically, the centre-Gix measures how 
representative a centre is compared to all the other centres in the jurisdiction of interest where 
the given intervention could be implemented.  
Once the relevant dimensions are identified, constructing the centre-Gix entails two 
steps: 1) quantifying how representative a given centre is of the jurisdiction, according to each 
of the Gix dimensions; and 2) aggregating these measures of representativeness across 
dimensions to obtain a centre-Gix. The steps are detailed below. 
To quantify representativeness, data for the included dimensions are collected for all 
the centres in the jurisdiction. For each dimension, centres are dichotomised into those which 
fall into the middle 80 percentile range (10th to 90th percentile) and those falling outside of it. 
This range was chosen arbitrarily as it was judged that 80% of observations would reasonably 
describe ‘commonness’. The influence of this assumption on the results is investigated further 
in sensitivity analyses (sub-section 8.4.4).  
For each dimension reflected by a continuous variable, a score of 1 is assigned to 
centres lying in this range and 0 otherwise. For dimensions reflected by dichotomous 
variables (e.g. teaching status – teaching hospital or non-teaching hospital), 1 is assigned to 
centres in the predominant category (e.g. non-teaching) and 0 to the other. For each 
dimension, a score of 1 thus denotes a centre which for that dimension is fairly typical, while 
0 denotes atypical centres in that dimension. The dichotomised score si (a) for a continuous 
dimension a can, thus, be defined as: 
si(a) =   (8.1), 
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where: 
si(a) – centre-level dichotomised score on dimension a for centre i; 
ai – centre-level raw value on dimension a for centre i; and 
P10(a), P90(a) – 10th and 90th percentiles for dimension a. 
The dichotomised score si (a) for a dichotomous dimension a can be defined as: 
si(a) =   (8.2), 
where: 
p(ai) – proportion of centre-level raw value ai in the total number of observations for 
dichotomous dimension a. 
The measures of representativeness for the dimensions are aggregated by summation 
to obtain a centre-level measure of representativeness. The resulting centre-Gix takes discrete 
values between 0 (outlier, most uncommon for all five dimensions) and D, where D is the 
number of dimensions considered (the centre is common across all D dimensions).  
Thus, the formula for the centre-Gix is: 
 = ( ) (8.3), 
where: 
 – the centre-Gix for centre i; 
D – the number of centre-level dimensions in the Gix (in the base case above, D=5); and 
sj( ) – centre-level dichotomised score (1 or 0) for dimension , derived from equations 
(8.1) or (8.2), as appropriate. 
 Equation (8.3) can be extended to incorporate differential weightings across the 
included dimensions (equation 8.4). Such weightings may reflect the relative influence of the 
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dimensions on clinical and cost-effectiveness results as indicated by the available evidence, 
expert opinion or belief. For example, if capacity is thought to correlate stronger with costs 
than teaching status, their contribution to the index can reflect this by assigning a larger 
weight wi to capacity. 
=  (8.4), 
where: 
wi( ) – the weight of dimension , subject to  = 1; and 
D – the number of centre-level dimensions in the Gix. 
The unweighted centre-Gix takes discrete values from 0 to D, where D is the number 
of dimensions incorporated in the Gix. In this case five dimensions have been considered, so 
the centre-Gix ranges from 0 to 5. Centres with high Gixc values (close to 5) can be 
considered ‘common’ across most of the dimensions when compared with the rest of the 
centres in the jurisdiction; conversely, centres with low Gixc values (positive and close to 0) 
are outliers across most dimensions and can, thus, be considered ‘less common’.   
 
8.3.3. The trial-level Gix 
The centre-level Gix outlined above can be used to compute a trial-level Gix (Gixt), 
which measures the extent to which a given RCT recruits in a representative manner from all 
the available centres. A representative recruitment might be measured straightforwardly in 
terms of patient volumes i.e. recruiting trial participants across centres so as to reflect the 
patient throughput across jurisdiction centres in current clinical practice. Alternatively, 
representative recruitment might be measured in terms of patient case-mix, which also 
accounts for the complexity of each case.  
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For the base case of this analysis, patient numbers were considered a measure of 
recruitment representativeness. As such, the trial-Gix is calculated as the weighted mean of 
the participating centres' Gixc values, where the weights qi are the proportions of patients 
recruited from each centre (equation 8.5). 
 =  (8.5), 
where: 
Gixt – the trial-Gix; 
n – the number of centres participating in the trial; 
 – the centre-Gix for centre i; and 
qi – the proportion of patients recruited from centre i relative to the trial sample size. 
The trial-Gix is bounded by the minimum and maximum values of the centre-Gix i.e. 
theoretically by 0 and D. As such, in the base case it ranges from 0 to 5, where values close to 
0 denote trials which recruit predominantly from centres with a low centre-Gix, and values 
close to 5 denote trials which recruit most patients from centres with a high centre-Gix. Gixt is 
a descriptive measure of the characteristics of a trial’s recruitment, but it cannot inform on the 
extent to which trial recruitment is a good reflection of the clinical practice landscape at 
jurisdiction level. To enable such an assessment, a jurisdiction-wide measure of 
representativeness is necessary. 
 
8.3.4. The jurisdiction-level Gix 
The jurisdiction-Gix (Gixj) summarises the distribution of the Gixc values across the 
jurisdiction. In the base-case, the weighted mean has been chosen as a summary statistic for 
this distribution, where the weights are given by centre-level patient throughput. Alternative 
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summary measures could have been the median or the geometric mean. The jurisdiction-Gix 
measures the extent to which patients in a jurisdiction come from more or less representative 
centres, as reflected by the centre-Gix.   
The Gixj is calculated in exactly the same manner as the Gixt, with two differences 
(equation 8.6): the sample of centres is the entire pool of relevant centres in the jurisdiction, 
not just the ones participating in the trial i.e. all centres where the intervention is expected to 
be implemented; and the patient weights are not given by local patient recruitment tallies, but 
by the local patient throughput in a specified time frame e.g. number of finished consultant 
episodes (FCEs) in a given year. It is, thus, assumed that trial recruitment and patient 
recruitment in usual practice are equivalent measures of patient volume. 
 =  (8.6), 
where: 
Gixj – summary measure of the jurisdiction-wide Gixc values; 
N – the total number of eligible centres in the jurisdiction; 
Gixc – the centre-Gix; and 
qi – the proportion of usual practice patient throughput at centre i relative to the jurisdiction-
wide patient throughput. 
Just as the trial-Gix, the Gixj is bounded by the minimum and maximum values of the 
centre-Gix. In the base case the jurisdiction-Gix ranges from 0 to 5. If closer to 5, this means 
that more patients in the jurisdiction receive care in centres lying within the middle 80 
percentile range for all five dimensions i.e. in ‘more common’ centres. Conversely, if closer 
to 0 this means that more patients receive care in centres lying outside the middle 80 
percentile range for all five dimensions i.e. in ‘less common’ centres. 
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In order to assess how representative a given trial is to the jurisdiction where it 
recruited, a comparison between the trial-Gix and the jurisdiction-wide distribution of Gixc 
values must be made by means of its summary measure Gixj. As presented above, the two 
metrics are calculated using analogous formulae, take values on the same scale and have 
similar interpretations. Box 8.2 describes the interpretation of a hypothetical numerical 
example. 
 
Box 8.2 A hypothetical example and interpretation of the trial- and jurisdiction-Gix 
 
 Suppose the centre-Gix (Gixc) incorporates five dimensions and thus ranges from 0 
(‘less common’ centres) to 5 (‘more common’ centres). Also suppose a given jurisdiction 
where the weighted (patient throughput) mean Gixj is 4.2. This suggests that most patients (or 
patient-episodes, depending on the calculation details) in the jurisdiction are seen in centres 
with high Gixc values. A trial with Gixt of 1.9, for example, recruited the majority of patients 
from ‘less common’ centres and cannot be considered a close reflection of patient throughput 
in the jurisdiction. 
 
In summary, the steps for constructing the three types of Gix for a given research 
question are as follows: 
 Define the jurisdiction, the population of centres, and each centre size, as all potential 
centres in the jurisdiction where the intervention could be implemented. 
 Identify the relevant centre-level dimensions e.g. capacity, teaching function, staff 
training etc.  
 Extract centre-level data for each of the dimensions of the Gix. 
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 Calculate the dimension level scores (1 or 0) by categorising individual centres as 
within/outside the middle 80th percentile range i.e. 10th to 90th percentile. 
 Calculate each centre-Gix by summing the dimension level scores. 
 Determine the distribution of the jurisdiction-wide Gixc and its summary measures e.g. 
weighted mean (Gixj) and SD.  
 Calculate the trial-Gix as the weighted (patient recruitment) mean of centre-Gix. 
 Calculate the standardised mean difference between Gixt and Gixj. 
 
The three sub-sections above introduced the centre-, trial- and jurisdiction-Gix. As 
explained at the beginning of the Methods section, these concepts were developed to assess 
the extent to which a given trial is representative of its jurisdiction and to further allow 
investigating whether this extent affects the generalisability of trial results. The following sub-
section outlines how the three types of Gix can be used to investigate the generalisability of 
trial results. 
 
8.3.5. Using the trial-Gix to evaluate the generalisability of trial results 
The objective of this investigation is to establish whether the representativeness of the 
sample of centres participating in a trial, as reflected by the trial-Gix, influences the 
generalisability of trial results. In order to estimate the association between the trial-Gix and 
trial results, simulation methods were used to artificially construct a large number of samples 
of centres from a real-world trial. Multiple simulated RCTs were thus obtained and the 
relationship between their Gixt values and their estimates of effectiveness and cost-
effectiveness was investigated.  
In this context, ‘generalisability of trial results’ refers to the accuracy of trial estimates 
compared to the jurisdiction ‘true values’. As pointed out at the beginning of the Chapter 
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(sections 8.1 and 8.2) , the motivating concern of this investigation is that trials which do not 
recruit representatively may systematically produce biased estimates in relation to 
jurisdiction-wide decision-making requirements. The prime difficulty when attempting to 
quantify this type of bias is that no reference point can be identified a priori. In other words, 
no jurisdiction-wide effectiveness and cost-effectiveness estimates are available and thus the 
‘true values’ against which trial results should be compared are unknown.  
The simulation method eliminates the need for knowledge of the ‘true’ clinical and 
cost-effectiveness parameters. The key assumption here is that the real-world trial is the 
jurisdiction where we assume that there are no other centres apart from those participating in 
the trial. The analogy is that with a country where every single centre participated in the trial 
and thus the nation-wide results are known.  
The chosen case study was the ROSSINI trial, which was presented at length in 
Chapter 5. A brief outline of its design and results is given in Box 8.3. Five thousand trials 
were simulated by sampling centres with replacement from the ROSSINI trial and all 
recruited patients were included from each sampled centre (52). For example, if a centre was 
sampled three times, all its patients would appear three times in the simulated trials. Standard 
analytical methods were then applied to derive estimates of clinical (odds ratio) and cost-
effectiveness estimates (incremental cost; incremental QALYs; and the probability of cost-
effectiveness at £20,000/QALY) for each simulated trial. The probability of cost-effectiveness 
for each simulated trial was calculated using non-parametric bootstrapping with 2,000 
iterations. Bootstrapped bias corrected and accelerated (BCa) 95% confidence intervals were 
also calculated for odds ratios, incremental costs and incremental QALYs in order to 
investigate the relationship between the trial-Gix and the precision of the estimates (51, 53). 
Bootstrap methods were described in more detail in Chapter 1. The result was a dataset of 
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5,000 simulated trials, each with its clinical and cost-effectiveness estimates as well as the 
trial-Gix. 
 
Box 8.3 Overview of the ROSSINI trial 
 
 The ROSSINI trial (Reduction of Surgical Site Infection using a Novel Intervention) is 
a parallel double-randomised trial comparing a wound-edge protection device (WEPD) with 
standard care in reducing the rate of surgical site infection in adult patients after open 
abdominal surgery (Chapter 5). The study recruited 769 patients from 21 hospitals across the 
UK. For the case study presented in this Chapter, the complete-case dataset was used i.e. 
patients with complete data on the clinical outcome, cost and health-related quality of life at 
baseline and 30 days post-operatively (585 patients from 21 hospitals). The trial-wide 
analyses indicated evidence of neither clinical effectiveness (OR 1.13, 95%CI 0.77 to 1.66) 
nor cost-effectiveness (14.1% probability of being cost-effective at £20,000/QALY) for the 
intervention. These estimates are, thus assumed to be the ‘true values’ of clinical and cost-
effectiveness in the simulation study. Of note, this estimate is slightly different from the one 
reported earlier in section 5.1 because it is based on a complete case dataset. 
 
The centre-Gix was calculated as per formula (8.3). The distributions for the five 
dimensions of the centre-Gix (Table 8.1) were constructed using only the information 
available from the 21 hospitals in ROSSINI because, for the purpose of the simulation, the 21 
centres constitute the pool of centres in the jurisdiction. Specialisation was calculated for each 
hospital as the proportion of FCEs in lower digestive tract interventions (most interventions in 
ROSSINI fell in this category) in the total number of FCE in 2011/2012. The data sources for 
all the five dimensions are indicated in Table 8.1. 
Chapter 8. Enhacing the generalisability of trial-based economic evaluations using a 
generalisability index (Gix) 
318 
 
Patient recruitment in ROSSINI was assumed to be equivalent to usual patient 
throughput in the jurisdiction as a measure of patient volume. The Gixj was calculated as the 
weighted (patient recruitment) mean of the centre-Gix (formula 9.5). For each simulated trial, 
the trial-Gix was calculated according to formula (9.6). The standardised mean difference was 
calculated by subtracting the Gixj from each Gixt individual value and dividing the difference 
by the standard deviation of the Gixj. This led to the standardised trial-Gix, which is a 
measure of the trial-Gix departure from the Gixj. Small positive and negative values of the 
standardised trial-Gix signify that the trial-Gix is close to the jurisdiction-wide Gix and 
therefore it can be assumed that the trial is a fairly accurate representation of it. Conversely, 
extreme positive and negative values of the standardised trial-Gix reflect more extreme trial-
Gix values and mean that the given trial is less representative of the jurisdiction as a whole. 
The standardised trial-Gix was categorised in terms of multiples of standard deviations (SD), 
as follows: -1 SD (-1.25 SD to -0.75 SD); -0.5 SD (-0.75 SD to -0.25 SD); 0 (-0.25 SD to 0.25 
SD); 0.5 SD (0.25 SD to 0.75 SD); and 1 SD (0.75 SD to 1.25 SD).  
The relationship between the standardised trial-Gix and generalisability was 
investigated by exploring the clinical and cost-effectiveness estimates (both the point 
estimates and the width of the confidence intervals) of the simulated trials across categories of 
the standardised trial-Gix. The simulations and analyses were performed in R 2.15.3 statistical 
software (359). Uncertainty in the point estimates was reflected by calculating bootstrapped 
95% confidence intervals (percentile method, based on 2,000 iterations) (54) for the clinical 
and cost-effectiveness outcomes across the five categories of the standardised trial-Gix. 
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Sensitivity analysis 
The base-case analysis referred to the centre-Gix informed by five dimensions 
(capacity, teaching status, market forces, cost performance and specialisation) and 
dichotomised centre-level information using the middle 80th percentile range. Additional 
scenarios were analysed to test the influence of these methodological choices, as presented 
below. 
 
The influence of Gix content 
While keeping the dichotomisation approach constant, three alternative Gix 
specifications included different combinations of centre-level dimensions: 
- Gix3 includes three dimensions: capacity, teaching status and specialisation;  
- Gix4a includes four dimensions: capacity, teaching status, market context and specialisation; 
and 
- Gix4b includes four dimensions: teaching status, market context, cost performance and 
specialisation. 
 
The influence of Gix construct 
Three alternative Gix formulations varied the approach to constructing the index: 
- Gix4z includes only the four continuous centre-level dimensions (excluding teaching status). 
The raw centre-level values for each dimension were standardised by subtracting the average 
from the individual value and dividing the difference by the standard deviation. Each centre 
retained the absolute z-score for each dimension to quantify the departure from the mean; the 
four absolute z-scores were summed to obtain the centre-level Gix. High values of centre-
Gix4z denote centres which are more extreme, while low values (closer to 0) denote 
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proximity to the mean i.e. more ‘common’ centres. Similarly, simulated trials with high trial-
Gix4z values recruited the majority of patients from more extreme centres, while simulated 
trials with low trial-Gix4z (closer to 0) denote trials which recruited predominantly for more 
‘common’ centres. 
- Gix90 included the five dimensions in the base-case Gix, but dichotomised centre-level 
information by considering the middle 90th percentile range (5th percentile to 95th percentile); 
and 
- Gix50 also included the five dimensions in the base-case Gix, but dichotomised centre-level 
information by considering the middle 50th percentile range or inter-quartile range (25th 
percentile to 75th percentile). 
 
 
 
8.4. Results 
8.4.1. The centre-level Gix 
The centre-level characteristics across the five representativeness dimensions and the 
centre-Gix for ROSSINI hospitals are presented in Table 8.2. For the sample of ROSSINI 
centres, the minimum centre-Gix is 2 and the maximum is 5.  
 
8.4.2. The jurisdiction-level Gix 
The mean Gixc in the ROSSINI trial i.e. Gixj, is 3.90 (median Gixc 4.00), which 
suggests that most patients in the 'jurisdiction' come from representative centres, as reflected 
by the centre-Gix. The weighted mean and the median are comparable, thereby suggesting 
that the weighted mean is a defensible choice to summarise the jurisdiction distribution of 
Gixc. 
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Table 8.2 Centre-level Gix for ROSSINI centres 
 
Centre  Raw dimension values Categorised dimension values Centre 
Gix ID Patients Beds Teaching MFF RCI Spec Beds_ix Teaching_ix MFF_ix RCI_ix Spec_ix 
1 47 1,019 1 0.96 117 0.05 0 0 1 0 1 2 
2 79 423 0 0.95 102 0.04 1 1 1 1 1 5 
3 35 696 1 0.94 101 0.04 1 0 1 1 1 4 
4 5 765 0 0.95 99 0.03 1 1 1 1 0 4 
5 5 472 0 0.95 105 0.05 1 1 1 0 1 4 
6 98 692 0 0.95 95 0.03 1 1 1 1 1 5 
7 10 458 0 0.97 94 0.05 1 1 1 0 1 4 
8 1 708 0 0.96 97 0.03 1 1 1 1 1 5 
9 4 532 0 0.96 97 0.03 1 1 1 1 1 5 
10 42 992 0 0.95 95 0.04 0 1 1 1 1 4 
11 145 886 1 0.93 96 0.05 1 0 0 1 1 3 
12 44 419 0 0.95 103 0.05 0 1 1 1 1 4 
13 5 544 0 1.01 100 0.05 1 1 1 1 1 5 
14 18 666 1 0.97 101 0.04 1 0 1 1 1 4 
15 6 756 0 0.94 94 0.05 1 1 1 0 1 4 
16 13 508 0 0.93 96 0.05 1 1 0 1 1 4 
17 13 458 0 1.10 99 0.09 1 1 0 1 0 3 
18 1 358 0 1.02 103 0.06 0 1 0 1 1 3 
19 10 436 0 0.96 99 0.07 1 1 1 1 1 5 
20 3 568 0 0.96 95 0.07 1 1 1 1 0 4 
21 1 916 1 0.95 102 0.03 1 0 1 1 0 3 
Median 568 0 0.96 99 0.05       
10th percentile 423 0 0.94 95 0.04       
90th percentile 916 1 1.01 103 0.07       
 
Legend: Teaching (1 - teaching hospital; 0 - non-teaching hospital); MFF - Market Forces Factor; RCI - Reference Cost Index; Spec - specialisation as % of lower 
digestive tract finished consultant episodes (FCEs) in the total number of FCEs per hospital in 2011/2012. Categorised dimension values (_ix) are 1 if raw value within 
10th-90th percentile and 0 otherwise; for binary variables (Teaching_ix), values are 1 for most common category and 0 otherwise.
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8.4.3. The simulated trials 
5,000 trials were simulated from the ROSSINI trial. 49 simulated trials were discarded 
because the probability of cost-effectiveness could not be calculated, resulting in 4,951 
simulations analysed. The distributions of the odds ratio, the probability of cost-effectiveness 
at £20,000/QALY, the incremental costs and the incremental QALYs across the simulated 
trials are presented in Figure 8.3. Table 8.3 compares the descriptive characteristics and 
results of the simulated RCTs with ROSSINI estimates. The median values of the parameters 
from the simulated trials approximate the ROSSINI values, thus suggesting that the 
simulations are a reasonable representation of the original data.  
 
8.4.4. The standardised trial-Gix and generalisability 
Table 8.4 presents the distribution of design characteristics i.e. sample size, the 
number of recruiting centres, the event rate (incidence of SSI in the RCT population) and the 
randomization ratio (intervention arm: control arm), across categories of the standardised 
trial-Gix. It is apparent the trial-Gix groups are similar in terms of the number of recruiting 
centres, SSI incidence and the relative number of patients in each arm. Trials with higher trial-
Gix values seem to have slightly smaller sample sizes than the other categories. 
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Figure 8.3 Distribution of effectiveness and cost-effectiveness estimates across the simulated RCTs 
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Table 8.3 Comparative characteristics and results of ROSSINI and the simulated RCTs 
 
Parameter 
Simulated trials ROSSINI 
Mean Mean [Median, IQR] 
   
Descriptive characteristics   
Sample size 584 [572, 463 to 697] 585 
Number of unique centres 13.5 [13, 13 to 14] 21 
Event rate (SSI incidence) 0.244 [0.241, 0.229 to 0.256] 0.241 
Intervention: control ratio 0.99 [1.00, 0.96 to 1.04] 1.00 
Trial-Gix 3.91 [3.91, 3.67 to 4.17] 3.90 
   
Results   
Odds ratio 1.15 [1.12, 0.95 to 1.33] 1.13 (95%CI 0.77 to 1.66) 
Probability of cost-effectiveness at £20k/QALY 0.18 [0.11, 0.04 to 0.27] 0.14 
Incremental costs (£) 425.30 [397.50, 200.10 to 627.40] 376.37 
Incremental QALYs -0.00076 [-0.00090, -0.00186 to 0.00021] -0.00089 
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Table 8.4 Characteristics of the simulated trials across categories of standardised trial-Gix 
 
Parameter 
Categories of standardised trial-Gix 
-1 SD  
(-1.25 to -0.75 SD) 
-0.5 SD  
(-0.75 to -0.25 SD) 
0  
(-0.25 to 0.25 SD) 
0.5 SD  
(0.25 to 0.75 SD) 
1 SD  
(0.75 to 1.25 SD) 
Number of simulated RCTs 160 1210 2131 1208 241 
      
Sample size      
Mean 568.2 607.6 594.0 562.2 538.7 
Median 558.5 603.5 584.0 546.0 531.0 
IQR 452.5 to 672.2 483.2 to 722.0 472.0 to 709.0 446.0 to 674.0 447.0 to 630.0 
Number of centres      
Mean 12.6 13.4 13.7 13.4 12.9 
Median 13 13 14 13 13 
IQR 12 to 13 12 to 14 13 to 15 12 to 14 12 to 14 
Event rate  
(SSI incidence) 
     
Mean 0.247 0.241 0.244 0.247 0.243 
Median 0.243 0.238 0.241 0.246 0.243 
IQR 0.227 to 0.264 0.225 to 0.252 0.229 to 0.255 0.234 to 0.260 0.233 to 0.252 
Intervention: control ratio      
Mean 0.98 0.99 1.00 1.01 1.01 
Median 0.98 1.00 1.00 1.01 1.01 
IQR 0.95 to 1.02 0.96 to 1.03 0.97 to 1.04 0.97 to 1.05 0.97 to 1.05 
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Table 8.5 summarises the clinical effectiveness and cost-effectiveness estimates in the 
simulated RCTs across the five categories of the standardised trial-Gix. Two observations can 
be made in relation to the odds ratio and the incremental QALYs: first, both quantities exhibit 
a monotonic pattern (decrease and increase, respectively) across the standardised trial-Gix 
subgroups, from the -1 SD to 1 SD subgroup; this suggests that simulated trials with higher 
trial-Gix values produce results more favourable to the intervention than trials with lower 
trial-Gix. Second, the average odds ratio and incremental QALYs are the closest to the ‘true 
values’ in ROSSINI (OR 1.13 and -0.00089 incremental QALYs) for the 0 subgroup (-0.25 
SD to 0.25 SD); this suggests that simulated RCTs with a trial-Gix close to the jurisdiction-
Gix give the closest results to the ‘true’ values. No trend is discernible for incremental costs 
and the probability of cost-effectiveness at £20,000/QALY.   
The distributions of the effectiveness and cost-effectiveness parameters across 
standardised trial-Gix subgroups are depicted as box plots in Figures 8.4 to 8.7. The box plots 
confirm the identified trends for odds ratio and incremental QALYs, as well as the lack 
thereof for incremental costs and the probability of cost-effectiveness. Figure 8.8 depicts the 
bootstrapped BCa 95% confidence intervals calculated around the subgroup point estimates 
across the four clinical and cost-effectiveness estimates. The non-overlapping confidence 
intervals for odds ratio and incremental QALYs confirm the result of the box plots, where 
there is still no apparent standardized Gix group-dependent effect for incremental costs and 
the probability of cost-effectiveness. 
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Table 8.5 Results of the simulated RCTs across categories of standardised trial-Gix 
 
Parameter 
Categories of standardised trial-Gix 
-1 SD  
(-1.25 to -0.75 SD) 
-0.5 SD  
(-0.75 to -0.25 SD) 
0  
(-0.25 to 0.25 SD) 
0.5 SD  
(0.25 to 0.75 SD) 
1 SD  
(0.75 to 1.25 SD) 
Number of simulated RCTs 160 1210 2131 1208 241 
      
Odds ratio      
Mean 1.58 1.30 1.14 1.01 0.91 
Median 1.53 1.28 1.12 0.99 0.88 
IQR 1.35 to 1.75 1.11 to 1.46 0.97 to 1.30 0.83 to 1.18 0.77 to 1.03  
Probability cost-effective      
Mean 0.21 0.17 0.17 0.20 0.17 
Median 0.17 0.10 0.11 0.13 0.10 
IQR 0.06 to 0.29 0.03 to 0.24 0.03 to 0.26 0.04 to 0.31 0.03 to 0.24 
Incremental costs (£)      
Mean 362.5 447.7 430.1 401.3 434.1 
Median 345.0 430.4 394.4 364.5 400.7 
IQR 205.7 to 547.8 215.6 to 642.1 205.0 to 630.7 156.5 to 583.9 215.6 to 627.7 
Incremental QALYs      
Mean -0.00203 -0.00150 -0.00081 0.00003 0.00033 
Median -0.00213 -0.00157 -0.00093 -0.00005 0.00016 
IQR -0.00302 to -0.00110 -0.00233 to -0.00150 -0.00180 to 0.00006 -0.00108 to 0.00105 -0.00077 to 0.00139 
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Figure 8.4 Clinical effectiveness estimates in simulated RCTs across categories of standardised trial-Gix 
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Figure 8.5 Incremental costs in simulated RCTs across categories of standardised trial-Gix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8. Enhacing the generalisability of trial-based economic evaluations using a generalisability index (Gix) 
330 
 
Figure 8.6 Incremental QALYs in simulated RCTs across categories of standardised trial-Gix 
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Figure 8.7 Probability of cost-effectiveness in simulated RCTs across categories of standardised trial-Gix 
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Figure 8.8 Bootstrapped 95% confidence intervals for point estimates across categories of standardised trial-Gix 
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Figure 8.9 Bootstrapped 95% confidence intervals for the precision of point estimates across categories of standardised trial-Gix 
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The relationship between the standardized trial-Gix and the width of the bootstrapped 
BCa 95% confidence intervals for the odds ratio, incremental costs and incremental QALYs 
was also analysed (Figure 8.9). It appears that simulated trials with higher trial-Gix values 
produce more precise estimates of odds ratio and incremental costs. The trend is reversed for 
incremental QALYs, where trials with the lowest trial-Gix values had more precise estimates 
of incremental QALYs. 
 
Sensitivity analysis 
The simulation results for the alternative indices are presented in Table 8.6 and the 
box plots are displayed in Appendix 17. Figures A17.1 to A17.3 present box plots of point 
estimates for clinical and cost-effectiveness results across categories of standardised Gix3, 
Gix4a and Gix4b, respectively, which were based on various combinations of centre-level 
dimensions. As with the base-case standardised trial-Gix, simulated trials with higher trial-
Gix values favour the clinical effectiveness and the incremental QALY benefit of the 
intervention for all the alternative indices. There is no discernible effect on incremental costs 
and probability of cost-effectiveness. 
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Table 8.6 Results of the simulated RCTs across various standardised trial-Gix formulations 
 
Parameter (mean, median) 
Categories of standardised trial-Gix 
-1 SD  
(-1.25 to -0.75 SD) 
-0.5 SD  
(-0.75 to -0.25 SD) 
0  
(-0.25 to 0.25 SD) 
0.5 SD  
(0.25 to 0.75 SD) 
1 SD  
(0.75 to 1.25 SD) 
      
Gix3      
Simulated RCTs 43 1040 2818 1011 39 
Odds ratio 1.78 (1.67) 1.33 (1.32) 1.13 (1.12) 1.00 (0.98) 0.94 (0.89) 
Probability cost-effective  0.38 (0.37) 0.19 (0.13) 0.17 (0.10) 0.19 (0.11) 0.17 (0.09) 
Incremental costs (£)  134.1 (157.6) 423.2 (407.4) 438.3 (404.1) 402.7 (372.3) 445.3 (441.6) 
Incremental QALYs  -0.00201  
(-0.00207) 
-0.00156 
(-0.00164) 
-0.00076 
(-0.00090) 
0.00006 
(-0.00003) 
0.00082 
(0.00006) 
Gix4a      
Simulated RCTs 109 1188 2167 1304 183 
Odds ratio  1.46 (1.45) 1.31 (1.29) 1.15 (1.12) 1.02 (0.99) 0.92 (0.89) 
Probability cost-effective  0.12 (0.06) 0.15 (0.09) 0.18 (0.11) 0.21 (0.14) 0.19 (0.14) 
Incremental costs (£)  467.5 (486.1) 459.3 (434.4) 418.0 (384.3) 406.6 (374.5) 398.3 (320.8) 
Incremental QALYs  -0.00214 
(-0.00226) 
-0.00153 
(-0.00160) 
-0.00079 
(-0.00088) 
-0.00005 
(-0.00015) 
0.00037 
(0.00006) 
Gix4b      
Simulated RCTs 231 1149 1904 1313 349 
Odds ratio  1.40 (1.37) 1.31 (1.27) 1.16 (1.13) 1.03 (1.00) 0.89 (0.87) 
Probability cost-effective  0.11 (0.06) 0.16 (0.10) 0.18 (0.12) 0.21 (0.15) 0.17 (0.10) 
Incremental costs (£)  522.1 (496.5) 447.8 (418.8) 410.5 (381.6) 409.8 (359.8) 425.7 (411.2) 
Incremental QALYs  -0.00189 
(-0.00201) 
-0.00133 
(-0.00144) 
-0.00081 
(-0.00092) 
-0.00015 
(-0.00026) 
-0.00011 
(-0.00021) 
Gix4z      
Simulated RCTs 715 1065 1039 732 481 
Odds ratio  0.97 (0.96) 1.06 (1.05) 1.16 (1.15) 1.25 (1.25) 1.33 (1.34) 
Probability cost-effective  0.11 (0.06) 0.13 (0.08) 0.17 (0.11) 0.20 (0.15) 0.27 (0.22) 
Incremental costs (£)  515.0 (491.4) 468.0 (427.6) 416.2 (375.1) 383.0 (351.1) 299.1 (258.9) 
Incremental QALYs  -0.00049 
(-0.00055) 
-0.00073 
(-0.00094) 
-0.00079 
(-0.00093) 
-0.00092 
(-0.00110) 
-0.00095 
(-0.00098) 
      
Chapter 8. Enhacing the generalisability of trial-based economic evaluations using a generalisability index (Gix) 
336 
 
Parameter (mean, median) 
Categories of standardised trial-Gix 
-1 SD  
(-1.25 to -0.75 SD) 
-0.5 SD  
(-0.75 to -0.25 SD) 
0  
(-0.25 to 0.25 SD) 
0.5 SD  
(0.25 to 0.75 SD) 
1 SD  
(0.75 to 1.25 SD) 
      
      
Gix90      
Simulated RCTs 76 963 2832 1074 0 
Odds ratio  1.68 (1.65) 1.40 (1.38) 1.14 (1.12) 0.92 (0.90) n/a 
Probability cost-effective  0.37 (0.33) 0.24 (0.18) 0.16 (0.10) 0.15 (0.08) n/a 
Incremental costs (£)  207.7 (182.4) 365.7 (333.3) 431.2 (407.3) 479.0 (438.1) n/a 
Incremental QALYs  -0.00155 
(-0.00179) 
-0.00137 
(-0.00149) 
-0.00077 
(-0.00090) 
-0.00012 
(-0.00021) 
n/a 
Gix50      
Simulated RCTs 0 1063 2570 1129 184 
Odds ratio  n/a 1.18 (1.15) 1.15 (1.12) 1.14 (1.12) 1.16 (1.16) 
Probability cost-effective  n/a 0.14 (0.08) 0.17 (0.11) 0.23 (0.16) 0.23 (0.16) 
Incremental costs (£)  n/a 408.0 (404.0) 425.8 (399.9) 430.2 (368.6) 481.6 (437.9) 
Incremental QALYs  n/a -0.00202  
(-0.00205) 
-0.00096 
(-0.00096) 
0.00042 
(0.00045) 
0.00194 
(0.00187) 
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Figures A17.4 to A17.6 present box plots of point estimates for clinical and cost-
effectiveness results across categories of standardised Gix4z, Gix90 and Gix50, respectively, 
where the ‘commonness’ of a centre was constructed differently compared to the base-case 
trial-Gix. The distributions of Gix90 and Gix50 across the simulated trials are skewed to the 
left and right, respectively, which explains the fact that extreme subgroups (+1SD and -1SD, 
respectively) are not populated with simulated values. The standardized Gix90 appears to 
exhibit the pattern identified in the base-case: trials with higher standardized trial-Gix produce 
clinical effectiveness and incremental QALY estimates which are more favourable to the 
intervention. Furthermore, the opposite pattern appears to apply to incremental costs and 
probability of cost-effectiveness, as well: the box plots in Figure A17.5 suggest that trials with 
higher trial-Gix values have slightly higher incremental costs and, overall, the intervention is 
less likely to be cost-effective despite being more likely to be clinically effective. As for 
Gix50, no differences between subgroups are apparent with the exception with incremental 
QALYs, in line with the base-case pattern (Figure A17.6). 
The standardised Gix4z, which uses the sum of absolute z-scores to quantify centre-
level ‘commonness’, displays a similar pattern: trials with low Gix4z values (recruiting 
predominantly from centres with low centre-Gix4z scores i.e. ‘common’ centres) favour the 
clinical effectiveness and QALY gains of the intervention. However, a notable difference 
from all the other indices is that patterns are discernible for incremental costs and the 
probability of cost-effectiveness at £20,000/QALY, as well. Simulated trials with low trial-
Gix4z also have higher incremental costs and a lower probability of the intervention to be 
cost-effective. Conversely, trials with higher values of the trial-Gix4z (recruiting 
predominantly from centres with high centre-Gix4z scores i.e. more extreme centres) have 
lower incremental costs and, due to a higher proportion of negative incremental costs i.e. cost 
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savings, also a higher probability of cost-effectiveness. Furthermore, the incremental QALY 
differences across the subgroups are much smaller than in the base-case. 
 
8.5. Discussion 
Summary of findings 
The representativeness of the sample of participating centres, as reflected by the 
standardised trial-Gix, appears to influence both the accuracy and precision of RCT results, 
thereby representing a potential source of bias. In this case study, trials which recruited from 
more representative centres (high values of standardised trial-Gix) tended to overestimate the 
benefits of the intervention, both in terms of clinical effectiveness and QALY gains. The 
simulated trials with lower values of the standardised trial-Gix i.e. trials which enrolled 
patients from more ‘extreme’ centres, underestimated the benefits of the intervention. There 
was generally no discernible association between the trial-Gix and incremental costs or 
overall cost-effectiveness, with the exception of the Gix4z, which used only continuous 
variables and absolute z-scores instead of dichotomised scores, and the Gix90, which used a 
wider percentile range to define centre ‘commonness’ (5th to 95th percentile).  
Furthermore, centre selection also appears to influence the precision of trial estimates. 
Simulated RCTs with a high trial-Gix produced narrower confidence intervals for the odds 
ratio and incremental costs, but wider confidence intervals for incremental QALYs. This may 
be because such ‘common’ centres deliver more uniform care, but receive a wide variety of 
patients which translates in the way they perceive their health improvements. The findings 
were generally robust to various specifications of the centre-Gix. The content of the Gix i.e. 
the included dimensions, and its construct i.e. the approach to aggregating centre-level 
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information, did not seem to affect the direction of the results, although there were differences 
in magnitude.  
 
Analytical considerations 
The approach presented in this Chapter should be viewed as a proof-of-concept 
exercise from several viewpoints. First, the choice of dimensions for the centre-Gix was based 
on their likely impact on effectiveness and cost-effectiveness results, as suggested in the 
literature. Other variables may well find their place in the Gix. In order to test how dependent 
the findings were on the choice of these five dimensions, parallel indices were constructed in 
sensitivity analyses based on various combinations of these variables. While the magnitude of 
the results differed, their interpretation was entirely consistent with the base-case, thereby 
suggesting that the results are robust to the Gix content. 
Moreover, the dimensions of the Gix are specific to a particular research context. The 
content of the Gix proposed in this case study refers primordially to hospital care and, as such, 
is mainly applicable to research questions where inpatient care is the most important 
determinant of health and economic outcomes. For other RCT settings, such as primary care 
or palliative care studies, the Gix may include entirely different dimensions, such as average 
length of consultation or Quality and Outcomes Framework scores (425).  
A legitimate concern when aggregating multiple dimensions in an index is 
autocorrelation. In this case, the potential is even higher because the MFF, a marker of the 
market environment, is an input in the formula for the RCI, a marker of the provider’s cost 
performance. The correlation matrices of the five centre-level dimensions based on the 21 
ROSSINI hospitals are presented in Table 8.7. The highest correlation coefficients are for 
capacity - teaching status (0.59) and market context – specialisation (0.68); however, these 
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values do not suggest a high degree of correlation among the dimensions for the purpose of 
constructing the centre-Gix. As it appears, the amount of correlation after dichotomisation is 
even lower (Table 8.7).   
Second, the proposed construct of the Gix is still simple, though intuitive. More 
complex approaches can be envisaged. For example, the dimensions’ scores could be 
weighted in accordance with existing evidence of their relative influence on effectiveness and 
cost-effectiveness measures. The current construct cannot offer an accurate description of a 
‘representative’ centre: there are centres which are ‘common’ under a number of dimensions, 
but much less so in others. The choice of the middle 80th percentile range was arbitrary, but in 
sensitivity analyses alternative ranges were tested (middle 90th percentile and inter-quartile 
range). The interpretation of the results was generally consistent with the one presented 
above, thus suggesting that the findings are robust to reasonable choices of the 'commonness' 
range. The differences between the choices of the ‘commonness’ interval appear to influence 
the discriminatory power of the trial-Gix across the relevant outcome measures, and thus the 
magnitude of the differences between subgroups of the standardised trial-Gix. Using the 
middle 90th percentile range discriminates strongly for clinical effectiveness i.e. the 
differences in odds ratio estimates between the extreme subgroups are larger than in the base-
case scenario, but also for incremental QALYs, incremental costs and even the probability of 
cost-effectiveness. The opposite can be observed when using the middle 50th percentile range 
to dichotomise centre-level information: the differences in odds ratio estimates, incremental 
costs and probability of cost-effectiveness across subgroups are negligible, while the variation 
in incremental QALYs is notable. This suggests that a wider ‘commonness’ range may 
improve the discriminatory power of the trial-Gix, albeit not for all outcomes. The choice of 
an appropriate threshold appears, thus, to deserve close consideration in future research. 
Chapter 8. Enhacing the generalisability of trial-based economic evaluations using a generalisability index (Gix) 
341 
 
Table 8.7 Correlation among the five centre-level dimensions in ROSSINI hospitals 
 
 Capacity (beds) Teaching status 
Market context 
(MFF) 
Cost performance 
(RCI) 
Specialisation 
(%FCE) 
 
Raw standardised values 
Capacity (beds) 1.0000000   0.5866778 -0.38512524 0.13883975 -0.45896312 
Teaching status 0.5866778   1.0000000   -0.23304984 0.42840681 -0.27203558 
Market context (MFF) -0.3851252 -0.2330498   1.0000000   0.09585704   0.67675033 
Cost performance (RCI) 0.1388397   0.4284068   0.09585704 1.0000000   0.04967891 
Specialisation (%FCE) -0.4589631 -0.2720356   0.67675033 0.04967891   1.0000000   
 
Dichotomised scores 
Capacity (beds) 1.0000000   0.01355815 0.07352941 0.07352941 -0.23529412 
Teaching status 0.01355815 1.0000000   0.01355815 0.01355815 0.01355815 
Market context (MFF) 0.07352941 0.01355815 1.0000000   -0.23529412 0.07352941 
Cost performance (RCI) 0.07352941 0.01355815 -0.23529412 1.0000000   -0.23529412 
Specialisation (%FCE) -0.23529412 0.01355815 0.07352941 -0.23529412 1.0000000   
 
Legend: 
MFF – Market Forces Factor 
RCI – Reference Cost Index 
%FCE – proportion of lower GI tract finished consultant episodes in 2011/2012 
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Third, the choice of a simulation approach particularly emphasizes the proof-of-
concept nature of this research. It has been argued that the usefulness of simulation studies is 
in investigating bias in the estimates of interest by exploiting the fact that the true values are 
known (426). The role of the simulations was, in this case, to create a hypothetical research 
environment which could 1) examine the bias in clinical and cost-effectiveness outcomes 
across various samples of centres; and 2) inform an assessment of the validity and usefulness 
of the Gix. The primary focus of this investigation was accuracy rather than precision, 
therefore ‘true values’ and an empirical distribution of estimates had to be generated. Two 
approaches are available to meet these requirements i.e. to inform the ‘true values’: the first is 
to use an existing case study. A similar strategy was used by Deeks et al., who investigated 
the bias in two non-randomised studies by simulating 8,000 and 14,000 RCTs, respectively, 
based on the participating patients in the original studies and then comparing the distributions 
of the odds ratios between the randomised and non-randomised experiments (427). 
An alternative approach involves generating the jurisdiction and the trial data de novo 
using simulation methods. At the expense of a more complex specification and 
computationally intensive algorithm, the latter allows a finer control of the model parameters. 
This has been applied, for example, by Gomes et al. in the context of refining economic 
evaluation methods for cluster-RCTs (428). McCarron et al. adopted a similar approach when 
testing the performance of different Bayesian models to combine the results of randomised 
and non-randomised studies (429). The case study method was preferred for the purpose of 
this thesis when considering the data available from the ROSSINI trial and its suitability for 
the research question given the number and variety of recruiting locations. 
Multi-level modelling has been used to investigate centre-level variations in cost-
effectiveness results (164, 430) and bivariate hierarchical modelling, a Bayesian extension of 
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multi-level modelling, is currently the recommended approach with this aim (134). It must be 
acknowledged that such techniques are best suited to produce centre-level incremental cost 
and effect estimates based on trial-wide results. The main research question addressed in this 
investigation was different: its focus was on how the sample of centres influences the overall 
trial-wide results as opposed to how trial-wide results can refine centre-level estimates. The 
question was formulated as such in light of addressing the practicality of decision-making 
processes: policy makers would often have to make jurisdiction-wide decision based on 
information collected from a sample of locations within the jurisdiction or even from an 
entirely different jurisdiction. The decision at hand is whether the research recommendations 
as suggested by the existing evidence are relevant, to varying extents, across the entire 
jurisdiction. Under this context, precise centre-level cost and benefit estimates are of limited 
value in the absence of a methodological framework that can assess similarity between 
locations and, in a broader context, the amount of overlap between the research space and the 
policy space (section 8.2). Only such information can inform the transferability of clinical and 
cost-effectiveness results and it is this knowledge gap that the Gix attempted to address. For 
this reason, the use of multi-level modelling was not considered a pre-requisite for this 
investigation. 
Aggregating the centre-Gix dimensions into a single index was necessary for 
constructing the trial-Gix. It can be argued that the dimensions could be left disaggregated. 
While this may be an option, the focus of this research was to investigate the properties of the 
Gix approach through comparing RCTs (rather than centres) by means of obtaining an 
empirical sampling distribution of RCT characteristics and result estimates. It would have 
been challenging to characterise the distributions of simulated RCTs characteristics and 
outcomes without an aggregated metric. As a future perspective, once the concept of bias due 
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to sample un-representativeness is demonstrated in a range of settings, accepted and addressed 
at design stage, it may not be always necessary to aggregate the dimensions in order to 
compare centres and identify the suitable ones. For example, centre-level ‘profiles’ can be 
constructed by simply juxtaposing the centre-level scores and an informed decision can be 
made based on the analysis of individual dimensions. 
 
Interpretation of findings  
The results of the case study have two important implications: first, there appears to be 
a discernible relationship between the sample of participating centres and the accuracy of trial 
estimates in relation to the jurisdiction point estimate. Consequently, there seems to be 
support towards the primary hypothesis of this research: there is a potential for bias in trial 
results (compared to jurisdiction-wide values) resulting from an inappropriate selection of 
centres. This statement is backed by the identifiable trend in trial results’ accuracy as a 
function of the measure of trial representativeness (standardised Gixt) – this trend was 
consistently observed for clinical effectiveness and incremental QALYs. In this context, the 
counterfactual is that no evidence towards such a relationship can be produced, as it appears 
to be the general case for incremental costs and probability of cost-effectiveness (although 
some alternative indices, such as Gix90 and Gix4z, actually did show such an association). 
Second, the results indicate that recruiting RCT centres such that the characteristics of 
the sample of centres resemble those of the jurisdiction as a whole leads to point estimates of 
trial results which are closest to ‘true values’. The main implication is that trial recruitment 
must closely mirror the jurisdiction clinical practice in order to obtain accurate estimates. 
Knowledge about both patient throughput and the distribution of centre characteristics at 
jurisdiction level are pre-requisites for making an informed choice on the appropriate sample 
Chapter 8. Enhacing the generalisability of trial-based economic evaluations using a 
generalisability index (Gix) 
345 
 
of centres. Several important implications become apparent: first, ensuring merely ‘a mix’ of 
centres may be insufficient if the mix doesn’t reflect the actual joint distribution of centre 
characteristics; second, the local recruitment contribution is an equally important 
consideration and must also be factored in the assessment of representativeness; third, 
recruiting predominantly from ‘average’ centres i.e. centres with high Gixc values leading to 
high Gixt values, does not seem to be an acceptable compromise – in the case study, such 
trials overestimated the ‘true values’ of clinical effectiveness and QALY gains. 
There appears to be a relationship between the sample of centres and the precision of 
trial estimates. However, accuracy and precision do not seem to be correlated strongly in 
terms of centre selection. For example, simulated trials which closely reflect recruitment at 
jurisdiction level produce the most accurate odds ratios, but the width of their bootstrapped 
95% confidence intervals is higher than that of trials with high standardized Gixt i.e. trials 
which recruited predominantly from ‘common’ centres. The reverse can be said about 
incremental QALYs, where trials with high standardized Gixt produced the widest confidence 
intervals across all subgroups. Furthermore, while no effect has been detected on the accuracy 
of incremental costs, the precision of cost estimates also seems to improve with recruiting 
predominantly from ‘common’ centres. The reasons for these non-uniform variations across 
outcomes are yet unknown and deserve further exploration in subsequent research. The 
emerging picture is, however, that a trade-off must be reached between accuracy and 
precision: there is no category of trials which provides optimal results under both these 
dimensions, but trials with Gixt close to the Gixj (the ‘0’ subgroup) appear to represent an 
acceptable solution as they produce the most accurate estimates with moderate precision. 
As pointed out above, bias due to recruiting from unrepresentative samples of centres 
appears to exist. Nevertheless, the magnitude of this bias in point estimates across the 
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categories of standardized Gixt varied across the different index specifications and across 
outcomes. It is of great interest to ascertain whether the identified bias actually matters for 
policy purposes i.e. can it alter a reimbursement decision or not? In this case study, the 
spectrum of odds ratios and incremental QALYs across types of trials was wide enough to 
produce conflicting recommendations as to the relative merits of the intervention. However, 
only replicating such studies in other trials, clinical settings and jurisdictions will reliably 
assess the impact of this bias on policy decisions.    
Gix90 and Gix4z were the only evaluated indices for which a pattern was apparent 
across all the trial results (Figures A17.4 and A17.5). This suggests that the definition of 
‘commonness’ is crucial to the application of the Gix. However, interpreting the findings of 
these indices is not straightforward. For example, simulated trials with high trial-Gix4z values 
i.e. recruiting from more extreme centres (+0.5SD and +1SD subgroups), underestimated the 
clinical benefits of the intervention as well as the incremental costs and QALYs. Incremental 
costs are underestimated to a larger extent than incremental QALYs, the overall effect being 
that the intervention appears to be much more cost-effective at £20,000/QALY than it actually 
is. Conversely, simulated trials recruiting from ‘common’ centres (-0.5SD and -1SD 
subgroups) overestimated the intervention’s clinical benefit as well as the incremental costs 
and incremental QALYs, thereby suggesting that the intervention is much less cost-effective 
than it actually is.  
The simulation results for the Gix4z are compatible with a health care setting where 
the clinical benefit of the intervention is proportional with the costs of care: higher 
incremental costs are correlated with better clinical and HRQoL outcomes, and vice versa. It 
is yet unknown how much of this relationship is due to the construct of the Gix4z and how 
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much due to the intrinsic nature of the dataset. The interpretation of the Gix90 results is 
analogous. 
Nevertheless, it must be acknowledged that Gix4z and Gix90 are the only indices 
which behave as one may hypothesise in the sense of showing consistent associations across 
both clinical and economic outcomes. The construct of the Gix is, thus, a fertile topic for 
further exploration in subsequent research. It may be that dichotomization discards so much 
cost information that any association between incremental costs and the trial-Gix is lost in the 
base-case Gix. 
 
Strengths and limitations 
The approach outlined in this Chapter is, to my knowledge, the first attempt to 
quantify representativeness at centre and trial level. Furthermore, results appear to be 
consistent across various content combinations of centre-Gix dimensions and constructs, as 
discussed above. As such, the proposed approach is novel and appears to be robust. 
There are several potential limitations. First, the proposed Gix may be regarded as 
difficult to interpret. The centre-Gix depends on the jurisdiction-wide distributions of its 
dimensions. It is unknown how the centre-Gix behaves in jurisdictions with two well-
balanced types of centres which take extreme values on most relevant dimensions. For 
example, in a hypothetical country with equally represented rural, low-staffed, small size 
hospitals and urban, high-staffed, teaching hospitals. Under the current method, in such a 
situation comparable proportions of low extremes and high extremes would be artificially 
coerced in the middle 80th percentile and thus be acknowledged as ‘common centres’, 
although they share few characteristics. 
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Second, categorising the five representativeness dimensions results in losing a large 
amount of information. Furthermore, potentially similar centres may receive different 
categorisations because of the choice of the ‘commonness’ range. However, this problem will 
always occur when synthesising continuous and categorical variables, as it is the case here. 
When only continuous variables are considered, the use of z-scores to quantify departure from 
a measure of location would be more efficient; this approach was explored in sensitivity 
analysis and results were generally in line with the base-case and all the other indices. The 
base-case for the method deliberately included both continuous and categorical variables in 
order to anticipate the practical challenges of constructing the index. Dichotomising 
information appears to be defensible in the presence of a reasonable number of dimensions, 
but future research on the merit of alternative approaches is needed. A further challenge 
relates to incorporating multi-categorical variables in the Gix: under the current approach, 
further categorisation would be required to incorporate such variables, resulting in further loss 
of information. 
Third, results are generally inconsistent across the studied outcomes i.e. no apparent 
centre effect on incremental costs or on overall cost-effectiveness with the exception of Gix90 
and Gix4z. This may be in part caused by the costing methodology in the ROSSINI trial, 
where nationally averaged unit costs for inpatient, outpatient and primary care were 
employed, or by the intrinsic nature of the trial data. Furthermore, it has been challenging to 
identify a suitable cost-effectiveness metric for the purpose of this investigation because the 
classical metrics for decision-making i.e. the ICER and the INB, were not appropriate. The 
difficulties around interpreting ICERs have been highlighted in the literature (431). The INB 
has the advantage of aggregating incremental costs and incremental effects in one easily 
interpretable metric (55), but the INB point estimate does not communicate information on 
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uncertainty (e.g. for a given comparator, it cannot be said that an intervention with an INB of 
£8,000 is twice as likely to be cost-effective relative to an intervention with an INB of £4,000) 
and therefore is not ideal for direct comparisons. The probability of cost-effectiveness at a 
meaningful WTP threshold, as reflected by the CEAC, has been chosen for the purpose of this 
investigation (58). However, there are no other sources that I am aware of where such a 
metric has been used to explore confounding factors. Future applications of this approach to 
other RCTs should also investigate the relative merit of alternative cost-effectiveness metrics. 
Although there is evidence to support the relevance of the five centre-level variables 
which were included in the generalisability index (Box 8.1), these were identified from a 
pragmatic literature and their inclusion in the Gix was, to an extent, arbitrary. This must be 
acknowledged as a limitation. Ideally the dimensions would have to be identified and 
developed by applying a robust methodology. Such an approach would include conducting a 
systematic literature review, assessing the strength of evidence and expert opinion elicitation. 
However, two issues must be further considered: first, sensitivity analyses around the content 
of the Gix were performed by testing various combinations of the five dimensions and the 
findings were consistent across the scenarios. Second, the available systematic reviews on 
centre-level factors have identified a very large number of such considerations - up to 77 in 
the publication by Goeree et al. (136). In the absence of a classification of these factors’ 
relative importance, it can be argued that any choice of dimensions for the Gix would 
presently be informed, to a large extent, by the investigators’ experience and intuition. 
Nevertheless, future work should include an update of the existing reviews and the 
development of a framework to allow the rational identification of candidate variables for the 
Gix.      
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The current version of the Gix does not include population characteristics as a 
dimension. As such, the proposed version assumed a homogenous patient population across 
the jurisdiction and, furthermore, that patients enrolled at each centre were an unbiased 
sample from this population. This is a strong assumption. The main reason why such 
information wasn’t incorporated in the present version was the difficulty to establish the 
association between area-specific demographic characteristics and health care outputs. For 
example, knowing that the prevalence of obesity, a risk factor for surgical infection, varies 
across locations cannot automatically inform the adjustment of hospital outputs without 
investigating the impact of such differences on health care utilization patterns. Detailed 
information on each centre’s case-mix, such as that provided by the Hospital Episode 
Statistics data (432), would address this knowledge gap. The time constraints did not allow 
for such data to be available for this research, but future research may well incorporate it. The 
proposed framework is sufficiently flexible to accommodate such developments. 
The simulation method sampled centres with replacement from ROSSINI centres and 
included all patients recruited at a given centre. This is equivalent to assuming that all 
relevant patients in a centre participated in the RCT. Such an extreme assumption is a 
limitation. It would be interesting to incorporate random patient selection at centre level in 
future developments of the method. 
The ROSSINI trial was used as a case study to demonstrate the application of the Gix. 
However, as pointed out in Chapter 5, evidence suggested that it was very unlikely that the 
intervention under scrutiny (WEPD strategy) was effective or cost-effective; moreover, the 
uncertainty around the trial findings was substantial. As such, the simulation method 
propagated this uncertainty and it is possible that simulation results reflect more the 
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propagated noise than true signal. For this reason, replicating the Gix methodology for other 
trials and in other clinical areas is a necessary future step. 
 
Implication of findings 
These results demonstrated that the sample of RCT centres can affect the accuracy and 
precision of trial results relative to jurisdiction-wide ‘true’ values. The main implication is 
that just because a trial was conducted in a given jurisdiction, this does not necessarily make 
its results representative of that jurisdiction. This result can be of interest to policy makers, 
research commissioners and researchers. 
Two types of practical applications of the Gix concept can be thought of. First, as the 
trial-Gix is calculated using the centre-Gix, these results suggest that there may be a potential 
for the centre-Gix to inform the design of trials. This would involve selecting centres 
rationally and adjusting local recruitment rates appropriately such that the resulting trial-Gix 
has as close a value as possible to the jurisdiction-wide Gix, thereby producing more 
generalisable results.  
Furthermore, a retrospective application of the Gix can also be envisaged. One of the 
current knowledge gaps is that extrapolations of cost-effectiveness results are difficult in 
locations which did not participate in the original trial because it is difficult to specify what 
'similar centres/locations' actually mean. The centre-Gix could fill this gap by providing a 
rational and quantitative measure of similarity between centres.  
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Further research 
This research produced a promising result, but also has several limitations which 
should be the object of future research. First, a systematic approach is needed to identify 
centre-level dimensions and to propose a framework, together with a set of transparent 
criteria, for quantifying the strength of the evidence for each dimension included in the index. 
This would also allow a rational, evidence-based weighting system for the Gix dimensions.  
Second, further approaches to the Gix construct should be explored. In particular, it 
would be of great interest to expand the approach beyond binomial variables in order to avoid 
dichotomisation and preserve more information. Categorising raw values was the 
methodological choice to combine categorical and continuous variables. The conceptual 
development of the Gix should investigate and propose alternative ways of summarising 
centre-level information. Furthermore, the definition of ‘commonness’ appears to be equally 
as important. 
Third, the scope of this demonstration was limited to a single case study RCT. The 
behaviour of the Gix in other settings must be further explored before making a judgement on 
its usefulness and potential for incorporation in study design. Two related directions are 
apparent: first, it would be of great interest to replicate this analysis using the same Gix across 
a range of surgical RCTs, just as ROSSINI, and establish whether findings are robust in 
suggesting between-centre variation in cost-effectiveness. Second, extending the approach to 
other health care settings and types of interventions with adapted generalisability indices 
would provide information on the extent of generalisability bias across clinical research areas.   
Finally, generalisability has often been discussed in the economic evaluation literature 
in the context of international trials due to the purported significant differences across 
countries in terms of health system characteristics, macroeconomics environment, 
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demography and other factors. The approach presented here looked at a within-country study 
and the results suggested that there is scope for bias due to centre selection for this type of 
studies, relative to jurisdiction-wide estimates. It will be worth extending the proposed 
framework to multinational studies, potentially by introducing a further level of the Gix: 
centre-Gix, country-Gix and multi-country-Gix (e.g. Europe).  
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8.6. Conclusion 
The generalisability index (Gix), a measure of centre- and trial-representativeness, has 
been proposed. Using a real-world RCT (the ROSSINI trial) as a case study, the simulation 
results indicated a relationship between the trial-Gix and the clinical and incremental HRQoL 
benefits of the intervention, thereby suggesting that recruiting from an unrepresentative 
sample of centres can bias trial results compared to the jurisdiction-wide point estimates. 
Furthermore, trials whose recruitment closely mirrored that of the jurisdiction produced the 
most accurate estimates. 
The findings were generally robust to alternative scenarios concerning different 
approaches to the content and construct of the Gix. From a methodological standpoint, further 
research should focus on devising a systematic way to including centre-level variables in the 
Gix and exploring potential construct approaches to the Gix, especially by avoiding 
dichotomisation and defining centre ‘commonness’. Furthermore, the results must be 
replicated in other trials, clinical areas and health care settings before making a judgement on 
the usefulness of the Gix. 
These preliminary findings suggest that trial results can be biased compared to 
jurisdiction ‘true values’ due to unrepresentative centre selection. The Gix appears to be a 
useful tool for identifying and quantifying this bias. The Gix has the potential to develop as an 
instrument to assist trialists in improving their sampling for generalisability purposes and to 
inform decision makers on the generalisability of a given trial’s findings. 
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 This Chapter summarises and integrates the findings presented throughout the thesis. 
The main objective of this work, as detailed previously in section 1.4, was to evaluate the 
implications of the current practice of centre selection to RCTs in the UK for the 
generalisability of trial results. A real-world example (the use of WEPDs vs. standard care to 
reduce SSI after open abdominal surgery) was used as a case study to support the 
methodological investigation. First, the existing evidence on WEPDs was synthesised 
(Chapter 3) and new clinical and cost-effectiveness evidence was generated (Chapter 4 and 
Chapter 5). Second, an empirical investigation of the impact of centre selection on trial results 
was conducted (Chapter 7), followed by a demonstration of the proposed methodology using 
the ROSSINI trial of WEPDs vs. standard care in the NHS as an example (Chapter 8). 
 
9.1. Summary of principal findings 
9.1.1. The benefits of WEPDs compared to standard care in reducing SSI 
 The clinical question at the heart of this thesis concerned the benefit of WEPDs in 
reducing SSI compared to standard care. WEPDs have been used informally to reduce SSI for 
more than 40 years, but the evidence around them had never been summarised. A systematic 
approach to produce evidence for decision-making was employed. First, a systematic review 
of existing studies (Chapter 3) and a preliminary cost-effectiveness decision model (Chapter 
4) were conducted, followed by a primary data collection exercise to provide definitive 
evidence (Chapter 5). 
 The systematic review and meta-analysis presented in Chapter 3 suggested that 
WEPDs were likely to be effective compared to standard care, but it was noted that the quality 
of the 12 included RCTs was generally poor. The results of the cost-effectiveness decision 
model presented in Chapter 4, which was informed by the clinical effectiveness systematic 
review, indicated that WEPDs were also likely to be cost-effective compared to standard care 
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in the UK setting. As such, conducting a large, high quality RCT was warranted to address the 
methodological shortcomings of previous studies and produce robust evidence on the 
effectiveness and cost-effectiveness of WEPDs in the UK. 
 The ROSSINI trial (Chapter 5) was a multi-centre RCT which demonstrated no 
benefit associated with the use of WEPDs in reducing SSI after open abdominal surgery (OR 
0.97, 95%CI 0.69 to 1.36). The economic evaluation alongside ROSSINI was conducted from 
the perspective of the NHS and employed a 30-day post-operatively time horizon. The base-
case analysis used multiple imputation to account for missing cost and HRQoL data. In 
addition, complete case and adjusted analyses were performed. The results of the base-case 
analysis suggested that the WEPD option had only an approximately 20% probability of being 
cost-effective at a WTP threshold of £20,000 to £30,000/QALY (39), thus standard care was 
the cost-effective alternative. The result was robust to the sensitivity analyses. As such, the 
ROSSINI trial showed no evidence of clinical or economic benefit associated with the use of 
WEPDs compared to standard care. 
  
9.1.2. Empirical evidence on centre selection for RCTs in the UK 
External validity was one of the main aims of ROSSINI: the inclusion criteria were 
deliberately broad; the standard care protocol was left at the discretion of the local operating 
teams; and the trial recruited from 21 centres across England, both university and general 
hospitals. However, an argument was made (section 1.3) that centre selection may influence 
the generalisability of trial findings and thus warranted further research. A significant gap in 
the current literature was that the characteristics of the sample of participating centres had not 
been formally incorporated in current analytical techniques and the assumption that centres 
were randomly selected from a jurisdiction was not supported by any evidence.  The mixed 
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methods study (Chapter 7) revealed that centre selection for RCTs in the UK is primarily 
determined by pragmatic considerations such as proximity of the centre to the trial office, 
having a positive recruitment history, complying with regulatory requirements and the ability 
to maintain good communication. The systematic review of NIHR trial protocols (section 7.2) 
demonstrated that reporting the reasons which guided the choice of participating centres is 
currently suboptimal and could be largely improved.  
Having a representative sample of centres at jurisdiction-level with a view to ensure 
the generalisability of trial results appears to be among the considerations which are factored 
in the centre selection decision. However, only 30% of the protocols included in the review 
mentioned it and considerations relating to particular trial participation criteria (e.g. regulatory 
requirements, staff training and research experience) were more often specified. Centre 
selection does not appear to be a random process, either: of the 129 RCT protocols included in 
the systematic review, only two used random sampling to select participating centres.  
The focus groups (section 7.3) and the online survey of trialists (section 7.4) identified 
a tension between the current and ideal practice of centre selection (discussed in section 7.5). 
While current practice seems to be driven by pragmatism in meeting recruitment targets, 
complying with funders’ and sponsors’ requirements and running the trial within the 
designated budget, in ideal practice considerations such as generalisability, patient 
convenience and a collaborative approach to decision making within trials (e.g. a broader role 
for the TMG as opposed to the Chief Investigator) should be emphasised. Trialists appear to 
acknowledge the importance of generalisability and of enrolling from such a sample of 
centres so that the generalisability of trial findings is ensured, but other concerns currently 
take precedence. 
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In light of the above, there are reasons to believe that the majority of RCTs in the UK 
do not explicitly aim to enrol a representative sample of centres. This may introduce bias in 
trial results relative to the jurisdiction-wide ‘true values’; in other words, it is possible that 
trials recruit from samples of centres which are not representative of the jurisdiction and 
produce results which cannot be generalised to the entire jurisdiction.  
 
9.1.3. The influence of centre selection on trial results  
The Generalisability index (Gix) was proposed as a measure of representativeness of a 
given centre and of a given trial relative to the population of centres in a given jurisdiction. 
The Gix incorporates a number of centre-level characteristics such as size/capacity, teaching 
status and market environment and quantifies the extent to which a centre or a sample of 
centre is ‘common’ or extreme relative to the distribution of these characteristics at 
jurisdiction-level. Using simulation methods and the ROSSINI trial as a hypothetical 
jurisdiction where the ‘true values’ of clinical and cost-effectiveness were known, 5,000 
RCTs were simulated. The relationship between the standardised trial-Gix and trial results 
was investigated in order to ascertain whether the sample of participating centres affects 
clinical and economic trial outcomes (section 8.4).  
The principal finding was that the characteristics of the sample of participating centres 
influence trial results (section 8.5). Simulated trials which produced results closest to the ‘true 
values’ were those whose trial-Gix was the closest to the summary measure of the 
jurisdiction-wide distribution of centre characteristics i.e. trials whose participating centres 
were a close reflection of the population of centres in the jurisdiction. Conversely, simulated 
trials with a more extreme trial-Gix compared to the jurisdiction-wide summary measure 
either underestimated or overestimated the results. Clinical effectiveness and HRQoL 
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improvements, measured in incremental QALYs, were most sensitive to variation in relation 
to the Gix. The effect was much less clear for incremental costs and the probability of cost-
effectiveness at £20,000/QALY. The explanation is yet unclear, but it may be related to the 
costing methodology in ROSSINI, which used nationally averaged unit costs for the NHS. 
The findings were robust to a number of sensitivity analyses which varied both the 
content (centre-level characteristics) and construct (approach to summarising and aggregating 
centre-level information) of the Gix. The alternative formulations of the Gix displayed 
different discriminatory powers across the clinical and economic outcomes and, thus, 
highlighted the impact of the definition of ‘commonness’ on the simulation results. 
 
9.2. Interpretation and implications of findings  
Chapter 6 integrated the findings of the ROSSINI trial, the previously reported RCTs 
and the preliminary cost-effectiveness decision model. The systematic review and the 
decision model had suggested that WEPDs may be effective and cost-effective, respectively, 
while ROSSINI results indicated the opposite. However, ROSSINI had superior 
methodological quality, was more generalisable than previous RCTs and is, thus, likely to 
have generated more robust results. In light of these considerations, it is likely that WEPDs 
are neither effective nor cost-effective compared to standard care in reducing SSI and cannot 
be recommended for routine use in the NHS. 
The findings of the generalisability research (Chapters 7 and 8) suggested that it is 
inappropriate to assume that a given RCT’s results can be generalised to the jurisdiction 
where it recruited from without a careful assessment of the characteristics of the participating 
sample of centres. As such, the importance of recruiting patients from RCTs from a 
representative sample of centres jurisdiction-wise becomes obvious. This finding must be 
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interpreted with caution in that the Gix methodology does not aim to assess the internal 
validity of RCTs and is not designed to assess the accuracy of trial estimates. If the risk of 
bias is minimised (sub-section 1.3.1), it is likely that trial estimates are correct for the sample 
of centres which contributed data, but may not be generalised to the entire jurisdiction. As 
such, just because a RCT recruited in country A and suggested that a given intervention may 
be clinically or cost-effective, it cannot be straightforwardly assumed that the given 
intervention is effective in country A. In order to make such an assessment, information on 
how the sample of participating centres reflect the jurisdiction as a whole is needed. In 
perspective, the assumption of exchangeability, crucial to the application of current cost-
effectiveness refinement methods (155), does not seem to hold as different samples of centres 
systematically appear to produce markedly different results. Consequently, there may be some 
merit in revisiting the currently recommended hierarchical trial analysis methods for cost-
effectiveness (134) in light of this finding. 
 The focus of the research has initially been on trial-based economic evaluations and 
the Gix was designed toward this end (section 1.4). However, the most striking results were 
observed for clinical effectiveness (section 8.5). It must be, thus, acknowledged that any 
proposed index will capture the influence of centre selection on both types of trial outcomes.  
The proposed Gix is not only a tool that can demonstrate the influence of the sample 
of centres on trial results, but also has the potential to address it. As suggested in section 8.2, 
two types of practical applications can be envisaged. The first is retrospective and refers to the 
analysis of trial data: the Gix could be used, on the one hand, to assess the relevance of a 
given RCT to the jurisdiction where it recruited from, and, on the other hand, to predict the 
clinical and cost-effectiveness of an intervention in locations which did not contribute patients 
in the RCT. The ultimate result would be to obtain a jurisdiction-wide estimate of clinical and 
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cost-effectiveness. Conceptually, this process implies measuring the overlap between the 
research space and the policy space and then characterising the policy space based on 
information contained in the research space (section 8.2). The Gix could act, thus, as a link 
between the two domains. Such an application would be of interest from a policy perspective, 
where decision makers are often faced with making jurisdiction-wide judgements based on 
evidence collected from a limited number of settings.  
The second practical application of the Gix is prospective and refers to trial design. As 
the Gix can characterise both a centre and a sample of centres in relation to the population of 
centres in the jurisdiction, it can be used as a tool in RCT design so as to purposively select 
the centres and corresponding recruitment rates which are likely to maximise the 
generalisability of trial findings. Furthermore, there is scope for dynamically monitoring 
throughout the trial how differential recruitment across participating centres affects 
generalisability. However, it must be noted that a pre-requisite for such an application is the 
validation of a given Gix for the therapeutic area where it is used (e.g. complications after 
general surgery, cardiovascular disease prevention etc.) to ensure that the Gix has sufficient 
predictive value of the trial’s deviation from jurisdiction-wide ‘true values’. Such a 
development would of interest to trialists and policy makers as it would allow them to plan 
the need for future RCTs so that their results will be as relevant as possible to the policy 
context. The approach would compel decision makers to think in advance of the locations 
where they are interested in applying the economic results of a clinical trial and also of how 
health services could be re-shaped in particular regions so that an intervention becomes 
locally cost-effective. 
It is important to note that the proposed Gix has not been imagined as a universal 
metric. As such, it cannot be applied in its current form across all therapeutic areas and all 
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settings. It was rather designed to be flexible enough so as to be adapted to particular research 
requirements in terms of its content (i.e. the dimensions it includes). Although demonstrated 
here in the context of SSI after abdominal surgery, its applications to other settings such as 
primary care may be very different (section 8.5), but the principles of the proposed method 
still apply. 
Finally, demonstrating that the sample of centres may indeed impact the 
generalisability of trial findings could also improve the reporting of considerations for centre 
selection both in trial protocols and trial publications. This would allow the readership to 
make an informed judgement on the extent to which trial findings are indeed representative of 
their jurisdiction. 
 
9.3. Strengths and limitations 
The thesis took a systematic approach to synthesise and produce high-quality evidence 
towards the clinical and economic benefit of WEPDs in reducing SSI after open abdominal 
surgery. There were no previous systematic reviews of WEPD clinical effectiveness and no 
economic evaluations of WEPDs against any comparator. As such, the systematic review of 
clinical effectiveness (Chapter 3), the SSI decision model (Chapter 4) and ROSSINI economic 
evaluation (Chapter 5) were all novel. Furthermore, the SSI utility systematic review (section 
4.1) synthesised for the first time health utility data in relation to SSIs, while ROSSINI 
generated the first EQ-5D estimates for SSI patients (Chapter 5). 
The methodological result of the thesis i.e. the characteristics of the sample of 
recruiting centres influences trial results, has strong intuitive appeal. Furthermore, this 
research moves forward the current understanding of the topic under a number of aspects. 
First, it highlights the importance of having an operational definition of representativeness. As 
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pointed out in the literature review on generalisability of economic evaluations (sub-section 
1.3.2), the absence of such a definition has made transferability efforts across locations 
difficult as the degree of similarity between locations could not be established (155). The Gix 
was devised as such a measure and, thus, addresses the gap by proposing a set of measurable 
centre-level characteristics which can be aggregated into a single metric. Second, it underlines 
the importance of having a quantitative measure of representativeness. The systematic review 
of HTA trial protocols (section 7.2) revealed that there is some interest in generalisability and 
diversity as far as participating centres are concerned, but this interest was not substantiated 
by demonstrating the appropriateness of the participating sample (for example, by comparing 
the proportion of rural hospitals enrolled in the study compared to the jurisdiction-wide 
distribution of rural hospitals). The construct of the Gix allows such a comparison to be made 
and can inform an assessment of representativeness relative to the jurisdiction of interest. 
Third, the Gix methodology broadens the scope of ‘similarity’ beyond centre-to-centre 
comparisons and highlights the importance of comparing the characteristics of the sample of 
participating centres in the RCT to the jurisdiction of interest. As such, the focus of the 
generic research question in generalisability shifts from obtaining locally adjusted cost-
effectiveness estimates to assessing the extent to which trial-wide results can be extrapolated 
to the jurisdiction level. Fourth, the proposed Gix demonstrated that trial results can vary in 
relation to centre-level characteristics. This is an advance in the current literature, which has 
been focusing on patient-level characteristics. Fifth, the approach can address both clinical 
and economic trial outcomes and can, thus, be extended to the generalisability of clinical 
effectiveness estimates. Finally, the case study demonstrated that within-country variations of 
trial clinical and cost-effectiveness results due to the sample of recruiting locations. This is 
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significant as the majority of the contributions in the literature to date have focused on cross-
country comparisons (section 7.2). 
 The research had several limitations. First, the limitations of the ROSSINI economic 
evaluation were discussed in detail in sub-section 5.2.3 and concerned the appropriateness of 
the 30-day time horizon, the amount of missing data and not capturing several resource use 
items such as wound dressings. Nevertheless, it was argued that it is unlikely that these 
limitations affected the final recommendation. Due consideration to collecting such 
information should be made in future SSI management studies.  
 Second, the mixed method study had a number of shortcomings, which were discussed 
in detail in sub-sections 7.2.4, 7.3.4 and 7.4.4. Of note, the systematic review only focused on 
publicly funded trials; the focus groups were conducted with trialists at a single institution; 
and the relatively small sample size of the online survey did not allow any inferential statistics 
to be computed. Nevertheless, the findings of the three methods were highly compatible both 
with one another and with previous literature findings (in relation to reporting of 
generalisability items), therefore it is unlikely that the emerging data lacked validity or 
relevance.  
Third, the limitations in the development of the Gix and the simulation study were 
acknowledged in section 8.4. In particular, the choice of the centre-level variables 
(dimensions) included in the Gix and the methods of aggregating the dimensions in a single 
index can be a subject of debate. Nevertheless, the sensitivity analyses tested a wide range of 
scenarios concerning these choices and the results were generally robust to variations in the 
formulation of the Gix.  
Of note, this research adopted a case study approach to demonstrate the usefulness of 
the Gix. As discussed in section 8.4, an alternative approach would have been to specify the 
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characteristics of a hypothetical jurisdiction and the design of a hypothetical trial, then 
conduct the simulations (428). This would have allowed a fine control of study parameters at 
the expense of allowing more programming time and making supplementary assumptions. 
However, the two approaches are complementary and identifying bias due to centre selection 
in a completely hypothetical design would require validation using a real-world case study. In 
this case, an effect was identified using a real-world trial and the robustness of the finding 
deserves further exploration using a more complex simulation design. 
Finally, in this research the methodological choice was to aggregate the relevant 
centre-level characteristics in a single generalisability metric (Gix). Such an approach has 
merits in that it allows head-to-head comparisons between centres and opens the way towards 
more informative study designs and trial analyses, as discussed above. However, it can be 
equally argued that the approach is reductionist because it attempts to capture centre-level 
variation, an obviously broad concept, into a single number. This sort of trade-off is common 
when attempting to measure complex processes. A relevant example at a larger scale is the 
controversy stirred by the publication of the World Health Report 2000 (433), which ranked 
national health systems according to their efficiency. The ethical, methodological and 
statistical underpinnings of the analysis came under close scrutiny and criticism (434). 
Among the lessons learned from the experience, of particular importance was the difficulty of 
capturing and representing all contextual factors relevant for health system performance in a 
composite measure that was, in addition, difficult to explain to the relevant public (435). As a 
matter of course, there is no substitute for judgement when reviewing and making policy 
decision based on contextual data. This challenge applies to the issue of assessing 
generalisability, as well. An alternative approach to the Gix would be presenting centre-level 
data in disaggregated form and allowing researchers and policy makers to make their own 
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decision regarding the relative importance of centre-level domains to describe ‘common’ 
centres and outliers. Such a course of action deserves future scrutiny. Nevertheless, proposing 
the Generalisability index, however imperfect a measure, may prove to be beneficial if only 
by bringing the issue of generalisability at the forefront of academic research just as the 
World Health Report 2000 did for health systems performance evaluation (436) and, thus, 
catalyse advancements in this area.     
 
 
9.4. Research in context 
 SSI remains a major concern for surgical patients. The most recent evidence 
concerning the interventions which may reduce SSI was summarised by NICE in an evidence 
update report published in June 2013 (437), which does not replace or supersede the current 
UK clinical guidelines (243). The use of WEPDs was thereby cited as a promising avenue 
where further research is needed and mentions the ROSSINI trial, but the document was 
published just before ROSSINI results were published and, thus, does not incorporate them. 
Of the 19 types of SSI reducing interventions reviewed, the majority either showed no effect 
or required further research, and only one (the use of antimicrobial-coated sutures vs. 
uncoated sutures for wound closure) has the potential to impact the current SSI guidance.  
 However, even if the effect of the potential interventions was convincingly 
demonstrated, it remains yet unclear whether strict adherence to current clinical protocols is 
likely to reduce SSI. For example, the Surgical Care Improvement Program (SCIP) was 
introduced in 2005 in US hospitals as a three-phase pay-for-performance mechanism for 
surgeons with the aim of reducing morbidity and mortality after surgery (438). However, 
Hawn et al. (439) analysed the relationship between the adherence to SCIP in 112 Veterans’ 
Affairs hospitals in the US (2005 to 2009) and SSI occurrence; they found that while 
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adherence to SCIP improved gradually over time, risk-adjusted SSI rates remained constant 
and there was no association between SCIP adherence and either patient-level or hospital-
level SSI rates, which suggests the need for a reassessment of current SSI-reduction policies.  
 Several directions for development have been proposed. First, it has been suggested 
that instead of a ‘one size fits all’ type of SSI prevention protocol (which both NICE and 
CDC currently adopt), an approach tailored to the characteristics of the relevant patient 
population may be more suitable, for example by recognising the role of body mass index as a 
risk factor (440). In addition, a strict adherence to the protocol may not be the only 
alternative: it has been demonstrated that adherence to individual SCIP measures is not 
associated with better SSI outcomes, but adherence to all SCIP measures (potentially a 
surrogate for superior coordination and team work) was (441). Such an interpretation is 
supported by the finding that a more empowering, collaborative interaction between the 
relevant healthcare professionals was effective in reducing SSI rates in colorectal patients 
(442). Second, the understanding of SSI pathophysiology may also require substantial 
updating: Lawson et al. (443) analysed 27,000 US patients and found that the risk factors for 
superficial and deep/organ-space SSIs differed in magnitude and significance. As such, the 
authors suggested that the two SSI categories could be viewed as two distinct disease 
processes, which may be instrumental for future research initiatives and practice guidelines. 
This is in line with the considerations discussed previously in sub-section 2.1.1, which 
highlighted the need for refining SSI definitions in the future. 
 In summary, the progress in SSI prevention has been slow to date and WEPDs do not 
appear to bring a favourable contribution. More importantly, however, the approach to SSI 
prevention is facing important challenges, as outlined above, and needs to incorporate recent 
research findings to produce cross-sectoral, personalised guidance to reduce SSI.  
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 Such an approach echoes the wider interest towards acknowledging context-specific 
factors in order to ensure the generalisability of RCT findings. As it has been presented 
previously (sub-section 1.3.1), patient characteristics have captured most of the attention in 
this research area. The illustration of the Generalisability index (Gix) approach (Chapter 8) 
using a surgical RCT highlighted the fact that centre characteristics may play a major role in 
determining trial results and, thus, affecting their generalisability. I have no knowledge of 
other initiatives to quantify the representativeness of trial centres for generalisability 
purposes. There have been attempts, however, to isolate systematically contextual factors 
which may influence the findings of surgical trials. For example, Pibouleau et al. (444) 
surveyed 87 surgeons to prioritise hospital-specific factors which could influence the 
applicability of trial results of four orthopaedic procedures; the selected determinants were: 
the number of participating centres, the centres’ surgical volume, the number of participating 
surgeons and the experience/training of surgeons. This is in accordance with the Gix 
formulation presented in Chapter 8, which incorporated measures of capacity and 
specialisation. However, the index did not consider practitioner-level information (e.g. 
surgeon-level characteristics). Such a development would add a further layer of complexity 
and may be the subject of further investigation. 
 As discussed in section 1.3, RCTs have several strong limitations with respect to 
generalisability. As far as economic evaluation results are concerned, updating pre-trial 
modelling results with trial data (69), potentially in a Bayesian framework (445), has been 
advocated as the appropriate approach. Under this paradigm, RCT findings can be viewed as 
merely an input in model-based economic evaluations. As such, other sources of information 
can also be integrated in the updated model to support the generalisability of findings. For 
instance, Freemantle and Hessel (446) argued that data from observational studies (e.g. 
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observational databases) may provide valuable information on current practice, especially on 
the characteristics of target population and local clinical processes, and can thus complement 
RCT results as inputs for economic models. 
 Incorporating contextual characteristics in the design and analysis of RCTs must 
become a priority for clinical research. However, such characteristics should not be merely 
acknowledged by way of reporting in trial protocols (15) and publications (27). As Bonell et 
al. (79) pointed out, researchers must also integrate process evaluations alongside RCTs and 
generate evidence-based theories on how contextual effects influence the intervention 
processes and how results may differ in other locations in order to enhance the 
generalisability of RCTs. Research funders, decision makers and journal editors can catalyse 
these advances by requiring and supporting increasingly complex and rigorous incorporation 
of generalisability issues in clinical research. 
  
9.5. Future research 
The research findings of this work and their limitations open several research 
directions. First, in terms of SSI reduction, Chapter 3 and Chapter 5 suggested that a head-to-
head comparison between the existing WEPD designs would clarify whether a mechanical 
barrier between the wound margins and the exterior is indeed a valid SSI prevention strategy. 
However, in the light of current results, the commercial interests of the manufacturers would 
probably not be aligned with such a comparison Chapter 4 highlighted the paucity of available 
SSI health utility data and ROSSINI was only the first study to generate such evidence; future 
studies conducted in alternative settings must address this information gap. Furthermore, the 
discussion in Chapter 5 raised the need for more in-depth SSI management research to 
account for the complexities in patient care pathways beyond the 30-day time horizon. 
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 Despite their apparent ineffectiveness, several important questions remain remained 
unanswered with regard to WEPDs, as well. For instance, WEPDs may still have a protective 
effect, but the pathogens responsible for SSI could be introduced to the wound when the 
device is not in place – either when opening the wound before the device is placed, or 
especially when closing the wound after the device has been removed, when gloves and 
instruments will clearly be dirtier. Evaluating WEPDs in conjunction with a changing gloves 
protocol before wound closure may thus be worth considering. It will also be interesting to 
compare ROSSINI findings with those of the upcoming BaFO trial (305), which has a similar 
pragmatic design. 
Second, there is a need for better understanding the centre selection process. The 
mixed methods study (Chapter 7) could only provide a descriptive account for the purpose of 
the thesis, but it appears that more needs be known about how centre selection takes place in 
practice, what are the implications of overcrowding research in ‘preferred’ locations at the 
expense of neglecting others and how to ensure that all centres where an intervention is likely 
to be implemented have equal opportunities and capabilities to participate in research. 
Furthermore, the development of a theoretical framework for centre selection would guide 
researchers, practitioners and policy makers.  
Third, the Gix requires further validation and refinement according to the priorities 
specified in section 8.4. It must be established whether the findings of this study can be 
replicated in other research areas and in other settings before considering a formal inclusion 
of the Gix approach alongside the available methodological tools addressing generalisability 
of trial results and, in particular, of trial-based economic evaluations.  
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9.6. Conclusion 
 The findings of this research suggest that WEPDs cannot be considered effective or 
cost-effective in reducing SSI after open abdominal surgery, therefore their use in the NHS 
cannot be recommended. More research on the impact of SSI on patient HRQoL and the cost 
of long-term care for SSI patients is warranted. This clinical context was used a case study to 
support a methodological investigation of the importance of centre selection for the 
generalisability of trial results. It was demonstrated that the characteristics of the sample of 
participating centres can influence trial results and can affect the generalisability of clinical 
and economic findings to the jurisdiction where the trial recruited from. Such a result may be 
of interest to researchers, health policy makers, funders and research commissioners. The 
Generalisability index could be a valuable tool in quantifying this type of bias and in 
designing RCTs with superior external validity. The robustness of the findings across 
therapeutic areas, clinical settings, geographic locations and formulations of the Gix is a 
fertile subject for further research. 
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Appendix 2. Search strategy for the systematic review of WEPD clinical effectiveness  
 
 Ovid SP Medline  
1 wound protect*.mp. 
2 wound-protect*.mp. 
3 wound guard.mp. 
4 wound-guard.mp. 
5 wound edge protect*.mp. 
6 wound-edge protect*.mp. 
7 impervious wound drape.mp. 
8 impervious wound protect*.mp. 
9 ring drape.mp. 
10 drape protect*.mp. 
11 barrier protect*.mp. 
12 ViDrape.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
13 Vi Drape.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
14 Steri Drape.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
15 SteriDrape.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
16 Alexis.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
or 16 
18 exp Surgical Wound Infection/ 
19 surgical infection*.mp. 
20 exp Wound Infection/ 
21 exp Postoperative Complications/ 
22 exp Bacterial Infections/ 
23 surgical site infection*.mp. 
24 wound complication*.mp. 
25 postoperative infection*.mp. 
26 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 
27 17 and 26 
 
 Ovid EMBASE Classic + Embase  
1 wound protect*.mp. 
2 wound-protect*.mp. 
3 wound guard.mp. 
4 wound-guard.mp. 
5 wound edge protect*.mp. 
6 wound-edge protect*.mp. 
7 impervious wound drape.mp. 
8 impervious wound protect*.mp. 
9 ring drape.mp. 
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10 drape protect*.mp. 
11 barrier protect*.mp. 
12 ViDrape.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
13 Vi Drape.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
14 Steri Drape.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
15 SteriDrape.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
16 Alexis.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
or 16 
18 exp surgical infection/ 
19 surgical wound infection*.mp. 
20 exp wound infection/ 
21 exp postoperative complication/ 
22 exp bacterial infection/ 
23 surgical site infection*.mp. 
24 exp wound complication/ 
25 exp postoperative infection 
26 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 
27 17 and 26 
 
EBSCO CINAHL Plus  
1 TX wound protect* 
2 TX wound-protect* 
3 TX wound guard 
4 TX wound-guard 
5 TX wound edge protect* 
6 TX wound-edge protect* 
7 TX impervious wound drape 
8 TX impervious wound protect* 
9 TX ring drape 
10 TX drape protect* 
11 TX barrier protect* 
12 TX ViDrape 
13 TX Vi Drape 
14 TX Steri Drape 
15 TX SteriDrape 
16 TX Alexis 
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
or 16 
18 TX surgical wound infection* 
19 TX surgical infection* 
20 TX wound infection* 
21 TX wound complication* 
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22 TX postoperative complication* 
23 TX bacterial infection* 
24 TX surgical site infection* 
25 TX postoperative infection* 
26 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 
27 17 and 26 
 
ISI Web of Knowledge – Science Citation Index Expanded, Conference Proceedings 
Citation Index- Science and Conference Proceedings Citation Index- Social Science & 
Humanities  
All Terms were searched as ‘Topic’. 
1 wound protect* 
2 wound-protect* 
3 wound guard 
4 wound-guard 
5 wound edge protect 
6 wound-edge protect* 
7 impervious wound drape 
8 impervious wound protect* 
9 ring drape 
10 drape protect* 
11 barrier protect* 
12 ViDrape 
13 Vi Drape 
14 Steri Drape 
15 SteriDrape 
16 Alexis 
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
or 16 
18 surgical wound infection* 
19 surgical site infection* 
20 surgical infection* 
21 wound infection* 
22 bacterial infection* 
23 wound complication* 
24 postoperative complication* 
25 postoperative infection* 
26 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 
27 17 and 26 
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Cochrane Library (all databases) 
1 wound protect*:ti,ab,kw 
2 wound-protect*: ti,ab,kw 
3 wound guard: ti,ab,kw 
4 wound-guard: ti,ab,kw 
5 wound edge protect:ti,ab,kw 
6 wound-edge protect*:ti,ab,kw 
7 impervious wound drape:ti,ab,kw 
8 impervious wound protect*:ti,ab,kw 
9 ring drape:ti,ab,kw 
10 drape protect*:ti,ab,kw 
11 barrier protect*: ti,ab,kw 
12 ViDrape: ti,ab,kw 
13 Vi Drape: ti,ab,kw 
14 Steri Drape: ti,ab,kw 
15 SteriDrape: ti,ab,kw 
16 Alexis: ti,ab,kw 
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
or 16 
18 surgical wound infection*: ti,ab,kw 
19 surgical site infection*: ti,ab,kw 
20 surgical infection*: ti,ab,kw 
21 wound infection*: ti,ab,kw 
22 bacterial infection*: ti,ab,kw 
23 wound complication*: ti,ab,kw 
24 postoperative complication*: ti,ab,kw 
25 postoperative infection*: ti,ab,kw 
26 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 
27 17 and 26 
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Appendix 3. Search strategy for the systematic review of SSI utility values 
 
OVID MEDLINE and MEDLINE-In-Process 
1 exp Quality of Life/ 
2 Quality of life.tw. 
3 Life quality.tw. 
4 Hrql.tw. 
5 Hrqol.tw. 
6 Hql.tw. 
7 Qol.tw. 
8 Ql.tw. 
9 Sf$.tw. 
10 Short form.tw. 
11 Shortform.tw. 
12 Euroqol.tw. 
13 Eq 5d.tw. 
14 Eq5d.tw. 
15 Qaly$.tw. 
16 Quality adjusted life year$.tw. 
17 Hye.tw. 
18 Psychological general well being.tw. 
19 Pgwb$.tw. 
20 Health utilit$.tw. 
21 Hui$.tw. 
22 Quality of wellbeing.tw. 
23 Quality of well being.tw. 
24 Qwb$.tw. 
25 General health questionnaire$.tw. 
26 Ghq.tw. 
27 Nottingham health profile.tw. 
28 Nhp.tw. 
29 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 
28 
30 Exp Surgical Wound Infection/ 
31 Exp Wound Infection/ 
32 Surgical wound$.tw. 
33 Postoperative wound infection.tw. 
34 Surgical wound infection.tw. 
35 (wound infection adj8 surgery).tw. 
36 Wound infec$.tw. 
37 30 or 31 or 32 or 33 or 34 or 35 or 36 
38 29 and 37 
 
 402 
 
OVID EMBASE 
1 exp Quality of Life/ 
2 Quality of life.tw. 
3 Life quality.tw. 
4 Hrql.tw. 
5 Hrqol.tw. 
6 Hql.tw. 
7 Qol.tw. 
8 Ql.tw. 
9 Sf$.tw. 
10 Short form.tw. 
11 Shortform.tw. 
12 Euroqol.tw. 
13 Eq 5d.tw. 
14 Eq5d.tw. 
15 Qaly$.tw. 
16 Quality adjusted life year$.tw. 
17 Hye.tw. 
18 Psychological general well being.tw. 
19 Pgwb$.tw. 
20 Health utilit$.tw. 
21 Hui$.tw. 
22 Quality of wellbeing.tw. 
23 Quality of well being.tw. 
24 Qwb$.tw. 
25 General health questionnaire$.tw. 
26 Ghq.tw. 
27 Nottingham health profile.tw. 
28 Nhp.tw. 
29 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 
16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 
30 Exp Surgical Wound Infection/ 
31 Exp Wound Infection/ 
32 Exp Surgical wound/ 
33 Exp Surgical infection/ 
34 Surgical wound infection.tw. 
35 (wound infection adj8 surgery).tw. 
36 Wound infec$.tw. 
37 30 or 31 or 32 or 33 or 34 or 35 or 36 
38 29 and 37 
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ISI Web of Science 
1 TS=(euroqol or euro qol or eq5d or eq 5d or eq-5d)  
2 TS=(hui or hui1 or hui2 or hui3) 
3 TS=(sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six 
or shortform thirtysix or shortform thirty six or short form thirtysix or short form 
thirty six) 
4 TS=(sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six 
or short form six) 
5 TS=(sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or 
shortform twelve or short form twelve) 
6 TS=(sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or 
shortform sixteen or short form sixteen) 
7 TS=(sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or 
shortform twenty or short form twenty) 
8 TS=(quality of wellbeing or qwb) 
9 TS=(quality adjusted life or qaly$) 
10 TS=(eortc) 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12 TS=(cost effective* or cost-effective or cost-utility or cost utility or cost-benefit 
or cost benefit or economic evaluation*)  
13 11 or 12 
14 TS=(surgical site infection*)  
15 TS=(surgical infection*) 
16 TS=(wound infection*) 
17 TS=(surgical wound infection*) 
18 TS=(wound infection adj8 surgery) 
19 TS=(surgical wound*) 
20 12 or 13 or 14 or 15 or 16 or 17 
21 13 and 20 
 
NHS Economic Evaluation Database (NHS EED) 
1 Surgical site infect*  
2 Surgical wound infect* 
3 Surg* infect* 
4 Wound infect* 
5 SSI 
6 1 or 2 or 3 or 4 or 5 
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Appendix 4. Screened papers not included in the systematic review of SSI utility values 
 
Study ID Study type Reason for exclusion 
Cooper 2002 Decision model Contains no utility data. 
Davey 1992 Decision model  Contains no utility data. 
Edwards 2006 Decision model Not relevant for SSI: utility refers to 'severe infections in ICU' and has been approximated as the utility value 
for the 'unconscious' state. 
Elliott 2010 Decision model Duplicate of Cranny et al (2009) 
Falavigna 2011 Primary study SF-36 instrument used to elicit HRQoL for deep wound infection after spine surgery. Time of elicitation was 
long and unclear, median 22 months (range 6 to 108 months). 
Fedorka 2011 Primary study SF-12 instrument used to elicit HRQoL after above the knee amputation in patients with infected total knee 
arthroplasty. Did not have an appropriate control group (uninfected). 
Fisman 2001 Decision model Not relevant for SSI: utility values refer to functional prosthesis and resection arthroplasty.  
Ginandes 2003 Primary study SF-36 instrument used to elicit HRQoL in a trial investigating the effect of hypnosis on wound healing. No 
relevant comparison reported i.e. infected vs uninfected. 
Hertzman 1990 Decision model Contains no utility data. 
Immer 2005 Primary study SF-36 instrument used to elicit HRQoL in patients with deep sternal wound infection after cardiac surgery. No 
relevant comparison reported i.e. infected vs uninfected. 
Juricek 2010 Primary study SF-36 instrument used to elicit HRQoL in patients with complications following spinal surgery. Time of 
elicitations was 6, 12 and 24 months post-operatively and reporting is unclear.  
Klesius 2004 Primary study Nottingham Health Profile used to assess HRQoL in patients undergoing sternal resection to treat deep sternal 
infections following cardiac surgery. No relevant comparison reported i.e. infected vs uninfected. 
Klinger 2006 Primary study SF-36 instrument to evaluate HRQoL of patients with infected total knee arthroplasty. Time of elicitation mean 
4.5 years (range 2 to 11 years). No relevant comparison reported i.e. infected vs uninfected. 
Kobayashi 2011 Primary study SF-36 instrument used to elicit HRQoL in patients with deep sternal wound infection after cardiac surgery. 
Time of elicitation mean 47.3 months after discharge. 
Laudermilch 2010 Primary study SF-36 instrument used to elicit HRQoL in patients undergoing revision total knee arthroplasty. Time of 
elicitation mean 3.3 years (range 2 to 5.7 years). 
Leung 2011 Primary study SF-12 instrument used to elicit HRQoL in patients with infected total knee arthroplasty. No relevant 
comparison reported i.e. infected vs uninfected. 
Mbah 2012 Primary study SF-36 to assess HRQoL in patients after pancreatic surgery. No relevant comparison reported i.e. infected vs 
uninfected. 
Meek 2004 Primary study SF-12 to evaluate HRQoL in patients after revision knee arthroplasty. Unclear whether patient groups being 
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Study ID Study type Reason for exclusion 
compared were infected/uninfected at the time of HRQoL elicitation. 
Melling 2001 Primary study No HRQoL instrument was administered. 
Mok 2009 Primary study SF-36 instrument to evaluate HRQoL in patients after instrumented posterior spinal fusion. Time of elicitation 
minimum 2 years post-operatively. 
Naylor 2009 Primary study SF-36 instrument to evaluate HRQoL in patients after total hip arthroplasty vs total knee arthroplasty. No 
relevant comparison reported i.e. infected vs uninfected. 
Nguyen 2001 Primary study SF-36 instrument to evaluate HRQoL in patients after laparoscopic vs open gastric bypass. No relevant 
comparison reported i.e. infected vs uninfected. 
Nguyen 2007 Primary study VascuQol questionnaire used to assess HRQoL after infrainguinal bypass in patients with wound 
complications. Wound complication defined as a composite of: infection, hematoma, seroma or lymphatic leak, 
necrosis, dehiscence, and erythema. 
Pada 2011 Primary study EQ-5D instrument used to assess HRQoL after general surgery. Estimates are presented for soft skin/tissue 
infection, which includes surgical site infection, decubitus ulcer infection and other types of infections not 
accounted for. Not clear whether utility estimates refer to SSI patients. 
Petilon 2012 Primary study SF-36 instrument to evaluate HRQoL in patients after lumbar fusion complicated by deep wound infection. 
Time of elicitation 2 years post-operatively. 
Poelman 2010 Primary study SF-36 instrument to evaluate HRQoL in patients after incisional hernia. No relevant comparison reported i.e. 
infected vs uninfected. 
Robotham 2011 Decision model Not relevant for SSI and long time horizon: QALYs estimated using a study for the first five years after ICU 
discharge. 
Saeed 2001 Primary study EQ-5D instrument used to assess HRQoL after coronary artery bypass surgery. No relevant comparison 
reported i.e. infected vs uninfected. 
Slover 2006 Decision model Invoked disutility values do not refer to SSI patients. 
Slover 2011 Decision model Contains no utility data. 
Sonnenberg 1999 Decision model Does not refer to SSI. 
Teshima 2009 Primary study No HRQoL instrument applied. 
Uyl-de Groot 2004 Primary study SF-36 instrument to evaluate HRQoL in patients after radical vulvectomy and bilateral inguino-femoral 
lymphadenectomy. No relevant comparison reported i.e. infected vs uninfected. 
VandenBergh 1996 Decision model Contains no utility data. 
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Study ID Study type Reason for exclusion 
Wassenberg 2011 Decision model Contains no utility data. 
Whitehouse 2002 Primary study SF-36 instrument to evaluate HRQoL in patients after general surgery. Time of elicitation was 1 year post-
operatively. 
Wynne 2004 Primary study Patient comfort assessed for three wound dressings used in patients with sternal wound infections. No relevant 
comparison reported i.e. infected vs uninfected. 
Young 2006 Decision model Contains no utility data. 
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Appendix 5. CHEERS Statement for the WEPD vs. standard care decision model 
 
 
Section/item Item 
No Recommendation 
Reported 
on page No 
    
Title and abstract    
Title 1 Identify the study as an economic evaluation or use 
more specific terms such as “cost-effectiveness 
analysis”, and describe the interventions compared. 
n/a 
Abstract 2 Provide a structured summary of objectives, 
perspective, setting, methods (including study 
design and inputs), results (including base case and 
uncertainty analyses), and conclusions. 
n/a 
Introduction    
Background and 
objectives 
3 Provide an explicit statement of the broader context 
for the study. 
133 
Present the study question and its relevance for 
health policy or practice decisions. 
133 
Methods    
Target population 
and subgroups 
4 Describe characteristics of the base case population 
and subgroups analysed, including why they were 
chosen. 
133 
Setting and location 5 State relevant aspects of the system(s) in which the 
decision(s) need(s) to be made. 
133 
Study perspective 6 Describe the perspective of the study and relate this 
to the costs being evaluated. 
133 
Comparators 7 Describe the interventions or strategies being 
compared and state why they were chosen. 
133 
Time horizon 8 State the time horizon(s) over which costs and 
consequences are being evaluated and say why 
appropriate. 
134 
Discount rate 9 Report the choice of discount rate(s) used for costs 
and outcomes and say why appropriate 
134 
Choice of health 
outcomes 
10 Describe what outcomes were used as the 
measure(s) of benefit in the evaluation and their 
relevance for the type of  
analysis performed. 
135 
Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the 
design features of the single effectiveness study 
and why the single study was a sufficient source of 
clinical effectiveness data. 
n/a 
 11b Synthesis-based estimates: Describe fully the 
methods used for identification of included studies 
and synthesis of clinical effectiveness data. 
135 
Measurement and 
valuation of 
preference based 
outcomes 
12 If applicable, describe the population and methods 
used to elicit preferences for outcomes. 
n/a 
Estimating resources  
and costs 
13a Single study-based economic evaluation: Describe 
approaches used to estimate resource use associated 
with the alternative interventions. Describe primary 
n/a 
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Section/item Item 
No Recommendation 
Reported 
on page No 
or secondary research methods for valuing each 
resource item in terms of its unit cost.  
Describe any adjustments made to approximate to 
opportunity costs. 
 13b Model-based economic evaluation: Describe 
approaches and data sources used to estimate 
resource use associated with model health states. 
Describe primary or secondary research  
methods for valuing each resource item in terms of 
its unit cost. Describe any adjustments made to 
approximate to opportunity costs. 
135-136 
Currency, price date, 
and conversion 
14 Report the dates of the estimated resource 
quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of 
reported costs if necessary. Describe methods for  
converting costs into a common currency base and 
the exchange rate. 
135 
Choice of model 15 Describe and give reasons for the specific type of 
decision analytical model used. Providing a figure 
to show model structure is strongly recommended. 
137-138 
Assumptions 16 Describe all structural or other assumptions 
underpinning the decision-analytical model. 
137-139 
Analytical methods 17 Describe all analytical methods supporting the 
evaluation. This could include methods for dealing 
with skewed, missing, or censored data; 
extrapolation methods; methods for pooling  
data; approaches to validate or make adjustments 
(such as half cycle corrections) to a model; and 
methods for handling population heterogeneity and 
uncertainty. 
140-143 
Results    
Study parameters 18 Report the values, ranges, references, and, if used, 
probability distributions for all parameters. Report 
reasons or sources for distributions used to 
represent uncertainty where appropriate.  
Providing a table to show the input values is 
strongly recommended. 
144-146 
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the 
main categories of estimated costs and outcomes of 
interest, as well as mean differences between the 
comparator groups. If applicable, report 
incremental cost-effectiveness ratios 
147-148 
Characterising 
uncertainty 
20a Single study-based economic evaluation: Describe 
the effects of sampling uncertainty for the 
estimated incremental cost and incremental 
effectiveness parameters, together with the impact  
of methodological assumptions (such as discount 
rate, study perspective). 
n/a 
 20b Model-based economic evaluation: Describe the 147-154 
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Section/item Item 
No Recommendation 
Reported 
on page No 
effects on the results of uncertainty for all input 
parameters, and uncertainty related to the structure 
of the model and assumptions. 
Characterising 
heterogeneity 
21 If applicable, report differences in costs, outcomes, 
or cost-effectiveness that can be explained by 
variations between subgroups of patients with 
different baseline characteristics or other observed 
variability in effects that are not reducible by  
more information. 
148 
Discussion    
Study findings, 
limitations, 
generalisability, and 
current knowledge 
22 Summarise key study findings and describe how 
they support the conclusions reached. Discuss 
limitations and the generalisability of the findings 
and how the findings fit with current knowledge. 
154-166 
Other    
Source of funding 23 Describe how the study was funded and the role of 
the funder in the identification, design, conduct, 
and reporting of the analysis. Describe other non-
monetary sources of support. 
n/a 
Conflicts of interest 24 Describe any potential for conflict of interest of 
study contributors in accordance with journal 
policy. In the absence of a journal policy, we 
recommend authors comply with International 
Committee of Medical Journal Editors 
recommendations. 
n/a 
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Appendix 6. CHEERS Statement for the ROSSINI trial economic evaluation 
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Appendix 8. Case report forms used in the ROSSINI trial 
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ROSSINI – Reduction of Surgical Site Infection using a Novel Intervention 
CRF 2 – Operative Data (Version 3.0 dated 14th March 2011) 
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Appendix 9. Studies included in the systematic review of RCT protocols 
 
Study 
ID 
Surname of 
Chief 
Investigator 
HTA 
Reference 
Project title 
1 Gregory 03/46/09 Development and evaluation by a cluster randomised trial of a psychosocial intervention in children and teenagers 
experiencing diabetes: the DEPICTED study 
2 Cockayne 05/513/02 EVerT: cryotherapy versus salicylic acid for the treatment of verrucae - a randomised controlled trial 
3 Crawford 04/39/04 Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial 
(MATISSE) 
4 Rintoul 06/302/216 Clinical effectiveness and costeffectiveness of endobronchial and endoscopic ultrasound relative to surgical staging 
in potentially resectable lung cancer: results from the ASTER randomised controlled trial 
5 Banerjee 04/11/02 Study of the use of antidepressants for depression in dementia: the HTA -SADD trial - a multicentre, randomised, 
double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and 
mirtazapine 
7 Collinson 09/22/16 Randomised Assessment of Treatment using Panel Assay of Cardiac markers - Contemporary Biomarker Evaluation 
(RATPAC CBE) 
8 Woods 06/304/229 REMCARE: reminiscence groups for people with dementia and their family caregivers - effectiveness and cost-
effectiveness pragmatic multicentre randomised trial 
9 Lenney 05/503/04 Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-
controlled, parallel study of efficacy and safety 
10 N’Dow 05/46/01 Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-
term catheterisation: multicentre randomised controlled trial and economic evaluation of antimicrobial- and 
antisepticimpregnated urethral catheters (the CATHETER trial) 
11 Molassiotis 07/31/02 The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related 
acute and delayed nausea 
12 Gilbody 07/41/05 Smoking cessation for people with severe mental illness: a pilot study and definitive randomised evaluation of a 
bespoke service 
13 Gilbody 08/19/04 Collaborative care and active surveillance for screen-positive elders with sub-clinical depression: a pilot study and 
definitive and randomised evaluation - the CASPER trial 
14 Gilbert 08/58/02 A randomised trial to increase the uptake of smoking cessation services using personal targeted risk information and 
taster sessions 
15 Powell 05/503/10 MAGnesium NEbuliser Trial In Children (MAGNETIC) 
16 Underwood 06/02/01 Exercise for depression in care home residents: a randomised controlled trial with cost-effectiveness analysis 
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Study 
ID 
Surname of 
Chief 
Investigator 
HTA 
Reference 
Project title 
(OPERA) 
17 Little 05/10/01 PRImary care Streptococcal Management study (PRISM) 
18 Russell 04/35/08 Folate Augmentation of Treatment - Evaluation for Depression: randomised controlled trial (FolATED) 
19 Willner 08/53/34 A cluster randomised controlled trial of a manualised cognitive behavioural anger management intervention 
delivered by supervised lay therapists to people with intellectual disabilities 
20 Wiles 06/404/02 Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: 
a randomised controlled trial 
21 Nashef 07/01/34 A randomised controlled trial to investigate the clinical and cost effectiveness of adding an ablation device-based 
maze procedure as a routine adjunct to elective cardiac surgery for patients with pre-existing atrial fibrillation 
(AMAZE) 
22 Macrae 05/506/03 Control of Hyperglycaemia in Paediatric intensive care trial (the CHIP trial)  
23 Coulton 06/304/142 The effectiveness and cost-effectiveness of opportunistic screening and stepped care interventions for older 
hazardous alcohol users in primary care (AESOPS) 
24 Lamb 07/32/05 SARAH: Strengthening And stretching for people with Rheumatoid Arthritis of the Hands: The clinical and cost-
effectiveness of an exercise programme over and above usual care 
25 Lloyd Scott 06/303/84 Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with 
conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: the TACIT trial  
26 Stallard 06/37/04 A single blind randomised controlled trial to determine the effectiveness of group cognitive behaviour therapy 
(CBT) in the prevention of depression in high risk adolescents 
27 Dumville 07/60/26 VenUS IV (Venous leg Ulcer Study IV): A randomised controlled trial of compression hosiery versus compression 
bandaging in the treatment of venous leg ulcers 
28 Snooks 07/01/21 Care of older people who fall: evaluation of the clinical and cost effectiveness of new protocols for emergency 
ambulance personnel to assess and refer to appropriate community based care 
29 Goyder 07/25/02 A randomised controlled trial and cost-effectiveness evaluation of "booster" interventions to sustain increases in 
physical activity in middle-aged adults in deprived urban neighbourhoods 
30 Williams 06/78/03 COmparison of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: a Trial (CONSTRUCT) 
31 Goodacre 06/01/02 The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for 
acute severe asthma 
32 Allen 06/39/02 A multicentre, randomised, placebo controlled trial of lactic acid bacteria in prevention of antibiotic-associated 
diarrhoea (AAD) & Clostridium difficile diarrhoea (CDD) in patients aged 65 years & over admitted to hospital and 
receiving antibiotics 
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Study 
ID 
Surname of 
Chief 
Investigator 
HTA 
Reference 
Project title 
33 Rai 08/38/01 First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: A randomised, 
double-blind, placebo-controlled, multi-centre trial [The PROMISE (PROgesterone in recurrent MIScarriage) Trial]  
34 Coleman 06/07/01 Double-blind, randomised, placebo-controlled trial of nicotine replacement therapy (NRT) in pregnancy - SNAP 
35 Wolf 05/515/01 SLEEPS: Safety profiLe, Efficacy and Equivalence in Paediatric intensive care Sedation: a comparison of clonidine 
and midazolam 
36 Logan 08/14/51 Getting out of the house: a multi centre trial to evaluate an outdoor mobility intervention for people who have had a 
stroke 
37 Field 09/61/01 United Kingdom Lung Cancer Screening Trial (UKLS) 
38 Chakravarthy 07/36/01 A randomised controlled trial (RCT) of alternative treatments to Inhibit VEGF in patients with Age-related 
choroidal Neovascularisation (IVAN) 
39 Christie 06/44/05 Maximising engagement, motivation and long term change in a structured intensive education programme in 
diabetes for children, young people and their families: child and adolescent structured competencies approach to 
diabetes education 
40 James 06/303/205 A randomised phase III trial of Docetaxel plus Prednisolone vs. Docetaxel with Prednisolone plus either Zoledronic 
acid, Strontium-89 or both agents combined (TRAPEZE) 
41 Gilbert 08/13/47 CATheter Infections in Children - the CATCH trial 
42 Earl 06/303/98 PERSEPHONE - duration of trastuzumab study with chemotherapy in early breast cancer: six versus twelve months 
43 Mehanna 06/302/129 Positron Emission Tomography-Computerised Tomography scans (PET-CT) guided watch and wait policy versus 
planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head 
and neck squamous cancer 
44 Young 06/04/01 A randomised controlled trial of high frequency oscillatory ventilation in patients with acute respiratory distress 
syndrome (OSCAR) 
45 Clark 06/404/84 A randomised controlled trial of Outpatient Polyp Treatment (OPT) for abnormal uterine bleeding 
46 Tyrer 07/01/26 Cognitive-behavioural therapy for Health Anxiety in Medical Patients (CHAMP) 
47 Cassell 07/43/01 The relative clinical and cost-effectiveness of three contrasting approaches to partner notification for curable 
sexually transmitted infections (STIs): a cluster randomised trial in primary care 
48 Powell 07/37/64 Can emergency endovascular aneurysm repair (eEVAR) improves the survival from ruptured abdominal aortic 
aneurysm? 
49 Knowles 09/104/16 CONtrol of Faecal Incontinence using Distal NeuromodulaTion (CONFIDeNT) 
50 Clark 06/80/01 Does home oxygen therapy (HOT) in addition to standard care improve disease severity and symptoms in chronic 
heart failure? 
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Study 
ID 
Surname of 
Chief 
Investigator 
HTA 
Reference 
Project title 
51 Iliffe 06/36/04 Multi-centre cluster trial in primary care comparing a community group exercise programme with home based 
exercise and with usual care for people aged 65 and over 
52 Brittended 06/45/02 Randomised controlled trial comparing foam sclerotherapy, alone or in combination with endovenous laser therapy, 
with conventional surgery as a treatment for varicose veins 
53 Morrell 08/56/02 A randomised controlled trial of continuous positive airway pressure treatment in older people with obstructive 
sleep apnoea hypopnoea syndrome (PREDICT) 
54 Williamson 09/01/27 An open randomised study of autoinflation in school age children (4-11 years) with otitis media with effusion 
(OME) in primary care 
55 Anie 07/48/01 An evaluation of the effectiveness of ibuprofen and morphine for acute pain in sickle cell disease 
56 Sackley 08/14/30 A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK 
care-homes 
57 Livingston 08/14/06 The START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the 
effectiveness of a manual based coping strategy programme in promoting the mental health of carers of people with 
dementia 
58 Cunningham 09/91/16 Bronchiolitis of Infancy Discharge Study (BIDS) 
59 Williams 06/403/51 A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with 
prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid 
60 Priebe 07/60/43 Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients - a 
cluster randomised controlled trial: FIAT (Financial Incentives for Adherence to Treatment) 
61 Gilbody 06/43/05 The Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) Trial 
62 Camobell 08/53/15 The effectiveness and cost effectiveness of telephone triage of patients requesting same day consultations in general 
practice: a cluster randomised controlled trial comparing nurse-led and GP-led management systems. - The 
ESTEEM trial 
63 Hillmen 07/01/38 A randomised, phase II trial in previously untreated patients with chronic lymphocytic leukaemia to compare 
fludarabine, cyclophosphamide and rituximab with fludarabine and cyclophosphamide, mitoxantrone and low dose 
rituximab. (CLL6)  
64 Reeves 06/402/94 A multi-centre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, 
morbidity and healthcare resource use following cardiac surgery (TITRe 2) 
65 McClinton 08/71/01 Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: multicentre placebo 
controlled randomised trial of calcium channel blockers (nifedipine) and alpha blockers (tamsulosin) - The 
SUSPEND trial 
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Study 
ID 
Surname of 
Chief 
Investigator 
HTA 
Reference 
Project title 
66 Little 09/127/19 Positive Online WEight Reduction (POWER) 
67 Clarke 07/01/07 Randomised controlled trial to assess the clinical- and cost-effectiveness of physiotherapy and occupational therapy 
in Parkinson's disease (PD REHAB) 
68 Costa 08/116/97 A randomised controlled trial of percutaneous fixation with Kirschner wires versus volar locking-plate fixation in 
the treatment of adult patients with a displaced fracture of the distal radius 
69 Rangan 06/404/53 Pragmatic multi-centre randomised trial of surgical versus non-surgical treatment for proximal fracture of the 
humerus in adults 
70 Mendelow 07/37/16 Surgical Trial In Traumatic intraCerebral Haemorrhage [STITCH) 
71 Halliday 06/301/233 Asymptomatic Carotid Surgery Trial-2 (ACST-2): an international randomised trial to compare carotid 
endarterectomy with carotid artery stenting to prevent stroke 
72 Rowan 07/52/03 CALORIES: A phase III, open, multicentre, randomised controlled trial comparing the clinical and cost-
effectiveness of early nutritional support in critically ill patients via the parenteral versus the enteral route  
73 Rowan 07/37/47 Protocolised Management In Sepsis (ProMISe): a multicentre, randomised controlled trial of the clinical and cost-
effectiveness of early protocolised resuscitation for emerging septic shock 
74 Kuyken 08/56/01 Preventing depressive relapse in NHS Practice through mindfulness-based cognitive therapy (MBCT) 
75 Barnes 08/116/12 Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS) 
76 Ussher 07/01/14 A pragmatic randomized controlled trial of physical activity as an aid to smoking cessation during pregnancy  
77 Brocklehurst 06/38/01 A multicentre randomised controlled trial of an intelligent system to support decision making in the management of 
labour using the cardiotocogram (INFANT) 
78 Song 09/91/36 A randomised controlled trial of self-help materials for the prevention of smoking relapse 
79 Carr 05/47/02 The clinical and cost-effectiveness of arthroscopic versus open surgical repair for tears of the rotator cuff (UKUFF 
trial) 
80 Paton 06/403/90 A randomised controlled trial of a protease inhibitor monotherapy versus continuing combination antiretroviral 
therapy for HIV-1 infected patients previously established on a dual nucleoside and non-nucleoside combination 
regimen 
81 Barnes 07/83/01 Antidepressant Controlled Trial of Negative symptoms in Schizophrenia (ACTIONS) 
82 Thursz 08/14/44 STeroids or Pentoxifyline for Alcoholic Hepatitis (STOPAH) Trial 
83 Orrell 08/116/06 Individual Cognitive Stimulation Therapy for dementia (iCST Trial) 
84 McMurran 08/53/06 Psychoeducation with problem solving (PEPS) therapy for adults with personality disorder: A community-based, 
randomised controlled trial  
85 Gates 07/37/69 A randomised controlled trial of the LUCAS mechanical compression/decompression device for out of hospital 
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Study 
ID 
Surname of 
Chief 
Investigator 
HTA 
Reference 
Project title 
cardiac arrest 
86 Brocklehurst 08/22/02 A study of position during the late stages of labour in women with an epidural 
87 Khan 09/22/50 Can magnetic resonance imaging scan replace, or triage the use of laparoscopy in establishing diagnosis among 
women presenting in secondary care with chronic pelvic pain? 
88 Cottrell 07/33/01 SHIFT. Self-Harm Intervention, Family Therapy: a randomised controlled trial of family therapy vs. treatment as 
usual for young people seen after second or subsequent episodes of self-harm 
89 Hewer 07/51/01 Torpedo-CF: Trial of optimal therapy for pseudomonas eradication in cystic fibrosis 
90 Robertson 09/127/41 A randomised controlled trial evaluating the effectiveness and cost-effectiveness of Families for Health, a family-
based childhood obesity management intervention delivered in a community setting for ages 7 to 11 
91 Willett 07/37/61 Comparison of close contact cast (CCC) technique to open surgical reduction and internal fixation (ORIF) in the 
treatment of unstable ankle fractures in patients over 60 years 
92 Priebe 08/116/68 Effectiveness and Cost-Effectiveness of Body Psychotherapy in the Treatment of Negative Symptoms of 
Schizophrenia. A multi-centre randomised controlled trial 
93 Khan 09/55/38 Antiepileptic drug (AED) management in Pregnancy: An evaluation of effectiveness, cost effectiveness and 
acceptability of dose adjustment strategies 
94 McDermott 09/55/33 A Randomised Controlled Trial In Patients With Respiratory Muscle Weakness Due to Motor Neurone Disease of 
the NeuRx RA/4 Diaphragm Pacing System (DiPALS) 
95 Tickle 08/14/19 A randomised control trial to measure the effects and costs of a dental caries prevention regime for young children 
attending primary care dental services (Northern Ireland Caries Prevention In Practice Trial - NIC-PIP trial) 
96 Goodyer 06/05/01 Randomised controlled trial of brief psychodynamic psychotherapy, cognitive behaviour therapy and treatment as 
usual in adolescents with moderate to severe depression attending routine child and adolescent mental health clinics 
97 Glazener 07/60/18 Clinical and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall 
prolapse: two randomised controlled trials within a Comprehensive Cohort Study 
98 Simpson 08/44/04 Weight Loss Maintenance in Adults: A 3 arm individually randomised controlled trial to evaluate the impact of a 
12-month multi-component intervention and less intensive version compared to a control on weight loss 
maintenance in obese adults 
99 Watson 08/24/02 A pragmatic multicentre randomised controlled trial comparing stapled haemorrhoidopexy to conventional 
excisional surgery for haemorrhoidal disease 
100 Lamb 09/80/04 Physical activity programmes for community dwelling people with mild to moderate dementia (DAPA - Dementia 
And Physical Activity) 
102 Webb 08/53/31 Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of 
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ID 
Surname of 
Chief 
Investigator 
HTA 
Reference 
Project title 
childhood nephrotic syndrome: national multicentre randomised double blind controlled trial 
103 Kitchener 09/164/01 Strategies to increase cervical screening uptake at first invitation (STRATEGIC) 
104 Jayne 07/89/01 FIAT (Fistula-in-ano trial) comparing Surgisis® anal fistula plug versus surgeon's preference (advancement flap, 
fistulotomy, cutting seton) for transsphincteric fistula-in-ano 
105 Buch 08/116/75 SWITCH - Randomised- controlled trial of switching to alternative tumour necrosis factor-blocking drugs or 
abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-blocking drug 
106 Heller 08/107/01 The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial 
107 Jeffcoate 09/01/53 Evaluation of lightweight fibreglass heel casts in the management of ulcers of the heel in diabetes 
108 Clarkson 09/01/45 Improving the Quality of Dentistry (IQuaD): A randomised controlled trial comparing oral hygiene advice and 
periodontal instrumentation for the prevention and management of periodontal disease in dentate adults attending 
dental primary care 
109 Walsh 09/144/51 The Age of Blood Evaluation Study (ABLE)  
110 Drayson 08/116/69 Tackling Early Morbidity and Mortality in Myeloma: Assessing the benefit of antibiotic prophylaxis and its effect 
on healthcare associated infections 
111 Jayne 08/56/04 Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody associated systemic vasculitis: a 
randomized controlled trial. PEXIVAS 
112 McPherson 08/53/22 FEMME trial: Randomised trial of treating Fibroids with either Embolisation or MyoMectomy to measure the 
Effect on quality of life 
113 Beard 08/14/08 Total or Partial Knee Arthroplasty Trial (TOPKAT) 
114 Barr 05/12/01 Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS 
(Barrett's Oesophagus Surveillance Study)  
115 Goodacre 06/302/19 The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised 
controlled trial of point-of-care cardiac markers in the emergency department 
116 Nelson 02/37/03 VenUS III: a randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers 
117 Williams 05/16/01 A multicentre randomised controlled trial and economic evaluation of ion-exchange water softeners for the 
treatment of eczema in children: the Softened Water Eczema Trial (SWET) 
118 Kitchener 03/04/02 MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial 
119 Rodgers 02/41/06 BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of 
treating upper limb spasticity due to stroke with botulinum toxin type A 
120 Cross 03/13/06 A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest 
physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease 
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ID 
Surname of 
Chief 
Investigator 
HTA 
Reference 
Project title 
(MATREX) 
121 Kilby 07/01/44 The PLUTO Trial: Percutaneous shunting in Lower Urinary Tract Obstruction 
122 Blair 08/14/39 Randomised controlled trial of continuous subcutaneous insulin infusion compared to multiple daily injection 
regimens in children and young people at diagnosis of type I diabetes mellitus 
123 Torgerson 09/77/01 Randomised trial of a multifaceted podiatry intervention for fall prevention 
124 Lovell 09/81/01 Obsessive Compulsive Treatment Efficacy Trial (OCTET) 
125 Johnson 09/144/50 Randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention for 
reduction of cannabis use and of relapse in early psychosis 
126 Hamilton-Shield 09/127/04 Changing eating behaviours to treat childhood obesity in the community using Mandolean: the ComMando, 
(Community Mandolean) randomised trial 
127 Brown 09/91/21 A randomised, multi-stage phase II/III study of Sunitinib comparing Temporary cessation with Allowing 
continuation, at the time of maximal response, in the first-line treatment of locally advanced/metastatic Renal cell 
carcinoma (the STAR trial) 
128 Blazeby 09/127/53 BY-BAND. Gastric BYpass or adjustable gastric BANDing surgery to treat morbid obesity: a multi-centre 
randomised controlled trial 
129 Lewis 03/45/07 A pragmatic randomised controlled trial to evaluate the cost-effectiveness of a physical activity intervention as a 
treatment for depression: the treating depression with physical activity (TREAD) trial 
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Appendix 10. Systematic review: complete results of meta-summary  
 
 
Number (%) of included RCTs reporting each consideration 
 
TOTAL 
NON-
PHARMACOLOGIC 
(n=33) 
PHARMACOLOGIC 
(n=96) 
CLUSTER 
(n=14) 
NON-CLUSTER 
(n=115) 
 
N 
% 
total N 
% 
total 
% 
group N 
% 
total 
% 
group N 
% 
total 
% 
group N 
% 
total 
% 
group 
CENTRE SELECTION CONSIDERATIONS 78 60% 56 43% 58% 22 17% 67% 13 10% 93% 65 50% 57% 
DIVERSITY AND 
REPRESENTATIVENESS 31 24% 26 20% 27% 5 4% 15% 6 5% 43% 25 19% 22% 
POPULATION CHARACTERISTICS 14 11% 13 10% 14% 1 1% 3% 2 2% 14% 12 9% 10% 
cultural background 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
ethnicity 9 7% 8 6% 8% 1 1% 3% 1 1% 7% 8 6% 7% 
socio-economic status 10 8% 9 7% 9% 1 1% 3% 2 2% 14% 8 6% 7% 
HEALTH SERVICE DELIVERY 15 12% 13 10% 14% 2 2% 6% 6 5% 43% 9 7% 8% 
patient case-mix 2 2% 2 2% 2% 1 1% 3% 2 2% 14% 2 2% 2% 
intervention throughput 1 1% 1 1% 1% 0 0% 0% 1 1% 7% 1 1% 1% 
organisations or practitioners 9 7% 9 7% 9% 1 1% 3% 9 7% 64% 9 7% 8% 
services offered 4 3% 4 3% 4% 0 0% 0% 4 3% 29% 4 3% 3% 
CENTRE SETTING 15 12% 12 9% 13% 3 2% 9% 2 2% 14% 13 10% 11% 
environment 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
regions 3 2% 1 1% 1% 2 2% 6% 0 0% 0% 3 2% 3% 
size 1 1% 1 1% 1% 0 0% 0% 1 1% 7% 0 0% 0% 
plain setting 2 2% 2 2% 2% 0 0% 0% 2 2% 14% 2 2% 2% 
type of communities 1 1% 1 1% 1% 0 0% 0% 1 1% 7% 1 1% 1% 
urban vs. rural 8 6% 8 6% 8% 1 1% 3% 8 6% 57% 8 6% 7% 
CENTRE CHARACTERISTICS 57 44% 39 30% 41% 18 14% 55% 7 5% 50% 50 39% 43% 
CENTRE SETTING 4 3% 3 2% 3% 1 1% 3% 2 2% 14% 2 2% 2% 
geographical location 2 2% 1 1% 1% 1 1% 3% 1 1% 7% 1 1% 1% 
uniqueness in the region 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
deprivation status 1 1% 1 1% 1% 0 0% 0% 1 1% 7% 0 0% 0% 
 
 
              HEALTH SERVICE DELIVERY ('RESEARCH- 16 12% 11 9% 11% 5 4% 15% 0 0% 0% 16 12% 14% 
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Number (%) of included RCTs reporting each consideration 
 
TOTAL 
NON-
PHARMACOLOGIC 
(n=33) 
PHARMACOLOGIC 
(n=96) 
CLUSTER 
(n=14) 
NON-CLUSTER 
(n=115) 
 
N 
% 
total N 
% 
total 
% 
group N 
% 
total 
% 
group N 
% 
total 
% 
group N 
% 
total 
% 
group 
READY') 
centre of excellence 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
clinical interest 6 5% 2 2% 2% 4 3% 12% 0 0% 0% 6 5% 5% 
computer systems 1 1% 0 0% 0% 1 1% 3% 0 0% 0% 1 1% 1% 
Department of Health approved centre 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
links with other facilities 3 2% 2 2% 2% 1 1% 3% 0 0% 0% 3 2% 3% 
NHS centre 7 5% 6 5% 6% 1 1% 3% 0 0% 0% 7 5% 6% 
satisfactory peer review 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
INTERVENTION 31 24% 24 19% 25% 7 5% 21% 3 2% 21% 28 22% 24% 
appropriate training 3 2% 3 2% 3% 0 0% 0% 0 0% 0% 3 2% 3% 
suitable to implement the intervention 16 12% 12 9% 13% 4 3% 12% 0 0% 0% 16 12% 14% 
experience in delivering the intervention 13 10% 10 8% 10% 3 2% 9% 0 0% 0% 13 10% 11% 
not running the intervention 6 5% 6 5% 6% 0 0% 0% 3 2% 21% 3 2% 3% 
performance in delivering the intervention 5 4% 4 3% 4% 1 1% 3% 0 0% 0% 5 4% 4% 
RESEARCH 19 15% 11 9% 11% 8 6% 24% 2 2% 14% 17 13% 15% 
able to support research 2 2% 2 2% 2% 0 0% 0% 0 0% 0% 2 2% 2% 
part of a research network 10 8% 4 3% 4% 6 5% 18% 1 1% 7% 9 7% 8% 
research experience 10 8% 6 5% 6% 4 3% 12% 0 0% 0% 10 8% 9% 
interest in research 3 2% 2 2% 2% 1 1% 3% 1 1% 7% 2 2% 2% 
CENTRE SIZE 22 17% 16 12% 17% 6 5% 18% 4 3% 29% 18 14% 16% 
catchment area 7 5% 4 3% 4% 3 2% 9% 1 1% 7% 6 5% 5% 
patient throughput 11 9% 8 6% 8% 3 2% 9% 1 1% 7% 10 8% 9% 
size of centre 5 4% 4 3% 4% 1 1% 3% 2 2% 14% 3 2% 3% 
TRIAL PARTICIPATION 37 29% 23 18% 24% 14 11% 42% 8 6% 57% 29 22% 25% 
RECRUITMENT 17 13% 10 8% 10% 7 5% 21% 3 2% 21% 14 11% 12% 
ability to recruit 10 8% 4 3% 4% 6 5% 18% 0 0% 0% 10 8% 9% 
access to study population 8 6% 6 5% 6% 2 2% 6% 3 2% 21% 5 4% 4% 
TRIAL CONSTRAINTS 5 4% 5 4% 5% 0 0% 0% 4 3% 29% 1 1% 1% 
proximity to study site 2 2% 2 2% 2% 0 0% 0% 2 2% 14% 0 0% 0% 
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Number (%) of included RCTs reporting each consideration 
 
TOTAL 
NON-
PHARMACOLOGIC 
(n=33) 
PHARMACOLOGIC 
(n=96) 
CLUSTER 
(n=14) 
NON-CLUSTER 
(n=115) 
 
N 
% 
total N 
% 
total 
% 
group N 
% 
total 
% 
group N 
% 
total 
% 
group N 
% 
total 
% 
group 
costs to trial 2 2% 2 2% 2% 0 0% 0% 1 1% 7% 1 1% 1% 
time frame of trial 1 1% 1 1% 1% 0 0% 0% 1 1% 7% 0 0% 0% 
ENSURING TRIAL PROCESSES AND REQ. 24 19% 13 10% 14% 11 9% 33% 3 2% 21% 21 16% 18% 
arrange follow-up 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
compliance with trial procedures and 
regulatory requirements 17 13% 8 6% 8% 9 7% 27% 2 2% 14% 15 12% 13% 
ensuring communication 6 5% 1 1% 1% 5 4% 15% 0 0% 0% 6 5% 5% 
identify champions 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
required time, staff, facilities 16 12% 7 5% 7% 9 7% 27% 2 2% 14% 14 11% 12% 
SUPPORT 7 5% 6 5% 6% 1 1% 3% 3 2% 21% 4 3% 3% 
support from centre management 4 3% 4 3% 4% 0 0% 0% 2 2% 14% 2 2% 2% 
support from funding bodies 0 0% 0 0% 0% 0 0% 0% 0 0% 0% 0 0% 0% 
support from local commissioners 1 1% 0 0% 0% 1 1% 3% 0 0% 0% 1 1% 1% 
support from local stakeholders 1 1% 1 1% 1% 0 0% 0% 0 0% 0% 1 1% 1% 
support from research network 1 1% 1 1% 1% 0 0% 0% 1 1% 7% 0 0% 0% 
WILLINGNESS 9 7% 7 5% 7% 2 2% 6% 1 1% 7% 8 6% 7% 
willing to randomise 4 3% 3 2% 3% 1 1% 3% 0 0% 0% 4 3% 3% 
willingness to perform the intervention 4 3% 3 2% 3% 1 1% 3% 0 0% 0% 4 3% 3% 
willing to participate 3 2% 3 2% 3% 0 0% 0% 1 1% 7% 2 2% 2% 
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Appendix 11. Invitation to participate in the focus groups 
 
Investigating the rationale for centre selection in randomised 
controlled trials coupled with economic evaluations 
 
 
 Dear Ms YYYY, 
 You are invited to participate in a focus group that will explore the rationale for 
centre selection in randomised controlled trials coupled with economic evaluations (RCT-
EEs). The aim of the study is to elicit a comprehensive list of both methodological and 
pragmatic considerations that should be taken into account when considering the 
enrolment of a centre (e.g. hospital, GP practice, school, community as a whole etc.).  
 If you agree to participate, you will be invited to participate in one focus group 
session on the topic explained above. Prior to expressing the intention to attend you will 
have the opportunity to contact the researchers and ask any questions you may have on 
the conduct of the study. Several weeks after attending the focus group you will receive 
an electronic questionnaire on the rationale for centre selection in RCT-EEs, which you 
will be invited to provide feedback to. You will not be asked to fill in the questionnaire, 
but simply to comment on its format and content. 
 This research is carried out as part of a PhD studentship in health economics and 
is based in Primary Care Clinical Sciences at the University of Birmingham. The study is 
sponsored by the University of Birmingham. 
 Your participation is very important for the successful completion of this PhD 
studentship and will be very much appreciated. 
 To register your interest and ask any questions, please contact 
 
Dr. Melanie Calvert (main investigator) 
Primary Care Clinical Sciences 
University of Birmingham 
 
 
Adrian Gheorghe (studentship holder) 
Primary Care Clinical Sciences 
University of Birmingham 
 
 
 
 
 
 Thank you. 
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Appendix 12. Informed consent form for participation in the focus groups 
 
Investigating the rationale for centre selection in randomised controlled 
trials coupled with economic evaluations 
Informed Consent form Version 1.0 26th July 2011 
 
____________________________                                                    ____________________________  
Name of Participant (please print)                                                    Name of Researcher (please print) 
____________________________                                                    ____________________________  
Signature of Participant                                                                       Signature of Researcher 
Date today __ __/__ __/__ __ __ __                                               Date today __ __/__ __/__ __ __ __ 
 
 
Participant: 
Please initial 
each section 
1 I confirm that I have read and understood the Participant Information Sheet for this study 
(version 2.0 26th July 2011) and have had the opportunity to ask questions. 
 
2 I understand that a copy of my Informed Consent form, information about me and my 
progress will be supplied in confidence to the study researchers at the University of 
Birmingham (Primary Care Clinical Sciences). 
 
3 I understand that my participation in this study is voluntary and that I may withdraw 
participation at any time, without giving a reason, and without my legal rights being 
affected. 
 
4 I understand that the information that I will provide during the focus group will be 
collected only with audio digital equipment, further transcribed and analysed by the 
study researchers. 
 
5 I understand that, if I decide to withdraw participation from the study, the information I 
had provided in the focus group discussion prior to my withdrawal cannot be eliminated 
and will be analysed by the researchers. 
 
6 I understand that due to the nature of the research, anonymity cannot be ensured, but 
the confidentiality of my data will be strictly protected by the researchers during every 
stage of the research, as detailed in the Participant Information Sheet (version 2.0 26th 
July 2011). 
 
7 I understand that after I have taken part in the focus group I will be sent a questionnaire 
and asked to provide feedback on its content and structure. I give permission for this 
questionnaire to be sent to me, and I understand that I do not have to send comments 
back if I do not want to. I understand that researchers may contact me by email or phone 
to remind me to send my comments.  
 
8 I agree to protect the confidentiality of data collected from the other participants in the 
focus group. 
 
9 I agree to take part in this study.  
 441 
 
Appendix 13. Focus group topic guide 
 
Investigating the rationale for centre selection in randomised 
controlled trials coupled with economic evaluations 
 
Focus group topic guide 
 
Scenario [as it will be presented to participants at the beginning of the focus group] 
The discussion will consider a hypothetical multi-centre parallel randomised 
controlled trial (RCT) coupled with an economic evaluation. Resource use 
data and outcome data (e.g. clinical markers, health-related quality of life 
information) are being collected alongside the RCT. A centre can range from 
a GP surgery to an entire community, depending on the nature of the 
investigation. 
 
Topic guide 
1. What sorts of things might you consider when selecting centres for 
this kind of trial? 
 
 a.Which things are the most important? 
 
 i)At what stage in the trial should these things be considered? 
 
 
2. Who should be involved in making the decision about centre 
selection? 
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Appendix 14. Full version of the online survey 
 
   
8% 
 
Thank you for your interest in this research. 
 
What is the purpose of this study? 
The aim of the study is to gather information on how centre selection is carried out in 
randomised controlled trials (RCTs) with a parallel economic evaluation. We are approaching 
staff affiliated with Clinical Trials Units and Research Design Services in the UK. We want to 
know your views on which considerations are the most relevant when deciding on which 
centres are included in such a RCT. 
 
Who is doing this research? 
This research is carried out as part of a PhD studentship in health economics, based in 
Primary Care Clinical Sciences at the University of Birmingham. The researchers involved in 
the study are Dr. Melanie Calvert (main investigator) and Adrian Gheorghe, MSc. 
(studentship holder). The Science, Technology, Engineering and Mathematics Ethical 
Review Committee at the University of Birmingham have favourably reviewed the study. 
 
How long will it take? 
The questionnaire has 9 questions and its completion is expected to last about 10 minutes. 
 
How will data collected from you be protected? 
All the data collected from you will be kept anonymous and confidential. You will not be 
asked for any personal information (e.g. name, socio-demographic characteristics, contact 
details). We will ask you, though, about your professional position and your work experience. 
The results of the questionnaire and any reports derived from it will be securely stored on the 
computer systems in Primary Care Clinical Sciences at the University of Birmingham for the 
duration of 10 years. After this period they will be deleted so that they cannot be recovered. 
 
Once you agree to take part, can you change your mind? 
Yes, you can exit the questionnaire at any time and your answers up to that point will 
not be analysed. Due to anonymity, you will not be able to withdraw after submitting the 
answers because there is no way we can retrieve your individual answers. 
 
Who can you contact should you want to ask questions? 
Primary Care Clinical Sciences, University of Birmingham  
Birmingham B15 2TT, UK  
Dr. Melanie Calvert  
 
 
 
Mr. Adrian Gheorghe  
 
 
 
NOTE: Advancing to the next page is equivalent to your giving CONSENT to have your 
answers analysed. Anonymity and confidentiality will be ensured. 
 
Next 
Exit this survey 
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15% 
 
Please consider a phase III multi-centre RCT with a parallel economic evaluation 
(within-trial economic evaluation). 
 
A 'centre' can be defined broadly, depending on the intervention. Examples of centres 
include, but are not limited to: GP practices, clinics, hospitals, tertiary centres, 
neighbourhoods or entire cities. 
 
'Parallel economic evaluation' refers to the collection of cost and outcome data (e.g. 
health-related quality of life information) alongside the RCT. 
 
In the following questions you will be asked about various considerations influencing 
the decision to include a centre in a RCT. 
 
Please ASSUME in all cases that any given centre fulfils two basic requirements:  
1. The centre has enough qualified staff, physical space and relevant equipment available 
for the RCT.  
2. The centre has access to the relevant study population.  
 
Prev         Next 
 
 
 
 
Exit this survey 
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23% 
 
The following 4 questions are about your CURRENT practice. 
 
 
Prev         Next 
 
 
 
 
Exit this survey 
 445 
 
 
 
 
 
 
31%  
 
1. YOUR CURRENT PRACTICE: When considering the inclusion of a centre in a RCT 
with a parallel economic evaluation, which centre characteristics do you usually look 
for? 
 
 
Please choose the most important characteristics from the list below. No explicit 
ranking is required. Please select a MINIMUM of 3 and a MAXIMUM of 5 answers. 
 
Local clinical staff understand the methodological underpinnings of RCTs. 
The geographical location of the centre is convenient for logistical reasons. 
The centre belongs to a relevant research network. 
 
Local staff have had experience with conducting RCTs in the past. 
 
The centre's computer systems are compatible with the trial centre's computer systems. 
The centre retains or contributes to generalisability in terms of clinical practice. 
 
The centre has support from local commissioners to participate in the RCT. 
 
The centre retains or contributes to generalisability in terms of population 
characteristics. There is a good communication relationship between the trials 
unit and centre staff. 
The centre is able to obtain necessary approvals (including R&D) in a 
timely manner. The centre is able to recruit the desired number of 
patients in a timely manner. 
The centre staff show a degree of interest in the RCT. 
 
The centre retains or contributes to generalisability in terms of economic 
evaluation results.  
Other (please complete below). 
 
150 characters limit 
 
 
 
 
 
 
 
 
Prev            Next  
Exit this survey 
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38%  
*2. YOUR CURRENT PRACTICE: What do you think has the most influence on a 
centre's enrolment in a RCT with a parallel economic evaluation? 
 
Please choose the most important considerations from the list below. No explicit 
ranking is required. Please select a MINIMUM of 3 and a MAXIMUM of 5 answers. 
 
The recruiting time frame of the RCT 
 
The state of the local research environment (e.g. competing 
RCTs, trial fatigue) The centre staff know the Chief Investigator. 
 
Patient convenience i.e. travel distance to the centre, additional costs (e.g. parking) 
etc. Characteristics of the RCT design: type of intervention, sample size, number of 
centres required etc. The budget of the RCT 
 
The extent to which local staff are motivated to participate in the RCT 
 
The type of geographical setting where the centre is located 
(rural vs. urban) The efficiency of the local R&D department 
at issuing approvals 
 
Requirements of funding and regulatory bodies (e.g. Cancer 
Research UK, NIHR) The rarity of the disease under investigation 
 
Other (please complete below) 
150 characters limit 
 
 
 
 
 
 
 
Prev            Next 
 
 
 
 
Exit this survey 
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46% 
 
3. YOUR CURRENT PRACTICE: In your opinion, who drives the centre enrolment 
process in a RCT with a parallel economic evaluation? 
 
Please choose a maximum of 2 answers from the list below. 
 
Trial health economist 
 
Trial coordinator/Trial manager 
 
Trial Management Group members as a team 
 
Chief Investigator 
 
Data Monitoring Committee members 
 
Trial statistician 
 
Research networks 
 
Other (please complete below) 150 characters limit 
 
 
 
 
 
 
 
Prev            Next 
 
 
 
 
Exit this survey 
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54%  
*4. YOUR CURRENT PRACTICE: Would you say that health economics 
considerations influence the decision to include a centre in a RCT with a parallel 
economic evaluation? 
 
Yes, but only to a limited extent. 
 
Not at all. 
 
Yes, to a great extent. 
 
If you have chosen either of the options starting with 'Yes', please could you explain in 
more detail why you gave this answer? (1000 character limit) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prev           Next 
 
 
 
Exit this survey 
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69%  
*5. OPTIMAL PRACTICE: When considering the inclusion of a centre in a RCT with a 
parallel economic evaluation, which centre characteristics do you think should 
IDEALLY be sought? 
 
 
Please choose the most important characteristics from the list below. No explicit 
ranking is required. Please select a MINIMUM of 3 and a MAXIMUM of 5 answers. 
 
The geographical location of the centre is convenient for logistical reasons. 
 
The centre's computer systems are compatible with the trial centre's computer systems. 
Local clinical staff understand the methodological underpinnings of RCTs. 
 
The centre retains or contributes to generalisability in terms of economic evaluation results. 
The centre staff show a degree of interest in the RCT. 
 
The centre is able to recruit the desired number of patients in a timely manner. The centre 
retains or contributes to generalisability in terms of clinical practice. 
 
The centre is able to obtain necessary approvals (including R&D) in a timely manner. There 
is a good communication relationship between the trials unit and centre staff. 
The centre retains or contributes to generalisability in terms of population characteristics. 
The centre has support from local commissioners to participate in the RCT. 
The centre belongs to a relevant research network. 
 
Local staff have had experience with conducting RCTs in the past. 
Other (please complete below) 
 
150 characters limit 
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Exit this survey 
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77%  
*6. OPTIMAL PRACTICE: Which considerations do you think should IDEALLY have 
the most influence on the practice of enrolling a centre in a RCT with a parallel 
economic evaluation? 
 
 
Please choose the most important considerations from the list below. No explicit 
ranking is required. Please select a MINIMUM of 3 and a MAXIMUM of 5 answers. 
 
The type of geographical setting where the centre is located (rural vs. urban) 
The rarity of the disease under investigation 
 
Characteristics of the RCT design: type of intervention, sample size, number of centres 
required etc.  
The recruiting time frame of the RCT 
 
The centre staff know the Chief Investigator. 
 
Patient convenience i.e. travel distance to the centre, additional costs (e.g. parking) etc. 
The extent to which local staff are motivated to participate in the RCT 
 
The budget of the RCT 
 
Requirements of funding and regulatory bodies (e.g. Cancer Research UK, NIHR)  
The efficiency of the local R&D department at issuing approvals 
 
The state of the local research environment (e.g. competing RCTs, trial fatigue)  
Other (please complete below) 
 
150 characters limit 
 
 
 
 
 
 
 
 
Prev           Next 
 
 
 
 
Exit this survey 
 451 
 
 
 
 
 
 
85% 
 
7. OPTIMAL PRACTICE: In your opinion, which of the following should IDEALLY 
drive the centre enrolment process in a RCT with a parallel economic evaluation? 
 
Please choose a maximum of 2 answers from the list below. 
 
Trial Management Group members as a team 
 
Chief Investigator 
 
Trial coordinator/Trial manager 
 
Data Monitoring Committee members 
 
Research networks 
 
Trial statistician 
 
Trial health economist 
 
Other (please complete below)  
150 characters limit 
 
 
 
 
 
 
 
Prev           Next 
 
 
 
 
Exit this survey 
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92% 
 
 
 
Please give us a bit of information about yourself.  
*8. What is your professional role within the trials unit? Please state your PRIMARY 
role if you have more than one professional position. 
 
Clinical investigator  
Statistician 
Trial coordinator/Trial manager  
Health economist 
 
Clinical trials methodologist  
Epidemiologist 
Evidence synthesis expert  
Qualitative researcher  
Outcomes research expert 
Other academic position (e.g. research associate, research fellow, senior research 
fellow) 
 Other (please complete below) 
 
150 characters limit 
 
 
*9. How long have you been involved in the design and/or conduct of RCTs? 
 
Less than 2 years  
Between 2 and 5 years  
Between 5 and 10 years  
More than 10 years 
 
 
Prev           Next 
 
 
 
 
Exit this survey 
 453 
 
 
 
 
 
 
100% 
 
 
 
 
THANK YOU for taking the time to complete this questionnaire. 
 
 
 
 
10. If you have any feedback or comments about this questionnaire and/or 
the nature of this research, please write them below. Your input is highly 
valued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prev SUBMIT 
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Appendix 15. Invitation to participate in the online survey 
 
 Investigating the rationale for centre selection in randomised 
controlled trials  
with parallel economic evaluations 
 Dear Prof. YYYY, 
 You are invited to participate in a study which aims to gather information on 
how centre selection is carried out in randomised controlled trials with a parallel 
economic evaluation (RCT-EEs). For this purpose we have devised an electronic 
questionnaire which is being circulated to all 48 UK Clinical Research Collaborative 
(UKCRC) Clinical Trials Units and 10 Research Design Services (RDS) in the UK. The 
questionnaire has 9 multiple-choice questions and its completion should last less than 
10 minutes. 
  If you agree to participate, you are invited to complete the online questionnaire 
(link below) and also to circulate it within Barts and the London Pragmatic Clinical Trials 
Unit for completion by staff involved in the design and conduct of RCT-EEs. We are 
interested in the views of the following professionals: clinical investigators, trial 
coordinators/trial managers, statisticians, health economists and any other academic 
position (e.g. research associate, research fellow).  
 https://surveymonkey.com/s/J9R7FKK 
 This research is carried out as part of a PhD studentship in health economics and 
is based in Primary Care Clinical Sciences at the University of Birmingham. The study is 
sponsored by the University of Birmingham. 
 Your participation is very important for the successful completion of this PhD 
studentship and will be very much appreciated. 
 For any questions you may have, please contact 
 
Dr. Melanie Calvert (main investigator) 
Primary Care Clinical Sciences 
University of Birmingham 
 
 
Adrian Gheorghe (studentship holder) 
Primary Care Clinical Sciences 
University of Birmingham 
 
 
 
 
 Thank you. 
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Appendix 16. Survey: Free text responses in the ‘Other’ field, by question 
 
Q1. YOUR CURRENT PRACTICE: When considering the inclusion of a centre in a RCT with a 
parallel economic evaluation, which centre characteristics do you usually look for? 
“Track record in delivering recruitment and high quality data” 
“Local knowledge, experience and expertise in the disease area/intervention under 
investigation” 
“These choices are often made by PI/TM rather than stats teams members but these 
would be my choices” 
“The only important thing for me is that the staff are interested and engaged” 
Q2. YOUR CURRENT PRACTICE: What do you think has the most influence on a centre's 
enrolment in a RCT with a parallel economic evaluation? 
“It is difficult to say what the centre perspective is, but critical issues are whether the research 
question is clinically relevant and how practical (i.e. easy) the enrolment pathway is (i.e. are 
patients easily identified)” 
“I presume you mean from centre's perspective?” 
“A PI who is keen and actively encourages staff to recruit to the RCT.” 
“Feeling the research question is of importance to them and the populations they serve” 
“If they think the trial is addressing a really important clinical question that they can 
relate to and want the answer to.  The support they receive to participate in the trial.” 
“Relationship with study CI” 
“I can't say that I see much relevance in most of the answers suggested.” 
“Promotion / raising the profile of the service they provide” 
Q3. YOUR CURRENT PRACTICE: In your opinion, who drives the centre enrolment process in a 
RCT with a parallel economic evaluation? 
“In the CTU environment we have a senior trialist with responsibility for operational 
delivery. This is a key oversight role and really pushed the Trial Manager and CI. Also 
sometime we have a clinical co-ordinator - they will take an active role in centre 
identification. In cluster trials, the lead stats methodologist also has oversight, as centre 
characteristics are key.” 
“Sponsors, in particular commercial sponsors” 
“LOCAL INVESTIGATOR OR NURSE” 
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“I don’t think this is any different for a trial without parallel economic evaluation” 
“Principal investigators, availability of research nurses either from the local R&D or one of 
the research networks or the CLRN.” 
Q4. YOUR CURRENT PRACTICE: Would you say that health economics considerations 
influence the decision to include a centre in a RCT with a parallel economic evaluation? 
“Efforts are usual made to recruit centres that serve different socio-economic 
backgrounds.” 
“In my experience, the health economic component is only considered in cluster trials” 
“We would consider generalisability and that includes economics, but not as a separate 
criteria.” 
“I have no idea - it is not in my experience. Maybe I have been included as a survey 
participant in error?” 
“It's surely obvious that if including a centre would vitiate a health economic component 
of a study  in which that component is quite essential, then the centre would not be used.  
As long as including an otherwise good centre wouldn't damage the study, I guess the 
economic side would play a pretty minor role, since the scientific integrity of the study 
would have to come first.” 
Q5. OPTIMAL PRACTICE: When considering the inclusion of a centre in a RCT with a parallel 
economic evaluation, which centre characteristics do you think should IDEALLY be sought? 
“I have problems with this question.  All of these should be ideally sought.  My perfect 
centre would meet all of these (although the IT system is irrelevant).  The next question 
asks for the prioritisation of these which is more useful.” 
“Able to collect additional resource use data” 
“As before - track record in delivery patient recruitment and high quality data” 
“Local staff have an interest, experience and expertise in the disease area or intervention 
of interest,  adequate facilities in place and good working relationships between research 
staff and local service providers e.g. labs, haematology, R&D etc.” 
“I think health economics should NOT be done in parallel. This is a hopeless questionnaire” 
Q6. OPTIMAL PRACTICE: Which considerations do you think should IDEALLY have the most 
influence on the practice of enrolling a centre in a RCT with a parallel economic evaluation? 
“Again I have a problem here as you have dropped items in this question which were 
previously important - all the ones about generalisability.” 
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“As before - question and whether clinically important is critical and ease of recruitment 
and follow up (does the research and clinical pathways facilitate the research process 
and/or where there is a mismatch, are there adequate resources)” 
“Importance of being involved in research and the benefits it could potentially have for 
patients” 
“This is a terrible questionnaire!” 
“Having a motivated PI” 
“Relevance to them and their population” 
“The importance of the clinical question” 
“The potential benefit to the NHS and its patients.” 
“The answer "know the CI" is nearly right, but gives an unfortunate "chummy" 
impression.  It's essential for there to be a good working relationship between the 
principal scientific staff.” 
Q7. OPTIMAL PRACTICE: In your opinion, which of the following should IDEALLY drive the 
centre enrolment process in a RCT with a parallel economic evaluation? 
“Local lead investigators” 
“Existing expertise across the UK in the disease area/intervention of interest” 
“LOCAL INVESITGATOR OR NURSE” 
“Not sure about this one, it all depends on what perspective you take. I am a CI and PI, 
ideally I would like a generalisable (nationally and locally) set of centres for my trials, but 
you rarely have all the information about centres that you would want to make selection 
of centres as informed by data as one would want.” 
“See answer to previous question.” 
“Principal investigator” 
Q10. Final comments 
“As indicated in my "other response" boxes I have problems with some of these questions 
as the options available changed.   What does "ideal" mean?   In an "ideal" world we 
would so much trouble doing R&D approvals, all staff would have time to recruit patients 
- I got the feeling that you are probing how the challenges of recruitment, logistics and 
bureaucracy stop us doing the most scientifically valid trials, where issues of 
generalisability might lead us to choose centres which would be more representative, 
rather than those where we can get through the approvals process and recruit lots of 
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patients quickly.  If that was you aim, I think that the questions could be better put, by 
defining "optimally" more clearly.” 
“Many of Qs difficult to understand so my answers will reflect that.  sorry” 
“Not easy to choose between the options given, and if I answered it again I am not sure I 
would give exactly the same answers!” 
“Good luck! I would be interested in the findings of this work.” 
“Good luck with your study” 
“The questions are tricky to be 'black and white' in responses. In the ideal world, we 
would carry out national audits / surveys before doing a RCT, and we would then 
benchmark local / national potential centres for our trial against the national picture, in 
order to be fully informed about generalisability of those centres - in terms of current 
clinical practice, skill mix of teams, population being served and current health economic 
information. In reality we rarely have that type of full information, and we hope that 
randomisation sorts out at least some of these problems and the trial is then focusing 
only on the between group comparisons. Clearly larger trials with many centres have a 
better chance of being nationally generalisable.” 
“My initial role in trials was as a trial health economist, but I am now more of a trial 
methodologist.  Despite my health economic background I don't take into account very 
much whether or not a centre enhances economic generalisability.  This is mainly because 
it is so difficult to recruit that the overwhelming objective is to get the numbers into the 
study. Furthermore, those centres that recruit are not so different in their general 
characteristics from those that do not.  Consequently, it seems to me that generalisability 
is high whether or not one seeks a generalisable sample or not.” 
“Interesting survey” 
“The questions themselves are not so clear.  There are two perspectives that they could 
be approached 1: study design e.g. ideally all those centres selected should participate, 2: 
the practicalities of conducting a study, which may contradict the requirements for good 
study design.” 
“This is a very well-organised way of conducting a survey. It makes it easy for people to 
participate. Although I have limited experience of 'running' an RCT, I have many years 
working with those who do. I didn't really have the opportunity to show that clearly in the 
body of the survey.” 
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Appendix 17. Generalisability index sensitivity analyses 
 
Figure A17.1 Clinical and cost-effectiveness estimates in simulated RCTs across categories of standardised trial-Gix3 
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Figure A17.2 Clinical and cost-effectiveness estimates in simulated RCTs across categories of standardised trial-Gix4a 
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Figure A17.3 Clinical and cost-effectiveness estimates in simulated RCTs across categories of standardised trial-Gix4b 
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Figure A17.4 Clinical and cost-effectiveness estimates in simulated RCTs across categories of standardised trial-Gix4z 
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Figure A17.5 Clinical and cost-effectiveness estimates in simulated RCTs across categories of standardised trial-Gix90 
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Figure A17.6 Clinical and cost-effectiveness estimates in simulated RCTs across categories of standardised trial-Gix50 
 
 
 
